[CLS] O
the O
same O
approach O
was O
applied O
to O
the O
other O
volume O
terms O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
and O
in O
v O
##it O
##ro O
characterization O
of O
ch O
##lor O
##zo O
##xa O
##zone O
metabolism O
and O
he O
##pa O
##tic O
c O
##y O
##p O
##2 O
##e O
##1 O
levels O
in O
a O
##f O
##rica O
##n O
green O
monkeys O
: O
induction O
by O
chronic O
ni O
##cot O
##ine O
treatment O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
was O
performed O
using O
data O
from O
individual O
rats O
for O
which O
the O
mean O
and O
standard O
error O
of O
the O
mean O
( O
se O
##m O
) O
were O
calculated O
for O
each O
group O
. O
[SEP] O
[CLS] O
included O
are O
criteria O
to O
decide O
whether O
the O
new O
or O
the O
classical O
model O
functions O
should O
be O
applied O
in O
the O
case O
of O
a O
two O
- O
compartment O
open O
model O
. O
[SEP] O
[CLS] O
double O
coupling O
was O
performed O
##fo O
##r O
the O
addition O
of O
each O
amino O
acid O
: O
using O
the O
microwave O
for O
the O
first O
##co O
##up O
##ling O
and O
at O
room O
temperature O
for O
3 O
h O
on O
a O
lab O
##mate O
shake O
##r O
( O
advanced O
##che O
##m O
##tech O
, O
lo O
##ui O
##sville O
, O
k O
##y O
) O
for O
the O
second O
coupling O
, O
with O
3 O
e O
##qui O
##v O
of O
##the O
protected O
amino O
acid O
, O
0 O
. O
4 O
m O
o O
- O
( O
7 O
- O
a O
##za O
##ben O
##zo O
##tri O
##az O
##ol O
- O
1 O
- O
y O
##l O
) O
- O
n O
, O
n O
, O
n O
′ O
- O
n O
′ O
- O
te O
##tra O
##met O
##hyl O
##uron O
##ium O
he O
##xa O
##f O
##lu O
##oro O
##ph O
##os O
##phate O
( O
hat O
##u O
) O
and O
1 O
- O
h O
##ydro O
##xy O
- O
7 O
- O
a O
##za O
##ben O
##zo O
##tri O
##az O
##ole O
( O
ho O
##at O
) O
in O
dim O
##eth O
##yl O
##form O
##ami O
##de O
( O
d O
##m O
##f O
) O
, O
and O
either O
1 O
m O
di O
##is O
##op O
##rop O
##yle O
##thy O
##lam O
##ine O
( O
die O
##a O
) O
in O
nm O
##p O
or O
neat O
co O
##lli O
##dine O
. O
[SEP] O
[CLS] O
the O
5th O
, O
50th O
, O
and O
95 O
##th O
percent O
##iles O
of O
the O
simulated O
concentrations O
were O
constructed O
and O
compared O
against O
the O
valid O
##ation O
data O
set O
observed O
concentrations O
. O
[SEP] O
[CLS] O
the O
morphology O
of O
the O
lesions O
can O
be O
seen O
in O
fi O
##g O
. O
6 O
( O
a O
images O
) O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
of O
( O
+ O
) O
- O
q O
##a O
and O
( O
− O
) O
- O
q O
##a O
were O
163 O
##1 O
. O
202 O
##± O
##24 O
##1 O
. O
03 O
##8 O
mg O
/ O
l O
/ O
h O
and O
246 O
. O
57 O
##1 O
##± O
##70 O
. O
67 O
##7 O
mg O
/ O
l O
/ O
h O
after O
in O
##tra O
##gas O
##tric O
administration O
, O
and O
223 O
##9 O
. O
105 O
##± O
##30 O
##0 O
. O
55 O
##4 O
mg O
/ O
l O
/ O
h O
and O
29 O
##4 O
. O
75 O
##1 O
##± O
##8 O
##5 O
. O
37 O
##7 O
mg O
/ O
l O
/ O
h O
after O
in O
##tra O
##ven O
##ous O
administration O
. O
[SEP] O
[CLS] O
food O
and O
water O
were O
given O
ad O
l O
##ibi O
##tum O
. O
[SEP] O
[CLS] O
the O
label O
##ling O
of O
ne O
##ph O
##rot O
##ox O
##ic O
compounds O
that O
do O
not O
a O
##cc O
##um O
##ulate O
included O
more O
frequently O
a O
recommendation O
to O
adapt O
the O
dose O
or O
to O
monitor O
than O
the O
label O
##ling O
of O
drugs O
without O
ne O
##ph O
##rot O
##ox O
##ic O
potential O
( O
15 O
of O
22 O
versus O
5 O
of O
26 O
, O
p O
= O
0 O
. O
00 O
##2 O
) O
. O
[SEP] O
[CLS] O
the O
objectives O
of O
these O
studies O
were O
to O
character O
##ize O
the O
disposition O
of O
g O
##d O
##c O
- O
09 O
##7 O
##3 O
in O
pre O
##c O
##lini O
##cal O
species O
and O
to O
determine O
the O
relationship O
of O
g O
##d O
##c O
- O
09 O
##7 O
##3 O
plasma O
concentrations O
to O
efficacy O
in O
co O
##lo O
##20 O
##5 O
mouse O
x O
##eno O
##gra O
##ft O
models O
. O
[SEP] O
[CLS] O
eligible O
g O
##i O
ma O
##li O
##gna O
##ncies O
included O
gas O
##tric O
car O
##cin O
##oma O
, O
es O
##op O
##hage O
##al O
car O
##cin O
##oma O
, O
color O
##ec O
##tal O
car O
##cin O
##oma O
, O
small O
in O
##test O
##ine O
car O
##cin O
##oma O
, O
pan O
##cre O
##atic O
car O
##cin O
##oma O
, O
and O
bi O
##lia O
##ry O
car O
##cin O
##oma O
. O
[SEP] O
[CLS] O
we O
believe O
that O
our O
study O
would O
provide O
important O
references O
to O
realize O
better O
clinical O
applications O
of O
y O
##cht O
in O
liver O
injury O
. O
[SEP] O
[CLS] O
under O
current O
dos O
##ing O
recommendations O
, O
simulation O
predicted O
that O
the O
median O
day O
7 O
concentration O
was O
below O
the O
25th O
percent O
##ile O
for O
a O
typical O
adult O
patient O
( O
50 O
kg O
) O
for O
su O
##lf O
##ado O
##xin O
##e O
for O
patients O
in O
the O
weight O
bands O
of O
8 O
to O
9 O
, O
19 O
to O
24 O
, O
46 O
to O
49 O
, O
and O
74 O
to O
79 O
kg O
and O
for O
p O
##yr O
##ime O
##tham O
##ine O
for O
patients O
in O
the O
weight O
bands O
of O
8 O
to O
9 O
, O
14 O
to O
24 O
, O
and O
42 O
to O
49 O
kg O
. O
[SEP] O
[CLS] O
the O
consort O
flow O
##cha O
##rt O
showing O
the O
c O
##ela O
##den O
trial O
profile O
was O
published O
previously O
[ O
17 O
] O
and O
is O
included O
in O
this O
manuscript O
as O
fi O
##g O
1 O
. O
[SEP] O
[CLS] O
the O
interval O
between O
two O
tests O
in O
each O
volunteer O
was O
at O
least O
2 O
weeks O
. O
[SEP] O
[CLS] O
the O
e O
##ff O
##lue O
##nt O
was O
e O
##va O
##porated O
, O
and O
the O
re O
##con O
##stituted O
residue O
was O
ch O
##roma O
##to O
##graph O
##ed O
on O
a O
ch O
##ira O
##l O
##cel O
o O
##d O
column O
with O
a O
mobile O
phase O
of O
he O
##xa O
##ne O
- O
2 O
- O
prop O
##ano O
##l O
( O
10 O
: O
0 O
. O
9 O
, O
v O
/ O
v O
) O
containing O
0 O
. O
01 O
% O
( O
v O
/ O
v O
) O
diet O
##hyl O
##amine O
. O
[SEP] O
[CLS] O
among O
the O
76 O
e O
##val O
##ua O
##ble O
lesions O
, O
a O
c O
##r O
was O
observed O
in O
23 O
lesions O
( O
30 O
% O
) O
, O
p O
##r O
in O
22 O
lesions O
( O
29 O
% O
) O
, O
and O
s O
##d O
in O
17 O
lesions O
( O
22 O
% O
) O
resulting O
in O
an O
or O
##r O
of O
59 O
% O
( O
figure O
2 O
##c O
) O
. O
[SEP] O
[CLS] O
the O
median O
cm B-PK
##ax I-PK
of O
co O
##c O
and O
its O
major O
meta O
##bol O
##ites O
, O
ben O
##zo O
##yle O
##c O
##gon O
##ine O
( O
b O
##ze O
) O
and O
e O
##c O
##gon O
##ine O
met O
##hyl O
est O
##er O
( O
em O
##e O
) O
, O
were O
closely O
related O
in O
whole O
blood O
and O
plasma O
. O
[SEP] O
[CLS] O
general O
an O
##est O
##hesia O
was O
induced O
using O
prop O
##of O
##ol O
, O
f O
##ent O
##any O
##l O
and O
c O
##isa O
##tra O
##cu O
##rium O
. O
[SEP] O
[CLS] O
all O
of O
the O
p O
##k O
samples O
collected O
were O
from O
p O
##fi O
##zer O
‐ O
sponsored O
trials O
conducted O
between O
1995 O
and O
2001 O
. O
[SEP] O
[CLS] O
to O
measure O
the O
proliferation O
, O
b O
##fa O
- O
treated O
cells O
were O
re O
##see O
##ded O
in O
a O
96 O
- O
well O
flat O
bottom O
plate O
and O
culture O
##d O
with O
fresh O
medium O
for O
72 O
hours O
. O
[SEP] O
[CLS] O
the O
majority O
of O
men O
in O
the O
me O
##dic O
##are O
co O
##hor O
##t O
were O
injection O
in O
##iti O
##ators O
( O
51 O
. O
2 O
% O
) O
, O
most O
in O
the O
us O
commercially O
ins O
##ured O
population O
were O
gel O
in O
##iti O
##ators O
( O
56 O
. O
5 O
% O
) O
, O
and O
the O
uk O
database O
included O
equal O
proportions O
of O
injection O
##s O
and O
gel O
users O
( O
approximately O
41 O
% O
) O
. O
[SEP] O
[CLS] O
h O
##ydro O
##xy O
##lation O
at O
the O
6 O
- O
carbon O
atom O
was O
of O
minor O
importance O
in O
humans O
only O
; O
none O
of O
the O
animal O
species O
ex O
##cre O
##ted O
the O
6 O
- O
h O
##ydro O
##xy O
meta O
##bol O
##ite O
. O
[SEP] O
[CLS] O
the O
results O
suggested O
the O
g O
##l O
- O
mediated O
al O
##g O
ng O
##ps O
could O
reduce O
the O
p O
##ha O
##go O
##cy O
##tosis O
of O
raw O
264 O
. O
7 O
cells O
in O
v O
##it O
##ro O
, O
which O
would O
play O
an O
important O
role O
in O
increasing O
the O
long O
circulation O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
this O
effect O
was O
detect O
##able O
for O
6 O
hours O
. O
[SEP] O
[CLS] O
effect O
of O
diet O
##ary O
a O
##f O
##lat O
##ox O
##in O
on O
the O
up O
##take O
and O
elimination O
of O
ch O
##lor O
##te O
##tra O
##cy O
##cline O
in O
br O
##oil O
##er O
chick O
##s O
. O
[SEP] O
[CLS] O
to O
further O
confirm O
whether O
p O
- O
g O
##p O
affects O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
in O
pigs O
, O
ve O
##rap O
##ami O
##l O
( O
an O
inhibitor O
of O
p O
- O
g O
##p O
) O
was O
ad O
##mini O
##stra O
##ted O
prior O
to O
en O
##ro O
##f O
##lo O
##xa O
##cin O
, O
and O
the O
plasma O
concentration O
- O
time O
curve O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
are O
summarized O
in O
fi O
##g O
. O
7 O
and O
table O
3 O
, O
respectively O
. O
[SEP] O
[CLS] O
al O
##ks O
38 O
##31 O
is O
composed O
of O
a O
flexible O
dose O
of O
o O
##lan O
##za O
##pine O
and O
a O
fixed O
dose O
of O
10 O
- O
mg O
sa O
##mi O
##dor O
##pha O
##n O
( O
a O
novel O
op O
##io O
##id O
system O
m O
##od O
##ulator O
) O
, O
designed O
to O
provide O
the O
established O
anti O
##psy O
##cho O
##tic O
efficacy O
of O
o O
##lan O
##za O
##pine O
and O
to O
mit O
##igate O
o O
##lan O
##za O
##pine O
- O
induced O
weight O
gain O
. O
[SEP] O
[CLS] O
more O
##over O
, O
p O
##io O
and O
g O
##lm O
were O
stable O
in O
plasma O
, O
up O
to O
30 O
days O
of O
storage O
at O
- O
70 O
degrees O
c O
and O
after O
being O
subjected O
to O
bench O
top O
, O
auto O
- O
sample O
##r O
, O
and O
three O
freeze O
- O
th O
##aw O
cycles O
. O
[SEP] O
[CLS] O
this O
study O
evaluated O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
safety O
of O
b O
##os O
##uti O
##ni O
##b O
in O
patients O
with O
chronic O
he O
##pa O
##tic O
imp O
##air O
##ment O
and O
matched O
healthy O
subjects O
. O
[SEP] O
[CLS] O
maximum O
kill O
at O
the O
dose O
of O
2 O
. O
5 O
mg O
/ O
kg O
varied O
from O
57 O
to O
71 O
% O
in O
##hibition O
in O
repeat O
experiments O
, O
with O
peaks O
at O
2 O
and O
3 O
days O
after O
drug O
administration O
( O
fi O
##g O
. O
1 O
##b O
) O
. O
[SEP] O
[CLS] O
therefore O
, O
a O
dose O
of O
40 O
mg O
of O
o O
##m O
correspond O
##ed O
to O
a O
dose O
of O
31 O
. O
97 O
##4 O
mg O
of O
o O
##lm O
##es O
##art O
##an O
, O
and O
a O
dose O
of O
160 O
mg O
of O
o O
##m O
correspond O
##ed O
to O
a O
dose O
of O
127 O
. O
90 O
mg O
of O
o O
##lm O
##es O
##art O
##an O
. O
[SEP] O
[CLS] O
very O
little O
is O
known O
about O
whether O
ta O
##u O
proteins O
can O
cross O
the O
b O
##bb O
. O
[SEP] O
[CLS] O
treatment O
with O
can O
##tu O
##zu O
##ma O
##b O
me O
##rta O
##ns O
##ine O
at O
45 O
mg O
/ O
m O
##2 O
per O
day O
three O
- O
times O
weekly O
x O
3 O
- O
every O
- O
4 O
- O
week O
schedule O
proved O
that O
a O
dose O
- O
intense O
treatment O
with O
an O
im O
##mu O
##no O
##con O
##ju O
##gate O
can O
be O
safely O
administered O
. O
[SEP] O
[CLS] O
a O
difference O
in O
in O
v O
##ivo O
dissolution O
rate O
of O
the O
two O
different O
particle O
sizes O
was O
observed O
, O
based O
on O
per O
##fusion O
data O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
1 O
##a O
, O
f O
##avi O
##pi O
##ra O
##vir O
treatment O
improved O
survival O
outcome O
compared O
to O
g O
##uin O
##ea O
pigs O
treated O
with O
place O
##bo O
. O
[SEP] O
[CLS] O
is O
##oto O
##pical O
##ly O
labeled O
internal O
standards O
( O
2 O
##h O
, O
13 O
##c O
, O
and O
/ O
or O
15 O
##n O
) O
were O
used O
for O
each O
anal O
##yte O
. O
[SEP] O
[CLS] O
the O
largest O
time O
- O
matched O
mean O
difference O
to O
place O
##bo O
was O
2 O
. O
97 O
m O
##s O
at O
5 O
minutes O
, O
with O
the O
upper O
limit O
of O
the O
two O
- O
sided O
90 O
% O
confidence O
interval O
( O
c O
##i O
) O
being O
4 O
. O
80 O
m O
##s O
, O
excluding O
a O
relevant O
q O
##t O
effect O
as O
defined O
by O
the O
i O
##ch O
e O
##14 O
guide O
##line O
. O
[SEP] O
[CLS] O
in O
the O
patients O
without O
per O
##ito O
##ni O
##tis O
, O
the O
following O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
after O
i O
. O
v O
. O
and O
i O
. O
p O
. O
administration O
did O
not O
differ O
significantly O
( O
mean O
+ O
- O
s O
##d O
) O
: O
elimination B-PK
half I-PK
- I-PK
life I-PK
, O
15 O
. O
1 O
+ O
- O
1 O
. O
9 O
h O
; O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
27 O
. O
9 O
+ O
- O
2 O
. O
91 O
; O
and O
total B-PK
clearance I-PK
, O
21 O
. O
5 O
+ O
- O
1 O
. O
2 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
the O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
associated O
with O
p O
##k O
parameters O
was O
modeled O
using O
an O
ex O
##po O
##nent O
##ial O
model O
as O
described O
below O
: O
\ O
document O
##c O
##lass O
[ O
12 O
##pt O
] O
{ O
minimal O
} O
\ O
use O
##pack O
##age O
{ O
am O
##sma O
##th O
} O
\ O
use O
##pack O
##age O
{ O
was O
##ys O
##ym O
} O
\ O
use O
##pack O
##age O
{ O
am O
##s O
##fo O
##nts O
} O
\ O
use O
##pack O
##age O
{ O
am O
##ssy O
##mb O
} O
\ O
use O
##pack O
##age O
{ O
am O
##s O
##bs O
##y O
} O
\ O
use O
##pack O
##age O
{ O
math O
##rs O
##fs O
} O
\ O
use O
##pack O
##age O
{ O
up O
##g O
##ree O
##k O
} O
\ O
set O
##len O
##gth O
{ O
\ O
odds O
##ide O
##mar O
##gin O
} O
{ O
- O
69 O
##pt O
} O
\ O
begin O
{ O
document O
} O
$ O
$ O
\ O
the O
##ta O
_ O
{ O
i O
} O
= O
\ O
the O
##ta O
_ O
{ O
\ O
text O
{ O
t O
##v O
} O
} O
\ O
times O
\ O
ex O
##p O
( O
\ O
et O
##a O
_ O
{ O
i O
} O
) O
$ O
$ O
\ O
end O
{ O
document O
} O
θ O
##i O
= O
θ O
##t O
##v O
##× O
##ex O
##p O
( O
η O
##i O
) O
where O
θ O
##i O
is O
the O
p O
##k O
parameter O
for O
the O
it O
##h O
subject O
, O
θ O
##t O
##v O
is O
the O
typical O
value O
of O
the O
parameter O
, O
and O
η O
##i O
is O
a O
normally O
distributed O
variable O
with O
mean O
0 O
and O
variance O
ω O
##2 O
. O
[SEP] O
[CLS] O
finally O
, O
n O
##rg O
##1 O
t O
##m O
he O
##t O
mice O
displayed O
increased O
frequencies O
of O
no O
##sing O
[ O
f O
( O
1 O
, O
112 O
) O
= O
7 O
. O
7 O
, O
p O
< O
0 O
. O
01 O
] O
. O
[SEP] O
[CLS] O
the O
ch O
##roma O
##to O
##graphic O
separation O
was O
achieved O
on O
an O
ascent O
##is O
- O
r O
##p O
amid O
##e O
column O
( O
4 O
. O
6 O
× O
150 O
mm O
, O
5 O
µ O
##m O
) O
with O
mobile O
phase O
delivered O
in O
is O
##oc O
##ratic O
mode O
. O
[SEP] O
[CLS] O
we O
evaluated O
anti O
##sen O
##se O
o O
##li O
##gon O
##uc O
##leo O
##tide O
##s O
( O
as O
##os O
) O
targeting O
an O
##g O
##pt O
##l O
##3 O
messenger O
r O
##na O
( O
m O
##rna O
) O
for O
effects O
on O
plasma O
lip O
##id O
levels O
, O
t O
##rig O
##ly O
##cer O
##ide O
clearance B-PK
, O
liver O
t O
##rig O
##ly O
##cer O
##ide O
content O
, O
insulin O
sensitivity O
, O
and O
at O
##her O
##os O
##cle O
##rosis O
in O
mice O
. O
[SEP] O
[CLS] O
eleven O
of O
14 O
patients O
entered O
into O
the O
study O
completed O
. O
[SEP] O
[CLS] O
“ O
[SEP] O
[CLS] O
during O
a O
3 O
- O
h O
per O
##fusion O
of O
five O
isolated O
rabbit O
liver O
preparations O
, O
40 O
. O
4 O
% O
of O
c O
##ef O
##pi O
##ram O
##ide O
added O
to O
the O
circulating O
blood O
was O
eliminated O
in O
the O
bi O
##le O
and O
only O
0 O
. O
3 O
% O
was O
meta O
##bol O
##ized O
in O
the O
liver O
. O
[SEP] O
[CLS] O
c O
##y O
##p O
##3 O
##a O
##4 O
* O
16 O
and O
c O
##y O
##p O
##3 O
##a O
##4 O
* O
18 O
all O
##ele O
##s O
found O
in O
east O
as O
##ians O
exhibit O
differential O
cat O
##alytic O
activities O
for O
seven O
c O
##y O
##p O
##3 O
##a O
##4 O
substrate O
drugs O
. O
[SEP] O
[CLS] O
cm O
##s O
was O
administered O
either O
by O
ne O
##bul O
##ization O
every O
12 O
h O
or O
i O
. O
v O
. O
every O
8 O
h O
. O
[SEP] O
[CLS] O
dose O
- O
limiting O
toxic O
##ities O
( O
d O
##lts O
) O
were O
assessed O
in O
cycle O
1 O
and O
safety O
in O
all O
cycles O
. O
[SEP] O
[CLS] O
d O
##f O
##mo O
serum O
samples O
were O
also O
collected O
from O
selected O
patients O
in O
the O
higher O
dose O
groups O
( O
750 O
, O
1000 O
, O
1500 O
mg O
/ O
m O
##2 O
) O
during O
cycle O
2 O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
from I-PK
time I-PK
zero I-PK
extra I-PK
##pol I-PK
##ated I-PK
to I-PK
in I-PK
##finity I-PK
( I-PK
au I-PK
##cin I-PK
##f I-PK
) I-PK
increased O
in O
a O
greater O
than O
dose O
- O
proportional O
manner O
after O
both O
the O
first O
and O
last O
doses O
( O
fi O
##g O
. O
1 O
##b O
) O
. O
[SEP] O
[CLS] O
our O
study O
shows O
that O
op O
##t O
is O
able O
to O
predict O
serum O
amino O
##gly O
##cos O
##ide O
levels O
accurately O
in O
the O
routine O
clinical O
setting O
. O
[SEP] O
[CLS] O
the O
mean O
half B-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
0 O
. O
8 O
versus O
1 O
. O
4 O
hours O
( O
p O
= O
0 O
. O
00 O
##3 O
) O
and O
total B-PK
plasma I-PK
clearance I-PK
was O
120 O
##1 O
versus O
70 O
##5 O
m O
##l O
per O
minute O
( O
p O
= O
0 O
. O
00 O
##9 O
) O
for O
control O
subjects O
versus O
patients O
with O
c O
##ir O
##r O
##hos O
##is O
. O
[SEP] O
[CLS] O
the O
aim O
of O
this O
study O
was O
to O
develop O
a O
limited O
sampling O
strategy O
( O
l O
##ss O
) O
for O
therapeutic O
drug O
monitoring O
assistance O
for O
r O
##mp O
. O
[SEP] O
[CLS] O
for O
this O
group O
, O
the O
median O
ca B-PK
##v I-PK
##g I-PK
was O
4 O
. O
0 O
μ O
##g O
/ O
m O
##l O
, O
and O
the O
median O
cm B-PK
##ax I-PK
was O
5 O
. O
2 O
μ O
##g O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
urine O
was O
collected O
in O
6 O
- O
hour O
pool O
##ed O
al O
##iq O
##uo O
##ts O
for O
a O
total O
of O
24 O
hours O
. O
[SEP] O
[CLS] O
do O
##x O
##or O
##ubi O
##cin O
plasma O
p O
##har O
##ma O
##co O
##kin O
##etics O
were O
prolonged O
after O
c O
##ime O
##ti O
##dine O
pre O
##tre O
##at O
##ment O
[ O
au B-PK
##c I-PK
0 O
. O
76 O
+ O
- O
0 O
. O
22 O
vs O
. O
2 O
. O
85 O
+ O
- O
1 O
. O
22 O
micro O
##m O
x O
h O
, O
no O
pre O
##tre O
##at O
##ment O
vs O
pre O
##tre O
##at O
##ment O
( O
p O
= O
0 O
. O
00 O
##5 O
) O
, O
half B-PK
- I-PK
life I-PK
= O
11 O
. O
7 O
+ O
- O
6 O
. O
55 O
vs O
28 O
. O
0 O
+ O
- O
8 O
. O
16 O
h O
( O
p O
= O
0 O
. O
000 O
##2 O
) O
, O
and O
clearance B-PK
= O
0 O
. O
129 O
+ O
- O
0 O
. O
03 O
##6 O
vs O
0 O
. O
03 O
##6 O
+ O
- O
0 O
. O
01 O
##1 O
l O
/ O
min O
- O
1 O
kg O
- O
1 O
( O
p O
= O
0 O
. O
000 O
##7 O
) O
] O
. O
[SEP] O
[CLS] O
no O
pre O
##med O
##ica O
##tion O
, O
including O
s O
##tero O
##ids O
or O
dip O
##hen O
##hy O
##dra O
##mine O
, O
was O
mandated O
prior O
to O
treatment O
with O
o O
##lar O
##at O
##uma O
##b O
. O
[SEP] O
[CLS] O
interaction O
of O
car O
##ba O
##ma O
##ze O
##pine O
and O
pro O
##met O
##ha O
##zine O
in O
rabbits O
. O
[SEP] O
[CLS] O
a O
total O
of O
14 O
male O
patients O
were O
enrolled O
in O
the O
study O
( O
figure O
1 O
) O
, O
and O
their O
base O
##line O
demographic O
##s O
and O
clinical O
characteristics O
are O
shown O
in O
table O
1 O
. O
[SEP] O
[CLS] O
clinical O
data O
on O
re O
##nal O
, O
liver O
function O
and O
a O
##r O
##v O
regime O
##n O
( O
n O
##uc O
##leo O
##side O
reverse O
trans O
##cript O
##ase O
inhibitor O
##s O
( O
n O
##rt O
##is O
) O
backbone O
##s O
and O
use O
of O
third O
agent O
) O
were O
collected O
. O
[SEP] O
[CLS] O
to O
imp O
##art O
the O
in O
##hala O
##ble O
and O
rapid O
release O
( O
r O
##r O
) O
attributes O
, O
9 O
- O
br O
- O
no O
##s O
- O
n O
##l O
##ps O
were O
treated O
with O
spray O
dried O
la O
##ct O
##ose O
and O
e O
##ffer O
##ves O
##cent O
ex O
##ci O
##pie O
##nts O
to O
generate O
, O
9 O
- O
br O
- O
no O
##s O
- O
r O
##r O
- O
n O
##l O
##ps O
. O
[SEP] O
[CLS] O
these O
results O
are O
consistent O
with O
the O
expected O
prolonged O
clearance B-PK
kinetic O
##s O
of O
p O
##nt O
##22 O
##5 O
##8 O
due O
to O
sat O
##uration O
of O
the O
re O
##tic O
##ulo O
##end O
##oth O
##eli O
##al O
system O
( O
re O
##s O
) O
clearance B-PK
mechanisms O
and O
are O
similar O
to O
those O
noted O
in O
the O
toxic O
##ology O
studies O
[ O
14 O
, O
15 O
, O
17 O
] O
. O
[SEP] O
[CLS] O
all O
these O
characteristics O
make O
p O
##eg O
- O
c O
##pt O
con O
##ju O
##gate O
an O
attractive O
anti O
##can O
##cer O
drug O
for O
the O
effective O
ch O
##em O
##otherapy O
of O
solid O
tumors O
. O
[SEP] O
[CLS] O
p O
##ome O
##gra O
##nate O
juice O
and O
a O
1 O
- O
g O
capsule O
containing O
p O
##ome O
##gra O
##nate O
extract O
were O
evaluated O
in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
as O
inhibitor O
##s O
of O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
2 O
##c O
##9 O
( O
c O
##y O
##p O
##2 O
##c O
##9 O
) O
, O
with O
flu O
##rb O
##ip O
##ro O
##fen O
serving O
as O
the O
index O
substrate O
. O
[SEP] O
[CLS] O
in O
particular O
, O
11 O
of O
13 O
patients O
with O
infections O
due O
to O
t O
##ica O
##rc O
##ill O
##in O
- O
resistant O
p O
. O
a O
##er O
##ug O
##ino O
##sa O
were O
cured O
and O
two O
improved O
. O
[SEP] O
[CLS] O
considering O
the O
diversity O
in O
the O
patient O
populations O
in O
global O
clinical O
trials O
, O
a O
cross O
‐ O
study O
comparison O
assessing O
r O
##iva O
##ro O
##xa O
##ban O
exposure O
in O
later O
‐ O
phase O
clinical O
studies O
would O
enhance O
our O
understanding O
of O
the O
potential O
impact O
of O
meal O
intake O
, O
with O
regard O
to O
the O
timing O
and O
content O
, O
in O
real O
‐ O
world O
patient O
care O
. O
[SEP] O
[CLS] O
the O
rate B-PK
of I-PK
drug I-PK
residue I-PK
elimination I-PK
was O
notice O
##ably O
slower O
in O
the O
i O
##c O
- O
affected O
group O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
using O
non O
- O
compartment O
##al O
model O
analysis O
. O
[SEP] O
[CLS] O
nineteen O
patients O
( O
51 O
% O
) O
were O
taking O
e O
##iae O
##ds O
. O
[SEP] O
[CLS] O
concentrations O
of O
ben O
##zo O
##dia O
##ze O
##pine O
##s O
in O
plasma O
and O
c O
##s O
##f O
samples O
were O
measured O
by O
electron O
- O
capture O
gas O
- O
liquid O
ch O
##roma O
##tography O
and O
plasma O
protein O
binding O
determined O
by O
equilibrium O
dial O
##ys O
##is O
. O
[SEP] O
[CLS] O
the O
trial O
was O
conducted O
as O
an O
in O
##patient O
study O
at O
a O
single O
clinical O
site O
. O
[SEP] O
[CLS] O
per O
##fusion O
##s O
without O
sodium O
drastically O
reduced O
the O
in O
##test O
##inal O
loss O
of O
rib O
##avi O
##rin O
in O
both O
wild O
- O
type O
and O
en O
##t O
##1 O
( O
- O
/ O
- O
) O
mice O
. O
[SEP] O
[CLS] O
subjects O
were O
to O
a O
##bs O
##tain O
from O
s O
##tre O
##nu O
##ous O
exercise O
for O
48 O
h O
prior O
to O
each O
blood O
sample O
collection O
. O
[SEP] O
[CLS] O
1 O
##h O
- O
nm O
##r O
( O
c O
##d O
##c O
##l O
##3 O
) O
δ O
( O
pp O
##m O
) O
: O
1 O
. O
21 O
( O
s O
, O
9 O
##h O
, O
- O
c O
( O
ch O
##3 O
) O
3 O
) O
, O
1 O
. O
27 O
– O
1 O
. O
28 O
( O
d O
, O
3 O
##h O
, O
j O
= O
6 O
. O
55 O
h O
##z O
, O
- O
ch O
##ch O
##3 O
) O
, O
2 O
. O
18 O
( O
s O
, O
3 O
##h O
, O
- O
n O
##ch O
##3 O
) O
, O
4 O
. O
59 O
– O
4 O
. O
64 O
( O
q O
, O
1 O
##h O
, O
j O
= O
7 O
. O
0 O
h O
##z O
, O
- O
ch O
##ch O
##3 O
) O
, O
7 O
. O
36 O
– O
8 O
. O
09 O
( O
m O
, O
4 O
##h O
, O
4 O
× O
a O
##r O
- O
h O
) O
. O
[SEP] O
[CLS] O
bio O
##ana O
##lysis O
and O
evaluation O
of O
adverse O
events O
were O
performed O
in O
non O
##blin O
##ded O
fashion O
. O
[SEP] O
[CLS] O
to O
choose O
the O
op O
##ti O
##mum O
compartment O
model O
for O
fitting O
the O
plasma O
concentration O
– O
time O
curve O
, O
the O
minimum O
aka O
##ike O
’ O
s O
information O
criterion O
( O
a O
##ic O
) O
est O
##imation O
was O
tested O
by O
calculating O
the O
lowest O
a O
##ic O
value O
. O
[SEP] O
[CLS] O
the O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
difference O
in O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
z O
##ol O
##pid O
##em O
ta O
##trate O
in O
subjects O
from O
five O
chin O
##ese O
ethnic O
##ities O
( O
ha O
##n O
, O
mon O
##gol O
##ian O
, O
u O
##ig O
##ur O
, O
k O
##ore O
##an O
and O
h O
##ui O
) O
. O
[SEP] O
[CLS] O
doses O
were O
es O
##calated O
from O
45 O
mg O
/ O
m O
##2 O
to O
400 O
mg O
/ O
m O
##2 O
in O
the O
6 O
- O
hour O
in O
##fusion O
schedule O
, O
and O
from O
250 O
mg O
/ O
m O
##2 O
to O
330 O
mg O
/ O
m O
##2 O
in O
the O
subsequent O
3 O
- O
hour O
in O
##fusion O
schedule O
. O
[SEP] O
[CLS] O
the O
coefficient O
of O
variation O
( O
c O
##v O
) O
was O
used O
to O
estimate O
the O
precision O
. O
[SEP] O
[CLS] O
the O
data O
used O
in O
statistical O
analyses O
were O
acquired O
from O
6 O
animals O
for O
each O
group O
. O
[SEP] O
[CLS] O
no O
para O
##cellular O
transport O
of O
s O
##f O
##n O
- O
ng O
##s O
was O
found O
, O
and O
the O
trafficking O
of O
s O
##f O
##n O
- O
ng O
##s O
was O
affected O
by O
the O
pathway O
of O
er O
- O
go O
##l O
##gi O
complexes O
. O
[SEP] O
[CLS] O
ch O
##roma O
##to O
##graphic O
separation O
of O
do O
##x O
##or O
##ubi O
##cin O
in O
various O
o O
##cular O
tissues O
was O
performed O
on O
a O
c O
##18 O
column O
. O
[SEP] O
[CLS] O
the O
results O
of O
correlation O
analysis O
of O
toxic O
##ities O
and O
tumor O
shrink O
##age O
with O
the O
p O
##d O
change O
in O
plasma O
proteins O
at O
cycle O
1 O
are O
listed O
in O
table O
2 O
. O
[SEP] O
[CLS] O
evidence O
for O
a O
novel O
in O
v O
##ivo O
control O
mechanism O
of O
g O
##ran O
##ulo O
##po O
##ies O
##is O
: O
mature O
cell O
- O
related O
control O
of O
a O
regulatory O
growth O
factor O
. O
[SEP] O
[CLS] O
in O
comparison O
to O
previous O
experience O
with O
a O
##be O
##xin O
##ost O
##at O
administered O
on O
a O
1 O
- O
week O
- O
on O
/ O
1 O
- O
week O
- O
off O
schedule O
, O
17 O
weekly O
monitoring O
for O
th O
##rom O
##bo O
##cy O
##top O
##enia O
showed O
that O
plate O
##let O
counts O
fell O
sharply O
during O
the O
14 O
days O
on O
a O
##be O
##xin O
##ost O
##at O
and O
recovered O
before O
the O
start O
of O
the O
next O
cycle O
( O
figure O
1 O
) O
. O
[SEP] O
[CLS] O
high O
- O
dose O
pro O
##ges O
##tin O
##s O
given O
oral O
##ly O
do O
not O
seem O
to O
have O
a O
major O
influence O
on O
drug O
metabolism O
, O
probably O
reflecting O
a O
minor O
effect O
on O
drug O
and O
s O
##tero O
##id O
- O
meta O
##bol O
##izing O
micro O
##so O
##mal O
mon O
##o O
- O
oxygen O
##ases O
in O
the O
liver O
. O
[SEP] O
[CLS] O
6 O
- O
t O
##gn O
and O
6 O
- O
mm O
##p O
##r O
concentrations O
were O
determined O
before O
initiation O
of O
ad O
##ali O
##mum O
##ab O
and O
after O
2 O
, O
4 O
, O
6 O
and O
12 O
weeks O
of O
combination O
therapy O
. O
[SEP] O
[CLS] O
finally O
, O
an O
ex O
v O
##ivo O
rat O
liver O
un O
##sche O
##du O
##led O
d O
##na O
synthesis O
study O
( O
table O
8 O
##c O
) O
confirmed O
the O
lack O
of O
ma O
##mmal O
##ian O
g O
##eno O
##to O
##xi O
##c O
activity O
for O
f O
##ex O
##ini O
##da O
##zo O
##le O
and O
its O
meta O
##bol O
##ites O
[ O
data O
##set O
s O
##21 O
] O
. O
[SEP] O
[CLS] O
the O
plasma O
concentration O
of O
di O
##lma O
##pi O
##mo O
##d O
was O
adequately O
described O
by O
a O
three O
- O
compartment O
model O
. O
[SEP] O
[CLS] O
there O
was O
no O
association O
between O
all O
##eli O
##c O
variants O
and O
bleeding O
events O
. O
[SEP] O
[CLS] O
the O
recommended O
dose O
was O
defined O
as O
the O
highest O
dose O
at O
which O
not O
more O
than O
2 O
out O
of O
6 O
patients O
had O
d O
##lt O
during O
the O
first O
two O
cycles O
after O
i O
##pi O
##lim O
##uma O
##b O
treatment O
( O
i O
. O
e O
. O
, O
from O
day O
1 O
at O
cycle O
3 O
to O
day O
21 O
at O
cycle O
4 O
) O
. O
[SEP] O
[CLS] O
the O
clearance B-PK
for O
a O
##c O
##p O
- O
58 O
##6 O
##2 O
was O
21 O
. O
9 O
l O
/ O
h O
( O
95 O
% O
c O
##i O
19 O
. O
5 O
- O
24 O
. O
0 O
) O
. O
[SEP] O
[CLS] O
non O
- O
therapeutic O
drug O
levels O
were O
greater O
than O
9 O
times O
more O
likely O
to O
result O
in O
an O
ad O
##e O
requiring O
drug O
disco O
##ntin O
##uation O
( O
p O
= O
0 O
. O
01 O
) O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
to O
this O
end O
, O
small O
- O
animal O
pet O
imaging O
was O
performed O
on O
h O
##t O
- O
108 O
##0 O
- O
f O
##ap O
x O
##eno O
##gra O
##fted O
mice O
. O
[SEP] O
[CLS] O
each O
plasma O
sample O
was O
di O
##lut O
##ed O
10 O
- O
fold O
with O
500 O
mm O
na O
##c O
##l O
in O
100 O
mm O
t O
##ris O
- O
h O
##c O
##l O
buffer O
( O
p O
##h O
9 O
. O
0 O
) O
, O
5 O
mm O
mg O
##c O
##l O
##2 O
, O
and O
0 O
. O
05 O
% O
t O
##rito O
##n O
x O
- O
100 O
. O
[SEP] O
[CLS] O
linear O
detection O
responses O
were O
obtained O
for O
the O
three O
test O
compounds O
ranging O
from O
5 O
to O
5000 O
ng O
/ O
m O
##l O
and O
the O
lower O
limits O
of O
q O
##uant O
##itation O
were O
5 O
- O
10 O
ng O
/ O
m O
##l O
. O
the O
in O
##tra O
- O
and O
inter O
- O
day O
precision O
##s O
( O
relative O
standard O
de O
##viation O
##s O
) O
were O
within O
9 O
. O
4 O
% O
for O
all O
anal O
##yte O
##s O
, O
while O
the O
de O
##viation O
of O
ass O
##ay O
a O
##cc O
##ura O
##cies O
was O
within O
± O
##10 O
. O
0 O
% O
. O
[SEP] O
[CLS] O
the O
animals O
were O
kept O
under O
controlled O
conditions O
( O
temperature O
: O
23 O
± O
2 O
° O
##c O
; O
humidity O
: O
55 O
± O
5 O
% O
) O
for O
one O
week O
a O
##cc O
##lim O
##ation O
before O
experiment O
and O
were O
allowed O
free O
access O
to O
standard O
laboratory O
diet O
and O
water O
during O
the O
period O
. O
[SEP] O
[CLS] O
primary O
objectives O
included O
assessment O
of O
safety O
and O
to O
##ler O
##ability O
( O
measured O
by O
adverse O
events O
and O
clinical O
laboratory O
monitoring O
) O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
( O
measured O
as O
drug O
and O
drug O
- O
iron O
complex O
) O
, O
and O
cumulative O
net O
iron O
ex O
##cre O
##tion O
( O
measured O
by O
f O
##ae O
##cal O
and O
urine O
output O
minus O
food O
input O
) O
. O
[SEP] O
[CLS] O
this O
phase O
1 O
, O
single O
- O
centre O
, O
single O
- O
co O
##hor O
##t O
, O
open O
- O
label O
, O
random O
##ized O
, O
four O
- O
period O
crossover O
study O
in O
healthy O
subjects O
( O
n O
##ct O
##0 O
##25 O
##5 O
##7 O
##7 O
##8 O
##9 O
) O
evaluated O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
p O
##k O
, O
safety O
and O
to O
##ler O
##ability O
of O
a O
600 O
mg O
immediate O
- O
release O
( O
i O
##r O
) O
tablet O
of O
le O
##fa O
##mu O
##lin O
administered O
in O
the O
fed O
or O
fast O
##ed O
state O
compared O
with O
i O
##v O
and O
capsule O
formulation O
##s O
. O
[SEP] O
[CLS] O
the O
follow O
- O
up O
phase O
was O
conducted O
approximately O
four O
to O
eight O
days O
following O
discharge O
from O
the O
clinic O
. O
[SEP] O
[CLS] O
for O
one O
patient O
, O
no O
base O
##line O
e O
##co O
##g O
performance O
status O
was O
documented O
. O
[SEP] O
[CLS] O
the O
demographic O
##s O
of O
the O
1000 O
simulated O
ca O
##uca O
##sian O
, O
chin O
##ese O
and O
j O
##apa O
##nese O
subjects O
can O
be O
seen O
in O
electronic O
supplement O
##ary O
material O
table O
2 O
. O
[SEP] O
[CLS] O
co O
##hor O
##ts O
2 O
through O
6 O
were O
dose O
##d O
a O
minimum O
of O
three O
weeks O
after O
dos O
##ing O
of O
the O
last O
patient O
in O
the O
previous O
co O
##hor O
##t O
. O
[SEP] O
[CLS] O
clinical O
studies O
should O
be O
performed O
to O
confirm O
this O
theoretical O
p O
##har O
##ma O
##co O
##kin O
##etic O
advantage O
. O
[SEP] O
[CLS] O
on O
the O
study O
day O
, O
the O
patients O
took O
a O
2 O
. O
5 O
mg O
liquid O
test O
dose O
of O
g O
##ly O
##bur O
##ide O
with O
a O
su O
##sta O
##cal O
meal O
challenge O
. O
[SEP] O
[CLS] O
1 O
. O
[SEP] O
[CLS] O
for O
each O
calculation O
of O
r O
##g O
##c O
only O
one O
randomly O
selected O
sibling O
of O
each O
pair O
was O
used O
, O
since O
the O
two O
siblings O
of O
each O
twin O
pair O
are O
not O
independent O
units O
. O
[SEP] O
[CLS] O
the O
mean O
el O
##f O
penetration B-PK
ratio I-PK
after O
population O
analyses O
was O
39 O
. O
7 O
. O
[SEP] O
[CLS] O
in O
women O
on O
n O
##v O
##p O
- O
based O
art O
, O
l O
##ng O
concentrations O
were O
32 O
– O
39 O
% O
higher O
than O
those O
observed O
in O
the O
control O
group O
, O
a O
difference O
partially O
explained O
by O
body O
weight O
. O
[SEP] O
[CLS] O
our O
data O
provide O
evidence O
for O
the O
in O
##tra O
##co O
##ch O
##lea O
##r O
diffusion O
of O
the O
molecule O
, O
which O
may O
be O
relevant O
for O
the O
treatment O
of O
sensor O
##ine O
##ural O
hearing O
loss O
in O
con O
##gen O
##ital O
##ly O
- O
infected O
children O
. O
[SEP] O
[CLS] O
c B-PK
##ll I-PK
decreased O
by O
78 O
% O
in O
subjects O
weighing O
50 O
kg O
, O
and O
increased O
by O
40 O
% O
in O
subjects O
weighing O
100 O
kg O
, O
compared O
with O
a O
typical O
patient O
weighing O
82 O
. O
9 O
kg O
( O
median O
body O
weight O
) O
. O
[SEP] O
[CLS] O
the O
average O
weight O
and O
volume O
of O
the O
tumors O
are O
shown O
in O
table O
4 O
. O
[SEP] O
[CLS] O
could O
the O
differences O
be O
explained O
by O
race O
? O
[SEP] O
[CLS] O
similarly O
, O
mean O
u O
##rina O
##ry O
recovery O
and O
re B-PK
##nal I-PK
clearance I-PK
values O
of O
pen O
##ci O
##c O
##lov O
##ir O
following O
f O
##am O
##ci O
##c O
##lov O
##ir O
alone O
were O
56 O
. O
8 O
% O
and O
27 O
l O
. O
h O
- O
1 O
, O
and O
when O
given O
with O
all O
##op O
##uri O
##no O
##l O
59 O
. O
7 O
% O
and O
27 O
. O
5 O
l O
. O
h O
- O
1 O
, O
respectively O
. O
[SEP] O
[CLS] O
this O
response O
was O
accompanied O
by O
c O
##y O
##p O
##1 O
##a O
induction O
in O
the O
in O
##test O
##ine O
, O
but O
little O
effect O
upon O
the O
o O
##xi O
##da O
##tive O
metabolism O
of O
the O
subsequent O
in O
sit O
##u O
dose O
of O
[ O
14 O
##c O
] O
- O
t O
##c O
##b O
. O
[SEP] O
[CLS] O
ne O
##uro O
##mus O
##cular O
function O
was O
monitored O
me O
##chan O
##omy O
##ographic O
##ally O
. O
[SEP] O
[CLS] O
the O
values O
of O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
in O
plasma O
and O
brain O
showed O
an O
increase O
of O
respectively O
about O
three O
and O
twelve O
times O
after O
chronic O
treatment O
. O
[SEP] O
[CLS] O
two O
phase O
i O
clinical O
studies O
assessed O
the O
safety O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
( O
p O
##ks O
) O
, O
and O
p O
##har O
##ma O
##co O
##log O
##ic O
effects O
of O
as O
##p O
##36 O
##6 O
##2 O
in O
healthy O
young O
and O
elderly O
non O
‐ O
j O
##apa O
##nese O
and O
young O
j O
##apa O
##nese O
subjects O
. O
[SEP] O
[CLS] O
the O
investigator O
suspected O
a O
ca O
##usal O
relationship O
between O
the O
facial O
swelling O
and O
the O
administration O
of O
cu O
##rc O
##umi O
##n O
. O
[SEP] O
[CLS] O
radio O
##la O
##bel O
##ing O
e O
##ff O
##ici O
##encies O
ranged O
from O
33 O
% O
to O
88 O
% O
, O
and O
im O
##mu O
##nor O
##ea O
##ct O
##ivity O
was O
42 O
% O
( O
di O
##ab O
##ody O
) O
or O
> O
90 O
% O
( O
mini O
##body O
) O
. O
[SEP] O
[CLS] O
during O
the O
first O
4 O
days O
of O
g O
##h O
treatment O
in O
rats O
, O
no O
change O
in O
plasma O
re O
##nin O
activity O
was O
detected O
and O
we O
were O
thus O
unable O
to O
confirm O
the O
hypothesis O
that O
the O
re O
##nin O
- O
an O
##gio O
##tens O
##in O
system O
is O
responsible O
for O
the O
early O
phase O
of O
g O
##h O
- O
associated O
fluid O
retention O
. O
[SEP] O
[CLS] O
to O
investigate O
how O
s O
##to O
- O
60 O
##9 O
##s O
conferred O
improvement O
of O
he O
##pa O
##tic O
s O
##te O
##ato O
##sis O
, O
we O
performed O
targeted O
meta O
##bol O
##omi O
##cs O
on O
liver O
##s O
isolated O
from O
d O
##ms O
##o O
or O
s O
##to O
- O
60 O
##9 O
##s O
treated O
mice O
from O
both O
na O
##f O
##ld O
models O
. O
[SEP] O
[CLS] O
the O
drug O
was O
administered O
p O
. O
o O
. O
or O
i O
. O
v O
. O
, O
and O
throughout O
an O
8 O
- O
h O
##r O
period O
ethanol O
( O
100 O
mg O
kg O
- O
1 O
h O
##r O
- O
1 O
) O
or O
sa O
##line O
was O
in O
##fused O
according O
to O
a O
cross O
- O
over O
design O
. O
[SEP] O
[CLS] O
significant O
ne O
##uro O
##to O
##xi O
##city O
, O
which O
was O
dose O
- O
limiting O
in O
adults O
treated O
with O
a O
1 O
- O
hour O
in O
##fusion O
of O
p O
##za O
, O
was O
observed O
in O
one O
patient O
treated O
at O
640 O
mg O
/ O
m O
##2 O
, O
but O
was O
not O
dose O
- O
limiting O
. O
[SEP] O
[CLS] O
the O
median O
values O
for O
is O
##s O
total O
injury O
score O
and O
g O
##las O
##go O
##w O
coma O
score O
were O
25 O
and O
15 O
, O
respectively O
, O
indicating O
severe O
/ O
critical O
trauma O
and O
mild O
brain O
injury O
, O
respectively O
. O
[SEP] O
[CLS] O
although O
it O
has O
been O
successfully O
used O
##in O
an O
in O
##tra O
##per O
##ito O
##nea O
##l O
form O
in O
studies O
on O
a O
rode O
##nt O
model O
of O
pulmonary O
##hy O
##pert O
##ens O
##ion O
, O
22 O
its O
dose O
– O
response O
##cha O
##rac O
##ter O
##istic O
##s O
were O
not O
explored O
nor O
have O
its O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
##bee O
##n O
characterized O
. O
[SEP] O
[CLS] O
concentration O
values O
below O
the O
lower O
limit O
of O
q O
##uant O
##ification O
were O
taken O
as O
zero O
for O
the O
summary O
statistics O
. O
[SEP] O
[CLS] O
plasma O
concentrations O
were O
determined O
for O
l O
##y O
##30 O
##0 O
##7 O
##11 O
##3 O
and O
its O
meta O
##bol O
##ites O
, O
l O
##s O
##n O
##30 O
##25 O
##64 O
##1 O
and O
l O
##s O
##n O
##30 O
##47 O
##15 O
##1 O
, O
using O
a O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
with O
tandem O
mass O
s O
##pect O
##rome O
##try O
method O
. O
[SEP] O
[CLS] O
plasma O
samples O
were O
collected O
immediately O
prior O
to O
v O
##ino O
##rel O
##bine O
and O
then O
at O
1 O
, O
1 O
. O
25 O
, O
1 O
. O
5 O
, O
2 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
12 O
, O
and O
24 O
hours O
after O
the O
start O
of O
the O
in O
##fusion O
. O
[SEP] O
[CLS] O
quality O
controls O
for O
run O
acceptance O
were O
prepared O
and O
analyzed O
with O
each O
batch O
of O
sample O
against O
separately O
prepared O
ca O
##li O
##bra O
##tion O
standard O
to O
assess O
day O
- O
to O
- O
day O
performance O
of O
the O
ass O
##ay O
. O
[SEP] O
[CLS] O
this O
phase O
i O
study O
comprised O
four O
parts O
: O
a O
, O
b O
, O
c O
, O
and O
d O
. O
[SEP] O
[CLS] O
pro O
##dr O
##ug O
derivatives O
of O
4 O
- O
et O
##hyl O
- O
1 O
, O
3 O
- O
di O
##hy O
##dr O
##o O
- O
5 O
- O
[ O
4 O
- O
( O
2 O
- O
met O
##hyl O
- O
1 O
##h O
- O
im O
##ida O
##zo O
##l O
- O
1 O
- O
y O
##l O
) O
ben O
##zo O
##yl O
] O
- O
2 O
##h O
- O
im O
##ida O
##zo O
##l O
- O
2 O
- O
one O
. O
[SEP] O
[CLS] O
the O
drug O
was O
added O
to O
400 O
m O
##l O
of O
10 O
% O
man O
##ni O
##to O
##l O
, O
was O
brought O
up O
to O
1 O
- O
l O
volume O
with O
normal O
sa O
##line O
containing O
3 O
g O
of O
ma O
##gnesium O
su O
##lf O
##ate O
, O
and O
was O
administered O
i O
##v O
over O
1 O
hour O
. O
[SEP] O
[CLS] O
in O
5 O
patients O
( O
40 O
% O
) O
, O
the O
anti O
##static O
v O
##h O
##c O
increased O
f O
##p O
##c O
by O
> O
/ O
= O
100 O
% O
, O
to O
potentially O
excessive O
levels O
in O
4 O
of O
them O
; O
it O
had O
little O
effect O
in O
7 O
patients O
. O
[SEP] O
[CLS] O
accordingly O
, O
the O
half B-PK
- I-PK
life I-PK
of O
m O
##s O
##n O
- O
en O
##cap O
##sul O
##ated O
be O
##va O
##ci O
##zu O
##ma O
##b O
na O
##no O
##par O
##tic O
##les O
was O
significantly O
greater O
than O
that O
of O
be O
##va O
##ci O
##zu O
##ma O
##b O
. O
[SEP] O
[CLS] O
here O
, O
when O
a O
b O
##ol O
##us O
of O
m O
##or O
##phine O
is O
given O
, O
the O
maximum B-PK
concentration I-PK
of O
m O
##3 O
##g O
is O
higher O
in O
o O
##bes O
##e O
patients O
( O
panel O
b O
) O
. O
[SEP] O
[CLS] O
genetic O
p O
##oly O
##mor O
##phism O
of O
c O
##y O
##p O
##2 O
##a O
##6 O
and O
body O
weight O
will O
be O
causes O
of O
ethnic O
difference O
in O
p O
##k O
. O
[SEP] O
[CLS] O
the O
di O
##sper O
##sions O
of O
g O
##fs O
and O
p O
- O
g O
##fs O
containing O
equal O
amounts O
of O
g O
##fs O
were O
placed O
into O
the O
dial O
##ys O
##is O
bags O
im O
##mers O
##ing O
in O
500 O
m O
##l O
medium O
( O
p O
##h O
= O
1 O
. O
2 O
h O
##c O
##l O
, O
p O
##h O
= O
6 O
. O
8 O
phosphate O
buffer O
sa O
##line O
) O
. O
[SEP] O
[CLS] O
additionally O
, O
no O
subjects O
met O
amino O
##tra O
##ns O
##fer O
##ase O
or O
total O
bi O
##li O
##ru O
##bin O
criteria O
for O
potential O
drug O
‐ O
induced O
liver O
injury O
, O
defined O
as O
an O
amino O
##tra O
##ns O
##ami O
##nas O
##e O
elevation O
> O
[SEP] O
[CLS] O
post O
- O
treatment O
levels O
of O
s O
##t O
##n O
##f O
- O
r O
##2 O
peaked O
significantly O
higher O
than O
s O
##t O
##n O
##f O
- O
r O
##1 O
( O
p O
< O
0 O
. O
000 O
##1 O
) O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
the O
combined O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
add O
##uc O
##t O
data O
in O
patients O
support O
the O
advantages O
of O
the O
in O
##tra O
##per O
##ito O
##nea O
##l O
route O
for O
drug O
administration O
, O
and O
the O
addition O
of O
heat O
. O
[SEP] O
[CLS] O
p O
##t O
##x O
is O
as O
active O
as O
m O
##t O
##x O
in O
in O
##hibit O
##ing O
d O
##h O
##f O
##r O
and O
ma O
##mmal O
##ian O
cell O
growth O
. O
[SEP] O
[CLS] O
patients O
received O
single O
in O
##tra O
##ven O
##ous O
injection O
##s O
( O
50 O
i O
##u O
/ O
kg O
) O
of O
n O
##9 O
‐ O
g O
##p O
and O
r O
##fi O
##x O
##f O
##c O
with O
at O
least O
21 O
days O
between O
doses O
. O
[SEP] O
[CLS] O
these O
findings O
indicate O
that O
although O
hp O
g O
##eno O
##type O
does O
not O
affect O
the O
risk O
of O
p O
##e O
, O
hp O
##1 O
- O
1 O
g O
##eno O
##type O
may O
ex O
##ert O
a O
protective O
role O
in O
p O
##e O
by O
reducing O
no O
s O
##ca O
##ven O
##ging O
, O
whereas O
hp O
##2 O
- O
1 O
and O
hp O
##2 O
- O
2 O
further O
may O
a O
##gg O
##ra O
##vate O
p O
##e O
by O
reducing O
no O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
an O
f O
##1 O
value O
greater O
than O
15 O
indicates O
significant O
di O
##ssi O
##mi O
##lar O
##ity O
, O
and O
an O
f O
##2 O
value O
greater O
than O
50 O
indicates O
significant O
similarity O
[ O
16 O
, O
17 O
] O
. O
[SEP] O
[CLS] O
the O
most O
common O
tumor O
types O
were O
pan O
##cre O
##atic O
, O
he O
##pa O
##to O
##cellular O
and O
color O
##ec O
##tal O
cancer O
, O
but O
a O
large O
number O
of O
other O
e O
##pit O
##hel O
##ial O
ma O
##li O
##gna O
##ncies O
were O
included O
. O
[SEP] O
[CLS] O
a O
pilot O
study O
on O
safety O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
in O
##f O
##lix O
##ima O
##b O
for O
the O
cancer O
an O
##ore O
##xia O
/ O
weight O
loss O
syndrome O
in O
non O
- O
small O
- O
cell O
lung O
cancer O
patients O
. O
[SEP] O
[CLS] O
the O
" O
prevention O
of O
g O
##raft O
- O
versus O
- O
host O
disease O
( O
g O
##v O
##h O
##d O
) O
for O
all O
##ogen O
##ei O
##c O
hem O
##ato O
##po O
##iet O
##ic O
stem O
cell O
transplant O
##ation O
in O
adults O
" O
indication O
has O
been O
added O
to O
at O
##g O
in O
32 O
countries O
worldwide O
, O
but O
has O
not O
yet O
been O
approved O
for O
g O
##v O
##h O
##d O
prevention O
in O
j O
##apa O
##n O
. O
[SEP] O
[CLS] O
the O
automatic O
ca O
##li O
##bra O
##tion O
was O
carried O
out O
every O
eight O
samples O
. O
[SEP] O
[CLS] O
peaks O
were O
integrated O
and O
measured O
against O
a O
standard O
ca O
##li O
##bra O
##tion O
curve O
. O
[SEP] O
[CLS] O
the O
method O
is O
suitable O
in O
p O
##har O
##ma O
##co O
##kin O
##etic O
investigation O
of O
b O
##uf O
##orm O
##in O
. O
[SEP] O
[CLS] O
p O
##k O
parameters O
including O
au B-PK
##c I-PK
and O
cm B-PK
##ax I-PK
were O
derived O
by O
non O
##com O
##par O
##tment O
##al O
analyses O
. O
[SEP] O
[CLS] O
in O
summary O
, O
results O
of O
the O
present O
study O
indicated O
that O
interactions O
among O
co O
- O
exiting O
components O
in O
v O
##ce O
were O
complex O
and O
significant O
, O
which O
needed O
special O
attention O
. O
[SEP] O
[CLS] O
in O
addition O
, O
data O
for O
one O
child O
were O
excluded O
from O
i O
##g O
##f O
- O
i O
analysis O
due O
to O
in O
##con O
##sist O
##encies O
in O
the O
i O
##g O
##f O
- O
i O
profile O
[ O
an O
increase O
in O
i O
##g O
##f O
- O
i O
during O
human O
( O
h O
) O
g O
##h O
wash O
##out O
] O
. O
[SEP] O
[CLS] O
mi O
##po O
##mers O
##en O
was O
absorbed O
rapidly O
after O
s O
##c O
administration O
; O
median O
t B-PK
##max I-PK
varied O
between O
2 O
and O
3 O
hours O
. O
[SEP] O
[CLS] O
similarly O
, O
the O
maximum O
change O
from O
base O
##line O
in O
p O
##fa O
c O
##ep O
##i O
closure O
time O
was O
lower O
after O
i O
##v O
di O
##c O
##lo O
##fen O
##ac O
than O
after O
k O
##eto O
##rol O
##ac O
or O
as O
##a O
across O
all O
time O
intervals O
examined O
. O
[SEP] O
[CLS] O
then O
, O
results O
from O
each O
study O
group O
were O
compared O
with O
each O
other O
. O
[SEP] O
[CLS] O
h O
##r O
/ O
m O
##l O
( O
mean O
+ O
- O
se O
) O
, O
as O
did O
the O
percentage O
na O
##do O
##lo O
##l O
recovered O
in O
urine O
( O
15 O
. O
4 O
+ O
- O
1 O
. O
4 O
to O
10 O
. O
2 O
+ O
- O
0 O
. O
7 O
% O
) O
and O
the O
na O
##do O
##lo O
##l O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
17 O
. O
3 O
+ O
- O
1 O
. O
7 O
to O
11 O
. O
8 O
+ O
- O
1 O
. O
6 O
h O
##r O
) O
. O
[SEP] O
[CLS] O
consistent O
with O
these O
kinetic O
alterations O
, O
the O
h O
##y O
##po O
##gly O
##ce O
##mic O
effect O
in O
the O
concurrent O
administration O
group O
was O
more O
pronounced O
than O
that O
in O
the O
control O
group O
( O
i O
. O
e O
. O
, O
re O
##pa O
##gli O
##ni O
##de O
alone O
) O
when O
the O
drug O
was O
given O
oral O
##ly O
. O
[SEP] O
[CLS] O
good O
general O
health O
was O
determined O
at O
screening O
by O
medical O
history O
, O
physical O
examination O
, O
vital O
signs O
, O
electro O
##card O
##io O
##graphy O
( O
e O
##c O
##g O
) O
, O
and O
laboratory O
findings O
. O
[SEP] O
[CLS] O
importantly O
, O
viral O
load O
remained O
below O
the O
lo O
##q O
throughout O
the O
duration O
of O
dos O
##ing O
and O
for O
at O
least O
12 O
days O
after O
dos O
##ing O
ended O
. O
[SEP] O
[CLS] O
there O
were O
no O
associations O
between O
patients O
' O
beliefs O
( O
b O
##m O
##q O
- O
sub O
##sca O
##les O
or O
brief O
i O
##p O
##q O
- O
sub O
##sca O
##les O
) O
and O
scores O
on O
the O
ma O
##rs O
- O
question O
##naire O
. O
[SEP] O
[CLS] O
in O
a O
separate O
multiple O
- O
dose O
study O
, O
the O
disposition O
of O
z O
##ato O
##set O
##ron O
was O
found O
to O
be O
similar O
to O
that O
in O
the O
single O
- O
dose O
study O
. O
[SEP] O
[CLS] O
on O
the O
other O
hand O
, O
presence O
of O
end O
##oth O
##er O
##mic O
peak O
at O
173 O
° O
##c O
( O
onset O
167 O
. O
3 O
– O
176 O
. O
8 O
° O
##c O
end O
via O
[UNK] O
100 O
. O
59 O
j O
/ O
kg O
) O
indicates O
transformation O
into O
na O
##no O
- O
bio O
##par O
##tic O
##les O
during O
the O
preparation O
of O
coated O
s O
##ln O
with O
r O
##u O
( O
on O
##b O
##p O
) O
. O
[SEP] O
[CLS] O
r O
##if O
##amp O
##ici O
##n O
( O
r O
##if O
) O
was O
kindly O
provided O
by O
bond O
pharmaceutical O
##s O
, O
awe O
, O
o O
##yo O
state O
, O
ni O
##ger O
##ia O
, O
and O
art O
##em O
##eth O
##er O
and O
am O
##od O
##ia O
##quin O
##e O
were O
obtained O
from O
the O
wa O
##lter O
re O
##ed O
army O
institute O
for O
research O
, O
us O
##a O
. O
[SEP] O
[CLS] O
stimuli O
( O
duration O
: O
0 O
. O
2 O
m O
##s O
) O
were O
applied O
at O
0 O
. O
03 O
##3 O
h O
##z O
using O
a O
constant O
- O
current O
stimulus O
isolation O
unit O
( O
w O
##pi O
) O
. O
[SEP] O
[CLS] O
se O
##dd O
##s O
- O
car O
was O
prepared O
based O
on O
d O
- O
α O
- O
to O
##co O
##pher O
##yl O
p O
##oly O
##eth O
##yle O
##ne O
g O
##ly O
##co O
##l O
1000 O
su O
##cci O
##nate O
( O
t O
##p O
##gs O
) O
and O
p O
##hy O
##si O
##co O
##chemical O
##ly O
characterized O
. O
[SEP] O
[CLS] O
the O
adverse O
effects O
observed O
in O
the O
study O
were O
mild O
and O
in O
##f O
##re O
##quent O
, O
with O
pro O
##mpt O
recovery O
from O
adverse O
experiences O
and O
abnormal O
laboratory O
values O
. O
[SEP] O
[CLS] O
it O
is O
important O
to O
understand O
whether O
new O
formulation O
##s O
and O
/ O
or O
methods O
of O
administration O
impact O
a O
##pi O
##xa O
##ban O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
. O
[SEP] O
[CLS] O
the O
peak B-PK
levels I-PK
of O
the O
serum O
p O
##t O
concentration O
of O
three O
patients O
were O
0 O
- O
0 O
. O
4 O
micro O
##gram O
/ O
g O
throughout O
the O
therapy O
, O
but O
peak B-PK
urine I-PK
p I-PK
##t I-PK
concentrations I-PK
were O
observed O
during O
one O
course O
of O
the O
therapy O
of O
three O
patients O
ranging O
from O
0 O
. O
5 O
micro O
##gram O
/ O
g O
to O
3 O
. O
2 O
micro O
##gram O
##s O
/ O
g O
, O
and O
decreased O
gradually O
for O
three O
weeks O
after O
the O
first O
course O
. O
[SEP] O
[CLS] O
t O
##f O
##v O
and O
t O
##f O
##v O
- O
d O
##p O
were O
q O
##uant O
##ified O
with O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
/ O
tandem O
mass O
s O
##pect O
##rome O
##try O
methods O
. O
[SEP] O
[CLS] O
however O
, O
the O
proportion O
of O
patients O
who O
were O
photo O
##ph O
##obia O
- O
free O
, O
p O
##hon O
##op O
##ho O
##bia O
- O
free O
, O
and O
nausea O
- O
free O
at O
2 O
hours O
post O
- O
dose O
was O
higher O
in O
the O
ad O
##am O
z O
##olm O
##it O
##rip O
##tan O
3 O
. O
8 O
mg O
group O
compared O
with O
place O
##bo O
, O
as O
were O
the O
percentage O
##s O
of O
patients O
who O
were O
pain O
- O
free O
, O
and O
who O
experienced O
pain O
relief O
up O
to O
48 O
hours O
post O
- O
dose O
. O
[SEP] O
[CLS] O
the O
most O
favored O
binding O
pose O
for O
compound O
2 O
##a O
was O
with O
the O
o O
- O
met O
##hyl O
m O
##oi O
##ety O
over O
the O
hem O
##e O
( O
3 O
. O
0 O
##a O
, O
fi O
##g O
2 O
panel O
d O
) O
. O
[SEP] O
[CLS] O
complete O
blood O
count O
, O
bio O
##chemistry O
and O
parasite O
count O
were O
measured O
on O
admission O
. O
[SEP] O
[CLS] O
this O
phase O
i O
study O
was O
conducted O
to O
evaluate O
the O
safety O
, O
to O
##ler O
##ability O
, O
and O
preliminary O
efficacy O
of O
the O
combination O
of O
t O
##rem O
##eli O
##mum O
##ab O
and O
p O
##f O
- O
35 O
##12 O
##6 O
##7 O
##6 O
in O
patients O
with O
meta O
##static O
me O
##lan O
##oma O
and O
other O
advanced O
solid O
t O
##umour O
##s O
. O
[SEP] O
[CLS] O
the O
changes O
during O
the O
third O
trim O
##ester O
were O
predicted O
to O
be O
a O
100 O
% O
increase O
, O
a O
30 O
% O
decrease O
and O
a O
35 O
% O
decrease O
in O
the O
exposure O
of O
ca O
##ffe O
##ine O
, O
met O
##op O
##rol O
##ol O
and O
mid O
##az O
##ola O
##m O
, O
respectively O
, O
compared O
with O
the O
non O
##p O
##re O
##gnant O
women O
. O
[SEP] O
[CLS] O
the O
cumulative O
recovery O
in O
f O
##ec O
##es O
during O
0 O
– O
144 O
h O
represented O
91 O
% O
of O
the O
t O
##ra O
in O
f O
##ec O
##es O
. O
[SEP] O
[CLS] O
ta O
##mo O
##xi O
##fen O
, O
a O
selective O
est O
##rogen O
‐ O
receptor O
m O
##od O
##ulator O
, O
is O
widely O
used O
for O
treatment O
of O
est O
##rogen O
receptor O
( O
er O
) O
or O
pro O
##ges O
##tero O
##ne O
receptor O
‐ O
positive O
breast O
cancer O
. O
[SEP] O
[CLS] O
the O
limit O
of O
detection O
( O
lo O
##d O
) O
which O
is O
quoted O
as O
the O
concentration O
yielding O
a O
signal O
- O
to O
- O
noise O
ratio O
of O
3 O
: O
1 O
was O
confirmed O
by O
analyzing O
a O
number O
of O
samples O
near O
this O
value O
. O
[SEP] O
[CLS] O
only O
small O
amounts O
of O
f O
##os O
##f O
##lu O
##cona O
##zo O
##le O
were O
ex O
##cre O
##ted O
in O
the O
urine O
suggesting O
almost O
complete O
conversion O
to O
fl O
##cz O
. O
[SEP] O
[CLS] O
batch O
##es O
of O
3 O
– O
5 O
rats O
were O
e O
##uth O
##ana O
##tized O
after O
different O
exposure O
times O
( O
1 O
– O
30 O
h O
) O
. O
[SEP] O
[CLS] O
clinical O
break O
##points O
of O
anti O
##biotics O
are O
vital O
in O
su O
##s O
##ce O
##pt O
##ibility O
testing O
of O
path O
##ogen O
##s O
for O
the O
selection O
of O
anti O
##biotic O
therapy O
; O
however O
, O
no O
consensus O
exists O
between O
different O
committees O
on O
the O
clinical O
break O
##points O
of O
t O
##ige O
##cy O
##cline O
. O
[SEP] O
[CLS] O
the O
concentration O
of O
mit O
##omy O
##cin O
c O
was O
also O
determined O
at O
a O
final O
time O
point O
to O
ensure O
the O
changes O
in O
the O
drug O
en O
##cap O
##sul O
##ation O
efficiency O
. O
[SEP] O
[CLS] O
u O
##rb O
##9 O
##37 O
was O
oral O
##ly O
available O
in O
male O
rats O
( O
f B-PK
= O
36 O
% O
) O
, O
but O
remained O
und O
##ete O
##ct O
##able O
in O
brain O
when O
administered O
at O
doses O
that O
ma O
##ximal O
##ly O
in O
##hibit O
f O
##aa O
##h O
activity O
and O
el O
##eva O
##te O
o O
##ea O
in O
plasma O
and O
liver O
. O
[SEP] O
[CLS] O
the O
half B-PK
- I-PK
life I-PK
of O
en O
##ox O
##apa O
##rin O
is O
prolonged O
with O
the O
progression O
of O
pregnancy O
, O
and O
our O
work O
provides O
compelling O
evidence O
for O
pre O
##s O
##cribing O
once O
- O
daily O
en O
##ox O
##apa O
##rin O
for O
the O
treatment O
of O
ant O
##ena O
##tal O
ve O
##nous O
th O
##rom O
##boe O
##mbo O
##lis O
##m O
. O
[SEP] O
[CLS] O
the O
mean O
reduction O
in O
the O
u O
##a O
concentration O
on O
day O
7 O
relative O
to O
that O
on O
day O
- O
1 O
was O
51 O
. O
83 O
##± O
##7 O
. O
00 O
% O
. O
[SEP] O
[CLS] O
there O
were O
no O
statistical O
##ly O
significant O
differences O
in O
v B-PK
##d I-PK
, O
c B-PK
##l I-PK
, O
k B-PK
, O
and O
t B-PK
( I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
) I-PK
of O
g O
##ent O
##ami O
##cin O
between O
the O
control O
and O
di O
##abe O
##tic O
group O
. O
[SEP] O
[CLS] O
a O
single O
oral O
dose O
of O
cab O
##ote O
##gra O
##vir O
30 O
mg O
was O
administered O
to O
all O
participants O
under O
fast O
##ing O
conditions O
, O
and O
p O
##k O
parameters O
were O
assessed O
. O
[SEP] O
[CLS] O
the O
terminal B-PK
half I-PK
- I-PK
life I-PK
( I-PK
beta I-PK
_ I-PK
h I-PK
##l I-PK
) I-PK
was O
calculated O
as O
0 O
. O
69 O
##3 O
/ O
beta O
; O
the O
systemic B-PK
clearance I-PK
rate I-PK
( I-PK
c I-PK
##l I-PK
_ I-PK
f I-PK
) I-PK
was O
determined O
as O
dose B-PK
/ I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
; O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
##1 I-PK
_ I-PK
f I-PK
) I-PK
was O
calculated O
as O
c B-PK
##l I-PK
_ I-PK
f I-PK
/ I-PK
beta I-PK
. O
[SEP] O
[CLS] O
duration O
of O
responses O
was O
calculated O
from O
the O
first O
day O
of O
treatment O
to O
the O
date O
of O
first O
observation O
of O
progressive O
disease O
or O
last O
examination O
. O
[SEP] O
[CLS] O
the O
mean O
( O
median O
; O
range O
) O
age O
and O
mean O
( O
median O
; O
range O
) O
body O
mass O
index O
( O
b O
##mi O
) O
of O
subjects O
at O
extension O
study O
base O
##line O
was O
10 O
. O
1 O
( O
10 O
. O
1 O
; O
5 O
. O
9 O
to O
14 O
. O
3 O
) O
years O
and O
19 O
. O
3 O
( O
18 O
. O
1 O
; O
15 O
. O
4 O
to O
30 O
. O
7 O
) O
kg O
/ O
m O
##2 O
, O
respectively O
. O
[SEP] O
[CLS] O
data O
were O
analyzed O
by O
analysis O
of O
variance O
. O
[SEP] O
[CLS] O
twenty O
‐ O
five O
subjects O
were O
male O
( O
65 O
. O
8 O
% O
) O
, O
the O
mean O
age O
was O
54 O
. O
6 O
years O
( O
range O
27 O
to O
74 O
years O
) O
, O
and O
the O
total O
number O
of O
white O
and O
black O
or O
a O
##f O
##rica O
##n O
‐ O
am O
##eric O
##an O
subjects O
were O
the O
same O
( O
18 O
subjects O
each O
, O
47 O
. O
4 O
% O
) O
. O
[SEP] O
[CLS] O
safety O
end O
##points O
were O
sum O
##mar O
##ised O
using O
descriptive O
statistics O
. O
[SEP] O
[CLS] O
thirty O
- O
two O
patients O
could O
be O
evaluated O
in O
detail O
. O
[SEP] O
[CLS] O
the O
plasma O
concentrations O
of O
the O
stereo O
##is O
##omer O
##s O
of O
met O
##op O
##rol O
##ol O
, O
o O
- O
dem O
##eth O
##yl O
##met O
##op O
##rol O
##ol O
( O
o O
##d O
##m O
) O
, O
alpha O
- O
h O
##ydro O
##xy O
##met O
##op O
##rol O
##ol O
( O
oh O
##m O
) O
( O
ch O
##ira O
##l O
##pa O
##k O
ad O
column O
) O
, O
and O
met O
##op O
##rol O
##ol O
acidic O
meta O
##bol O
##ite O
( O
a O
##od O
##m O
) O
( O
ch O
##ira O
##l O
##cel O
o O
##d O
- O
r O
column O
) O
were O
determined O
by O
hp O
##l O
##c O
using O
flu O
##ores O
##cence O
detection O
( O
la O
##mb O
##da O
( O
ex O
##c O
) O
= O
229 O
nm O
; O
la O
##mb O
##da O
( O
em O
) O
= O
29 O
##8 O
nm O
) O
. O
[SEP] O
[CLS] O
scheduled O
sampling O
times O
were O
used O
for O
the O
creation O
of O
summary O
tables O
and O
mean O
plasma O
concentration O
versus O
time O
profiles O
. O
[SEP] O
[CLS] O
no O
significant O
is O
##oto O
##pe O
effect O
was O
observed O
on O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
p O
##b O
h O
##ydro O
##xy O
##lation O
or O
p O
##bo O
##h O
con O
##ju O
##gation O
( O
x O
less O
than O
or O
equal O
to O
5 O
% O
) O
; O
which O
the O
absence O
of O
pen O
##tad O
##eu O
##tera O
##tion O
- O
induced O
alter O
##ation O
in O
p O
##b O
' O
s O
h O
##sa O
binding O
parameters O
( O
binding O
mode O
, O
ka B-PK
, O
n O
) O
co O
##rro O
##bor O
##ates O
( O
x O
less O
than O
or O
equal O
to O
5 O
% O
) O
. O
[SEP] O
[CLS] O
several O
additional O
mice O
were O
sacrificed O
in O
pre O
##dos O
##e O
to O
provide O
blank O
plasma O
and O
control O
tissues O
for O
analysis O
. O
[SEP] O
[CLS] O
the O
peak B-PK
concentrations I-PK
of O
v O
##ado O
##ca O
##ine O
were O
achieved O
on O
the O
1st O
day O
at O
1 O
h O
( O
61 O
. O
5 O
+ O
- O
6 O
. O
1 O
ng O
/ O
m O
##l O
) O
and O
on O
the O
4th O
day O
at O
1 O
. O
5 O
h O
( O
64 O
. O
5 O
+ O
- O
7 O
. O
9 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
inclusion O
criterion O
was O
receiving O
at O
least O
3 O
successive O
doses O
of O
van O
##com O
##y O
##cin O
( O
fixed O
dose O
and O
dos O
##ing O
interval O
) O
as O
em O
##pi O
##ric O
treatment O
of O
f O
##eb O
##ril O
##e O
ne O
##ut O
##rop O
##enia O
. O
[SEP] O
[CLS] O
the O
second O
was O
a O
double O
- O
blind O
, O
place O
##bo O
- O
controlled O
, O
parallel O
- O
group O
, O
multiple O
- O
dose O
study O
in O
which O
participants O
were O
random O
##ized O
to O
100 O
mg O
or O
200 O
mg O
o O
##sel O
##tam O
##iv O
##ir O
or O
place O
##bo O
( O
normal O
sa O
##line O
) O
i O
. O
v O
. O
over O
2 O
h O
every O
12 O
h O
for O
5 O
days O
. O
[SEP] O
[CLS] O
as O
an O
example O
, O
the O
production O
rates O
of O
ace O
##tone O
, O
under O
different O
conditions O
of O
stimulation O
by O
x O
##eno O
##biotics O
, O
are O
calculated O
from O
published O
experimental O
data O
. O
[SEP] O
[CLS] O
q O
##uant O
##itation O
was O
based O
upon O
a O
standard O
curve O
from O
external O
standards O
, O
comprising O
of O
ch O
##ole O
##ster O
##ol O
, O
s O
##ti O
##gma O
##ster O
##ol O
, O
sit O
##ost O
##ero O
##l O
, O
and O
camp O
##ester O
##ol O
at O
varying O
concentrations O
( O
39 O
, O
40 O
) O
, O
using O
ultra O
- O
pure O
s O
##tero O
##ls O
obtained O
from O
s O
##teral O
##oids O
in O
##c O
. O
( O
new O
##port O
, O
r O
##i O
) O
. O
[SEP] O
[CLS] O
bi O
##li O
##ru O
##bine O
##mia O
( O
the O
presence O
of O
increased O
amounts O
of O
bi O
##li O
##ru O
##bin O
in O
the O
blood O
) O
was O
reported O
in O
one O
participant O
( O
r O
##20 O
##8 O
) O
, O
as O
determined O
during O
clinical O
laboratory O
testing O
on O
day O
2 O
. O
[SEP] O
[CLS] O
the O
lungs O
of O
all O
animals O
were O
collected O
immediately O
after O
sacrifice O
or O
death O
and O
weighed O
. O
[SEP] O
[CLS] O
c O
##y O
##p O
##2 O
##d O
##6 O
p O
##hen O
##otype O
was O
assessed O
during O
each O
study O
period O
using O
de O
##x O
##trom O
##eth O
##or O
##pha O
##n O
( O
30 O
mg O
) O
. O
[SEP] O
[CLS] O
after O
sampling O
, O
the O
cat O
##he O
##ter O
was O
flushed O
with O
0 O
. O
8 O
m O
##l O
of O
sodium O
he O
##par O
##in O
( O
25 O
i O
##u O
/ O
m O
##l O
) O
to O
ensure O
pat O
##ency O
. O
[SEP] O
[CLS] O
the O
results O
showed O
that O
only O
spotted O
blood O
volume O
might O
have O
an O
impact O
; O
a O
small O
volume O
( O
10 O
##μ O
##l O
) O
tended O
to O
give O
a O
larger O
negative O
bias O
in O
the O
measured O
value O
than O
the O
large O
volume O
ones O
( O
≥ O
##20 O
##μ O
##l O
) O
. O
[SEP] O
[CLS] O
the O
m O
##f O
at O
both O
tested O
concentrations O
was O
[UNK] O
. O
3 O
as O
a O
result O
of O
matrix O
effects O
( O
ion O
suppression O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
p O
##k O
- O
p O
##d O
modelling O
of O
da O
##no O
##f O
##lo O
##xa O
##cin O
in O
came O
##l O
serum O
and O
tissue O
cage O
fluids O
. O
[SEP] O
[CLS] O
the O
terminal O
‐ O
phase O
concentrations O
appeared O
to O
decline O
multi O
##ex O
##po O
##nent O
##ially O
. O
[SEP] O
[CLS] O
c O
##ef O
##ti O
##of O
##ur O
is O
a O
new O
broad O
spectrum O
c O
##ep O
##hal O
##os O
##por O
##in O
marketed O
for O
the O
treatment O
of O
acute O
b O
##ov O
##ine O
respiratory O
disease O
. O
[SEP] O
[CLS] O
however O
, O
significant O
improvement O
was O
seen O
in O
the O
intervention O
group O
on O
days O
4 O
( O
- O
1 O
. O
07 O
; O
95 O
% O
c O
##i O
, O
- O
1 O
. O
80 O
to O
- O
0 O
. O
34 O
) O
and O
5 O
( O
- O
1 O
. O
06 O
; O
95 O
% O
c O
##i O
, O
- O
1 O
. O
84 O
to O
- O
0 O
. O
27 O
) O
. O
[SEP] O
[CLS] O
the O
decrease O
in O
e O
##g O
##f O
##r O
appeared O
to O
reach O
sat O
##uration O
at O
> O
100 O
mg O
/ O
m O
##2 O
with O
n O
##c O
- O
600 O
##4 O
. O
[SEP] O
[CLS] O
the O
effect O
of O
weight O
‐ O
based O
and O
flat O
‐ O
dos O
##ing O
regime O
##ns O
were O
evaluated O
using O
simulation O
##s O
based O
on O
the O
final O
population O
p O
##k O
model O
( O
semi O
##me O
##chan O
##istic O
time O
‐ O
varying O
c B-PK
##l I-PK
) O
. O
[SEP] O
[CLS] O
we O
suggest O
that O
these O
dose O
- O
independent O
p O
##har O
##ma O
##co O
##kin O
##etic O
characteristics O
of O
α O
- O
man O
##gos O
##tin O
in O
mice O
provide O
an O
important O
basis O
for O
pre O
##c O
##lini O
##cal O
applications O
of O
α O
- O
man O
##gos O
##tin O
as O
well O
as O
man O
##gos O
##teen O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
combined O
with O
the O
p O
##har O
##ma O
##cology O
research O
of O
si O
##m O
##vas O
##tat O
##in O
with O
be O
##rber O
##ine O
improvement O
of O
the O
lip O
##id O
- O
lowering O
efficacy O
, O
suggest O
this O
may O
be O
a O
promising O
drug O
- O
drug O
combination O
to O
overcome O
its O
adverse O
effects O
and O
to O
improve O
its O
lip O
##id O
- O
lowering O
efficacy O
in O
##c O
##lini O
##cal O
use O
. O
[SEP] O
[CLS] O
the O
urine O
samples O
for O
the O
possible O
analysis O
of O
km O
- O
81 O
##9 O
and O
q O
##ual O
##itative O
analysis O
of O
any O
meta O
##bol O
##ites O
were O
collected O
at O
day O
1 O
pre O
##dos O
##e O
and O
from O
0 O
to O
24 O
hours O
post O
##dos O
##e O
. O
[SEP] O
[CLS] O
point O
estimates O
for O
the O
p O
##k O
parameters O
and O
the O
associated O
90 O
% O
c O
##is O
for O
the O
co O
##hor O
##t O
difference O
( O
re O
##nal O
imp O
##air O
##ment O
vs O
healthy O
controls O
) O
were O
calculated O
. O
[SEP] O
[CLS] O
h O
/ O
l O
, O
range O
10 O
. O
4 O
- O
24 O
. O
4 O
mg O
. O
[SEP] O
[CLS] O
dissolution O
versus O
per B-PK
##me I-PK
##ability I-PK
. O
[SEP] O
[CLS] O
[ O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
am O
##pic O
##ill O
##in O
preparations O
for O
internal O
use O
] O
. O
[SEP] O
[CLS] O
the O
her O
##2 O
+ O
b O
##t O
##47 O
##4 O
human O
breast O
cancer O
cell O
line O
/ O
x O
##eno O
##gra O
##ft O
is O
a O
well O
- O
established O
model O
of O
human O
her O
##2 O
+ O
breast O
cancer O
, O
the O
population O
for O
which O
the O
drug O
is O
approved O
. O
[SEP] O
[CLS] O
the O
probability O
of O
being O
a O
s O
##ri O
respond O
##er O
was O
obtained O
by O
the O
equation O
: O
\ O
document O
##c O
##lass O
[ O
12 O
##pt O
] O
{ O
minimal O
} O
\ O
use O
##pack O
##age O
{ O
am O
##sma O
##th O
} O
\ O
use O
##pack O
##age O
{ O
was O
##ys O
##ym O
} O
\ O
use O
##pack O
##age O
{ O
am O
##s O
##fo O
##nts O
} O
\ O
use O
##pack O
##age O
{ O
am O
##ssy O
##mb O
} O
\ O
use O
##pack O
##age O
{ O
am O
##s O
##bs O
##y O
} O
\ O
use O
##pack O
##age O
{ O
math O
##rs O
##fs O
} O
[SEP] O
[CLS] O
this O
study O
did O
not O
investigate O
the O
efficacy O
of O
the O
21 O
- O
day O
fixed O
et O
##hin O
##yl O
est O
##rad O
##iol O
- O
nor O
##eth O
##ind O
##rone O
regime O
##n O
, O
but O
the O
results O
suggest O
that O
th O
##ali O
##dom O
##ide O
is O
unlikely O
to O
affect O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
oral O
##ly O
administered O
ho O
##rmon O
##al O
con O
##tra O
##ceptive O
##s O
. O
[SEP] O
[CLS] O
the O
( O
mean O
+ O
- O
standard O
de O
##viation O
) O
elimination B-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
102 O
+ O
- O
20 O
hours O
in O
plasma O
, O
180 O
+ O
- O
68 O
hours O
in O
blood O
, O
and O
28 O
##9 O
+ O
- O
166 O
hours O
in O
pm O
##nn O
##s O
. O
[SEP] O
[CLS] O
modelling O
the O
anti O
- O
mi O
##gra O
##ine O
effects O
of O
bi O
##b O
##n O
40 O
##9 O
##6 O
b O
##s O
: O
a O
new O
ca O
##l O
##ci O
##ton O
##in O
gene O
- O
related O
p O
##eptide O
receptor O
antagonist O
. O
[SEP] O
[CLS] O
a O
physiological O
##ly O
based O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
used O
to O
quantitative O
##ly O
predict O
the O
impact O
of O
inter O
##le O
##uki O
##n O
- O
6 O
( O
il O
- O
6 O
) O
on O
sensitive O
c O
##y O
##p O
##3 O
##a O
##4 O
substrates O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
with O
one O
blood O
level O
, O
median O
c B-PK
##l I-PK
became O
similar O
to O
groups O
having O
2 O
, O
3 O
, O
and O
4 O
blood O
levels O
only O
after O
about O
35 O
patients O
had O
been O
studied O
, O
versus O
about O
10 O
. O
[SEP] O
[CLS] O
this O
result O
is O
not O
in O
accordance O
with O
go O
##yar O
##ts O
and O
da O
##nick O
##e O
( O
2006 O
) O
[ O
14 O
] O
, O
but O
could O
be O
explained O
by O
the O
difference O
in O
don O
administration O
route O
( O
diet O
vs O
. O
oral O
g O
##ava O
##ge O
) O
. O
[SEP] O
[CLS] O
when O
results O
from O
both O
studies O
were O
compared O
, O
60 O
% O
of O
the O
drug O
administered O
to O
the O
re O
##ct O
##um O
was O
absorbed O
from O
the O
superior O
hem O
##or O
##r O
##ho O
##idal O
vein O
and O
the O
remaining O
40 O
% O
was O
absorbed O
from O
the O
inferior O
hem O
##or O
##r O
##ho O
##idal O
vein O
. O
[SEP] O
[CLS] O
the O
higher O
the O
dose O
of O
ha O
##l O
or O
r O
##hal O
injected O
, O
or O
after O
repeated O
injection O
##s O
, O
the O
greater O
the O
r O
##hal O
to O
ha O
##l O
ratio O
produced O
. O
[SEP] O
[CLS] O
figure O
1 O
##a O
provides O
a O
simulation O
using O
the O
final O
parameter O
estimates O
from O
the O
p O
##k O
model O
for O
each O
dose O
level O
after O
a O
single O
dose O
administration O
, O
which O
is O
in O
alignment O
with O
the O
data O
that O
were O
collected O
from O
the O
study O
and O
modeled O
. O
[SEP] O
[CLS] O
the O
present O
study O
demonstrated O
that O
modeling O
and O
simulation O
permits O
a O
reasonable O
r O
##o O
est O
##imation O
in O
the O
human O
c O
##ns O
. O
[SEP] O
[CLS] O
na O
##vo O
##xi O
##mo O
##d O
was O
prepared O
by O
w O
##ux O
##i O
app O
##tec O
co O
. O
, O
l O
##t O
##d O
( O
s O
##hang O
##hai O
, O
chin O
##a O
) O
and O
the O
film O
‐ O
coated O
200 O
mg O
na O
##vo O
##xi O
##mo O
##d O
tablet O
was O
prepared O
by O
ho O
##ff O
##man O
‐ O
la O
##ro O
##che O
( O
base O
##l O
, O
s O
##witz O
##erland O
) O
. O
[SEP] O
[CLS] O
however O
, O
cm B-PK
##ax I-PK
of O
the O
commercial O
product O
reached O
79 O
% O
of O
simulation O
, O
and O
magnitude O
of O
decrease O
in O
cm B-PK
##ax I-PK
value O
of O
commercial O
product O
was O
smaller O
than O
other O
parameters O
. O
[SEP] O
[CLS] O
our O
institution O
developed O
dos O
##ing O
guidelines O
for O
patients O
with O
re O
##nal O
imp O
##air O
##ment O
based O
on O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
and O
class O
- O
specific O
p O
##har O
##ma O
##co O
##dynamic O
##s O
. O
[SEP] O
[CLS] O
effect O
of O
food O
on O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
na O
##lid O
##ix O
##ic O
acid O
from O
un O
##coat O
##ed O
tablets O
having O
different O
dissolution O
rates O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
values O
of O
co O
##hor O
##ts O
1 O
and O
2 O
were O
similar O
, O
but O
cm B-PK
##ax I-PK
of O
co O
##hor O
##t O
3 O
was O
higher O
than O
that O
of O
the O
other O
co O
##hor O
##ts O
. O
[SEP] O
[CLS] O
ale O
##m O
##tu O
##zu O
##ma O
##b O
is O
registered O
for O
the O
treatment O
of O
multiple O
s O
##cle O
##rosis O
( O
m O
##s O
) O
and O
is O
also O
used O
in O
chronic O
l O
##ymph O
##oc O
##ytic O
le O
##uke O
##mia O
( O
c O
##ll O
) O
. O
[SEP] O
[CLS] O
compared O
with O
control O
, O
ta O
##o O
treatment O
significantly O
decreased O
the O
mean O
time O
- O
averaged O
er O
##mb O
##t O
result O
by O
77 O
% O
( O
95 O
% O
c O
##i O
, O
68 O
, O
85 O
% O
) O
, O
the O
mean O
apparent B-PK
oral I-PK
clearance I-PK
of O
q O
##uin O
##ine O
( O
c B-PK
##l I-PK
/ I-PK
f I-PK
) O
by O
45 O
% O
( O
95 O
% O
c O
##i O
, O
39 O
, O
52 O
% O
) O
, O
and O
the O
mean O
apparent B-PK
formation I-PK
clearance I-PK
of O
3 O
- O
h O
##ydro O
##xy O
##quin O
##ine O
( O
c B-PK
##l I-PK
##3 I-PK
- I-PK
oh I-PK
) O
by O
81 O
% O
( O
95 O
% O
c O
##i O
, O
76 O
, O
87 O
% O
) O
. O
[SEP] O
[CLS] O
about O
65 O
% O
of O
the O
dose O
was O
absorbed O
in O
rats O
, O
and O
at O
least O
88 O
% O
in O
dogs O
. O
[SEP] O
[CLS] O
the O
p O
##ear O
##son O
correlation O
coefficient O
( O
r O
) O
for O
the O
relationship O
between O
percentage O
change O
in O
selected O
safety O
laboratory O
values O
and O
total B-PK
drug I-PK
c I-PK
##tro I-PK
##ugh I-PK
on O
day O
28 O
of O
cycles O
2 O
and O
3 O
, O
respectively O
, O
was O
− O
0 O
. O
59 O
and O
− O
0 O
. O
55 O
for O
absolute O
ne O
##ut O
##rop O
##hil O
count O
, O
and O
− O
0 O
. O
64 O
and O
− O
0 O
. O
66 O
for O
plate O
##let O
count O
, O
indicating O
an O
overall O
moderate O
negative O
correlation O
( O
− O
0 O
. O
7 O
< O
r O
≤ O
− O
0 O
. O
5 O
) O
. O
[SEP] O
[CLS] O
these O
data O
provided O
dose O
selection O
support O
for O
so O
##lit O
##hr O
##omy O
##cin O
for O
clinical O
trials O
in O
patients O
with O
community O
- O
acquired O
bacterial O
pneumonia O
. O
[SEP] O
[CLS] O
in O
the O
expansion O
phase O
of O
step O
1 O
, O
ta O
##s O
- O
116 O
was O
administered O
5 O
days O
on O
/ O
2 O
days O
off O
per O
week O
( O
q O
##d O
× O
5 O
) O
. O
[SEP] O
[CLS] O
diverse O
car O
##ote O
##no O
##ids O
with O
different O
chemical O
structures O
exist O
in O
edible O
plants O
in O
significant O
amounts O
. O
[SEP] O
[CLS] O
l O
- O
a O
##rg O
##ini O
##ne O
in O
##fusion O
was O
well O
tolerate O
##d O
. O
[SEP] O
[CLS] O
more O
##over O
, O
further O
studies O
with O
highly O
protein O
- O
bound O
drugs O
are O
recommended O
to O
check O
the O
classical O
' O
hem O
##od O
##ial O
##ys O
##is O
' O
equation O
as O
the O
standard O
equation O
in O
calculating O
the O
c O
##v O
##v O
##h O
clearance B-PK
of O
highly O
protein O
- O
bound O
drugs O
. O
[SEP] O
[CLS] O
the O
pattern O
of O
heart O
rate O
observed O
in O
all O
subjects O
, O
including O
those O
who O
received O
place O
##bo O
, O
was O
consistent O
with O
the O
circa O
##dian O
rhythm O
, O
and O
heart O
rate O
reduction O
in O
the O
second O
12 O
hours O
was O
also O
consistent O
with O
normal O
di O
##urn O
##al O
variation O
. O
[SEP] O
[CLS] O
the O
actual O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
occurring O
at O
time B-PK
to I-PK
maximum I-PK
concentration I-PK
( I-PK
t I-PK
##max I-PK
) I-PK
were O
recorded O
. O
[SEP] O
[CLS] O
plasma O
concentrations O
were O
computer O
fitted O
to O
a O
three O
- O
compartment O
open O
model O
using O
a O
zero O
- O
order O
input O
function O
for O
the O
injection O
period O
. O
[SEP] O
[CLS] O
the O
limit O
of O
q O
##uant O
##ification O
was O
0 O
. O
4 O
ng O
. O
m O
##l O
- O
1 O
. O
[SEP] O
[CLS] O
serial O
blood O
samples O
were O
collected O
to O
character O
##ize O
the O
plasma O
concentration O
curve O
. O
[SEP] O
[CLS] O
cumulative O
incidence O
##s O
of O
grades O
ii O
- O
i O
##v O
and O
ii O
##i O
- O
i O
##v O
acute O
g O
##v O
##h O
##d O
at O
day O
100 O
were O
50 O
% O
and O
17 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
first O
group O
was O
subjected O
to O
me O
##so O
##ca O
##val O
s O
##hun O
##t O
( O
m O
##cs O
) O
and O
the O
other O
employed O
as O
a O
control O
. O
[SEP] O
[CLS] O
si O
##lica O
coating O
marked O
##ly O
improved O
the O
stability O
of O
flexible O
lip O
##oso O
##mes O
, O
and O
cu O
##r O
- O
s O
##ls O
exhibited O
a O
3 O
. O
31 O
- O
fold O
increase O
in O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
compared O
with O
cu O
##r O
- O
fl O
##s O
, O
indicating O
that O
si O
##lica O
- O
coated O
flexible O
lip O
##oso O
##mes O
may O
be O
employed O
as O
a O
potential O
carrier O
to O
deliver O
drugs O
with O
poor O
water O
so O
##lub O
##ility O
via O
the O
oral O
route O
with O
improved O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
lab O
##ras O
##ol O
was O
determined O
to O
be O
the O
most O
likely O
cu O
##l O
##p O
##rit O
for O
this O
double O
peaking O
phenomenon O
. O
[SEP] O
[CLS] O
blood O
samples O
at O
the O
first O
dose O
of O
na O
##b O
- O
p O
##ac O
##lit O
##ax O
##el O
were O
collected O
for O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
. O
[SEP] O
[CLS] O
demographic O
##s O
, O
clinical O
characteristics O
, O
and O
genetic O
p O
##oly O
##mor O
##phism O
##s O
were O
screened O
as O
co O
##var O
##iate O
##s O
. O
[SEP] O
[CLS] O
[ O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
3 O
' O
- O
a O
##zi O
##do O
- O
3 O
de O
##ox O
##y O
- O
thy O
##mi O
##dine O
( O
a O
##z O
##t O
) O
in O
a O
patient O
undergoing O
hem O
##od O
##ial O
##ys O
##is O
] O
. O
[SEP] O
[CLS] O
a O
significant O
difference O
was O
observed O
between O
but O
not O
within O
the O
tested O
products O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
p O
##har O
##ma O
##co O
##dynamic O
##s O
of O
p O
##ones O
##imo O
##d O
, O
a O
selective O
s O
##1 O
##p O
##1 O
receptor O
m O
##od O
##ulator O
, O
in O
the O
first O
- O
in O
- O
human O
study O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
co O
##ad O
##mini O
##stra O
##tion O
of O
m O
##k O
##5 O
##7 O
##1 O
or O
mid O
##az O
##ola O
##m O
increased O
sq O
##v O
absorption O
only O
2 O
- O
to O
3 O
- O
fold O
without O
improving O
the O
variation O
in O
au B-PK
##cs I-PK
. O
[SEP] O
[CLS] O
the O
au B-PK
##cs I-PK
for O
tablets O
alone O
, O
with O
ch O
##ole O
##sty O
##ram O
##ine O
, O
and O
with O
prop O
##ant O
##hel O
##ine O
were O
32 O
. O
8 O
+ O
- O
13 O
. O
3 O
( O
+ O
- O
s O
##d O
) O
, O
22 O
. O
4 O
+ O
- O
12 O
. O
1 O
, O
and O
40 O
. O
6 O
+ O
- O
13 O
. O
9 O
, O
respectively O
, O
while O
corresponding O
values O
for O
capsule O
##s O
were O
31 O
. O
7 O
+ O
- O
9 O
. O
3 O
, O
24 O
. O
7 O
+ O
- O
7 O
. O
9 O
, O
and O
35 O
. O
9 O
+ O
- O
12 O
. O
8 O
. O
[SEP] O
[CLS] O
it O
was O
recommended O
to O
perform O
the O
treatment O
with O
monitoring O
the O
anti O
##biotic O
plasma O
concentrations O
to O
prevent O
the O
drug O
failure O
because O
of O
the O
changes O
in O
the O
distribution O
and O
ex O
##cre O
##tion O
patterns O
. O
[SEP] O
[CLS] O
the O
analytical O
method O
was O
applied O
in O
a O
random O
##ized O
, O
crossover O
bio O
##e O
##qui O
##valence O
study O
of O
v O
##als O
##art O
##an O
tablets O
; O
the O
study O
enrolled O
18 O
chin O
##ese O
volunteers O
( O
12 O
were O
men O
and O
6 O
were O
women O
) O
. O
[SEP] O
[CLS] O
published O
and O
unpublished O
p O
##k O
/ O
p O
##d O
data O
from O
2 O
, O
187 O
b O
##al O
##b O
/ O
c O
and O
nude O
mice O
were O
used O
. O
2 O
, O
9 O
, O
14 O
, O
15 O
, O
16 O
mice O
in O
each O
experiment O
were O
block O
‐ O
random O
##ized O
to O
treatment O
assignment O
after O
a O
##ero O
##sol O
infection O
with O
m O
. O
tuberculosis O
h O
##37 O
##r O
##v O
. O
[SEP] O
[CLS] O
at O
present O
, O
prediction O
of O
flu O
##cona O
##zo O
##le O
doses O
according O
to O
developmental O
changes O
in O
flu O
##cona O
##zo O
##le O
clearance B-PK
is O
not O
being O
done O
in O
these O
patients O
. O
[SEP] O
[CLS] O
all O
adverse O
events O
were O
re O
##versible O
. O
[SEP] O
[CLS] O
the O
h O
##y O
##poli O
##pid O
##em O
##ic O
agent O
f O
##eno O
##fi O
##bra O
##te O
is O
an O
ideal O
model O
drug O
for O
testing O
the O
performance O
of O
drug O
delivery O
systems O
designed O
for O
poorly O
soluble O
compounds O
. O
[SEP] O
[CLS] O
the O
most O
common O
a O
##es O
were O
viral O
infection O
( O
16 O
. O
7 O
% O
) O
, O
na O
##so O
##pha O
##ryn O
##git O
##is O
( O
11 O
. O
1 O
% O
) O
, O
and O
h O
##yper O
##cal O
##ce O
##mia O
( O
11 O
. O
1 O
% O
) O
in O
the O
place O
##bo O
group O
, O
and O
r O
##hin O
##itis O
( O
16 O
. O
7 O
% O
) O
in O
the O
par O
##ical O
##ci O
##to O
##l O
group O
. O
[SEP] O
[CLS] O
among O
tested O
formulation O
##s O
, O
f O
##b O
- O
am O
##p O
( O
3 O
) O
, O
dramatically O
increased O
the O
dissolution O
of O
f O
##b O
and O
achieved O
rapid O
and O
complete O
drug O
release O
within O
2 O
hours O
. O
[SEP] O
[CLS] O
written O
consent O
was O
obtained O
from O
the O
patients O
prior O
to O
the O
trial O
. O
[SEP] O
[CLS] O
in O
the O
event O
that O
it O
is O
difficult O
to O
determine O
which O
structure O
best O
character O
##izes O
the O
data O
, O
it O
may O
be O
helpful O
to O
fit O
each O
subject O
individually O
to O
explore O
the O
reasons O
for O
une O
##x O
##plain O
##ed O
var O
##iability O
. O
[SEP] O
[CLS] O
the O
following O
for O
all O
anal O
##yte O
##s O
after O
administration O
were O
also O
calculated O
: O
t B-PK
##max I-PK
and O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
. O
[SEP] O
[CLS] O
consistent O
with O
overall O
survival O
and O
event O
free O
survival O
, O
the O
complete O
re O
##mission O
rates O
7 O
+ O
3 O
treatment O
, O
first O
, O
second O
, O
third O
, O
and O
fourth O
q O
##ua O
##rt O
##iles O
were O
26 O
. O
5 O
% O
, O
30 O
. O
3 O
% O
, O
37 O
. O
5 O
% O
, O
30 O
. O
3 O
% O
, O
and O
59 O
. O
4 O
% O
, O
respectively O
( O
table O
s O
##8 O
) O
. O
[SEP] O
[CLS] O
initial O
absorption B-PK
rate I-PK
constant I-PK
##s I-PK
were O
determined O
by O
the O
plot O
of O
log O
% O
remaining O
amount O
of O
drug O
in O
per O
##fu O
##sat O
##e O
vs O
time O
. O
[SEP] O
[CLS] O
in O
radio O
##im O
##mu O
##not O
##her O
##ap O
##y O
trials O
, O
12 O
patients O
with O
breast O
or O
pro O
##state O
cancer O
were O
given O
two O
imaging O
doses O
( O
5 O
m O
##ci O
each O
) O
of O
( O
111 O
) O
in O
- O
dot O
##a O
- O
g O
##ly O
##3 O
##phe O
- O
m O
##17 O
##0 O
1 O
week O
apart O
. O
[SEP] O
[CLS] O
detect O
##able O
serum O
concentrations O
of O
c O
##lar O
##ith O
##rom O
##y O
##cin O
were O
found O
in O
3 O
of O
6 O
f O
##oa O
##ls O
at O
10 O
minutes O
and O
in O
all O
f O
##oa O
##ls O
by O
20 O
minutes O
post O
- O
administration O
. O
[SEP] O
[CLS] O
to O
sum O
##mar O
##ize O
, O
43 O
analog O
##s O
were O
synthesized O
out O
of O
which O
15 O
compounds O
showed O
very O
potent O
sub O
- O
na O
##no O
##mo O
##lar O
efficacy O
in O
in O
v O
##it O
##ro O
systems O
but O
the O
liability O
of O
metabolic O
instability O
seemed O
to O
be O
the O
major O
challenge O
for O
this O
chemical O
class O
and O
remains O
to O
be O
addressed O
. O
[SEP] O
[CLS] O
the O
automatic O
p O
##ca O
- O
based O
approach O
minimize O
##s O
the O
var O
##iability O
associated O
to O
obtaining O
individual O
volume O
- O
based O
a O
##if O
##s O
in O
d O
##ce O
- O
m O
##r O
studies O
of O
the O
pro O
##state O
. O
[SEP] O
[CLS] O
the O
mean O
sa O
##liva O
/ O
plasma O
concentration O
of O
test O
and O
reference O
were O
2 O
. O
29 O
and O
2 O
. O
33 O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
c O
##dd O
##p O
and O
p O
##t O
##x O
in O
co O
- O
n O
##ps O
are O
mainly O
dispersed O
to O
the O
blood O
, O
liver O
, O
and O
s O
##ple O
##en O
, O
and O
bone O
ma O
##rrow O
, O
followed O
by O
secondary O
distribution O
in O
the O
kidney O
and O
tumor O
. O
[SEP] O
[CLS] O
to O
investigate O
sequence O
effects O
on O
toxicity O
, O
tumor O
response O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
do O
##ce O
##ta O
##xe O
##l O
and O
car O
##bo O
##p O
##lat O
##in O
, O
together O
with O
a O
determination O
of O
the O
maximum O
- O
tolerate O
##d O
dose O
( O
m O
##t O
##d O
) O
and O
recommended O
dose O
for O
each O
schedule O
. O
[SEP] O
[CLS] O
the O
peak O
area O
of O
r O
##s O
- O
1 O
was O
enhanced O
after O
en O
##zy O
##mo O
##lysis O
of O
the O
samples O
with O
β O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
or O
su O
##lf O
##ata O
##se O
, O
which O
indicated O
that O
it O
contains O
r O
##s O
- O
1 O
g O
##lu O
##cu O
##ron O
##ide O
and O
su O
##lf O
##ate O
con O
##ju O
##gate O
##s O
. O
[SEP] O
[CLS] O
m O
##s O
( O
es O
##i O
) O
( O
m O
/ O
z O
) O
: O
[ O
m O
] O
+ O
302 O
. O
00 O
, O
[ O
m O
+ O
h O
] O
+ O
303 O
. O
00 O
. O
[SEP] O
[CLS] O
h O
##r O
) O
than O
in O
men O
( O
3 O
. O
19 O
+ O
- O
0 O
. O
48 O
mm O
##ol O
/ O
l O
. O
[SEP] O
[CLS] O
liquid O
mi O
##cs O
were O
performed O
as O
described O
above O
with O
the O
additional O
step O
of O
determining O
the O
number O
of O
bacteria O
added O
to O
each O
well O
. O
[SEP] O
[CLS] O
reaction O
was O
halted O
by O
the O
addition O
of O
5 O
μ O
##l O
of O
1 O
m O
su O
##l O
##ph O
##uri O
##c O
acid O
. O
[SEP] O
[CLS] O
a O
good O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
( O
serum O
and O
brain O
concentrations O
and O
u O
##rina O
##ry O
recovery O
) O
was O
obtained O
for O
the O
two O
c O
##yclic O
compounds O
( O
3 O
##e O
and O
3 O
##g O
) O
, O
but O
that O
of O
the O
vinyl O
##ic O
compounds O
( O
3 O
##m O
and O
3 O
##o O
) O
was O
less O
favorable O
. O
[SEP] O
[CLS] O
all O
patients O
had O
received O
prior O
systemic O
therapy O
. O
[SEP] O
[CLS] O
j O
##ej O
##un O
##um O
portions O
of O
1 O
cm O
were O
stored O
in O
the O
tissue O
proceeding O
medium O
o O
##ct O
and O
frozen O
at O
− O
##80 O
° O
##c O
. O
[SEP] O
[CLS] O
re O
##sm O
##ino O
##sta O
##t O
was O
safely O
administered O
with O
a O
dose O
- O
proportional O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
, O
optimal O
on O
- O
target O
p O
##har O
##ma O
##co O
##dynamic O
activity O
at O
dose O
levels O
≥ O
##40 O
##0 O
mg O
and O
signs O
of O
anti O
##tum O
##or O
efficacy O
. O
[SEP] O
[CLS] O
all O
4 O
antagonist O
##s O
bound O
to O
their O
respective O
receptors O
with O
high O
affinity O
and O
select O
##ivity O
in O
v O
##it O
##ro O
. O
[SEP] O
[CLS] O
based O
on O
pre O
- O
dose O
p O
##k O
samples O
obtained O
, O
er O
##yt O
##hr O
##omy O
##cin O
plasma B-PK
concentrations I-PK
at I-PK
t I-PK
##rough I-PK
were O
determined O
and O
attain O
##ment O
of O
steady O
- O
state O
conditions O
was O
assessed O
visually O
. O
[SEP] O
[CLS] O
the O
dose O
of O
co O
##u O
that O
promoted O
the O
br O
##on O
##cho O
##di O
##lator O
effect O
in O
g O
##uin O
##ea O
pigs O
( O
ad O
##50 O
: O
75 O
mg O
/ O
kg O
) O
[ O
15 O
] O
was O
used O
as O
a O
reference O
to O
conduct O
the O
study O
. O
[SEP] O
[CLS] O
data O
acquisition O
and O
processing O
were O
operated O
through O
mass O
##lyn O
##x O
v O
##4 O
. O
1 O
works O
##tation O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
recorded O
after O
a O
##ero O
##sol O
administration O
, O
v O
##iz O
. O
[SEP] O
[CLS] O
the O
workers O
had O
previously O
been O
found O
to O
have O
elevated O
levels O
of O
high O
- O
and O
medium O
- O
br O
##omi O
##nated O
dip O
##hen O
##yl O
et O
##hers O
compared O
with O
the O
refer O
##ent O
populations O
. O
[SEP] O
[CLS] O
a O
selective O
and O
sensitive O
liquid O
ch O
##roma O
##tography O
tandem O
mass O
s O
##pect O
##rome O
##try O
method O
was O
developed O
for O
the O
first O
time O
for O
the O
identification O
and O
q O
##uant O
##ification O
of O
cu O
##rdi O
##one O
in O
rabbit O
plasma O
after O
v O
##agi O
##nal O
drug O
administration O
and O
in O
##tra O
##ven O
##ous O
administration O
of O
z O
##ed O
##oar O
##y O
t O
##ur O
##mer O
##ic O
oil O
( O
z O
##to O
) O
solution O
( O
10 O
mg O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
benefits O
must O
be O
weighed O
against O
the O
potential O
for O
higher O
var O
##iability O
in O
drug O
exposure O
after O
la O
##i O
administration O
. O
[SEP] O
[CLS] O
no O
clinical O
##ly O
significant O
changes O
were O
observed O
with O
respect O
to O
body O
weight O
and O
vital O
signs O
throughout O
the O
study O
. O
[SEP] O
[CLS] O
for O
example O
, O
one O
re O
##nal O
cell O
car O
##cin O
##oma O
patient O
( O
p O
##t O
01 O
) O
with O
disease O
progression O
following O
c O
##yt O
##oki O
##ne O
and O
anti O
- O
an O
##gio O
##genic O
therapy O
, O
initially O
treated O
at O
4 O
mg O
m O
##− O
##2 O
en O
##tino O
##sta O
##t O
, O
had O
dose O
reduction O
to O
2 O
mg O
m O
##− O
##2 O
after O
the O
second O
cycle O
. O
[SEP] O
[CLS] O
the O
anal O
##yte O
##s O
were O
separated O
by O
a O
reversed O
phase O
c O
##18 O
column O
( O
150 O
##x O
##4 O
. O
6 O
mm O
i O
. O
d O
. O
, O
particle O
size O
5 O
micro O
##m O
) O
and O
el O
##uted O
with O
ace O
##ton O
##it O
##ril O
##e O
- O
1 O
##mm O
h O
##co O
##oh O
mobile O
phase O
( O
70 O
: O
30 O
, O
v O
/ O
v O
) O
with O
a O
flow O
rate O
of O
0 O
. O
8 O
m O
##l O
/ O
min O
in O
rat O
plasma O
and O
herb O
##al O
extract O
##s O
. O
[SEP] O
[CLS] O
the O
authors O
determined O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
c O
##ef O
##tri O
##ax O
##one O
, O
a O
c O
##ep O
##hal O
##os O
##por O
##in O
that O
binds O
strongly O
to O
album O
##in O
in O
posts O
##urg O
##ical O
patients O
with O
h O
##ydro O
##xy O
##eth O
##yl O
star O
##ch O
- O
induced O
h O
##y O
##po O
##al O
##bu O
##mine O
##mia O
. O
[SEP] O
[CLS] O
double O
peaks O
and O
extended O
terminal B-PK
half I-PK
- I-PK
life I-PK
were O
observed O
, O
which O
was O
likely O
caused O
by O
enter O
##oh O
##ep O
##atic O
re O
##ci O
##rc O
##ulation O
. O
[SEP] O
[CLS] O
efficacy O
assessments O
included O
clinical O
and O
para O
##si O
##to O
##logical O
evaluation O
. O
[SEP] O
[CLS] O
recovery O
the O
relative O
recover O
##ies O
for O
o O
##s O
( O
75 O
ng O
/ O
m O
##l O
) O
and O
o O
##s O
##c O
( O
200 O
ng O
/ O
m O
##l O
) O
were O
determined O
with O
92 O
. O
8 O
% O
and O
100 O
. O
2 O
% O
, O
respectively O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
that O
vitamin O
d O
##3 O
supplement O
##ation O
( O
1000 O
i O
##u O
per O
day O
) O
in O
human O
volunteers O
does O
not O
produce O
a O
p O
- O
g O
##p O
- O
mediated O
drug O
interaction O
with O
oral O
##ly O
administered O
dig O
##ox O
##in O
. O
[SEP] O
[CLS] O
to O
assess O
the O
inter O
- O
day O
( O
over O
3 O
days O
) O
ass O
##ay O
accuracy O
and O
precision O
, O
three O
sets O
of O
plasma O
samples O
were O
spike O
##d O
with O
o O
##t O
##c O
at O
0 O
. O
05 O
, O
0 O
. O
25 O
, O
5 O
, O
and O
10 O
μ O
##g O
/ O
m O
##l O
concentrations O
. O
[SEP] O
[CLS] O
ma O
##gnesium O
is O
##og O
##ly O
##cy O
##rr O
##hi O
##zin O
##ate O
( O
mi O
) O
has O
been O
complement O
##arily O
used O
for O
restoring O
the O
he O
##pa O
##tic O
imp O
##air O
##ments O
caused O
by O
tax O
##ol O
plus O
platinum O
based O
ch O
##em O
##oth O
##era O
##pies O
in O
chin O
##a O
. O
[SEP] O
[CLS] O
maximum O
residual O
levels O
in O
milk O
were O
below O
the O
maximum O
acceptable O
level O
of O
20 O
micro O
##g O
/ O
kg O
; O
however O
, O
e O
##p O
##r O
was O
detected O
in O
all O
samples O
investigated O
. O
[SEP] O
[CLS] O
the O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
new O
formulation O
is O
about O
100 O
% O
. O
[SEP] O
[CLS] O
significant O
changes O
in O
dig O
##ox O
##in O
half B-PK
- I-PK
life I-PK
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
were O
also O
observed O
with O
c O
##lar O
##ith O
##rom O
##y O
##cin O
. O
[SEP] O
[CLS] O
the O
standard O
curve O
for O
d O
##hm O
in O
plasma O
was O
linear O
in O
the O
concentration O
range O
of O
0 O
. O
5 O
– O
200 O
ng O
/ O
m O
##l O
( O
y O
= O
0 O
. O
125 O
##x O
+ O
0 O
. O
116 O
, O
r O
= O
0 O
. O
99 O
##9 O
) O
. O
[SEP] O
[CLS] O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
model O
was O
built O
, O
which O
contains O
three O
distinct O
compartment O
##s O
, O
to O
describe O
the O
distribution O
of O
r O
##it O
##ux O
##ima O
##b O
within O
the O
ne O
##uro O
##ax O
##is O
after O
in O
##tra O
##vent O
##ric O
##ular O
administration O
. O
[SEP] O
[CLS] O
the O
plasma O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
c O
##ere O
##bro O
##sp O
##inal O
fluid O
penetration O
of O
the O
thy O
##mi O
##dy O
##late O
s O
##ynth O
##ase O
inhibitor O
r O
##al O
##ti O
##tre O
##xed O
( O
to O
##mu O
##de O
##x O
) O
in O
a O
non O
##human O
p O
##rima O
##te O
model O
. O
[SEP] O
[CLS] O
to O
op O
##ti O
##mize O
an O
im O
##mu O
##no O
##pha O
##rma O
##cot O
##her O
##ap O
##eu O
##tic O
strategy O
for O
re O
##versing O
severe O
cocaine O
toxicity O
, O
the O
therapeutic O
properties O
of O
ma O
##b O
g O
##nc O
##9 O
##2 O
##h O
##2 O
i O
##gg O
were O
compared O
to O
those O
of O
its O
engineered O
formats O
in O
a O
mouse O
over O
##dos O
##e O
model O
. O
[SEP] O
[CLS] O
n O
##us O
##iner O
##sen O
( O
previously O
is O
##is O
- O
s O
##m O
##n O
##r O
##x O
and O
also O
known O
as O
is O
##is O
39 O
##64 O
##43 O
) O
is O
an O
anti O
##sen O
##se O
o O
##li O
##gon O
##uc O
##leo O
##tide O
designed O
to O
bind O
to O
the O
s O
##m O
##n O
##2 O
pre O
- O
m O
##rna O
and O
promote O
inclusion O
of O
ex O
##on O
7 O
( O
figure O
1 O
) O
. O
6 O
, O
7 O
in O
mouse O
models O
of O
s O
##ma O
, O
n O
##us O
##iner O
##sen O
enhanced O
ex O
##on O
7 O
inclusion O
, O
increased O
s O
##m O
##n O
protein O
production O
, O
and O
improved O
function O
. O
6 O
– O
9 O
n O
##us O
##iner O
##sen O
is O
delivered O
by O
in O
##tra O
##the O
##cal O
injection O
as O
anti O
##sen O
##se O
o O
##li O
##gon O
##uc O
##leo O
##tide O
drugs O
do O
not O
cross O
an O
intact O
blood O
– O
brain O
barrier O
when O
delivered O
systemic O
##ally O
. O
10 O
this O
first O
- O
in O
- O
human O
, O
open O
- O
label O
, O
single O
- O
ascending O
dose O
study O
was O
designed O
to O
assess O
safety O
, O
to O
##ler O
##ability O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
and O
clinical O
effects O
of O
in O
##tra O
##the O
##cal O
n O
##us O
##iner O
##sen O
in O
patients O
with O
childhood O
s O
##ma O
. O
[SEP] O
[CLS] O
further O
details O
and O
results O
for O
t O
##s O
##cc O
derived O
from O
solid O
cultures O
are O
described O
in O
the O
supplement O
##ary O
material O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
0 I-PK
to I-PK
in I-PK
##finity I-PK
) I-PK
was O
239 O
. O
3 O
± O
121 O
. O
1 O
μ O
##g O
· O
h O
##r O
/ O
m O
##l O
. O
no O
significant O
adverse O
drug O
reactions O
were O
clinical O
##ly O
observed O
, O
and O
no O
visible O
injection O
site O
reactions O
were O
noted O
. O
[SEP] O
[CLS] O
this O
study O
attempts O
to O
fabric O
##ate O
the O
c O
##ef O
##uro O
##xi O
##me O
- O
loaded O
na O
##no O
##em O
##ul O
##sion O
( O
c O
##ln O
) O
to O
increase O
drug O
penetration O
into O
the O
brain O
when O
parent O
##eral O
##ly O
administered O
. O
[SEP] O
[CLS] O
that O
is O
, O
in O
both O
fluids O
d O
##z O
and O
d O
##m O
##d O
concentrations O
were O
different O
from O
those O
at O
the O
time O
of O
death O
and O
post O
- O
m O
##ort O
##em O
distribution O
and O
red O
##ist O
##ri O
##but O
##ion O
phenomena O
occurred O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
p O
##har O
##ma O
##co O
##dynamic O
parameters O
were O
summarized O
with O
descriptive O
statistics O
( O
arithmetic O
mean O
and O
standard O
de O
##viation O
, O
or O
median O
and O
inter O
##qua O
##rt O
##ile O
range O
, O
as O
appropriate O
) O
. O
[SEP] O
[CLS] O
m O
##otes O
##ani O
##b O
125 O
mg O
q O
##d O
was O
, O
therefore O
, O
established O
as O
the O
m O
##t O
##d O
, O
and O
12 O
additional O
patients O
were O
enrolled O
into O
co O
##hor O
##t O
b O
##3 O
and O
received O
m O
##otes O
##ani O
##b O
125 O
mg O
q O
##d O
plus O
do O
##ce O
##ta O
##xe O
##l O
75 O
mg O
/ O
m O
##2 O
; O
no O
d O
##lts O
occurred O
in O
this O
co O
##hor O
##t O
. O
[SEP] O
[CLS] O
two O
dos O
##ing O
schedules O
of O
the O
novel O
in O
##den O
##ois O
##o O
##quin O
##olin O
##e O
, O
in O
##dote O
##can O
( O
l O
##mp O
##40 O
##0 O
) O
, O
were O
evaluated O
in O
patients O
with O
advanced O
solid O
tumors O
. O
[SEP] O
[CLS] O
hazard O
ratios O
and O
corresponding O
95 O
% O
confidence O
intervals O
( O
c O
##i O
) O
were O
calculated O
and O
considered O
statistical O
##ly O
significant O
when O
the O
c O
##i O
excluded O
1 O
. O
0 O
. O
[SEP] O
[CLS] O
cu O
##rc O
##umi O
##n O
was O
en O
##cap O
##sul O
##ated O
with O
97 O
. O
5 O
% O
efficiency O
in O
bio O
##de O
##grad O
##able O
na O
##no O
##par O
##tic O
##ulate O
formulation O
based O
on O
p O
##oly O
( O
la O
##ct O
##ide O
- O
co O
- O
g O
##ly O
##co O
##lide O
) O
( O
p O
##l O
##ga O
) O
and O
a O
stab O
##ilizer O
p O
##oly O
##eth O
##yle O
##ne O
g O
##ly O
##co O
##l O
( O
p O
##eg O
) O
- O
5000 O
. O
[SEP] O
[CLS] O
no O
s O
##yne O
##rgy O
, O
add O
##iti O
##vity O
, O
or O
ant O
##agon O
##ism O
was O
observed O
. O
[SEP] O
[CLS] O
the O
training O
trial O
was O
performed O
on O
the O
first O
day O
. O
[SEP] O
[CLS] O
the O
precision O
and O
accuracy O
of O
the O
uh O
##p O
##l O
##c O
method O
were O
evaluated O
by O
anal O
##ys O
##ing O
blank O
samples O
of O
urine O
spike O
##d O
with O
high O
, O
medium O
, O
and O
low O
concentrations O
of O
the O
fl O
##av O
##ono O
##ids O
and O
is O
##of O
##lav O
##ones O
. O
[SEP] O
[CLS] O
we O
showed O
that O
administration O
of O
c O
##yn O
##omo O
##l O
##gus O
il O
- O
31 O
induce O
##s O
trans O
##ient O
scratching O
behaviour O
in O
c O
##yn O
##omo O
##l O
##gus O
monkeys O
and O
by O
that O
were O
able O
to O
establish O
a O
monkey O
model O
of O
scratching O
. O
[SEP] O
[CLS] O
regarding O
the O
particle O
size O
, O
there O
was O
no O
significant O
change O
after O
storage O
at O
4 O
. O
0 O
##± O
##1 O
##° O
##c O
, O
but O
at O
25 O
##± O
##2 O
##° O
##c O
, O
there O
was O
a O
slight O
increase O
in O
particle O
size O
of O
the O
s O
##ln O
##s O
( O
from O
96 O
nm O
to O
106 O
nm O
) O
, O
which O
could O
be O
due O
to O
a O
##gg O
##regation O
of O
s O
##ln O
at O
this O
temperature O
. O
[SEP] O
[CLS] O
re O
##mi O
##fen O
##tani O
##l O
p O
##har O
##ma O
##co O
##kin O
##etics O
was O
described O
with O
a O
two O
- O
compartment O
model O
, O
parameter O
estimates O
were O
2 O
. O
99 O
l O
x O
min O
( O
- O
1 O
) O
x O
70 O
kg O
( O
- O
1 O
) O
for O
clearance B-PK
and O
16 O
. O
23 O
l O
x O
70 O
kg O
( O
- O
1 O
) O
for O
steady B-PK
state I-PK
volume I-PK
of I-PK
distribution I-PK
. O
[SEP] O
[CLS] O
to O
determine O
the O
influence O
of O
h O
. O
p O
##yl O
##ori O
infection O
on O
effectiveness O
of O
r O
##abe O
##pra O
##zo O
##le O
in O
primary O
and O
secondary O
care O
, O
wit O
et O
al O
( O
2004 O
) O
tested O
for O
h O
. O
p O
##yl O
##ori O
1787 O
patients O
from O
primary O
and O
secondary O
care O
centers O
with O
un O
##in O
##ves O
##ti O
##gated O
suspected O
g O
##erd O
( O
based O
on O
symptoms O
only O
) O
and O
investigated O
g O
##erd O
( O
end O
##os O
##copic O
##ally O
confirmed O
o O
##es O
##op O
##ha O
##git O
##is O
or O
end O
##os O
##copy O
- O
negative O
re O
##f O
##lux O
disease O
) O
and O
then O
treated O
them O
with O
r O
##abe O
##pra O
##zo O
##le O
20 O
mg O
once O
daily O
for O
4 O
– O
8 O
weeks O
in O
a O
non O
- O
random O
##ized O
, O
multi O
##cent O
##er O
, O
open O
- O
label O
study O
. O
[SEP] O
[CLS] O
p O
##q O
is O
also O
classified O
as O
a O
" O
direct O
he O
##pa O
##to O
##to O
##xi O
##can O
##t O
" O
following O
an O
acute O
high O
dose O
exposure O
. O
[SEP] O
[CLS] O
restricted O
maximum O
‐ O
likelihood O
est O
##imation O
was O
used O
. O
[SEP] O
[CLS] O
no O
clear O
relationship O
between O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
and O
response O
to O
therapy O
( O
x O
##4 O
log O
r O
##lu O
reduction O
) O
was O
observed O
. O
[SEP] O
[CLS] O
dose O
- O
normal O
##ized O
concentrations O
plot O
##ted O
over O
time O
did O
not O
overlap O
. O
[SEP] O
[CLS] O
an O
increasing O
number O
of O
hem O
##or O
##r O
##ha O
##gic O
and O
th O
##rom O
##bot O
##ic O
events O
prompted O
us O
to O
initiate O
a O
monitoring O
program O
for O
as O
##par O
##agi O
##nas O
##e O
treatment O
. O
[SEP] O
[CLS] O
from O
the O
boots O
##tra O
##p O
analysis O
, O
86 O
##9 O
( O
86 O
. O
9 O
% O
) O
of O
the O
1000 O
non O
##me O
##m O
runs O
con O
##ver O
##ged O
successfully O
within O
the O
specified O
1000 O
it O
##eration O
##s O
. O
[SEP] O
[CLS] O
in O
addition O
, O
clinical O
is O
##olate O
##s O
of O
s O
. O
e O
##pid O
##er O
##mi O
##dis O
from O
infected O
s O
##hun O
##ts O
are O
typically O
resistant O
to O
met O
##hic O
##ill O
##in O
. O
[SEP] O
[CLS] O
the O
t B-PK
##½ I-PK
was O
defined O
as O
l O
##n O
##2 O
/ O
λ O
##z O
and O
c B-PK
##l I-PK
/ I-PK
f I-PK
was O
estimated O
as O
dose B-PK
/ I-PK
au I-PK
##c I-PK
##∞ I-PK
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
he O
##sper O
##id O
##in O
are O
affected O
by O
treatment O
with O
g O
##lu O
##cos O
##idas O
##e O
- O
like O
b O
##g O
##la O
protein O
isolated O
from O
yeast O
##s O
. O
[SEP] O
[CLS] O
the O
brain O
’ O
s O
target O
was O
higher O
in O
s O
##tri O
##at O
##um O
and O
c O
##ere O
##bell O
##um O
. O
[SEP] O
[CLS] O
quantitative O
structure O
- O
p O
##har O
##ma O
##co O
##kin O
##etic O
relationships O
for O
plasma B-PK
clearance I-PK
of O
basic O
drugs O
with O
consideration O
of O
the O
major O
elimination O
pathway O
. O
[SEP] O
[CLS] O
a O
ch O
##olic O
acid O
con O
##ju O
##gate O
that O
retained O
these O
properties O
would O
be O
expected O
to O
have O
exceptionally O
substantial O
he O
##pa O
##tic O
levels O
and O
a O
high O
liver B-PK
- I-PK
to I-PK
- I-PK
plasma I-PK
ratio I-PK
##13 O
. O
[SEP] O
[CLS] O
once O
daily O
administration O
of O
high O
dose O
of O
amino O
##gly O
##cos O
##ides O
, O
resulted O
in O
effective O
serum O
concentrations O
and O
absence O
of O
ne O
##ph O
##rot O
##ox O
##icit O
##y O
. O
[SEP] O
[CLS] O
a O
method O
for O
the O
determination O
of O
plasma O
concentration O
of O
lie O
##ns O
##ini O
##ne O
with O
hp O
##l O
##c O
and O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
of O
lie O
##ns O
##ini O
##ne O
in O
rabbits O
were O
reported O
. O
[SEP] O
[CLS] O
accordingly O
, O
the O
g O
##ly O
##cos O
##uria O
- O
and O
/ O
or O
h O
##yper O
##gly O
##ce O
##mia O
- O
induced O
decrease O
in O
the O
biological B-PK
half I-PK
- I-PK
life I-PK
of O
o O
##xy O
##pur O
##ino O
##l O
must O
be O
considered O
in O
the O
administration O
of O
all O
##op O
##uri O
##no O
##l O
to O
go O
##ut O
##y O
patients O
with O
un O
##con O
##tro O
##lled O
diabetes O
me O
##lli O
##tus O
. O
[SEP] O
[CLS] O
in O
these O
patients O
, O
combination O
anti O
##vir O
##al O
drug O
treatment O
should O
be O
considered O
. O
[SEP] O
[CLS] O
for O
each O
level O
of O
q O
##c O
samples O
including O
the O
lower O
limit O
of O
q O
##uant O
##ification O
, O
both O
inter O
- O
and O
in O
##tra O
- O
day O
precision O
##s O
( O
r O
. O
s O
. O
d O
. O
) O
were O
< O
or O
= O
14 O
. O
0 O
% O
for O
c O
##ef O
##ale O
##xin O
and O
< O
or O
= O
11 O
. O
4 O
% O
for O
trim O
##eth O
##op O
##rim O
, O
and O
accuracy O
( O
re O
) O
was O
- O
1 O
. O
4 O
% O
for O
c O
##ef O
##ale O
##xin O
and O
- O
3 O
. O
0 O
% O
for O
trim O
##eth O
##op O
##rim O
. O
[SEP] O
[CLS] O
adverse O
events O
( O
a O
##es O
) O
, O
vital O
signs O
, O
laboratory O
tests O
, O
p O
##k O
, O
and O
evidence O
of O
bio O
##log O
##ic O
activity O
were O
descriptive O
##ly O
compared O
across O
the O
various O
treatment O
groups O
with O
no O
formal O
statistical O
testing O
. O
[SEP] O
[CLS] O
the O
relationship O
between O
doses O
and O
concentrations O
, O
doses O
and O
u O
##rina O
##ry O
ex O
##cre O
##tion O
of O
unchanged O
compound O
and O
major O
meta O
##bol O
##ites O
was O
linear O
in O
all O
species O
, O
except O
rabbits O
. O
[SEP] O
[CLS] O
a O
secondary O
goal O
was O
to O
estimate O
the O
response O
rate O
in O
a O
group O
of O
heavily O
pre O
##tre O
##ated O
patients O
with O
advanced O
solid O
tumors O
. O
[SEP] O
[CLS] O
the O
correlation O
coefficient O
between O
years O
delay O
for O
various O
cat O
##ara O
##cts O
sub O
##cate O
##gor O
##ies O
versus O
as O
##pi O
##rin O
taken O
( O
in O
tablets O
per O
day O
x O
years O
of O
intake O
) O
was O
0 O
. O
69 O
. O
[SEP] O
[CLS] O
maximum O
tolerate O
##d O
dose O
( O
m O
##t O
##d O
) O
studies O
, O
performed O
on O
6 O
– O
8 O
weeks O
- O
old O
b O
##al O
##b O
/ O
c O
w O
##t O
mice O
, O
revealed O
that O
or O
##x O
- O
301 O
was O
safe O
up O
to O
a O
dose O
of O
2000 O
mg O
/ O
kg O
when O
administered O
sub O
##cut O
##aneous O
##ly O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
after O
p O
##o O
administration O
, O
au B-PK
##c I-PK
values O
for O
the O
control O
and O
t O
- O
2 O
group O
were O
nearly O
identical O
on O
average O
. O
[SEP] O
[CLS] O
here O
##in O
, O
we O
describe O
a O
novel O
am O
##phi O
##pathic O
ch O
##ito O
##san O
derivative O
( O
n O
- O
o O
##ct O
##yl O
- O
n O
' O
- O
p O
##ht O
##hal O
##yl O
- O
o O
- O
p O
##hos O
##ph O
##ory O
##l O
ch O
##ito O
##san O
, O
abbreviated O
as O
op O
##p O
##c O
) O
as O
an O
effective O
oral O
delivery O
platform O
for O
p O
- O
g O
##p O
substrates O
, O
especially O
p O
##ac O
##lit O
##ax O
##el O
( O
p O
##t O
##x O
) O
. O
[SEP] O
[CLS] O
p O
. O
c O
##yn O
##omo O
##l O
##gi O
m O
strain O
( O
a O
non O
- O
human O
p O
##rima O
##te O
malaria O
closely O
related O
to O
the O
human O
malaria O
p O
. O
v O
##iva O
##x O
and O
forming O
dormant O
liver O
stages O
) O
was O
used O
for O
in O
v O
##it O
##ro O
liver O
stage O
drug O
ass O
##ays O
( O
the O
m O
strain O
b O
##p O
##rc O
was O
obtained O
from O
centers O
for O
disease O
control O
and O
prevention O
( O
c O
##d O
##c O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
the O
disposition O
of O
the O
individual O
en O
##anti O
##omer O
##s O
and O
their O
electro O
##phy O
##sio O
##log O
##ic O
actions O
are O
unknown O
. O
[SEP] O
[CLS] O
sample O
clean O
- O
up O
was O
achieved O
by O
solid O
- O
phase O
extraction O
on O
an O
##ion O
- O
exchange O
cartridges O
, O
which O
proved O
to O
be O
sufficient O
to O
obtain O
mass O
ch O
##roma O
##to O
##gram O
##s O
devoid O
of O
matrix O
interference O
##s O
. O
[SEP] O
[CLS] O
apparently O
healthy O
; O
[SEP] O
[CLS] O
re O
##comb O
##ina O
##nt O
human O
an O
##gio O
##sta O
##tin O
by O
twice O
- O
daily O
sub O
##cut O
##aneous O
injection O
in O
advanced O
cancer O
: O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
long O
- O
term O
safety O
study O
. O
[SEP] O
[CLS] O
reviewer O
# O
1 O
: O
[SEP] O
[CLS] O
the O
plasma O
concentrations O
of O
h O
##ydro O
##ly O
##za O
##tes O
which O
are O
sa O
##lic O
##yl O
##ic O
acid O
and O
para O
##ce O
##tam O
##ol O
from O
ben O
##ori O
##late O
in O
v O
##ivo O
were O
measured O
by O
hp O
##l O
##c O
. O
[SEP] O
[CLS] O
plasma O
samples O
were O
extracted O
using O
a O
liquid O
– O
liquid O
extraction O
technique O
. O
[SEP] O
[CLS] O
elimination B-PK
clearance I-PK
of O
both O
meta O
##bol O
##ites O
decreased O
with O
t O
##b O
##w O
( O
c B-PK
##le I-PK
m O
##3 O
##g O
##p O
< O
0 O
. O
00 O
##1 O
, O
− O
##16 O
of O
##v O
, O
c B-PK
##le I-PK
m O
##6 O
##g O
##p O
< O
0 O
. O
00 O
##1 O
, O
− O
##9 O
##2 O
of O
##v O
) O
, O
and O
the O
peripheral B-PK
volume I-PK
of O
m O
##or O
##phine O
increased O
significantly O
with O
increasing O
t O
##b O
##w O
( O
p O
< O
0 O
. O
00 O
##1 O
, O
− O
##34 O
of O
##v O
) O
. O
[SEP] O
[CLS] O
this O
study O
indicates O
that O
me O
##ga O
##zo O
##l O
crosses O
the O
blood O
- O
brain O
barrier O
after O
oral O
administration O
. O
[SEP] O
[CLS] O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
was O
expressed O
as O
the O
ratio O
of O
dose O
‐ O
normal O
##ized O
adjusted O
geometric O
means O
of O
au B-PK
##c I-PK
##0 I-PK
‐ I-PK
∞ I-PK
for O
oral O
and O
i O
##v O
g O
##las O
##de O
##gi O
##b O
. O
[SEP] O
[CLS] O
all O
dos O
##ing O
co O
##hor O
##ts O
were O
fully O
enrolled O
; O
all O
subjects O
completed O
the O
safety O
follow O
- O
up O
. O
[SEP] O
[CLS] O
to O
determine O
and O
compare O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
it O
##rac O
##ona O
##zo O
##le O
in O
dogs O
after O
oral O
administration O
of O
commercially O
available O
capsule O
and O
solution O
formulation O
##s O
intended O
for O
use O
in O
humans O
. O
[SEP] O
[CLS] O
la O
##tam O
##ox O
##ef O
( O
l O
##mo O
##x O
, O
si O
##oma O
##rin O
) O
at O
a O
dose O
of O
2 O
g O
was O
in O
##tra O
##ven O
##ously O
administered O
to O
each O
of O
23 O
patients O
undergoing O
the O
open O
heart O
surgery O
and O
the O
concentrations O
in O
serum O
, O
per O
##ica O
##rdi O
##al O
fluid O
and O
au O
##ric O
##le O
of O
heart O
were O
measured O
. O
[SEP] O
[CLS] O
in O
the O
diet O
with O
no O
p O
##hy O
##tase O
, O
ca O
and O
a O
##p O
were O
at O
0 O
. O
50 O
% O
and O
0 O
. O
19 O
% O
, O
respectively O
, O
and O
, O
in O
the O
diet O
with O
p O
##hy O
##tase O
, O
ca O
and O
a O
##p O
were O
each O
decreased O
by O
0 O
. O
12 O
% O
. O
[SEP] O
[CLS] O
the O
in O
##tra O
- O
day O
and O
inter O
- O
day O
precision O
##s O
of O
n O
##f O
and O
n O
- O
n O
##f O
were O
less O
than O
20 O
% O
, O
and O
the O
accuracy O
ranged O
from O
91 O
. O
09 O
to O
113 O
. O
03 O
% O
at O
30 O
, O
300 O
and O
3 O
, O
000 O
ng O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
such O
negative O
charge O
is O
anticipated O
to O
be O
decreased O
upon O
r O
##l O
##x O
addition O
, O
where O
part O
of O
tea O
will O
react O
with O
r O
##l O
##x O
salt O
, O
leading O
to O
the O
formation O
of O
r O
##l O
##x O
base O
and O
chloride O
salt O
of O
tea O
, O
which O
is O
water O
- O
soluble O
salt O
lost O
after O
di O
##lution O
. O
[SEP] O
[CLS] O
to O
determine O
the O
disposition O
of O
co O
##list O
##in O
met O
##hane O
##sul O
##phon O
##ate O
( O
cm O
##s O
) O
and O
co O
##list O
##in O
following O
in O
##tra O
##ven O
##ous O
( O
i O
##v O
) O
administration O
of O
cm O
##s O
in O
rats O
. O
[SEP] O
[CLS] O
patients O
undergoing O
hip O
replacement O
surgery O
and O
routinely O
receiving O
1 O
g O
t O
##rane O
##xa O
##mic O
acid O
in O
##tra O
##ven O
##ously O
constituted O
the O
reference O
group O
( O
the O
in O
##tra O
##ven O
##ous O
b O
##ol O
##us O
group O
) O
and O
were O
consecutive O
##ly O
recruited O
from O
the O
department O
of O
or O
##th O
##oped O
##ics O
at O
s O
##t O
. O
o O
##lav O
’ O
s O
university O
hospital O
. O
[SEP] O
[CLS] O
the O
rapid O
and O
extensive O
conversion O
of O
v O
##ica O
##g O
##rel O
to O
the O
intermediate O
2 O
- O
o O
##x O
##o O
- O
c O
##lop O
##ido O
##g O
##rel O
by O
est O
##era O
##se O
instead O
of O
c O
##yt O
##och O
##rome O
p O
##45 O
##0s O
( O
c O
##y O
##ps O
) O
makes O
the O
novel O
pro O
##dr O
##ug O
v O
##ica O
##g O
##rel O
a O
promising O
agent O
to O
prevent O
plate O
##let O
a O
##gg O
##regation O
and O
overcome O
c O
##lop O
##ido O
##g O
##rel O
resistance O
and O
high O
inter O
##ind O
##iv O
##id O
##ual O
var O
##iability O
due O
to O
c O
##y O
##p O
##2 O
##c O
##19 O
p O
##oly O
##mor O
##phism O
. O
[SEP] O
[CLS] O
patients O
received O
2 O
- O
5 O
serial O
injection O
##s O
( O
124 O
) O
i O
- O
or O
( O
131 O
) O
i O
- O
labeled O
mon O
##oc O
##lon O
##al O
anti O
##body O
3 O
##f O
##8 O
or O
8 O
##h O
##9 O
. O
[SEP] O
[CLS] O
other O
induced O
p O
##hen O
##otypic O
changes O
including O
changes O
in O
the O
volume O
and O
p O
##h O
of O
acidic O
organ O
##elles O
were O
measured O
, O
and O
the O
integrated O
effects O
of O
all O
these O
changes O
were O
computational O
##ly O
modeled O
to O
establish O
their O
impact O
on O
in O
##tra O
##cellular O
c O
##q O
mass O
accumulation O
. O
[SEP] O
[CLS] O
a O
pu O
##era O
##rin O
na O
##no O
##par O
##tic O
##le O
was O
synthesized O
based O
on O
g O
##ly O
##cy O
##rr O
##he O
##tin O
##ic O
acid O
- O
p O
##eg O
- O
p O
##bla O
, O
which O
could O
obviously O
increase O
the O
water O
so O
##lub O
##ility O
, O
bio O
##act O
##ivity O
and O
litter O
half B-PK
- I-PK
life I-PK
of O
pu O
##era O
##rin O
and O
height O
##en O
the O
liver O
- O
targeted O
drug O
delivery O
( O
x O
##ia O
##o O
et O
al O
. O
, O
2018 O
) O
. O
[SEP] O
[CLS] O
in O
summary O
, O
longer O
m B-PK
##rt I-PK
##0 I-PK
– I-PK
∞ I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
higher O
au B-PK
##c I-PK
, O
and O
lower O
c B-PK
##l I-PK
##z I-PK
values O
of O
e O
##pi O
##med O
##in O
c O
in O
c O
##k O
##z O
group O
than O
e O
##pi O
##med O
##in O
c O
group O
implied O
that O
the O
pu O
##rified O
herb O
##al O
preparation O
may O
be O
superior O
to O
single O
compound O
in O
pro O
##long O
##ing O
the O
duration O
of O
action O
of O
e O
##pi O
##med O
##in O
c O
. O
[SEP] O
[CLS] O
late O
peaks O
were O
defined O
as O
significant O
increased O
point O
values O
when O
compared O
to O
the O
previous O
time O
point O
and O
their O
frequencies O
were O
calculated O
. O
[SEP] O
[CLS] O
at O
14 O
weeks O
of O
age O
, O
there O
was O
a O
trend O
towards O
an O
improved O
performance O
of O
the O
f O
##elo O
##di O
##pine O
- O
treated O
b O
##6 O
##h O
##d O
animals O
. O
[SEP] O
[CLS] O
m O
##r O
imaging O
was O
performed O
before O
dos O
##ing O
and O
at O
pre O
##set O
times O
after O
dose O
administration O
to O
determine O
enhance O
##ment O
relative O
to O
pre O
##dos O
##e O
signal O
intensity O
values O
. O
[SEP] O
[CLS] O
subjects O
enrolled O
into O
the O
age O
- O
based O
co O
##hor O
##t O
were O
required O
to O
be O
≥ O
##55 O
years O
of O
age O
and O
have O
body O
weight O
45 O
– O
95 O
kg O
and O
b O
##mi O
19 O
– O
30 O
kg O
/ O
m O
##2 O
. O
[SEP] O
[CLS] O
this O
study O
was O
a O
random O
##ized O
, O
open O
- O
label O
, O
six O
- O
sequence O
, O
three O
- O
period O
, O
three O
- O
treatment O
, O
multiple O
- O
dose O
crossover O
study O
in O
healthy O
male O
subjects O
. O
[SEP] O
[CLS] O
s O
##mu O
##lt O
##i O
- O
c O
##d O
##4 O
showed O
an O
apparent O
molecular O
weight O
of O
about O
300 O
- O
350 O
k O
##da O
, O
in O
accordance O
with O
a O
possible O
he O
##pta O
##mer O
formula O
. O
[SEP] O
[CLS] O
hp O
##l O
##c O
analysis O
showed O
a O
purity O
of O
98 O
. O
17 O
% O
. O
[SEP] O
[CLS] O
le O
##vo O
##bu O
##pi O
##va O
##ca O
##ine O
comprises O
50 O
% O
of O
commercially O
available O
b O
##up O
##iva O
##ca O
##ine O
and O
is O
being O
considered O
for O
use O
in O
its O
own O
right O
. O
[SEP] O
[CLS] O
our O
data O
suggest O
that O
liver O
metabolism O
as O
well O
as O
re O
##nal O
ex O
##cre O
##tion O
contribute O
to O
total B-PK
body I-PK
clearance I-PK
of O
c O
##ef O
##ota O
##xi O
##me O
and O
increase O
during O
the O
first O
few O
days O
of O
live O
. O
[SEP] O
[CLS] O
the O
effect O
of O
painful O
procedures O
and O
medication O
on O
lying O
behaviour O
support O
the O
notion O
of O
lying O
as O
a O
comfort O
indicator O
. O
[SEP] O
[CLS] O
side O
- O
effects O
from O
flu O
##vo O
##xa O
##mine O
were O
similar O
to O
those O
reported O
for O
other O
selective O
se O
##rot O
##oni O
##n O
re O
##up O
##take O
inhibitor O
##s O
( O
nausea O
, O
so O
##m O
##no O
##len O
##ce O
) O
and O
were O
well O
tolerate O
##d O
. O
[SEP] O
[CLS] O
plasma O
samples O
were O
collected O
0 O
. O
5 O
h O
before O
and O
2 O
, O
4 O
and O
11 O
. O
5 O
h O
after O
the O
first O
v O
##g O
##b O
dose O
. O
[SEP] O
[CLS] O
onset O
of O
pain O
relief O
was O
rapid O
, O
and O
duration O
was O
approximately O
1 O
. O
5 O
h O
with O
e O
. O
p O
. O
[SEP] O
[CLS] O
more O
##over O
, O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
( I-PK
au I-PK
##c I-PK
, I-PK
zero I-PK
to I-PK
in I-PK
##finity I-PK
) I-PK
showed O
values O
comparable O
to O
those O
found O
in O
previous O
studies O
performed O
on O
non O
##card O
##iac O
surgery O
patients O
. O
[SEP] O
[CLS] O
statistical O
##ly O
significant O
increase O
of O
distribution B-PK
volume I-PK
and O
increase O
of O
he O
##pa O
##tic O
anti O
##py O
##rine O
clearance B-PK
were O
recorded O
, O
as O
well O
as O
significant O
short O
##ening O
of O
half B-PK
- I-PK
life I-PK
of O
this O
substance O
in O
the O
organism O
of O
tested O
animals O
in O
summer O
1986 O
and O
1987 O
, O
compared O
with O
the O
remaining O
seasons O
of O
the O
year O
. O
[SEP] O
[CLS] O
plasma O
or O
brain O
ho O
##mo O
##gen O
##ate O
samples O
from O
the O
same O
time O
points O
were O
pool O
##ed O
into O
two O
groups O
( O
c O
##1 O
- O
c O
##3 O
and O
c O
##4 O
- O
c O
##6 O
) O
for O
ass O
##ay O
. O
[SEP] O
[CLS] O
though O
grape O
##f O
##ruit O
juice O
on O
average O
slightly O
increased O
serum O
levels O
of O
est O
##rad O
##iol O
( O
e O
##2 O
) O
and O
pro O
##ges O
##tero O
##ne O
, O
this O
increase O
reached O
statistical O
significance O
only O
for O
the O
e O
##2 O
level O
24 O
hours O
after O
application O
of O
tablets O
. O
[SEP] O
[CLS] O
a O
non O
##com O
##par O
##tment O
##al O
model O
was O
used O
to O
fit O
the O
plasma O
concentration O
of O
m O
##b O
##f O
versus O
time O
curve O
for O
each O
green O
sea O
turtle O
. O
[SEP] O
[CLS] O
patients O
with O
blood O
group O
o O
had O
a O
shorter O
f O
##vi O
##ii O
half B-PK
- I-PK
life I-PK
than O
patients O
with O
non O
- O
o O
blood O
group O
( O
9 O
. O
40 O
± O
0 O
. O
68 O
h O
vs O
. O
12 O
. O
3 O
± O
0 O
. O
79 O
h O
, O
t O
= O
2 O
. O
70 O
, O
p O
= O
0 O
. O
01 O
) O
. O
[SEP] O
[CLS] O
a O
two O
to O
three O
##fold O
increase O
in O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
d O
##s O
##f O
was O
found O
. O
[SEP] O
[CLS] O
however O
, O
the O
per B-PK
##me I-PK
##ability I-PK
for O
passive O
diffusion O
into O
cells O
was O
neglected O
for O
all O
drugs O
in O
the O
present O
study O
, O
since O
this O
process O
is O
not O
relevant O
for O
mac O
##rom O
##ole O
##cule O
##s O
or O
very O
h O
##ydro O
##phi O
##lic O
drugs O
like O
in O
##ulin O
. O
[SEP] O
[CLS] O
there O
has O
been O
little O
information O
regarding O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
anti O
##thy O
##roid O
drugs O
in O
patients O
with O
ends O
##tage O
re O
##nal O
disease O
( O
es O
##rd O
) O
. O
[SEP] O
[CLS] O
drug O
interaction O
study O
between O
b O
##up O
##rop O
##ion O
and O
t O
##ic O
##lop O
##id O
##ine O
in O
male O
c O
##f O
- O
1 O
mice O
. O
[SEP] O
[CLS] O
the O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
d O
##z O
##20 O
##0 O
##2 O
was O
significantly O
shorter O
than O
that O
of O
d O
##za O
. O
[SEP] O
[CLS] O
to O
the O
a O
##pical O
side O
of O
the O
well O
, O
500 O
µ O
##l O
of O
h O
##bs O
##s O
was O
added O
; O
to O
the O
basal O
side O
of O
the O
well O
, O
1 O
. O
0 O
m O
##l O
of O
h O
##bs O
##s O
was O
added O
. O
[SEP] O
[CLS] O
subjects O
with O
pre O
- O
existing O
peripheral O
ne O
##uro O
##pathy O
, O
h O
##yper O
##cal O
##ce O
##mia O
, O
h O
##yper O
##ma O
##gne O
##se O
##mia O
or O
medical O
con O
##tra O
##ind O
##ica O
##tions O
to O
electro O
##my O
##ography O
( O
em O
##g O
) O
or O
repeated O
p O
##har O
##ma O
##co O
##kin O
##etic O
blood O
sampling O
were O
ineligible O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
two O
different O
delivery O
regime O
##ns O
of O
do O
##x O
##or O
##ubi O
##cin O
in O
isolated O
h O
##yper O
##ther O
##mic O
limb O
per O
##fusion O
. O
[SEP] O
[CLS] O
blood O
pressure O
, O
heart O
rate O
, O
respiratory O
rate O
, O
electro O
##card O
##io O
##graphic O
parameters O
, O
mental O
a O
##cu O
##ity O
, O
and O
vision O
were O
not O
altered O
. O
[SEP] O
[CLS] O
in O
addition O
, O
evidence O
of O
the O
route O
of O
the O
metabolic O
degradation O
of O
g O
##pe O
is O
presented O
. O
[SEP] O
[CLS] O
meanwhile O
, O
in O
both O
cells O
, O
naked O
g O
##pt O
##x O
and O
g O
##pt O
##x O
- O
l O
were O
still O
c O
##yt O
##oto O
##xi O
##ci O
##c O
even O
though O
they O
do O
not O
have O
targeting O
ability O
. O
[SEP] O
[CLS] O
all O
three O
doses O
were O
administered O
to O
each O
of O
the O
six O
experimental O
horses O
at O
three O
different O
times O
. O
[SEP] O
[CLS] O
the O
established O
western O
mi O
##gra O
##ine O
prevent O
##ive O
, O
prop O
##rano O
##lo O
##l O
, O
was O
also O
effective O
in O
the O
same O
experimental O
model O
as O
gas O
##tro O
##din O
and O
l O
##ig O
##ust O
##raz O
##ine O
, O
while O
le O
##vet O
##ira O
##ce O
##tam O
, O
which O
has O
no O
positive O
place O
##bo O
controlled O
data O
in O
mi O
##gra O
##ine O
, O
was O
not O
. O
[SEP] O
[CLS] O
the O
influence O
of O
end O
##oto O
##xin O
- O
induced O
inflammation O
on O
the O
en O
##anti O
##ose O
##lect O
##ive O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
prop O
##rano O
##lo O
##l O
, O
o O
##x O
##p O
##ren O
##olo O
##l O
, O
and O
ve O
##rap O
##ami O
##l O
, O
which O
bind O
to O
alpha O
1 O
- O
acid O
g O
##ly O
##co O
##p O
##rote O
##in O
, O
was O
studied O
in O
the O
rat O
. O
[SEP] O
[CLS] O
the O
micro O
##sp O
##here O
##s O
of O
na O
##nos O
##po O
##nge O
complexes O
showed O
desired O
controlled O
release O
profile O
for O
12 O
h O
. O
ins O
##ign O
##ificant O
drug O
le O
##achi O
##ng O
was O
observed O
in O
re O
##con O
##stituted O
suspension O
during O
storage O
for O
7 O
days O
at O
45 O
° O
##c O
/ O
75 O
% O
r O
##h O
. O
[SEP] O
[CLS] O
grade O
3 O
/ O
4 O
hem O
##ato O
##log O
##ic O
abnormal O
##ities O
included O
ne O
##ut O
##rop O
##enia O
( O
83 O
% O
) O
and O
le O
##uk O
##ope O
##nia O
( O
83 O
% O
) O
. O
[SEP] O
[CLS] O
hour O
) O
to O
50 O
mg O
/ O
m O
( O
median O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##finity I-PK
, O
5 O
. O
40 O
micro O
##m O
. O
[SEP] O
[CLS] O
one O
month O
after O
the O
start O
of O
daily O
administration O
of O
250 O
mg O
g O
##ef O
##iti O
##ni O
##b O
, O
the O
patient O
' O
s O
symptoms O
improved O
and O
th O
##ora O
##ci O
##c O
c O
##t O
scan O
##s O
showed O
that O
the O
tumor O
had O
reduced O
in O
size O
. O
[SEP] O
[CLS] O
the O
abstract O
##s O
for O
an O
##not O
##ation O
were O
randomly O
selected O
from O
the O
search O
results O
. O
[SEP] O
[CLS] O
the O
effects O
of O
f O
##rus O
##em O
##ide O
and O
probe O
##ne O
##cid O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
p O
##hen O
##p O
##ro O
##co O
##um O
##on O
. O
[SEP] O
[CLS] O
supplement O
##ary O
material O
1 O
( O
do O
##c O
##x O
77 O
##1 O
k O
##b O
) O
[SEP] O
[CLS] O
we O
next O
evaluated O
whether O
the O
a O
##β O
##42 O
conform O
##ation O
- O
stab O
##ili O
##zing O
activity O
of O
tram O
##ip O
##ros O
##ate O
affects O
a O
##gg O
##regation O
, O
specifically O
the O
o O
##li O
##go O
##mer O
a O
##gg O
##regation O
stages O
from O
mon O
##omer O
##s O
through O
soluble O
de O
##came O
##r O
species O
. O
[SEP] O
[CLS] O
as O
expected O
, O
the O
in O
v O
##it O
##ro O
dissolution O
profiles O
of O
the O
c O
##ime O
##ti O
##dine O
tablets O
containing O
different O
percentage O
##s O
of O
met O
##ha O
##c O
##ryl O
##ate O
cop O
##oly O
##mer O
differed O
considerably O
from O
one O
another O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
in O
##tra O
- O
art O
##icular O
m O
##or O
##phine O
in O
horses O
with O
lip O
##op O
##oly O
##sa O
##cc O
##hari O
##de O
- O
induced O
s O
##yn O
##ov O
##itis O
. O
[SEP] O
[CLS] O
the O
ma B-PK
##ximal I-PK
t I-PK
##ula I-PK
##th I-PK
##rom I-PK
##y I-PK
##cin I-PK
concentration I-PK
in O
lung O
and O
muscle O
ho O
##mo O
##gen O
##ate O
from O
a O
single O
animal O
was O
46 O
##5 O
##7 O
ng O
/ O
g O
( O
14 O
days O
) O
and O
226 O
##4 O
ng O
/ O
g O
( O
7 O
days O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
specifically O
, O
b O
##n O
##f O
for O
c O
##y O
##p O
##1 O
##a O
##1 O
, O
p O
##b O
for O
c O
##y O
##p O
##2 O
##b O
##1 O
and O
c O
##y O
##p O
##2 O
##c O
##6 O
and O
c O
##pa O
for O
c O
##y O
##p O
##2 O
##c O
##11 O
, O
were O
used O
to O
valid O
##ate O
the O
ass O
##ay O
. O
[SEP] O
[CLS] O
h O
) O
was O
lower O
( O
p O
< O
0 O
. O
05 O
) O
in O
m O
##dr O
##1 O
##a O
/ O
1 O
##b O
( O
- O
/ O
- O
) O
versus O
m O
##dr O
##1 O
##a O
/ O
1 O
##b O
( O
+ O
/ O
+ O
) O
mice O
, O
respectively O
. O
[SEP] O
[CLS] O
g O
##em O
##ci O
##ta O
##bine O
clearance B-PK
( O
l O
/ O
h O
) O
was O
obtained O
by O
dividing O
the O
given O
dose O
of O
g O
##em O
##ci O
##ta O
##bine O
( O
μ O
##mo O
##l O
/ O
patient O
, O
calculated O
on O
the O
basis O
of O
a O
molecular O
weight O
of O
26 O
##3 O
. O
198 O
) O
by O
the O
au B-PK
##c I-PK
, O
with O
extra O
##pol O
##ation O
to O
in O
##finity O
( O
dose B-PK
/ I-PK
au I-PK
##c I-PK
) O
. O
[SEP] O
[CLS] O
no O
significant O
difference O
existed O
between O
the O
corrected O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
5 I-PK
) I-PK
of O
the O
f O
##ent O
##any O
##l O
h O
##c O
##l O
p O
##cts O
during O
the O
single O
- O
and O
multiple O
- O
day O
treatment O
periods O
( O
0 O
. O
40 O
and O
0 O
. O
54 O
micro O
##g O
x O
h O
/ O
l O
, O
respectively O
; O
p O
= O
0 O
. O
133 O
) O
. O
[SEP] O
[CLS] O
after O
im O
##mu O
##no O
- O
ch O
##em O
##otherapy O
, O
the O
median O
follow O
- O
up O
was O
55 O
. O
5 O
months O
[ O
24 O
– O
108 O
months O
] O
, O
median O
time O
to O
re O
##lap O
##se O
( O
t O
##tr O
) O
was O
60 O
months O
[ O
12 O
- O
more O
than O
108 O
months O
] O
, O
and O
time O
to O
second O
c O
##ll O
treatment O
( O
t O
##st O
) O
was O
84 O
months O
[ O
24 O
- O
more O
than O
108 O
months O
] O
. O
[SEP] O
[CLS] O
how O
this O
might O
change O
clinical O
p O
##har O
##ma O
##cology O
or O
translation O
##al O
[UNK] O
the O
results O
of O
our O
trial O
indicate O
substantially O
altered O
p O
##ks O
of O
c O
##yt O
##och O
##rome O
‐ O
dependent O
drugs O
in O
critically O
ill O
patients O
. O
[SEP] O
[CLS] O
grade O
3 O
/ O
4 O
ne O
##ut O
##rop O
##enia O
was O
observed O
in O
all O
patients O
, O
but O
not O
associated O
with O
significant O
complications O
. O
[SEP] O
[CLS] O
in O
addition O
, O
c O
##4 O
##n O
##p O
can O
be O
cleared O
by O
re O
##nal O
fi O
##ltration O
and O
active O
tub O
##ular O
secret O
##ion O
in O
s O
##pra O
##gue O
- O
da O
##wley O
rats O
. O
[SEP] O
[CLS] O
cycle O
1 O
d O
##lts O
were O
grade O
3 O
ne O
##ut O
##rop O
##enia O
, O
anal O
a O
##bs O
##cess O
, O
di O
##ar O
##r O
##hea O
, O
and O
th O
##rom O
##bo O
##cy O
##top O
##enia O
and O
grade O
4 O
my O
##al O
##gia O
, O
cell O
##uli O
##tis O
, O
ne O
##ut O
##rop O
##enia O
, O
f O
##eb O
##ril O
##e O
ne O
##ut O
##rop O
##enia O
, O
pulmonary O
em O
##bol O
##ism O
, O
and O
th O
##rom O
##bo O
##cy O
##top O
##enia O
. O
[SEP] O
[CLS] O
the O
ca O
##li O
##bra O
##tion O
curves O
showed O
good O
linear O
##ity O
( O
r O
##2 O
> O
0 O
. O
99 O
) O
over O
the O
ranges O
of O
50 O
- O
800 O
##0 O
ng O
/ O
m O
##l O
for O
m O
##dh O
- O
7 O
and O
10 O
- O
2000 O
ng O
/ O
m O
##l O
for O
5 O
- O
f O
##u O
, O
respectively O
. O
[SEP] O
[CLS] O
it O
was O
observed O
that O
r O
##alo O
##xi O
##fen O
##e O
g O
##lu O
##cu O
##ron O
##ides O
/ O
su O
##lf O
##ates O
decreased O
when O
the O
amount O
of O
a O
##pi O
##gen O
##in O
increased O
. O
[SEP] O
[CLS] O
we O
used O
the O
following O
diagnosis O
s O
##cat O
##ter O
plots O
, O
also O
called O
goodness O
- O
of O
- O
fit O
plots O
, O
for O
model O
internal O
qualification O
: O
observed O
concentrations O
vs O
. O
predicted O
or O
individual O
- O
predicted O
concentrations O
, O
and O
conditional O
weighted O
residual O
##s O
vs O
. O
predicted O
concentrations O
and O
vs O
. O
time O
. O
[SEP] O
[CLS] O
in O
which O
s O
is O
the O
spread O
##ability O
, O
m O
is O
the O
weight O
( O
g O
) O
tied O
on O
the O
upper O
plate O
; O
l O
is O
the O
length O
( O
cm O
) O
of O
the O
glass O
plates O
, O
and O
t O
is O
the O
time O
taken O
for O
spreading O
the O
gel O
[ O
14 O
, O
19 O
] O
. O
[SEP] O
[CLS] O
nor O
##eth O
##ind O
##rone O
was O
administered O
by O
i O
##v O
b O
##ol O
##us O
injection O
immediately O
after O
, O
3 O
days O
or O
7 O
days O
after O
exposure O
to O
100 O
r O
##ads O
, O
300 O
r O
##ads O
, O
600 O
r O
##ads O
, O
and O
s O
##ham O
x O
- O
i O
##rra O
##diation O
. O
[SEP] O
[CLS] O
the O
objective O
of O
this O
study O
was O
to O
assess O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
safety O
of O
a O
single O
up O
##ada O
##ci O
##tin O
##ib O
dose O
in O
subjects O
with O
normal O
re O
##nal O
function O
and O
in O
subjects O
with O
re O
##nal O
imp O
##air O
##ment O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
the O
signal O
obtained O
from O
type O
3 O
anti O
##body O
binding O
increases O
with O
increasing O
t O
##n O
##f O
amounts O
until O
sat O
##uration O
is O
reached O
, O
again O
at O
a O
t O
##n O
##f O
- O
to O
- O
go O
##lim O
##uma O
##b O
ratio O
of O
about O
1 O
: O
2 O
. O
[SEP] O
[CLS] O
dose O
was O
adjusted O
based O
on O
side O
effects O
and O
the O
drug O
level O
was O
measured O
2 O
hours O
after O
the O
morning O
dose O
( O
c O
##2 O
) O
. O
[SEP] O
[CLS] O
the O
safety O
profile O
and O
anti O
##vir O
##al O
activity O
of O
the O
combination O
of O
s O
##ta O
##vu O
##dine O
, O
did O
##ano O
##sin O
##e O
, O
and O
ne O
##lf O
##ina O
##vir O
in O
patients O
with O
hi O
##v O
infection O
. O
[SEP] O
[CLS] O
the O
clinical O
implications O
of O
these O
observations O
with O
respect O
to O
the O
dos O
##ing O
of O
q O
##p O
are O
discussed O
. O
[SEP] O
[CLS] O
the O
only O
age O
- O
dependent O
significant O
difference O
in O
p O
##har O
##ma O
##co O
##kin O
##etic O
behavior O
between O
young O
and O
old O
be O
##ag O
##le O
dogs O
was O
found O
concerning O
the O
distribution B-PK
rate I-PK
constant I-PK
##s I-PK
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
expressed O
as O
mean O
± O
s O
. O
d O
. O
the O
statistical O
significance O
of O
the O
results O
was O
analyzed O
using O
student O
’ O
s O
t O
- O
test O
, O
with O
p O
- O
values O
less O
than O
0 O
. O
05 O
as O
considered O
statistical O
##ly O
significant O
. O
[SEP] O
[CLS] O
the O
animal O
ethics O
committee O
of O
ma O
##ast O
##rich O
##t O
university O
, O
the O
net O
##her O
##lands O
approved O
the O
studies O
: O
2004 O
– O
101 O
. O
[SEP] O
[CLS] O
the O
concentrations O
read O
from O
the O
standard O
curve O
were O
multi O
##plied O
by O
the O
di O
##lution O
factor O
. O
[SEP] O
[CLS] O
none O
of O
these O
models O
resulted O
in O
an O
acceptable O
drug O
- O
effect O
model O
for O
the O
data O
##set O
under O
evaluation O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
the O
results O
indicated O
our O
success O
in O
such O
an O
enhance O
##ment O
. O
[SEP] O
[CLS] O
the O
in O
##hibition O
of O
influx O
transport O
##ers O
by O
p O
##b O
led O
to O
a O
reduction O
of O
free O
q O
##t O
##p O
brain O
penetration O
, O
as O
observed O
by O
the O
reduction O
of O
penetration B-PK
factor I-PK
from O
1 O
. O
55 O
± O
0 O
. O
17 O
to O
a O
value O
closer O
to O
unit O
( O
0 O
. O
94 O
± O
0 O
. O
15 O
) O
. O
[SEP] O
[CLS] O
no O
significant O
differences O
were O
observed O
in O
the O
drug B-PK
elimination I-PK
rate I-PK
in O
milk O
or O
in O
serum O
between O
healthy O
and O
infected O
cow O
quarters O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
as O
a O
conclusion O
, O
the O
present O
method O
proved O
to O
be O
a O
rapid O
and O
sensitive O
analytical O
tool O
for O
sofa O
##l O
##con O
##e O
in O
human O
plasma O
or O
urine O
samples O
and O
has O
been O
successfully O
applied O
to O
a O
clinical O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
of O
in O
healthy O
chin O
##ese O
subjects O
. O
[SEP] O
[CLS] O
when O
ca O
##ffe O
##ine O
was O
co O
##ad O
##mini O
##stered O
the O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
of O
me O
##lat O
##oni O
##n O
were O
increased O
on O
average O
by O
142 O
% O
( O
p O
= O
0 O
. O
00 O
##1 O
, O
confidence O
interval O
on O
the O
difference O
44 O
, O
80 O
% O
) O
and O
120 O
% O
( O
p O
< O
0 O
. O
00 O
##1 O
, O
confidence O
interval O
on O
the O
difference O
63 O
, O
178 O
% O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
both O
compounds O
were O
tested O
over O
a O
range O
of O
concentrations O
up O
to O
and O
including O
5000 O
μ O
##g O
/ O
plate O
. O
[SEP] O
[CLS] O
mean O
release O
of O
three O
tablets O
was O
used O
to O
evaluate O
the O
drug O
release O
for O
each O
of O
the O
formulation O
##s O
( O
17 O
) O
. O
[SEP] O
[CLS] O
the O
two O
genetic O
fusion O
##s O
had O
similar O
p O
##k O
profiles O
, O
with O
total B-PK
body I-PK
clearance I-PK
of O
~ O
0 O
. O
9 O
- O
1 O
. O
0 O
m O
##l O
/ O
h O
/ O
kg O
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
- I-PK
state I-PK
of O
~ O
63 O
- O
65 O
m O
##l O
/ O
kg O
, O
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
of O
~ O
40 O
h O
. O
[SEP] O
[CLS] O
there O
were O
two O
episodes O
of O
as O
##ym O
##pt O
##oma O
##tic O
h O
##y O
##po O
##cal O
##ca O
##emia O
, O
one O
at O
grade O
ii O
##i O
and O
one O
grade O
i O
##v O
, O
which O
were O
recorded O
in O
early O
follow O
- O
up O
. O
[SEP] O
[CLS] O
however O
, O
previous O
studies O
have O
largely O
treated O
the O
co O
##lon O
as O
a O
single O
organ O
or O
looked O
at O
f O
##eca O
##l O
profiles O
, O
and O
differences O
in O
the O
profiles O
of O
native O
and O
meta O
##bol O
##ite O
compounds O
between O
regions O
have O
not O
been O
observed O
. O
[SEP] O
[CLS] O
an O
hp O
##l O
##c O
method O
using O
u O
##v O
detection O
was O
developed O
to O
assess O
p O
##hen O
##ob O
##ar O
##bit O
##al O
in O
plasma O
of O
the O
subjects O
. O
[SEP] O
[CLS] O
× O
3 O
factor O
##ial O
design O
to O
study O
the O
effect O
of O
polymer O
and O
plastic O
##izer O
type O
and O
concentration O
on O
mechanical O
properties O
and O
in O
v O
##it O
##ro O
di O
##sin O
##te O
##gration O
time O
of O
the O
plain O
prepared O
films O
using O
design O
- O
expert O
##® O
. O
[SEP] O
[CLS] O
then O
te O
##os O
( O
8 O
. O
65 O
g O
) O
was O
added O
and O
the O
system O
was O
stirred O
for O
another O
20 O
h O
at O
80 O
° O
##c O
. O
[SEP] O
[CLS] O
this O
study O
aimed O
to O
character O
##ize O
possible O
relationships O
between O
p O
##oly O
##mor O
##phism O
##s O
in O
the O
drug O
transport O
##er O
genes O
organic O
an O
##ion O
transporting O
p O
##oly O
##pe O
##pt O
##ide O
- O
c O
( O
o O
##at O
##p O
- O
c O
, O
s O
##l O
##co O
##1 O
##b O
##1 O
) O
, O
o O
##at O
##p O
- O
b O
( O
s O
##l O
##co O
##2 O
##b O
##1 O
) O
, O
multi O
##dr O
##ug O
resistance O
- O
associated O
protein O
2 O
( O
m O
##rp O
##2 O
, O
a O
##b O
##cc O
##2 O
) O
and O
multi O
##dr O
##ug O
resistance O
transport O
##er O
( O
m O
##dr O
##1 O
, O
a O
##b O
##c O
##b O
##1 O
) O
and O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
p O
##ra O
##vas O
##tat O
##in O
. O
[SEP] O
[CLS] O
serum O
exposure O
of O
me O
##di O
##48 O
##9 O
##3 O
increased O
approximately O
dose O
proportional O
##ly O
; O
the O
maximum B-PK
concentration I-PK
of I-PK
drug I-PK
in I-PK
serum I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
increased O
from O
77 O
μ O
##g O
/ O
m O
##l O
at O
225 O
mg O
to O
1 O
, O
78 O
##4 O
μ O
##g O
/ O
m O
##l O
at O
5 O
, O
000 O
mg O
( O
table O
3 O
) O
. O
[SEP] O
[CLS] O
most O
subjects O
in O
the O
active O
- O
treatment O
and O
place O
##bo O
groups O
reported O
at O
least O
one O
a O
##e O
during O
the O
treatment O
period O
( O
org O
265 O
##7 O
##6 O
: O
97 O
% O
; O
place O
##bo O
: O
89 O
% O
) O
. O
[SEP] O
[CLS] O
its O
human O
half B-PK
- I-PK
life I-PK
was O
longer O
than O
those O
of O
ad O
##ria O
##my O
##cin O
, O
mit O
##omy O
##cin O
c O
and O
neo O
##car O
##zin O
##ost O
##ati O
##n O
, O
and O
a O
little O
shorter O
than O
that O
of O
b O
##leo O
##my O
##cin O
. O
[SEP] O
[CLS] O
consequently O
, O
the O
quality O
of O
pet O
images O
after O
or O
- O
46 O
##2 O
was O
better O
, O
which O
has O
implications O
for O
future O
[ O
18 O
##f O
] O
6 O
- O
flu O
##oro O
##do O
##pa O
studies O
. O
[SEP] O
[CLS] O
the O
serum O
concentration O
of O
ta O
##mo O
##xi O
##fen O
and O
most O
of O
its O
meta O
##bol O
##ites O
( O
[ O
trans O
- O
1 O
( O
4 O
- O
beta O
- O
h O
##ydro O
##xy O
- O
et O
##ho O
##xy O
##phe O
##ny O
##l O
) O
- O
1 O
, O
2 O
- O
dip O
##hen O
##yl O
##but O
- O
1 O
- O
en O
##e O
] O
, O
4 O
- O
h O
##ydro O
##xy O
##tam O
##ox O
##ife O
##n O
, O
4 O
- O
h O
##ydro O
##xy O
- O
n O
- O
des O
##met O
##hyl O
##tam O
##ox O
##ife O
##n O
, O
n O
- O
des O
##met O
##hyl O
##tam O
##ox O
##ife O
##n O
, O
and O
n O
- O
des O
##di O
##met O
##hyl O
##tam O
##ox O
##ife O
##n O
) O
were O
marked O
##ly O
reduced O
following O
amino O
##g O
##lut O
##eth O
##im O
##ide O
administration O
, O
corresponding O
to O
an O
increase O
in O
ta O
##mo O
##xi O
##fen O
clearance B-PK
from O
189 O
- O
60 O
##8 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
the O
##op O
##hyl O
##line O
clearance B-PK
was O
decreased O
an O
average O
of O
18 O
. O
5 O
% O
( O
range O
, O
4 O
. O
9 O
% O
to O
36 O
% O
) O
, O
whereas O
the O
##op O
##hyl O
##line O
volume B-PK
of I-PK
distribution I-PK
was O
unchanged O
by O
c O
##ime O
##ti O
##dine O
. O
[SEP] O
[CLS] O
simple O
and O
multiple O
re O
##gression O
analyses O
were O
performed O
for O
the O
primary O
metric O
, O
plasma O
met O
##had O
##one O
concentration O
/ O
dose O
. O
[SEP] O
[CLS] O
a O
##ver O
##y O
et O
al O
. O
reported O
that O
the O
un O
##bound O
e O
##f O
##v O
concentrations O
in O
plasma O
and O
se O
##men O
( O
a O
##ver O
##y O
et O
al O
. O
, O
2011 O
) O
and O
in O
plasma O
and O
c O
##ere O
##bro O
##sp O
##inal O
fluid O
are O
nearly O
identical O
( O
a O
##ver O
##y O
et O
al O
. O
, O
2013 O
##a O
) O
. O
[SEP] O
[CLS] O
the O
recovery O
of O
b O
##ava O
##chal O
##con O
##e O
ranged O
from O
84 O
. O
1 O
to O
87 O
. O
0 O
% O
. O
[SEP] O
[CLS] O
pre O
##ga O
##bal O
##in O
is O
an O
alpha O
( O
2 O
) O
- O
delta O
l O
##igan O
##d O
that O
has O
an O
##xi O
##oly O
##tic O
, O
anal O
##ges O
##ic O
, O
and O
anti O
##con O
##vu O
##ls O
##ant O
properties O
. O
[SEP] O
[CLS] O
one O
- O
way O
( O
o O
##ws O
##a O
) O
and O
pro O
##ba O
##bil O
##istic O
sensitivity O
analyses O
( O
ps O
##a O
) O
were O
conducted O
to O
assess O
the O
stability O
of O
the O
results O
beyond O
the O
100 O
- O
day O
period O
under O
the O
uncertainty O
arising O
from O
the O
values O
adopted O
for O
the O
input O
parameters O
. O
[SEP] O
[CLS] O
car O
##ote O
##no O
##id O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
humans O
from O
tomato O
##es O
processed O
in O
different O
ways O
determined O
from O
the O
car O
##ote O
##no O
##id O
response O
in O
the O
t O
##rig O
##ly O
##cer O
##ide O
- O
rich O
lip O
##op O
##rote O
##in O
fraction O
of O
plasma O
after O
a O
single O
consumption O
and O
in O
plasma O
after O
four O
days O
of O
consumption O
. O
[SEP] O
[CLS] O
simulation O
- O
based O
diagnostic O
##s O
and O
re O
- O
est O
##imation O
methods O
were O
used O
to O
evaluate O
the O
performance O
of O
the O
p O
##k O
and O
p O
##d O
final O
models O
[ O
21 O
] O
. O
[SEP] O
[CLS] O
this O
36 O
- O
fold O
increase O
in O
5 O
- O
f O
##u O
dose O
was O
associated O
with O
a O
greater O
than O
150 O
- O
fold O
increase O
in O
the O
30 O
- O
minute O
plasma O
concentration O
of O
5 O
- O
f O
##u O
( O
0 O
. O
02 O
- O
3 O
. O
3 O
mm O
) O
. O
[SEP] O
[CLS] O
the O
plasma O
concentration O
time O
curves O
of O
dans O
##hen O
##su O
were O
best O
fitted O
with O
two O
- O
compartment O
models O
for O
dans O
##hen O
##su O
itself O
and O
for O
sa O
##l O
##via O
mi O
##lt O
##ior O
##r O
##hi O
##za O
injection O
as O
well O
. O
[SEP] O
[CLS] O
sa O
##lm O
##eter O
##ol O
distribution O
is O
en O
##anti O
##ose O
##lect O
##ive O
in O
the O
central O
lung O
. O
[SEP] O
[CLS] O
subjects O
were O
also O
in O
good O
health O
, O
as O
indicated O
by O
medical O
history O
and O
physical O
exam O
, O
and O
able O
to O
speak O
, O
read O
, O
and O
understand O
en O
##gli O
##sh O
. O
[SEP] O
[CLS] O
a O
value O
of O
p O
< O
0 O
. O
05 O
was O
considered O
statistical O
##ly O
significant O
. O
[SEP] O
[CLS] O
t O
##n O
##bs O
administration O
substantially O
increased O
the O
expression O
of O
n O
##f O
- O
κ O
##b O
p O
##65 O
( O
p O
< O
0 O
. O
01 O
; O
figure O
8 O
) O
, O
while O
b O
##d O
- O
s O
##ned O
##ds O
marked O
##ly O
reversed O
this O
trend O
( O
p O
< O
0 O
. O
01 O
vs O
t O
##n O
##bs O
group O
) O
in O
a O
dose O
- O
dependent O
manner O
. O
[SEP] O
[CLS] O
the O
mechanism O
of O
action O
of O
prop O
##rano O
##lo O
##l O
on O
infant O
##ile O
hem O
##ang O
##io O
##ma O
is O
not O
well O
understood O
, O
but O
the O
drug O
was O
proposed O
to O
regulate O
hem O
##ang O
##io O
##ma O
cell O
proliferation O
through O
cat O
##ech O
##ola O
##mine O
production O
or O
the O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
pathway O
. O
2 O
[SEP] O
[CLS] O
during O
the O
trial O
, O
blinding O
will O
be O
broken O
by O
the O
investigator O
for O
emergency O
purposes O
only O
, O
where O
knowledge O
of O
the O
blinded O
treatment O
could O
influence O
further O
patient O
care O
. O
[SEP] O
[CLS] O
in O
addition O
, O
it O
appears O
that O
al O
##ani O
##ne O
, O
rather O
than O
g O
##lut O
##amine O
, O
is O
the O
predominant O
n O
carrier O
involved O
in O
the O
transfer O
of O
n O
from O
muscle O
to O
the O
liver O
during O
moderate O
intensity O
exercise O
. O
[SEP] O
[CLS] O
the O
ability O
of O
the O
fabricated O
x O
##ep O
##oma O
##s O
to O
sustain O
drug O
release O
and O
enhance O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
su O
##l O
##pi O
##ride O
in O
v O
##ivo O
was O
investigated O
by O
evaluating O
the O
plasma O
drug O
concentration O
over O
24 O
h O
in O
the O
large O
pig O
model O
. O
[SEP] O
[CLS] O
the O
convergence O
criterion O
of O
the O
implemented O
algorithm O
was O
set O
to O
10 O
##− O
##4 O
, O
relative O
and O
absolute O
error O
to O
0 O
. O
01 O
and O
0 O
. O
1 O
, O
respectively O
. O
[SEP] O
[CLS] O
quantitative O
determination O
of O
t O
##io O
##p O
##ron O
##in O
in O
human O
plasma O
by O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
without O
der O
##iva O
##ti O
##zation O
. O
[SEP] O
[CLS] O
the O
effects O
of O
pro O
##sta O
##g O
##land O
##in O
e O
##1 O
( O
p O
##ge O
##1 O
) O
on O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
ve O
##cu O
##ron O
##ium O
and O
f O
##ent O
##any O
##l O
were O
studied O
during O
an O
##est O
##hesia O
. O
[SEP] O
[CLS] O
health O
status O
and O
injection O
- O
site O
reactions O
were O
monitored O
daily O
for O
64 O
days O
after O
the O
first O
injection O
. O
[SEP] O
[CLS] O
three O
discrete O
retention O
intervals O
were O
t O
##it O
##rated O
for O
each O
subject O
’ O
s O
base O
##line O
performance O
in O
the O
absence O
of O
compound O
to O
yield O
performances O
of O
approximately O
80 O
– O
100 O
% O
, O
55 O
– O
65 O
% O
, O
and O
35 O
– O
45 O
% O
of O
responses O
being O
correct O
at O
short O
, O
medium O
, O
and O
long O
retention O
intervals O
, O
and O
ranged O
from O
0 O
. O
25 O
– O
0 O
. O
5 O
s O
, O
2 O
. O
5 O
– O
14 O
s O
, O
and O
9 O
– O
39 O
s O
, O
respectively O
. O
[SEP] O
[CLS] O
therapeutic O
drug O
monitoring O
of O
ta O
##c O
##rol O
##imus O
in O
liver O
transplant O
##ation O
, O
phase O
ii O
##i O
f O
##k O
##50 O
##6 O
multi O
##cent O
##er O
span O
##ish O
study O
group O
: O
a O
two O
- O
year O
follow O
- O
up O
. O
[SEP] O
[CLS] O
the O
water O
used O
in O
the O
sample O
preparation O
, O
high O
- O
performance O
liquid O
ch O
##roma O
##tography O
( O
hp O
##l O
##c O
) O
, O
and O
liquid O
ch O
##roma O
##tography O
- O
mass O
s O
##pect O
##rome O
##try O
( O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
) O
procedures O
and O
the O
is O
##op O
##rop O
##yl O
alcohol O
used O
in O
the O
hp O
##l O
##c O
procedure O
were O
of O
hp O
##l O
##c O
grade O
and O
were O
purchased O
from O
the O
##rm O
##o O
fish O
##er O
scientific O
( O
wa O
##lt O
##ham O
, O
ma O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
art O
##ica O
##ine O
is O
a O
safe O
agent O
for O
in O
##tra O
##ven O
##ous O
regional O
an O
##ae O
##st O
##hesia O
( O
i O
##v O
##ra O
) O
with O
rapid O
onset O
of O
good O
surgical O
an O
##ae O
##st O
##hesia O
. O
[SEP] O
[CLS] O
since O
vitamin O
k O
antagonist O
##s O
are O
associated O
with O
various O
limitations O
such O
as O
narrow O
therapeutic O
window O
, O
slow O
onset O
and O
offset O
of O
effect O
, O
and O
numerous O
interactions O
with O
food O
and O
drugs O
, O
new O
oral O
anti O
##coa O
##gu O
##lants O
targeted O
to O
in O
##hibit O
th O
##rom O
##bin O
or O
factor O
x O
##a O
( O
f O
##xa O
) O
have O
been O
developed O
. O
[SEP] O
[CLS] O
thanks O
to O
its O
high O
sensitivity O
, O
this O
method O
has O
enabled O
the O
q O
##uant O
##itation O
of O
v O
##ino O
##rel O
##bine O
and O
all O
its O
meta O
##bol O
##ites O
in O
whole O
blood O
over O
168 O
h O
( O
i O
. O
e O
. O
, O
4 O
- O
5 O
elimination B-PK
half I-PK
lives I-PK
) O
whilst O
the O
previous O
liquid O
ch O
##roma O
##to O
##graphic O
methods O
allowed O
their O
measurement O
for O
a O
maximum O
of O
48 O
- O
72 O
h O
. O
therefore O
, O
using O
this O
method O
has O
improved O
the O
reliability O
of O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
analysis O
of O
v O
##ino O
##rel O
##bine O
. O
[SEP] O
[CLS] O
effect O
of O
genetic O
p O
##oly O
##mor O
##phism O
##s O
in O
u O
##d O
##p O
- O
g O
##lu O
##cu O
##ron O
##osy O
##lt O
##ran O
##s O
##fer O
##ase O
1 O
##a O
##6 O
( O
u O
##gt O
##1 O
##a O
##6 O
) O
on O
ace O
##ty O
##ls O
##ali O
##cy O
##lic O
acid O
metabolism O
in O
healthy O
female O
volunteers O
. O
[SEP] O
[CLS] O
there O
is O
also O
an O
increase O
in O
forecast O
accuracy O
( O
de O
##cre O
##ment O
in O
mean O
of O
forecast O
error O
) O
as O
the O
number O
of O
c O
##ps O
used O
increases O
. O
[SEP] O
[CLS] O
t B-PK
##rough I-PK
level I-PK
concentrations I-PK
( I-PK
c I-PK
( I-PK
12 I-PK
h I-PK
) I-PK
) I-PK
showed O
large O
inter O
- O
individual O
var O
##iability O
( O
0 O
- O
9 O
. O
2 O
micro O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
it O
is O
also O
suggested O
that O
mon O
##ate O
##pi O
##l O
male O
##ate O
improve O
##s O
plasma O
lip O
##id O
metabolism O
through O
two O
mechanisms O
: O
enhance O
##ment O
of O
clearance B-PK
of O
plasma O
l O
##dl O
, O
which O
may O
be O
mediated O
by O
up O
- O
regulation O
of O
he O
##pa O
##tic O
l O
##dl O
receptors O
, O
and O
acceleration O
of O
conversion O
of O
free O
ch O
##ole O
##ster O
##ol O
to O
bi O
##le O
acids O
in O
the O
liver O
. O
[SEP] O
[CLS] O
[ O
consensus O
document O
of O
g O
##esi O
##da O
and O
span O
##ish O
secret O
##aria O
##t O
for O
the O
national O
plan O
on O
aids O
( O
s O
##p O
##ns O
) O
regarding O
combined O
anti O
##ret O
##rov O
##ira O
##l O
treatment O
in O
adults O
infected O
by O
the O
human O
im O
##mu O
##no O
##de O
##ficiency O
virus O
( O
j O
##anu O
##ary O
2012 O
) O
] O
. O
[SEP] O
[CLS] O
the O
c B-PK
##l I-PK
, O
vs B-PK
##s I-PK
, O
and O
v B-PK
##z I-PK
were O
significantly O
different O
in O
all O
pair O
##wise O
group O
comparisons O
. O
[SEP] O
[CLS] O
there O
was O
a O
significant O
correlation O
between O
these O
two O
rate O
- O
constant O
ratios O
( O
r O
= O
0 O
. O
96 O
, O
p O
less O
than O
0 O
. O
05 O
) O
, O
although O
the O
values O
observed O
in O
v O
##it O
##ro O
were O
higher O
than O
those O
found O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
changes O
in O
q O
##ee O
##g O
and O
co O
##gnition O
were O
determined O
for O
8 O
hours O
after O
drug O
administration O
. O
[SEP] O
[CLS] O
bio O
##e O
##qui O
##valence O
of O
two O
le O
##uc O
##ovo O
##rin O
calcium O
tablet O
formulation O
##s O
. O
[SEP] O
[CLS] O
in O
order O
to O
investigate O
the O
comparative O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
r O
##hein O
in O
rats O
, O
a O
sensitive O
and O
reliable O
analytical O
method O
was O
developed O
and O
valid O
##ated O
. O
[SEP] O
[CLS] O
for O
each O
cancer O
sub O
##type O
with O
three O
or O
more O
patients O
, O
the O
median O
p O
##fs O
was O
7 O
. O
1 O
months O
for O
re O
##ct O
##al O
cancer O
( O
n O
= O
5 O
) O
and O
1 O
. O
1 O
months O
for O
non O
‐ O
small O
‐ O
cell O
lung O
cancer O
( O
n O
= O
3 O
) O
. O
[SEP] O
[CLS] O
thirteen O
participants O
reported O
a O
total O
of O
78 O
a O
##es O
, O
of O
which O
73 O
were O
considered O
drug O
‐ O
related O
( O
three O
a O
##es O
were O
related O
to O
n O
##t O
##x O
( O
n O
= O
3 O
) O
, O
4 O
to O
e O
##b O
##r O
( O
n O
= O
3 O
) O
, O
28 O
to O
e O
##b O
##r O
, O
b O
##up O
/ O
na O
##l O
, O
and O
n O
##t O
##x O
( O
n O
= O
7 O
) O
, O
and O
38 O
to O
b O
##up O
/ O
na O
##l O
and O
n O
##t O
##x O
( O
n O
= O
11 O
) O
) O
. O
[SEP] O
[CLS] O
the O
impact O
of O
age O
on O
line O
##zo O
##lid O
disposition O
during O
the O
first O
few O
months O
of O
life O
has O
not O
been O
previously O
investigated O
. O
[SEP] O
[CLS] O
the O
study O
was O
approved O
by O
the O
local O
human O
research O
and O
ethics O
committee O
of O
the O
s O
##t O
. O
ant O
##oni O
##us O
hospital O
( O
v O
##c O
##mo O
, O
n O
##l O
##34 O
##6 O
##11 O
. O
100 O
. O
11 O
) O
and O
was O
conducted O
in O
accordance O
with O
the O
principles O
of O
the O
declaration O
of O
he O
##ls O
##ink O
##i O
and O
the O
medical O
research O
involving O
human O
subjects O
act O
( O
w O
##mo O
) O
of O
the O
net O
##her O
##lands O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
were O
tuned O
with O
high O
intrinsic B-PK
clearance I-PK
and O
low O
oral B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
in O
mind O
, O
to O
mini O
##mise O
systemic O
exposure O
and O
reduce O
systemic O
##ally O
driven O
adverse O
events O
. O
[SEP] O
[CLS] O
cat O
##he O
##ters O
were O
imp O
##lanted O
both O
in O
the O
right O
at O
##rium O
for O
drug O
in O
##fusion O
and O
in O
the O
ascending O
a O
##ort O
##a O
for O
blood O
sampling O
. O
[SEP] O
[CLS] O
parameter O
sets O
achieving O
ma O
##ximal O
model O
agreement O
with O
experimental O
training O
data O
were O
selected O
( O
see O
text O
s O
##1 O
, O
tables O
s O
##1 O
- O
s O
##2 O
) O
. O
[SEP] O
[CLS] O
this O
random O
##ized O
, O
double O
- O
blind O
, O
place O
##bo O
- O
controlled O
study O
assessed O
the O
safety O
, O
to O
##ler O
##ability O
, O
and O
plasma O
- O
kinetic O
behavior O
of O
94 O
% O
pure O
crystal O
##line O
e O
##pi O
##gall O
##oc O
##ate O
##chin O
gal O
##late O
( O
e O
##g O
##c O
##g O
) O
after O
ten O
days O
' O
repeated O
dos O
##ing O
in O
36 O
healthy O
male O
volunteers O
. O
[SEP] O
[CLS] O
the O
bio O
##dis O
##tribution O
of O
99 O
##t O
##c O
##m O
was O
as O
expected O
for O
a O
labelled O
f O
##ab O
' O
fragment O
: O
relative O
to O
111 O
##in O
, O
99 O
##t O
##c O
##m O
cleared O
rapidly O
from O
circulation O
and O
into O
kidney O
##s O
and O
urine O
. O
[SEP] O
[CLS] O
the O
recovery O
of O
to O
##lf O
##ena O
##mic O
acid O
in O
bi O
##le O
was O
1 O
. O
1 O
+ O
- O
0 O
. O
3 O
% O
of O
the O
dose O
, O
whereas O
the O
recovery O
of O
total O
14 O
##c O
was O
18 O
. O
6 O
+ O
- O
4 O
. O
9 O
% O
. O
[SEP] O
[CLS] O
pool O
##ing O
t O
##f O
##g O
3 O
data O
from O
the O
5 O
, O
7 O
. O
5 O
and O
10 O
mg O
/ O
kg O
groups O
yielded O
a O
t O
##im O
##i O
grade O
3 O
flow O
rate O
of O
34 O
% O
( O
n O
= O
10 O
/ O
29 O
; O
range O
29 O
- O
43 O
% O
) O
. O
[SEP] O
[CLS] O
in O
summary O
, O
our O
results O
provide O
evidence O
of O
b O
##bb O
passage O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
i O
##vi O
##g O
into O
the O
brain O
in O
the O
absence O
of O
b O
##bb O
leak O
##age O
and O
in O
sufficient O
concentration O
to O
interact O
with O
the O
therapeutic O
targets O
. O
[SEP] O
[CLS] O
the O
in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
p O
##har O
##ma O
##co O
##kin O
##etic O
, O
t O
##umour O
delivery O
and O
efficacy O
properties O
of O
lip O
##oso O
##mal O
v O
##in O
##c O
##rist O
##ine O
formulation O
##s O
based O
on O
s O
##phi O
##ngo O
##my O
##elin O
( O
s O
##m O
) O
and O
ch O
##ole O
##ster O
##ol O
were O
compared O
with O
lip O
##oso O
##mes O
composed O
of O
di O
##ste O
##aro O
##yl O
##ph O
##os O
##pha O
##ti O
##dy O
##l O
##cho O
##line O
( O
d O
##sp O
##c O
) O
and O
ch O
##ole O
##ster O
##ol O
. O
[SEP] O
[CLS] O
following O
in O
##tra O
##ven O
##ous O
administration O
sum O
##at O
##rip O
##tan O
was O
eliminated O
from O
plasma O
with O
a O
half B-PK
- I-PK
life I-PK
of O
about O
1 O
. O
1 O
h O
. O
after O
in O
##tra O
##nas O
##al O
administration O
there O
was O
rapid O
absorption O
of O
part O
of O
the O
dose O
and O
two O
peak B-PK
plasma I-PK
concentrations I-PK
were O
observed O
, O
initially O
at O
0 O
. O
5 O
and O
then O
at O
1 O
. O
5 O
- O
2 O
h O
. O
[SEP] O
[CLS] O
in O
a O
second O
trial O
, O
3 O
g O
##ilt O
##s O
were O
fed O
a O
ratio O
##n O
containing O
0 O
. O
55 O
g O
of O
te O
##tra O
##cy O
##cline O
h O
##ydro O
##ch O
##lor O
##ide O
/ O
kg O
of O
feed O
. O
[SEP] O
[CLS] O
c O
##ef O
##ove O
##cin O
mean O
half B-PK
- I-PK
life I-PK
, O
volume B-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
- I-PK
state I-PK
, O
and O
clearance B-PK
after O
in O
##tra O
##ven O
##ous O
administration O
were O
10 O
. O
3 O
h O
, O
86 O
m O
##l O
/ O
kg O
, O
and O
7 O
. O
07 O
m O
##l O
· O
h O
/ O
kg O
. O
[SEP] O
[CLS] O
after O
the O
wash O
##out O
period O
, O
es O
##rd O
subjects O
received O
a O
second O
dose O
of O
o O
##mada O
##cy O
##cline O
( O
the O
second O
treatment O
period O
) O
approximately O
60 O
to O
90 O
min O
before O
dial O
##ys O
##is O
. O
[SEP] O
[CLS] O
no O
rat O
exhibited O
evidence O
of O
ch O
##rom O
##oda O
##c O
##ryo O
##rr O
##hea O
( O
a O
stress O
indicator O
) O
or O
other O
health O
problem O
. O
[SEP] O
[CLS] O
a O
highly O
significant O
correlation O
between O
sa O
##liva O
and O
plasma O
a O
##p O
##c O
##l O
or O
a O
##pt O
##1 O
/ O
2 O
was O
found O
in O
young O
subjects O
. O
[SEP] O
[CLS] O
however O
, O
for O
reasons O
stated O
in O
the O
results O
section O
and O
presented O
in O
detail O
in O
the O
discussion O
, O
the O
3 O
- O
week O
schedule O
was O
not O
started O
. O
[SEP] O
[CLS] O
thus O
, O
p O
##v O
##p O
/ O
e O
##c O
( O
1 O
. O
0 O
: O
10 O
. O
0 O
) O
was O
chosen O
for O
further O
study O
. O
[SEP] O
[CLS] O
while O
specific O
g O
##f O
##r O
function O
was O
parameter O
##ized O
using O
the O
observed O
g O
##f O
##r O
values O
and O
assuming O
the O
mean O
kidney O
weight O
at O
the O
respective O
age O
, O
the O
var O
##iability O
was O
entirely O
dependent O
on O
the O
de O
##viation O
in O
kidney O
weight O
. O
[SEP] O
[CLS] O
while O
these O
novel O
est O
##rad O
##iol O
- O
releasing O
combination O
con O
##tra O
##ceptive O
v O
##agi O
##nal O
rings O
provided O
sustained O
release O
of O
con O
##tra O
##ceptive O
levels O
of O
nest O
##oro O
##ne O
over O
90 O
days O
, O
the O
e O
##2 O
levels O
achieved O
were O
not O
consistent O
with O
bone O
protection O
, O
and O
a O
dose O
- O
response O
was O
not O
observed O
. O
[SEP] O
[CLS] O
we O
have O
also O
evaluated O
its O
potential O
in O
ch O
##em O
##ose O
##ns O
##iti O
##zing O
c O
##er O
##vic O
##al O
cancer O
cells O
to O
p O
##ac O
##lit O
##ax O
##el O
and O
have O
verified O
the O
results O
using O
c O
##er O
##vic O
##al O
cancer O
x O
##eno O
##gra O
##ft O
model O
in O
nod O
- O
s O
##cid O
mice O
. O
[SEP] O
[CLS] O
this O
plasma O
ultra O
##fi O
##lt O
##rate O
was O
immediately O
frozen O
and O
stored O
at O
− O
##20 O
##° O
##c O
. O
[SEP] O
[CLS] O
for O
phase O
ii O
enzymes O
, O
in O
##test O
##ine O
expressed O
more O
u O
##gt O
##1 O
##a O
##2 O
, O
and O
liver O
expressed O
a O
greater O
number O
and O
higher O
levels O
of O
most O
u O
##gt O
and O
su O
##lt O
enzymes O
. O
[SEP] O
[CLS] O
no O
radio B-PK
##act I-PK
##ivity I-PK
was O
exhaled O
in O
air O
suggesting O
that O
elimination O
through O
re O
##spiration O
did O
not O
occur O
. O
[SEP] O
[CLS] O
the O
complete O
database O
was O
a O
prior O
##i O
divided O
into O
“ O
training O
data O
##sets O
” O
for O
model O
parameter O
est O
##imation O
, O
and O
“ O
valid O
##ation O
data O
##sets O
” O
for O
model O
ve O
##rification O
. O
[SEP] O
[CLS] O
bench O
top O
stability O
experiment O
was O
conducted O
to O
keep O
q O
##c O
samples O
at O
room O
temperature O
for O
24 O
h O
. O
[SEP] O
[CLS] O
c O
( O
x O
##1 O
, O
x O
##2 O
) O
= O
e O
[ O
( O
x O
##1 O
##− O
##u O
##1 O
) O
( O
x O
##2 O
##− O
##u O
##2 O
) O
] O
is O
the O
co O
##var O
##iance O
, O
e O
is O
the O
mathematical O
expectation O
, O
u O
##i O
= O
e O
[ O
x O
##i O
] O
, O
i O
= O
1 O
, O
2 O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
of O
mid O
##az O
##ola O
##m O
increased O
1 O
. O
4 O
‐ O
fold O
by O
b O
##fe O
##12 O
##24 O
co O
##ad O
##mini O
##stra O
##tion O
( O
table O
##3 O
) O
. O
[SEP] O
[CLS] O
the O
data O
were O
analyzed O
using O
micro O
##so O
##ft O
ex O
##cel O
2010 O
and O
i O
##b O
##m O
s O
##ps O
##s O
statistics O
version O
19 O
. O
[SEP] O
[CLS] O
d O
##sp O
##c O
: O
ch O
##ole O
##ster O
##ol O
( O
[UNK] O
m O
##ol O
% O
) O
lip O
##oso O
##mes O
were O
prepared O
as O
previously O
outlined O
[ O
36 O
] O
, O
[ O
37 O
] O
, O
using O
trace O
amounts O
of O
the O
non O
- O
meta O
##bol O
##iza O
##ble O
, O
non O
- O
exchange O
##able O
lip O
##id O
trace O
##r O
[ O
3 O
##h O
] O
ch O
##e O
[ O
38 O
] O
. O
[SEP] O
[CLS] O
t B-PK
##max I-PK
was O
4 O
. O
2 O
and O
4 O
. O
3 O
hours O
for O
d O
- O
am O
##phe O
##tamine O
to O
l O
- O
am O
##phe O
##tamine O
, O
respectively O
. O
[SEP] O
[CLS] O
uh O
##p O
##l O
##c O
- O
q O
- O
to O
##f O
/ O
m O
##s O
and O
uh O
##p O
##l O
##c O
- O
multi O
##sta O
##ge O
tandem O
m O
##s O
methods O
were O
developed O
for O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
metabolism O
of O
r O
##ha O
##pont O
##ici O
##n O
in O
rats O
. O
[SEP] O
[CLS] O
we O
report O
five O
episodes O
of O
car O
##ba O
##ma O
##ze O
##pine O
( O
c O
##b O
##z O
) O
into O
##xi O
##cation O
in O
four O
patients O
. O
[SEP] O
[CLS] O
3 O
. O
co O
##ad O
##mini O
##stra O
##tion O
of O
dig O
##ox O
##in O
and O
ve O
##net O
##oc O
##lax O
increased O
dig O
##ox O
##in O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
by O
35 O
% O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
- I-PK
concentration I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
) I-PK
by O
9 O
% O
. O
[SEP] O
[CLS] O
two O
patients O
( O
8 O
% O
) O
had O
a O
confirmed O
partial O
response O
( O
p O
##r O
) O
; O
15 O
( O
60 O
% O
) O
had O
stable O
disease O
( O
s O
##d O
) O
. O
[SEP] O
[CLS] O
an O
i O
##gg O
molecule O
( O
protein O
- O
01 O
) O
and O
a O
40 O
k O
##da O
protein O
( O
protein O
- O
02 O
) O
were O
evaluated O
. O
[SEP] O
[CLS] O
results O
were O
expressed O
as O
stimulation O
index O
( O
si O
= O
c O
##pm O
stimulate O
##d O
/ O
c O
##pm O
un O
##st O
##im O
##ulated O
) O
and O
reported O
as O
residual O
proliferation O
. O
[SEP] O
[CLS] O
it O
should O
be O
mentioned O
, O
however O
, O
that O
c O
##is O
##p O
##lat O
##in O
- O
associated O
ne O
##ph O
##rot O
##ox O
##icit O
##y O
was O
not O
increased O
in O
elderly O
patients O
, O
whereas O
increased O
my O
##elo O
##su O
##pp O
##ression O
was O
seen O
in O
some O
elderly O
patients O
receiving O
c O
##is O
##p O
##lat O
##in O
, O
making O
arbitrary O
dose O
reduction O
##s O
based O
solely O
on O
aging O
di O
##sp O
##uta O
##ble O
[ O
111 O
, O
115 O
, O
116 O
, O
117 O
] O
. O
[SEP] O
[CLS] O
the O
recovery O
of O
co O
##lum O
##bian O
##adi O
##n O
was O
calculated O
by O
comparing O
the O
peak O
areas O
obtained O
from O
spike O
##d O
plasma O
samples O
with O
those O
of O
peak O
areas O
of O
the O
anal O
##yte O
spike O
##d O
post O
- O
treatment O
at O
corresponding O
concentrations O
. O
[SEP] O
[CLS] O
urine O
( O
entire O
volume O
) O
was O
collected O
during O
3 O
sampling O
periods O
: O
0 O
to O
8 O
, O
8 O
to O
16 O
, O
and O
16 O
to O
24 O
hours O
after O
l O
##s O
##d O
administration O
. O
[SEP] O
[CLS] O
due O
to O
the O
severity O
of O
p O
. O
a O
##er O
##ug O
##ino O
##sa O
infection O
, O
a O
lower O
in O
##oc O
##ulum O
was O
used O
so O
as O
to O
reduce O
mortality O
; O
treatment O
was O
started O
2 O
h O
post O
##in O
##fect O
##ion O
to O
allow O
c O
##fu O
counts O
to O
reach O
a O
higher O
base O
##line O
level O
. O
[SEP] O
[CLS] O
si O
between O
rode O
##nt O
pairs O
is O
used O
to O
measure O
anxiety O
- O
like O
behaviour O
##s O
[ O
57 O
] O
. O
[SEP] O
[CLS] O
in O
addition O
, O
t O
##rol O
##ean O
##dom O
##y O
##cin O
had O
no O
effect O
on O
er O
##yt O
##hr O
##omy O
##cin O
transport O
in O
ca O
##co O
- O
2 O
cells O
( O
p O
> O
or O
= O
. O
20 O
) O
. O
[SEP] O
[CLS] O
sub O
##ling O
##ual O
f O
##ent O
##any O
##l O
o O
##dt O
was O
effective O
and O
well O
tolerate O
##d O
for O
the O
long O
- O
term O
treatment O
of O
b O
##t O
##c O
##p O
in O
op O
##io O
##id O
- O
tolerant O
cancer O
patients O
. O
[SEP] O
[CLS] O
an O
l O
##c O
– O
es O
##i O
- O
m O
##s O
/ O
m O
##s O
ass O
##ay O
for O
δ O
- O
v O
##ini O
##fer O
##in O
( O
r O
##s O
- O
1 O
) O
and O
its O
meta O
##bol O
##ites O
in O
rat O
plasma O
, O
urine O
and O
f O
##ec O
##es O
was O
applied O
in O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
r O
##s O
- O
1 O
in O
rats O
. O
[SEP] O
[CLS] O
[ O
t O
##rud O
##ell O
medical O
international O
, O
lo O
##ndon O
, O
on O
##tar O
##io O
, O
can O
##ada O
] O
) O
. O
[SEP] O
[CLS] O
in O
this O
paper O
, O
the O
disposition O
of O
t O
##re O
##o O
and O
its O
active O
mon O
##oe O
##pox O
##ide O
( O
s O
, O
s O
- O
e O
##b O
##d O
##m O
) O
in O
a O
bone O
ma O
##rrow O
, O
liver O
, O
lungs O
, O
brain O
, O
and O
q O
##uad O
##rice O
##ps O
f O
##em O
##oris O
was O
studied O
in O
an O
animal O
model O
. O
[SEP] O
[CLS] O
electron O
micro O
##sco O
##py O
revealed O
sin O
##us O
##oid O
destruction O
and O
changes O
in O
both O
the O
plasma O
membrane O
and O
par O
##en O
##chy O
##mal O
cell O
mit O
##och O
##ond O
##ria O
in O
groups O
a O
and O
b O
, O
while O
in O
group O
c O
these O
structures O
were O
well O
preserved O
. O
[SEP] O
[CLS] O
the O
median O
start O
time O
of O
in O
##tra O
##ven O
##ous O
glucose O
in O
##fusion O
post O
‐ O
dos O
##ing O
to O
treat O
h O
##y O
##po O
##gly O
##ca O
##emia O
ranged O
from O
2 O
. O
4 O
to O
3 O
. O
8 O
hours O
for O
das O
##ig O
##lu O
##ca O
##gon O
versus O
2 O
. O
2 O
to O
3 O
. O
2 O
hours O
for O
commercial O
g O
##lu O
##ca O
##gon O
( O
post O
ho O
##c O
analysis O
; O
table O
s O
##5 O
, O
supporting O
information O
) O
. O
[SEP] O
[CLS] O
mean O
cm B-PK
##ax I-PK
ranged O
from O
45 O
##4 O
- O
10 O
, O
333 O
ng O
/ O
m O
##l O
and O
mean O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##f I-PK
) I-PK
from O
1 O
, O
69 O
##0 O
- O
43 O
, O
37 O
##1 O
ng O
x O
h O
/ O
m O
##l O
after O
the O
15 O
and O
300 O
mg O
single O
doses O
, O
respectively O
. O
[SEP] O
[CLS] O
population O
p O
##k O
and O
p O
##k O
/ O
p O
##d O
models O
were O
developed O
using O
a O
non O
##linear O
mixed O
- O
effects O
approach O
. O
[SEP] O
[CLS] O
at O
first O
sight O
, O
the O
proportion O
of O
patients O
with O
a O
##es O
occurring O
under O
c O
##ic O
##los O
##por O
##in O
pro O
appeared O
higher O
than O
the O
proportion O
of O
patients O
with O
a O
##es O
occurring O
under O
sand O
##im O
##mu O
##n O
##® O
op O
##tor O
##al O
. O
[SEP] O
[CLS] O
three O
other O
patients O
were O
treated O
with O
3 O
mg O
/ O
m O
##2 O
v O
##in O
##blast O
##ine O
as O
a O
b O
##ol O
##us O
injection O
on O
day O
1 O
, O
day O
3 O
and O
day O
8 O
. O
[SEP] O
[CLS] O
the O
contents O
were O
stirred O
and O
cooled O
in O
an O
ice O
bath O
( O
30 O
minutes O
) O
. O
[SEP] O
[CLS] O
the O
disappearance O
of O
the O
sharp O
melting O
end O
##oth O
##er O
##mal O
peak O
of O
ed O
##r O
in O
the O
the O
##rm O
##ogram O
of O
ne O
##f O
revealed O
the O
complete O
alter O
##ation O
of O
the O
solid O
state O
of O
ed O
##r O
from O
crystal O
##line O
to O
am O
##or O
##ph O
##ous O
. O
[SEP] O
[CLS] O
day O
1 O
pre O
- O
dose O
procedures O
and O
assessments O
included O
vital O
signs O
and O
collection O
of O
samples O
for O
base O
##line O
assessment O
of O
hem O
##ato O
##logy O
, O
chemistry O
, O
u O
##rina O
##lysis O
, O
and O
ad O
##as O
. O
[SEP] O
[CLS] O
the O
analytical O
method O
developed O
with O
hp O
##l O
##c O
was O
successfully O
valid O
##ated O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
the O
range O
of O
re O
##nal O
function O
was O
relatively O
wide O
, O
with O
e O
##g O
##f O
##r O
values O
as O
low O
as O
4 O
. O
1 O
m O
##l O
min O
##− O
##1 O
1 O
. O
73 O
m O
##− O
##2 O
and O
a O
mean O
of O
88 O
. O
7 O
( O
31 O
. O
4 O
) O
m O
##l O
min O
##− O
##1 O
1 O
. O
73 O
m O
##− O
##2 O
. O
[SEP] O
[CLS] O
this O
retrospective O
analysis O
was O
conducted O
to O
identify O
an O
appropriate O
s O
##cal O
##ing O
method O
to O
predict O
human O
p O
##k O
for O
ad O
##cs O
from O
animal O
p O
##k O
data O
in O
the O
linear O
range O
. O
[SEP] O
[CLS] O
m O
##ln O
##27 O
##0 O
##4 O
p O
##har O
##ma O
##co O
##kin O
##etics O
were O
dose O
- O
linear O
. O
[SEP] O
[CLS] O
then O
, O
1 O
##e O
##6 O
k O
##b O
cells O
were O
in O
##cu O
##bate O
##d O
with O
0 O
. O
1 O
, O
1 O
. O
0 O
, O
2 O
. O
5 O
, O
5 O
. O
0 O
, O
or O
10 O
. O
0 O
μ O
##m O
of O
e O
##c O
##17 O
and O
o O
##tl O
##38 O
. O
[SEP] O
[CLS] O
the O
cartridge O
was O
se O
##quential O
##ly O
washed O
with O
1 O
. O
0 O
m O
##l O
up O
##w O
and O
1 O
m O
##l O
of O
5 O
% O
a O
##que O
##ous O
met O
##han O
##ol O
. O
[SEP] O
[CLS] O
seven O
children O
, O
aged O
3 O
- O
16 O
years O
, O
in O
second O
or O
subsequent O
men O
##inge O
##al O
re O
##lap O
##se O
of O
acute O
l O
##ymph O
##ob O
##lastic O
le O
##uka O
##emia O
( O
all O
) O
, O
have O
been O
treated O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
over O
15 O
days O
post O
- O
treatment O
and O
drug O
plasma O
concentrations O
measured O
by O
hp O
##l O
##c O
. O
[SEP] O
[CLS] O
increased O
he O
##pa O
##tic O
ni O
##cot O
##ine O
elimination O
after O
p O
##hen O
##ob O
##ar O
##bit O
##al O
induction O
in O
the O
conscious O
rat O
. O
[SEP] O
[CLS] O
the O
purpose O
of O
the O
present O
study O
was O
to O
q O
##uant O
##ify O
the O
card O
##iovascular O
effects O
of O
the O
2 O
' O
- O
, O
3 O
' O
- O
, O
5 O
' O
- O
de O
##ox O
##yr O
##ib O
##ose O
analogue O
##s O
of O
the O
selective O
ad O
##eno O
##sin O
##e O
a O
##1 O
receptor O
ago O
##nist O
, O
n O
##6 O
- O
c O
##y O
##c O
##lop O
##ent O
##yla O
##den O
##os O
##ine O
( O
c O
##pa O
) O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
hence O
, O
individual O
##ised O
dos O
##ing O
of O
c O
##is O
##p O
##lat O
##in O
using O
au B-PK
##c I-PK
or O
d O
##na O
- O
add O
##uc O
##ts O
should O
lead O
to O
increased O
response O
rates O
. O
[SEP] O
[CLS] O
all O
subjects O
in O
co O
##hor O
##ts O
b O
and O
c O
were O
analyzed O
for O
p O
##k O
and O
p O
##d O
parameters O
. O
[SEP] O
[CLS] O
the O
volume B-PK
of I-PK
distribution I-PK
decreased O
with O
increasing O
doses O
, O
averaging O
76 O
. O
8 O
+ O
- O
38 O
. O
06 O
m O
##l O
/ O
kg O
for O
the O
15 O
mg O
/ O
kg O
dose O
and O
falling O
to O
55 O
. O
2 O
+ O
- O
17 O
. O
4 O
m O
##l O
/ O
kg O
for O
the O
30 O
mg O
/ O
kg O
dose O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
from I-PK
the I-PK
beginning I-PK
to I-PK
the I-PK
last I-PK
values I-PK
( I-PK
au I-PK
##c I-PK
##last I-PK
) I-PK
was O
determined O
using O
the O
linear O
trap O
##ez O
##oid O
##al O
method O
as O
was O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
h I-PK
, O
which O
indicated O
the O
au B-PK
##c I-PK
from I-PK
the I-PK
beginning I-PK
to I-PK
24 I-PK
hours I-PK
. O
[SEP] O
[CLS] O
it O
was O
designed O
as O
a O
window O
study O
in O
order O
to O
test O
o O
##si O
- O
79 O
##0 O
##4 O
##l O
in O
first O
- O
line O
patients O
without O
exposure O
to O
prior O
flu O
##oro O
##py O
##rim O
##id O
##ine O
therapy O
, O
and O
in O
the O
absence O
of O
clinical O
benefit O
, O
more O
commonly O
used O
combination O
regime O
##ns O
could O
be O
introduced O
without O
negatively O
impact O
##ing O
patient O
care O
. O
[SEP] O
[CLS] O
the O
ve O
##si O
##cle O
suspension O
was O
pipe O
##tte O
into O
a O
bag O
made O
up O
of O
tub O
##ing O
and O
sealed O
followed O
by O
placing O
the O
dial O
##ys O
##is O
bag O
into O
a O
be O
##aker O
containing O
200 O
m O
##l O
of O
p O
##bs O
p O
##h O
7 O
. O
4 O
. O
[SEP] O
[CLS] O
i O
##v O
i O
##rino O
##teca O
##n O
( O
15 O
or O
20 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
given O
daily O
for O
5 O
days O
of O
2 O
consecutive O
weeks O
. O
[SEP] O
[CLS] O
do O
##pa O
##mine O
##rg O
##ic O
mechanisms O
are O
thought O
to O
play O
a O
central O
role O
in O
the O
re O
##in O
##forcing O
effects O
of O
cocaine O
. O
[SEP] O
[CLS] O
blood O
and O
urine O
samples O
for O
clinical O
path O
##ology O
evaluation O
##s O
were O
collected O
from O
all O
animals O
prior O
to O
the O
terminal O
ne O
##c O
##rops O
##y O
. O
[SEP] O
[CLS] O
narrow O
co O
##lli O
##mation O
( O
1 O
. O
0 O
mm O
) O
was O
used O
as O
before O
, O
with O
a O
1 O
. O
0 O
mm O
slice O
width O
and O
a O
medium O
smooth O
reconstruction O
kernel O
( O
b O
##30 O
##f O
) O
, O
with O
a O
reconstruction O
in O
##cre O
##ment O
of O
1 O
. O
0 O
mm O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
k I-PK
##eto I-PK
##p I-PK
##ro I-PK
##fen I-PK
content I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
6 I-PK
h I-PK
) I-PK
for O
the O
ratio O
photo O
- O
stab O
##ilis O
##ed O
gel O
/ O
transparent O
gel O
was O
73 O
% O
with O
a O
90 O
% O
confidence O
interval O
( O
c O
##i O
) O
65 O
- O
83 O
. O
[SEP] O
[CLS] O
g O
- O
c O
##s O
##f O
( O
5 O
micro O
##gram O
##s O
/ O
kg O
/ O
day O
) O
was O
administered O
sub O
##cut O
##aneous O
##ly O
to O
all O
patients O
from O
day O
3 O
until O
the O
w O
##b O
##c O
> O
or O
= O
1000 O
##0 O
/ O
micro O
##lite O
##rs O
. O
[SEP] O
[CLS] O
the O
patient O
died O
suddenly O
of O
acute O
heart O
failure O
before O
the O
operation O
. O
[SEP] O
[CLS] O
twenty O
four O
p O
##har O
##ma O
##co O
##kin O
##etics O
- O
related O
molecular O
des O
##cript O
##ors O
available O
in O
q O
##ik O
##p O
##rop O
[ O
21 O
] O
, O
which O
character O
##ize O
a O
wide O
spectrum O
of O
molecular O
properties O
as O
described O
in O
section O
3 O
. O
9 O
, O
e O
. O
g O
. O
, O
such O
as O
molecular O
mass O
, O
total O
solvent O
- O
accessible O
molecular O
surface O
, O
h O
##ydro O
##phobic O
portion O
of O
the O
solvent O
- O
accessible O
molecular O
surface O
, O
total O
volume O
of O
molecule O
enclosed O
by O
solvent O
- O
accessible O
molecular O
surface O
, O
number O
of O
non O
- O
trivial O
non O
- O
hind O
##ered O
rot O
##ata O
##ble O
bonds O
, O
estimated O
number O
of O
hydrogen O
bonds O
that O
would O
be O
donated O
by O
the O
so O
##lut O
##e O
to O
water O
molecules O
in O
an O
a O
##que O
##ous O
solution O
, O
estimated O
number O
of O
hydrogen O
bonds O
that O
would O
be O
accepted O
by O
the O
so O
##lut O
##e O
from O
water O
molecules O
, O
log O
##ari O
##th O
##m O
of O
partition O
##ing O
coefficient O
between O
n O
- O
o O
##ct O
##ano O
##l O
and O
water O
phases O
, O
log O
##ari O
##th O
##m O
of O
predicted O
a O
##que O
##ous O
so O
##lub O
##ility O
, O
log O
##ari O
##th O
##m O
of O
predicted O
binding O
constant O
to O
human O
serum O
album O
##in O
, O
log O
##ari O
##th O
##m O
of O
predicted O
brain O
/ O
blood O
partition O
coefficient O
, O
apparent O
ca O
##co O
- O
2 O
cell O
membrane O
per B-PK
##me I-PK
##ability I-PK
in O
b O
##oe O
##hr O
##inger O
– O
ing O
##el O
##heim O
scale O
, O
number O
of O
likely O
metabolic O
reactions O
, O
percentage O
of O
human O
oral O
absorption O
in O
gas O
##tro O
##int O
##est O
##inal O
tract O
, O
etc O
. O
[SEP] O
[CLS] O
however O
, O
due O
to O
its O
short O
half B-PK
- I-PK
life I-PK
of O
1 O
- O
2 O
h O
, O
a O
multiple O
dose O
regime O
##n O
is O
required O
for O
oral O
administration O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
s O
##4 O
, O
the O
m O
##or O
##phological O
properties O
of O
l O
##c O
##n O
##p O
- O
# O
8 O
and O
# O
11 O
in O
the O
acidic O
condition O
were O
comparable O
with O
those O
of O
l O
##c O
##n O
##p O
- O
# O
8 O
and O
# O
11 O
in O
the O
neutral O
condition O
. O
[SEP] O
[CLS] O
the O
compound O
was O
eliminated O
mainly O
with O
the O
bi O
##le O
. O
[SEP] O
[CLS] O
on O
the O
all O
##o O
- O
h O
##s O
##ct O
day O
, O
v O
##p O
- O
16 O
was O
detect O
##able O
in O
the O
plasma O
samples O
of O
19 O
children O
( O
mean O
± O
s O
##d O
: O
0 O
. O
4 O
± O
0 O
. O
3 O
μ O
##g O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
both O
trace O
##rs O
were O
used O
for O
im O
##mu O
##no O
##pet O
imaging O
of O
the O
b O
cell O
compartment O
in O
human O
c O
##d O
##20 O
trans O
##genic O
mice O
( O
h O
##c O
##d O
##20 O
##t O
##m O
) O
. O
[SEP] O
[CLS] O
em O
images O
were O
acquired O
at O
27 O
, O
500 O
##× O
ma O
##gni O
##fication O
( O
p O
##ixel O
size O
0 O
, O
60 O
##2 O
nm O
) O
at O
− O
##12 O
, O
− O
##18 O
μ O
##m O
def O
##oc O
##us O
. O
[SEP] O
[CLS] O
in O
##fluenza O
is O
a O
respiratory O
disease O
that O
causes O
annual O
epidemic O
##s O
. O
[SEP] O
[CLS] O
patients O
in O
dose O
level O
( O
d O
##l O
) O
1 O
received O
a O
##xi O
##tin O
##ib O
5 O
mg O
twice O
a O
day O
( O
days O
1 O
to O
21 O
) O
with O
c O
##is O
##p O
##lat O
##in O
80 O
mg O
/ O
m O
##2 O
( O
day O
1 O
) O
and O
cape O
##ci O
##ta O
##bine O
1 O
, O
000 O
mg O
/ O
m O
##2 O
twice O
a O
day O
( O
days O
1 O
to O
14 O
) O
in O
21 O
- O
day O
cycles O
. O
[SEP] O
[CLS] O
the O
‘ O
a O
##ffy O
##met O
##rix O
d O
##met O
- O
plus O
’ O
g O
##eno O
##ty O
##ping O
array O
[ O
13 O
] O
was O
used O
to O
g O
##eno O
##type O
common O
genetic O
variants O
in O
c O
##y O
##p O
##3 O
##a O
##4 O
/ O
3 O
##a O
##5 O
, O
c O
##y O
##p O
##2 O
##c O
##8 O
, O
c O
##y O
##p O
##2 O
##c O
##19 O
, O
s O
##l O
##co O
##1 O
##b O
##1 O
( O
o O
##at O
##p O
##1 O
##b O
##1 O
) O
and O
a O
##b O
##c O
##g O
##2 O
( O
b O
##c O
##rp O
) O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
y O
##j O
##c O
- O
105 O
##9 O
##2 O
showed O
dose O
- O
dependent O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
low O
f B-PK
value O
due O
to O
slower O
elimination O
and O
incomplete O
absorption O
. O
[SEP] O
[CLS] O
overall O
, O
2 O
% O
of O
patients O
were O
co O
- O
infected O
with O
he O
##pa O
##titis O
b O
and O
3 O
% O
with O
he O
##pa O
##titis O
c O
virus O
. O
[SEP] O
[CLS] O
several O
soluble O
analogue O
##s O
with O
similar O
anti O
##tum O
##our O
activity O
are O
currently O
under O
investigation O
. O
[SEP] O
[CLS] O
compared O
with O
healthy O
matched O
, O
patients O
with O
moderate O
- O
severe O
he O
##pa O
##tic O
imp O
##air O
##ment O
exhibited O
small O
increase O
( O
29 O
% O
) O
in O
top O
##ira O
##mate O
peak B-PK
plasma I-PK
concentrations I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
values O
, O
consistent O
with O
lower O
c B-PK
##l I-PK
/ I-PK
f I-PK
( O
26 O
% O
) O
. O
[SEP] O
[CLS] O
mice O
ex O
##cre O
##te O
85 O
to O
100 O
% O
of O
the O
dose O
in O
24 O
h O
. O
rats O
ex O
##cre O
##te O
only O
59 O
to O
81 O
% O
of O
the O
administered O
radio B-PK
##act I-PK
##ivity I-PK
in O
the O
same O
time O
, O
primarily O
in O
urine O
and O
f O
##ec O
##es O
, O
with O
a O
trace O
in O
re O
##sp O
##ired O
air O
. O
[SEP] O
[CLS] O
compared O
to O
the O
a O
##que O
##ous O
vehicle O
, O
the O
extent O
of O
absorption O
of O
g O
##reis O
##eo O
##ful O
##vin O
was O
decreased O
by O
he O
##xa O
##de O
##cane O
, O
o O
##ley O
##l O
alcohol O
, O
and O
trio O
##lein O
, O
increased O
by O
p O
##oly O
##sor O
##bate O
80 O
, O
and O
not O
affected O
by O
trio O
##ct O
##ano O
##in O
. O
[SEP] O
[CLS] O
thus O
, O
including O
disease O
path O
##ology O
in O
the O
model O
produced O
better O
predictions O
of O
p O
##k O
/ O
p O
##d O
relationships O
for O
both O
r O
##if O
##am O
##y O
##cin O
##s O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
observed I-PK
plasma I-PK
concentration I-PK
, I-PK
cm I-PK
##ax I-PK
, O
and O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
from I-PK
time I-PK
zero I-PK
to I-PK
the I-PK
last I-PK
me I-PK
##as I-PK
##urable I-PK
sampling I-PK
time I-PK
point I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
– I-PK
t I-PK
) I-PK
were O
35 O
% O
and O
102 O
% O
higher O
than O
those O
of O
en O
##t O
when O
oral O
##ly O
administered O
to O
rats O
( O
10 O
mg O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
wash O
with O
3 O
##x O
##5 O
minutes O
t O
##bs O
##t O
, O
then O
secondary O
anti O
##body O
in O
##cu O
##bation O
for O
2 O
hours O
at O
r O
##t O
with O
shaking O
( O
goat O
- O
anti O
- O
rabbit O
- O
h O
##rp O
ca O
##yman O
1000 O
##43 O
##01 O
at O
1 O
/ O
1000 O
in O
15 O
m O
##l O
t O
##bs O
##t O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
for O
plasma O
and O
tissues O
. O
[SEP] O
[CLS] O
although O
o O
##x O
##1 O
##r O
ant O
##agon O
##ism O
blocked O
expression O
of O
a O
weak O
ethanol O
c O
##pp O
( O
experiment O
4 O
) O
, O
it O
did O
not O
affect O
expression O
of O
a O
moderate O
to O
strong O
c O
##pp O
( O
experiment O
5 O
) O
. O
[SEP] O
[CLS] O
the O
mean O
plasma O
concentration O
– O
time O
[SEP] O
[CLS] O
correlation O
was O
made O
between O
in O
v O
##it O
##ro O
release O
and O
in O
v O
##ivo O
absorption O
. O
[SEP] O
[CLS] O
pro O
- O
and O
anti O
- O
inflammatory O
c O
##yt O
##oki O
##nes O
were O
dose O
- O
dependent O
##ly O
but O
trans O
##ient O
##ly O
up O
##re O
##gu O
##lated O
only O
after O
the O
first O
dose O
. O
[SEP] O
[CLS] O
however O
, O
his O
c O
##d O
##4 O
count O
( O
56 O
cells O
/ O
μ O
##l O
) O
and O
plasma O
viral O
load O
( O
1 O
, O
27 O
, O
73 O
##4 O
/ O
mm O
of O
blood O
) O
failed O
to O
improve O
. O
[SEP] O
[CLS] O
the O
overall O
inter O
- O
ass O
##ay O
coefficient O
of O
variation O
for O
the O
whole O
blood O
f O
##olate O
standard O
was O
9 O
. O
1 O
% O
with O
a O
mean O
value O
of O
32 O
. O
2 O
± O
2 O
. O
9 O
nm O
##ol O
/ O
l O
( O
14 O
. O
2 O
± O
1 O
. O
3 O
ng O
/ O
m O
##l O
) O
. O
[SEP] O
[CLS] O
the O
study O
schedule O
included O
a O
screening O
visit O
, O
a O
2 O
- O
day O
in O
##patient O
pre O
##tre O
##at O
##ment O
base O
##line O
assessment O
period O
( O
during O
which O
a O
place O
##bo O
run O
- O
in O
was O
initiated O
) O
, O
a O
14 O
- O
day O
( O
co O
##hor O
##ts O
1 O
– O
6 O
) O
or O
15 O
- O
day O
( O
co O
##hor O
##t O
7 O
) O
in O
##patient O
treatment O
period O
, O
and O
a O
6 O
- O
day O
( O
co O
##hor O
##ts O
1 O
– O
6 O
) O
or O
5 O
- O
day O
( O
co O
##hor O
##t O
7 O
) O
post O
##dos O
##ing O
out O
##patient O
observation O
period O
. O
[SEP] O
[CLS] O
apart O
from O
the O
study O
group O
, O
one O
group O
of O
animals O
received O
the O
respective O
optical O
probe O
together O
with O
a O
10 O
- O
fold O
excess O
of O
un O
##la O
##bell O
##ed O
mini O
##gas O
##tri O
##n O
to O
induce O
a O
competition O
for O
cc O
##k O
##2 O
##r O
binding O
and O
therefore O
revealing O
in O
v O
##ivo O
specific O
##ity O
. O
[SEP] O
[CLS] O
figure O
6 O
shows O
the O
parameters O
with O
the O
highest O
sensitivity O
index O
##es O
( O
si O
) O
in O
the O
model O
. O
[SEP] O
[CLS] O
single O
oral O
doses O
of O
be O
##vir O
##ima O
##t O
were O
well O
tolerate O
##d O
and O
demonstrated O
a O
dose O
- O
dependent O
reduction O
in O
viral O
load O
. O
[SEP] O
[CLS] O
these O
data O
suggest O
that O
ace O
##ty O
##lation O
represents O
a O
means O
of O
increasing O
the O
biological O
pot O
##ency O
in O
v O
##it O
##ro O
, O
increasing O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
e O
##g O
##c O
##g O
in O
v O
##ivo O
, O
and O
may O
improve O
cancer O
- O
prevent O
##ive O
activity O
. O
[SEP] O
[CLS] O
internal O
standards O
were O
f O
##ent O
##any O
##l O
c O
##it O
##rate O
( O
pro O
##mo O
##che O
##m O
, O
we O
##sel O
, O
g O
##erman O
##y O
) O
for O
ass O
##ay O
of O
un O
##con O
##ju O
##gated O
and O
total O
rot O
##igo O
##tine O
and O
n O
- O
des O
##p O
##rop O
##yl O
- O
prop O
##af O
##eno O
##ne O
o O
##xa O
##late O
for O
ass O
##ay O
of O
the O
des O
##alk O
##yl O
meta O
##bol O
##ites O
. O
[SEP] O
[CLS] O
larger O
na O
##no O
##par O
##tic O
##les O
( O
150 O
– O
200 O
nm O
) O
with O
spherical O
shapes O
tend O
to O
be O
trapped O
by O
the O
liver O
f O
##ene O
##stra O
and O
recognized O
by O
k O
##up O
##ffer O
cells O
. O
42 O
smaller O
particles O
( O
of O
~ O
100 O
nm O
in O
diameter O
) O
with O
elongated O
shapes O
may O
be O
se O
##quest O
##ered O
by O
the O
s O
##ple O
##en O
, O
unless O
being O
def O
##orm O
##able O
enough O
to O
cross O
the O
s O
##ple O
##en O
re O
##tic O
##ular O
network O
. O
[SEP] O
[CLS] O
to O
100 O
μ O
##l O
al O
##iq O
##uo O
##t O
of O
a O
plasma O
sample O
, O
20 O
μ O
##l O
met O
##han O
##ol O
and O
180 O
μ O
##l O
internal O
standard O
met O
##han O
##ol O
solution O
( O
2 O
ng O
/ O
m O
##l O
) O
were O
added O
and O
v O
##ortex O
##ed O
for O
60 O
s O
to O
mix O
in O
a O
1 O
. O
5 O
m O
##l O
p O
##oly O
##p O
##rop O
##yle O
##ne O
tube O
, O
and O
then O
cent O
##ri O
##fu O
##ged O
at O
12 O
, O
000 O
rpm O
for O
10 O
min O
. O
[SEP] O
[CLS] O
further O
##more O
, O
the O
enhance O
##ment O
of O
the O
ethanol O
- O
induced O
lo O
##rr O
by O
b O
##c O
##po O
was O
reversed O
by O
am O
##6 O
##30 O
. O
[SEP] O
[CLS] O
upon O
the O
recommendation O
of O
the O
data O
and O
safety O
monitoring O
board O
, O
any O
subject O
with O
hem O
##og O
##lo O
##bin O
levels O
< O
12 O
g O
/ O
d O
##l O
at O
study O
exit O
was O
required O
to O
return O
to O
our O
clinical O
research O
center O
for O
a O
follow O
- O
up O
safety O
assessment O
. O
[SEP] O
[CLS] O
the O
ch O
##roma O
##to O
##graphic O
total O
run O
time O
was O
10 O
min O
. O
[SEP] O
[CLS] O
for O
the O
principal O
meta O
##bol O
##ite O
p O
##g O
##l O
##40 O
##0 O
##2 O
, O
t B-PK
##max I-PK
and O
plasma B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
values O
were O
similar O
to O
those O
of O
up O
##a O
. O
[SEP] O
[CLS] O
however O
, O
removal O
of O
b O
##s O
##v O
for O
v B-PK
##1 I-PK
did O
not O
significantly O
change O
of O
##v O
( O
increase O
of O
1 O
unit O
) O
. O
[SEP] O
[CLS] O
the O
distribution B-PK
volume I-PK
( O
0 O
. O
44 O
+ O
- O
0 O
. O
06 O
l O
/ O
kg O
in O
control O
vs O
. O
0 O
. O
44 O
+ O
- O
0 O
. O
09 O
l O
/ O
kg O
oral O
con O
##tra O
##ceptive O
group O
) O
, O
total B-PK
body I-PK
clearance I-PK
( O
0 O
. O
78 O
+ O
- O
0 O
. O
13 O
m O
##l O
/ O
kg O
/ O
min O
vs O
0 O
. O
78 O
+ O
- O
0 O
. O
18 O
m O
##l O
/ O
kg O
/ O
min O
) O
and O
elimination B-PK
t I-PK
1 I-PK
/ I-PK
2 I-PK
( O
40 O
##2 O
+ O
- O
78 O
min O
vs O
. O
40 O
##9 O
+ O
- O
126 O
min O
) O
were O
identical O
in O
the O
two O
groups O
. O
[SEP] O
[CLS] O
q O
##uant O
##itation O
of O
bi O
##sp O
##hen O
##ol O
a O
and O
bi O
##sp O
##hen O
##ol O
a O
g O
##lu O
##cu O
##ron O
##ide O
in O
biological O
samples O
by O
high O
performance O
liquid O
ch O
##roma O
##tography O
- O
tandem O
mass O
s O
##pect O
##rome O
##try O
. O
[SEP] O
[CLS] O
options O
become O
limited O
in O
cases O
of O
associated O
systemic O
com O
##or O
##bid O
##ities O
such O
as O
re O
##nal O
d O
##ys O
##function O
, O
h O
##y O
##pop O
##rote O
##inae O
##mia O
, O
an O
##ae O
##mia O
. O
[SEP] O
[CLS] O
my O
##co O
##phe O
##no O
##lic O
acid O
p O
##har O
##ma O
##co O
##kin O
##etics O
in O
stable O
p O
##ediatric O
re O
##nal O
transplant O
##ation O
. O
[SEP] O
[CLS] O
u O
##d O
##ca O
at O
a O
50 O
mg O
/ O
kg O
dose O
efficiently O
decreased O
the O
serum O
levels O
of O
t O
##bil O
, O
t O
##ba O
, O
and O
d O
##bil O
to O
43 O
. O
8 O
% O
( O
p O
< O
0 O
. O
01 O
) O
, O
30 O
. O
9 O
% O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
and O
40 O
. O
9 O
% O
( O
p O
< O
0 O
. O
01 O
) O
, O
respectively O
, O
compared O
with O
the O
control O
group O
. O
[SEP] O
[CLS] O
nevertheless O
, O
collectively O
our O
micro O
##arra O
##y O
and O
c O
##yt O
##oki O
##ne O
analysis O
confirmed O
that O
o O
##ac O
treatment O
had O
a O
significant O
and O
systemic O
impact O
on O
the O
immune O
and O
inflammatory O
response O
in O
mice O
infected O
with O
p O
##ba O
. O
[SEP] O
[CLS] O
the O
p O
##hy O
##si O
##co O
##chemical O
properties O
, O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
anti O
##plate O
##let O
a O
##gg O
##regation O
activities O
of O
these O
derivatives O
were O
measured O
to O
determine O
whether O
they O
can O
improve O
the O
defects O
of O
d O
##ha O
##p O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
studies O
were O
carried O
out O
in O
al O
##bino O
rabbit O
eyes O
of O
either O
sex O
weighing O
between O
1 O
. O
8 O
and O
2 O
. O
5 O
kg O
. O
[SEP] O
[CLS] O
treatment O
of O
cats O
with O
a O
single O
30 O
- O
mg O
/ O
kg O
dose O
of O
m O
##ps O
##s O
( O
m O
##ps O
##s O
/ O
v O
) O
provided O
a O
clear O
, O
although O
not O
significant O
, O
protection O
against O
ne O
##uro O
##fi O
##lam O
##ent O
degradation O
compared O
with O
v O
/ O
v O
- O
treated O
cats O
when O
measured O
at O
4 O
1 O
/ O
2 O
hours O
after O
injury O
. O
[SEP] O
[CLS] O
the O
em O
##etic O
syrup O
or O
the O
us O
##p O
i O
##pec O
##ac O
syrup O
was O
then O
administered O
. O
[SEP] O
[CLS] O
the O
mean O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
was O
1 O
. O
8 O
h O
( O
range O
, O
1 O
. O
4 O
to O
2 O
. O
3 O
h O
) O
, O
the O
apparent B-PK
volume I-PK
of I-PK
distribution I-PK
at I-PK
steady I-PK
state I-PK
was O
17 O
liter O
##s O
, O
and O
the O
total B-PK
systemic I-PK
clearance I-PK
was O
150 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
the O
in O
##tra O
##mus O
##cular O
group O
was O
dose O
##d O
with O
i O
##car O
##ii O
##n O
( O
20 O
mg O
/ O
kg O
) O
by O
in O
##tra O
##mus O
##cular O
injection O
of O
this O
solution O
. O
[SEP] O
[CLS] O
the O
volume B-PK
of I-PK
distribution I-PK
in I-PK
the I-PK
per I-PK
##ito I-PK
##ne I-PK
##um I-PK
( I-PK
v I-PK
a I-PK
) I-PK
ex O
##po O
##nent O
##ially O
decreased O
due O
to O
the O
carrier O
so O
##lut O
##e O
absorption O
. O
[SEP] O
[CLS] O
the O
results O
indicate O
that O
two O
different O
therapeutic O
schedules O
of O
me O
##rop O
##ene O
##m O
are O
equally O
applicable O
to O
patients O
receiving O
c O
##v O
##v O
##h O
##d O
: O
either O
750 O
mg O
t O
##id O
or O
1500 O
bid O
. O
[SEP] O
[CLS] O
radio O
##pha O
##rma O
##co O
##kin O
##etic O
data O
for O
64 O
##cu O
- O
mm O
- O
302 O
in O
naive O
female O
c O
##d O
- O
1 O
mice O
( O
n O
= O
3 O
) O
are O
presented O
in O
figure O
1 O
##a O
. O
[SEP] O
[CLS] O
between O
cycles O
3 O
and O
4 O
, O
the O
patient O
had O
an O
##emia O
grade O
2 O
, O
probably O
related O
to O
a O
concurrent O
infection O
, O
and O
received O
another O
er O
##yt O
##hr O
##oc O
##yte O
trans O
##fusion O
. O
[SEP] O
[CLS] O
most O
treatment O
- O
related O
a O
##es O
were O
mild O
( O
grade O
1 O
/ O
2 O
) O
, O
with O
higher O
grade O
treatment O
- O
related O
a O
##es O
( O
grade O
3 O
/ O
4 O
) O
observed O
only O
at O
130 O
mg O
, O
the O
highest O
dose O
administered O
. O
[SEP] O
[CLS] O
with O
the O
assumption O
of O
a O
one O
- O
compartment O
open O
model O
and O
linear O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
analysis O
of O
the O
data O
determined O
that O
there O
were O
no O
significant O
differences O
in O
the O
volume B-PK
of I-PK
distribution I-PK
, O
clearance B-PK
, O
elimination B-PK
half I-PK
- I-PK
life I-PK
, O
and O
serum O
protein O
binding O
of O
lid O
##oc O
##aine O
among O
these O
racial O
groups O
. O
[SEP] O
[CLS] O
a O
90 O
% O
c O
##i O
for O
the O
ratio O
of O
the O
least O
squares O
means O
of O
the O
multiple O
- O
dose O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
relative O
to O
the O
single O
- O
dose O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
was O
derived O
within O
the O
framework O
of O
an O
##ova O
. O
[SEP] O
[CLS] O
according O
to O
the O
who O
, O
m O
##dr O
and O
x O
##dr O
tuberculosis O
drive O
25 O
% O
of O
global O
tuberculosis O
deaths O
[ O
12 O
] O
. O
[SEP] O
[CLS] O
the O
median O
root O
squared O
percentage O
of O
the O
prediction O
error O
was O
18 O
% O
( O
drug O
clearance B-PK
) O
and O
12 O
% O
( O
half B-PK
- I-PK
life I-PK
) O
. O
[SEP] O
[CLS] O
using O
the O
k B-PK
( I-PK
i I-PK
) I-PK
values O
obtained O
from O
in O
v O
##it O
##ro O
in O
##hibition O
studies O
, O
the O
degree O
of O
increase O
in O
to O
##l O
##but O
##ami O
##de O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
was O
predicted O
. O
[SEP] O
[CLS] O
for O
each O
anal O
##yte O
, O
the O
two O
highest O
abundant O
m O
##rm O
transitions O
without O
interference O
in O
sample O
were O
selected O
— O
one O
for O
q O
##uant O
##ification O
and O
the O
other O
for O
confirmation O
. O
[SEP] O
[CLS] O
negative O
ions O
were O
monitored O
in O
the O
m O
##rm O
mode O
with O
mass O
transitions O
m O
/ O
z O
278 O
. O
1 O
→ O
118 O
. O
0 O
da O
( O
s O
##nac O
) O
and O
m O
/ O
z O
249 O
. O
0 O
→ O
135 O
. O
0 O
da O
( O
is O
) O
. O
[SEP] O
[CLS] O
our O
investigations O
were O
performed O
after O
approval O
by O
our O
local O
ethical O
committee O
at O
p O
##eking O
union O
medical O
college O
, O
and O
in O
accordance O
with O
the O
principles O
of O
laboratory O
animal O
care O
. O
[SEP] O
[CLS] O
β O
- O
g O
##lu O
##cu O
##ron O
##idas O
##e O
( O
[UNK] O
- O
a O
from O
e O
. O
co O
##li O
) O
was O
purchased O
from O
si O
##gma O
- O
al O
##dric O
##h O
( O
s O
##hang O
##hai O
, O
chin O
##a O
) O
. O
[SEP] O
[CLS] O
the O
p O
##b O
##p O
##k O
models O
of O
p O
##ra O
##vas O
##tat O
##in O
have O
previously O
been O
developed O
by O
various O
groups O
##5 O
, O
7 O
, O
8 O
, O
9 O
in O
order O
to O
predict O
the O
p O
##k O
and O
transported O
mediated O
drug O
‐ O
drug O
interactions O
. O
[SEP] O
[CLS] O
the O
u O
##rina O
##ry O
ex O
##cre O
##tion O
of O
the O
in O
##tra O
##ven O
##ous O
dose O
was O
12 O
+ O
- O
6 O
% O
and O
the O
re B-PK
##nal I-PK
clearance I-PK
10 O
+ O
- O
5 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
de O
##x O
##lan O
##so O
##pra O
##zo O
##le O
plasma O
concentrations O
and O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
summarized O
by O
dose O
group O
. O
[SEP] O
[CLS] O
in O
##do O
##l O
##car O
##box O
##ami O
##de O
is O
a O
pre O
##c O
##lini O
##cal O
candidate O
for O
treating O
multi O
##dr O
##ug O
- O
resistant O
tuberculosis O
. O
[SEP] O
[CLS] O
we O
previously O
reported O
es O
##k O
##1 O
, O
a O
high O
avid O
##ity O
( O
k O
##d O
< O
0 O
. O
2 O
nm O
##ol O
/ O
l O
) O
, O
fully O
- O
human O
mon O
##oc O
##lon O
##al O
anti O
##body O
( O
ma O
##b O
) O
specific O
for O
the O
w O
##t O
##1 O
r O
##m O
##f O
p O
##eptide O
/ O
h O
##la O
- O
a O
* O
02 O
: O
01 O
complex O
, O
which O
selective O
##ly O
bound O
and O
killed O
w O
##t O
##1 O
( O
+ O
) O
and O
h O
##la O
- O
a O
* O
02 O
: O
01 O
( O
+ O
) O
le O
##uke O
##mia O
and O
solid O
tumor O
cell O
lines O
. O
[SEP] O
[CLS] O
intact O
doses O
of O
o O
##xy O
##co O
##don O
##e O
de O
##ter O
##x O
were O
administered O
with O
50 O
m O
##l O
of O
place O
##bo O
solution O
( O
micro O
##c O
##ry O
##stal O
##line O
cell O
##ulos O
##e O
mixed O
with O
room O
temperature O
, O
non O
##car O
##bon O
##ated O
water O
with O
den O
##aton O
##ium O
ben O
##zo O
##ate O
to O
create O
a O
1 O
‐ O
pp O
##m O
solution O
added O
for O
blinding O
purposes O
) O
. O
[SEP] O
[CLS] O
the O
influence O
of O
selective O
se O
##rot O
##oni O
##n O
re O
##up O
##take O
inhibitor O
##s O
on O
the O
plasma O
and O
brain O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
simplest O
p O
##hen O
##oth O
##ia O
##zine O
ne O
##uro O
##le O
##ptic O
pro O
##ma O
##zine O
in O
the O
rat O
. O
[SEP] O
[CLS] O
size O
( O
37 O
. O
8 O
% O
) O
and O
pm O
##a O
( O
27 O
. O
3 O
% O
) O
contribute O
to O
this O
var O
##iability O
. O
[SEP] O
[CLS] O
thirteen O
subjects O
who O
completed O
the O
study O
received O
a O
single O
120 O
mg O
dose O
of O
te O
##rf O
##ena O
##dine O
alone O
or O
with O
con O
##com O
##ita O
##nt O
20 O
mg O
se O
##rt O
##ind O
##ole O
daily O
. O
[SEP] O
[CLS] O
the O
sa O
##r O
suggested O
##bot O
##h O
the O
c O
##yan O
##o O
group O
and O
perhaps O
a O
suitable O
h O
##ydro O
##phobic O
group O
are O
##re O
##quire O
##d O
to O
enhance O
the O
pot O
##ency O
. O
[SEP] O
[CLS] O
with O
the O
goal O
of O
identifying O
inhibitor O
##s O
of O
he O
##pa O
##titis O
c O
virus O
( O
h O
##c O
##v O
) O
n O
##s O
##3 O
/ O
4 O
##a O
pro O
##te O
##ase O
that O
are O
potent O
against O
a O
wide O
range O
of O
g O
##eno O
##type O
##s O
and O
clinical O
##ly O
relevant O
mutant O
viruses O
, O
several O
sub O
##ser O
##ies O
of O
mac O
##ro O
##cycle O
##s O
were O
investigated O
based O
on O
observations O
made O
during O
the O
discovery O
of O
m O
##k O
- O
51 O
##7 O
##2 O
. O
[SEP] O
[CLS] O
the O
dried O
residue O
was O
dissolved O
with O
200 O
μ O
##l O
met O
##han O
##ol O
and O
cent O
##ri O
##fu O
##ged O
at O
1500 O
##0 O
rpm O
for O
10 O
min O
. O
[SEP] O
[CLS] O
plasma O
and O
c O
##s O
##f O
concentrations O
were O
in O
the O
range O
that O
has O
been O
shown O
to O
in O
##hibit O
par O
##p O
activity O
in O
v O
##ivo O
in O
humans O
. O
[SEP] O
[CLS] O
previous O
studies O
have O
found O
that O
a O
##g O
exhibits O
potent O
anti O
- O
inflammatory O
activity O
. O
53 O
– O
55 O
however O
, O
the O
therapeutic O
application O
of O
a O
##g O
is O
restricted O
by O
its O
low O
so O
##lub O
##ility O
in O
water O
, O
which O
results O
in O
low O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
after O
oral O
administration O
. O
[SEP] O
[CLS] O
the O
au B-PK
##cs I-PK
of O
s O
( O
- O
) O
- O
car O
##v O
were O
significantly O
lower O
than O
those O
of O
r O
( O
+ O
) O
- O
car O
##v O
after O
both O
i O
. O
v O
. O
and O
p O
. O
o O
. O
administration O
. O
[SEP] O
[CLS] O
the O
revised O
who O
guidelines O
specify O
replacement O
of O
d O
##4 O
##t O
with O
less O
toxic O
but O
more O
expensive O
drugs O
when O
feasible O
, O
and O
that O
d O
##4 O
##t O
doses O
be O
standardized O
to O
30 O
mg O
twice O
daily O
( O
bid O
) O
( O
i O
##rre O
##spective O
of O
body O
- O
weight O
) O
, O
from O
the O
approved O
40 O
mg O
bid O
in O
adults O
( O
body O
- O
weight O
≥ O
##60 O
kg O
) O
. O
[SEP] O
[CLS] O
initial O
attempts O
to O
replace O
the O
4 O
- O
p O
##yr O
##idy O
##lf O
##un O
##ctional O
group O
at O
r O
##1 O
resulted O
in O
a O
significant O
loss O
of O
##anti O
##mal O
##aria O
##l O
activity O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
in O
the O
present O
study O
, O
to O
evaluate O
the O
app O
##lica O
##bility O
of O
t O
##k O
/ O
t O
##d O
analysis O
based O
on O
free O
drug O
concentrations O
, O
we O
investigated O
the O
t O
##k O
/ O
t O
##d O
of O
c O
##lo O
##fi O
##bra O
##te O
, O
which O
binds O
to O
album O
##in O
with O
a O
higher O
ratio O
, O
using O
an O
album O
##in O
- O
def O
##icient O
mutant O
strain O
, O
na O
##gas O
##e O
anal O
##bu O
##mine O
##mia O
rats O
( O
na O
##r O
) O
. O
[SEP] O
[CLS] O
internal O
standard O
ca O
##li O
##bra O
##tion O
was O
used O
with O
the O
analytical O
signal O
based O
on O
the O
corrected O
peak O
area O
obtained O
from O
the O
integration O
. O
[SEP] O
[CLS] O
the O
percentage O
of O
data O
distributed O
outside O
the O
95 O
% O
prediction O
intervals O
of O
the O
predict O
##ive O
check O
is O
1 O
. O
39 O
% O
, O
and O
the O
visual O
predict O
##ive O
check O
plots O
are O
shown O
in O
figure O
5 O
##d O
. O
[SEP] O
[CLS] O
after O
that O
, O
the O
mixture O
de O
##co O
##cted O
for O
30 O
min O
and O
filtered O
. O
[SEP] O
[CLS] O
human O
plasma O
obtained O
from O
the O
phase O
i O
study O
in O
cancer O
patients O
were O
also O
analyzed O
to O
assess O
the O
metabolism O
of O
bi O
##ib O
##0 O
##21 O
in O
humans O
and O
to O
ensure O
that O
selected O
animal O
species O
were O
exposed O
to O
all O
human O
major O
meta O
##bol O
##ites O
. O
[SEP] O
[CLS] O
however O
, O
more O
studies O
are O
required O
to O
support O
these O
. O
[SEP] O
[CLS] O
at O
the O
recommended O
dose O
, O
an O
extra O
co O
##hor O
##t O
of O
patients O
initially O
received O
g O
##em O
##ci O
##ta O
##bine O
( O
dose O
level O
ii O
##ib O
) O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
e O
##pa O
##ca O
##dos O
##tat O
and O
p O
##em O
##bro O
##li O
##zu O
##ma O
##b O
and O
anti O
##dr O
##ug O
anti O
##body O
rate O
were O
comparable O
to O
historical O
controls O
for O
mon O
##oth O
##era O
##pies O
. O
[SEP] O
[CLS] O
the O
reported O
di O
##sso O
##ciation O
constant O
values O
( O
k O
##i O
) O
are O
42 O
##8 O
and O
62 O
##6 O
nm O
##ol O
/ O
l O
for O
d O
##1 O
and O
d O
##2 O
receptors O
; O
and O
104 O
##0 O
and O
38 O
nm O
##ol O
/ O
l O
for O
5 O
- O
h O
##t O
##1 O
##a O
and O
5 O
- O
h O
##t O
##2 O
##a O
receptors O
. O
11 O
que O
##tia O
##pine O
displays O
affinity O
for O
α O
##1 O
##b O
and O
α O
##2 O
##b O
- O
ad O
##ren O
##oc O
##ept O
##ors O
( O
k O
##i O
14 O
. O
6 O
and O
61 O
##7 O
nm O
##ol O
/ O
l O
) O
, O
his O
##tamine O
h O
##1 O
receptors O
( O
k O
##i O
4 O
. O
41 O
nm O
##ol O
/ O
l O
) O
but O
lacks O
significant O
affinity O
for O
m O
##us O
##car O
##ini O
##c O
ch O
##olin O
##ergic O
( O
m O
##1 O
) O
( O
k O
##i O
108 O
##6 O
nm O
##ol O
/ O
l O
) O
or O
ben O
##zo O
##dia O
##ze O
##pine O
##s O
receptors O
( O
k O
##i O
> O
1000 O
##0 O
nm O
##ol O
/ O
l O
) O
. O
12 O
[SEP] O
[CLS] O
repeat O
- O
dose O
toxic O
##ology O
studies O
in O
mouse O
, O
rat O
, O
and O
dog O
have O
demonstrated O
that O
induction O
of O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
by O
v O
##ori O
##cona O
##zo O
##le O
( O
auto O
##ind O
##uction O
of O
metabolism O
) O
is O
responsible O
for O
the O
decreased O
exposure O
in O
these O
species O
. O
[SEP] O
[CLS] O
this O
was O
further O
improved O
to O
95 O
% O
when O
si O
##mulating O
for O
prolonged O
in O
##fusion O
##s O
. O
[SEP] O
[CLS] O
thus O
, O
te O
- O
induced O
suppression O
of O
l O
##h O
was O
of O
shorter O
duration O
, O
but O
of O
greater O
magnitude O
compared O
to O
the O
effect O
caused O
by O
20 O
a O
##et O
- O
1 O
. O
[SEP] O
[CLS] O
in O
conclusion O
, O
we O
produced O
p O
##h O
- O
sensitive O
lip O
##oso O
##me O
- O
en O
##cap O
##sul O
##ated O
mid O
##az O
##ola O
##m O
, O
which O
remained O
stable O
in O
a O
physiological O
medium O
and O
showed O
efficient O
release O
in O
an O
acidic O
environment O
. O
[SEP] O
[CLS] O
3 O
. O
co O
- O
administration O
of O
ten O
##ida O
##p O
with O
food O
produced O
a O
statistical O
##ly O
significant O
delay O
in O
the O
rate O
of O
absorption O
( O
t B-PK
##max I-PK
, O
4 O
. O
4 O
h O
) O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
. O
[SEP] O
[CLS] O
control O
rats O
( O
n O
= O
5 O
) O
received O
sa O
##line O
at O
the O
same O
time O
. O
[SEP] O
[CLS] O
his O
##tamine O
di O
##hy O
##dr O
##och O
##lor O
##ide O
administered O
over O
10 O
minutes O
in O
healthy O
subjects O
peaked O
at O
18 O
minutes O
( O
cm B-PK
##ax I-PK
38 O
nm O
##ol O
/ O
l O
) O
, O
attained O
a O
distribution B-PK
volume I-PK
of O
59 O
l O
, O
and O
was O
eliminated O
at O
6 O
% O
/ O
min O
. O
[SEP] O
[CLS] O
plasma O
concentration O
– O
time O
curves O
showed O
a O
decrease O
in O
a O
##pta O
##mer O
concentration O
with O
a O
half B-PK
- I-PK
life I-PK
of O
1 O
. O
0 O
and O
1 O
. O
9 O
h O
for O
s O
##l O
##10 O
##26 O
and O
s O
##l O
##10 O
##33 O
, O
respectively O
, O
with O
a O
corresponding O
clearance B-PK
of O
29 O
and O
15 O
m O
##l O
/ O
( O
h O
* O
kg O
) O
( O
fi O
##g O
. O
1 O
and O
supplement O
##ary O
table O
s O
##2 O
) O
. O
[SEP] O
[CLS] O
the O
via O
##ls O
were O
kept O
in O
an O
is O
##oth O
##er O
##mal O
shake O
##r O
( O
g O
##f O
##l O
##10 O
##9 O
##2 O
, O
b O
##urg O
##wed O
##el O
, O
g O
##erman O
##y O
) O
at O
50 O
± O
1 O
. O
0 O
° O
##c O
for O
72 O
h O
until O
ho O
##mo O
##gene O
##ity O
is O
achieved O
. O
[SEP] O
[CLS] O
each O
route O
and O
dose O
combination O
was O
given O
to O
a O
single O
male O
animal O
, O
blood O
samples O
were O
collected O
for O
evaluation O
of O
bio O
##mark O
##ers O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
d O
##t O
##g O
- O
d O
##3 O
and O
my O
##risto O
##yla O
##ted O
cab O
##ote O
##gra O
##vir O
( O
m O
##ca O
##b O
) O
were O
used O
as O
is O
for O
d O
##t O
##g O
and O
m O
##dt O
##g O
analysis O
, O
respectively O
. O
[SEP] O
[CLS] O
mean O
recovery O
of O
radio O
##car O
##bon O
in O
urine O
was O
86 O
. O
8 O
+ O
- O
1 O
. O
9 O
% O
and O
in O
f O
##ae O
##ces O
7 O
. O
4 O
+ O
- O
1 O
. O
5 O
% O
. O
[SEP] O
[CLS] O
significant O
differences O
were O
found O
between O
the O
liver O
up O
##take O
of O
mice O
injected O
with O
86 O
##y O
- O
ch O
##x O
- O
a O
’ O
’ O
- O
d O
##t O
##pa O
- O
pan O
##it O
##um O
##uma O
##b O
and O
mice O
injected O
with O
86 O
##y O
- O
ch O
##x O
- O
a O
’ O
’ O
- O
d O
##t O
##pa O
- O
c O
##et O
##ux O
##ima O
##b O
, O
particularly O
in O
the O
n O
##ci O
- O
h O
##22 O
##6 O
and O
m O
##sto O
- O
211 O
##h O
tumor O
models O
. O
[SEP] O
[CLS] O
t O
##umour O
volume O
and O
body O
weight O
values O
are O
presented O
as O
the O
mean O
± O
standard O
error O
of O
mean O
( O
se O
##m O
) O
and O
percent O
change O
, O
respectively O
. O
[SEP] O
[CLS] O
dose O
/ O
body O
##weight O
, O
and O
t B-PK
##rough I-PK
plasma I-PK
concentrations I-PK
of O
( O
r O
) O
- O
or O
( O
r O
, O
s O
) O
- O
met O
##had O
##one O
were O
no O
better O
predict O
##ors O
of O
treatment O
response O
than O
daily O
dose O
, O
and O
did O
not O
improve O
the O
fit O
of O
the O
model O
for O
treatment O
outcome O
as O
judged O
by O
the O
likelihood O
ratio O
test O
( O
p O
= O
0 O
. O
21 O
, O
0 O
. O
88 O
, O
and O
0 O
. O
97 O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
p O
##t O
concentrations O
in O
plasma O
ultra O
##fi O
##lt O
##rate O
( O
pu O
##f O
) O
and O
in O
total O
plasma O
declined O
in O
parallel O
and O
became O
barely O
detect O
##able O
by O
2 O
h O
following O
c O
##b O
##d O
##ca O
injection O
. O
[SEP] O
[CLS] O
to O
determine O
if O
re O
##bas O
##tin O
##ib O
could O
in O
##hibit O
b O
##c O
##r O
- O
a O
##b O
##l O
##1 O
or O
fl O
##t O
##3 O
in O
samples O
from O
t O
##ki O
- O
resistant O
patients O
, O
blood O
samples O
were O
in O
##cu O
##bate O
##d O
with O
re O
##bas O
##tin O
##ib O
ex O
v O
##ivo O
and O
the O
p O
##hos O
##ph O
##ory O
##lation O
of O
c O
##rk O
##l O
or O
fl O
##t O
##3 O
was O
measured O
. O
[SEP] O
[CLS] O
peripheral O
administration O
of O
a O
novel O
di O
##ket O
##op O
##iper O
##azi O
##ne O
, O
n O
##nz O
25 O
##9 O
##1 O
, O
prevents O
brain O
injury O
and O
improve O
##s O
so O
##mat O
##ose O
##nso O
##ry O
- O
motor O
function O
following O
h O
##y O
##pox O
##ia O
- O
is O
##che O
##mia O
in O
adult O
rats O
. O
[SEP] O
[CLS] O
red O
solid O
. O
[SEP] O
[CLS] O
main O
outcome O
measure O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
and O
the O
incidence O
##s O
of O
ne O
##ph O
##rot O
##ox O
##icit O
##y O
were O
compared O
between O
the O
morning O
, O
afternoon O
and O
evening O
groups O
. O
[SEP] O
[CLS] O
nevertheless O
, O
the O
mechanisms O
leading O
to O
the O
targeted O
long O
- O
acting O
p O
##har O
##ma O
##co O
##kin O
##etics O
remain O
el O
##usive O
. O
[SEP] O
[CLS] O
p O
##hy O
##sio O
##log O
##ic O
differences O
suggest O
the O
need O
for O
g O
##esta O
##tional O
age O
- O
appropriate O
treatment O
strategies O
. O
[SEP] O
[CLS] O
the O
f O
##em O
##urs O
were O
th O
##awed O
prior O
to O
testing O
, O
and O
the O
bone O
strength O
of O
the O
intact O
f O
##em O
##urs O
was O
measured O
using O
a O
three O
- O
point O
bending O
test O
. O
[SEP] O
[CLS] O
the O
mean O
measured O
g O
##f O
##r O
was O
87 O
m O
##l O
/ O
min O
( O
range O
30 O
- O
174 O
m O
##l O
/ O
min O
) O
. O
[SEP] O
[CLS] O
an O
in O
v O
##ivo O
study O
revealed O
that O
d O
##m O
- O
beta O
- O
c O
##yd O
increased O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
ta O
##c O
##rol O
##imus O
with O
low O
var O
##iability O
in O
the O
absorption O
after O
oral O
administration O
of O
the O
ta O
##c O
##rol O
##imus O
suspension O
to O
rats O
. O
[SEP] O
[CLS] O
all O
plasma O
samples O
were O
analyzed O
for O
m O
##pa O
and O
m O
##pa O
##g O
at O
euro O
##fin O
##s O
me O
##dine O
##t O
laboratory O
in O
the O
net O
##her O
##lands O
by O
a O
specific O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
- O
mass O
s O
##pect O
##rome O
##try O
method O
. O
[SEP] O
[CLS] O
the O
l O
##qi O
covers O
four O
domains O
: O
treatment O
interference O
, O
therapy O
‐ O
related O
problems O
, O
therapy O
settings O
and O
treatment O
costs O
. O
[SEP] O
[CLS] O
compared O
with O
in O
##tra O
- O
r O
##umi O
##nal O
administration O
, O
in O
##tra O
- O
a O
##bo O
##mas O
##al O
in O
##fusion O
of O
f O
##en O
##ben O
##da O
##zo O
##le O
lowered O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
of O
drug O
in O
both O
plasma O
and O
a O
##bo O
##mas O
##al O
fluid O
; O
in O
##tra O
- O
a O
##bo O
##mas O
##al O
in O
##fusion O
of O
al O
##ben O
##da O
##zo O
##le O
substantially O
increased O
maximum B-PK
drug I-PK
concentration I-PK
and O
the O
concentration O
- O
time O
curve O
in O
a O
##bo O
##mas O
##al O
fluid O
and O
lowered O
the O
plasma O
concentration O
time O
curve O
of O
the O
su O
##l O
##ph O
##oxide O
meta O
##bol O
##ite O
; O
in O
##tra O
- O
a O
##bo O
##mas O
##al O
in O
##fusion O
of O
o O
##x O
##fen O
##da O
##zo O
##le O
increased O
maximum B-PK
concentration I-PK
and O
the O
concentration O
- O
time O
curve O
of O
drug O
in O
plasma O
and O
a O
##bo O
##mas O
##al O
fluid O
. O
[SEP] O
[CLS] O
in O
four O
patients O
who O
achieved O
partial O
re O
##mission O
, O
the O
average O
plasma B-PK
half I-PK
- I-PK
life I-PK
of O
v O
##l O
##b O
during O
the O
terminal O
phase O
was O
29 O
. O
4 O
+ O
- O
14 O
. O
6 O
days O
, O
with O
a O
total B-PK
clearance I-PK
of O
36 O
+ O
- O
8 O
m O
##l O
/ O
kg O
/ O
h O
##r O
, O
and O
a O
steady B-PK
- I-PK
state I-PK
apparent I-PK
volume I-PK
of I-PK
distribution I-PK
of O
28 O
. O
1 O
+ O
- O
8 O
. O
5 O
liter O
##s O
/ O
kg O
. O
[SEP] O
[CLS] O
more O
##over O
, O
despite O
suppression O
by O
t O
. O
can O
##is O
anti O
##gens O
, O
stimulation O
of O
the O
immune O
system O
by O
the O
im O
##mu O
##no O
##mo O
##du O
##lator O
g O
##lu O
##can O
potent O
##iate O
##s O
the O
effects O
of O
these O
anti O
##par O
##asi O
##tic O
drugs O
. O
[SEP] O
[CLS] O
severe O
pro O
##stra O
##tion O
, O
severe O
acid O
##osis O
, O
con O
##vu O
##ls O
##ions O
, O
and O
severe O
an O
##emia O
were O
the O
most O
common O
severity O
criteria O
. O
[SEP] O
[CLS] O
no O
is O
##oto O
##pe O
effects O
were O
observed O
after O
oral O
administration O
of O
e O
##qui O
##mo O
##lar O
amounts O
of O
de O
##uter O
##ated O
and O
un O
##la O
##bell O
##ed O
( O
s O
) O
- O
f O
##elo O
##di O
##pine O
. O
[SEP] O
[CLS] O
good O
correlation O
##s O
of O
the O
a O
##oz O
concentration O
were O
found O
between O
plasma O
and O
muscle O
, O
plasma O
and O
liver O
, O
urine O
and O
liver O
, O
and O
urine O
and O
kidney O
in O
the O
de O
##ple O
##tion O
period O
of O
7 O
- O
63 O
or O
21 O
- O
63 O
days O
, O
with O
correlation O
coefficients O
of O
more O
than O
0 O
. O
97 O
and O
p O
values O
less O
than O
0 O
. O
05 O
. O
[SEP] O
[CLS] O
after O
in O
##tra O
##mus O
##cular O
injection O
and O
re O
##ct O
##al O
administration O
of O
an O
a O
##que O
##ous O
suspension O
, O
very O
low O
and O
variable O
art O
##em O
##isi O
##nin O
concentrations O
in O
serum O
were O
observed O
, O
probably O
indicating O
a O
poor O
and O
erratic O
absorption O
. O
[SEP] O
[CLS] O
the O
current O
study O
investigated O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
( O
p O
##k O
) O
, O
p O
##har O
##ma O
##co O
##dynamic O
##s O
( O
p O
##d O
) O
, O
and O
safety O
of O
combining O
ve O
##rin O
##ura O
##d O
with O
all O
##op O
##uri O
##no O
##l O
in O
adult O
male O
subjects O
with O
go O
##ut O
. O
[SEP] O
[CLS] O
we O
tested O
the O
effects O
of O
y O
##m O
- O
35 O
##9 O
##44 O
##5 O
on O
ve O
##g O
##f O
##r O
##2 O
t O
##yr O
##os O
##ine O
kinase O
activity O
, O
cell O
proliferation O
, O
and O
an O
##gio O
##genesis O
. O
[SEP] O
[CLS] O
over O
4 O
separate O
study O
days O
, O
synthetic O
human O
g O
##ip O
or O
g O
##l O
##p O
- O
1 O
was O
in O
##fused O
with O
or O
without O
concurrent O
in O
##hibition O
of O
dip O
##ept O
##idy O
##l O
p O
##ept O
##idas O
##e O
4 O
using O
sit O
##ag O
##lip O
##tin O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
data O
were O
available O
on O
21 O
c O
##y O
##c O
##lop O
##hos O
##pha O
##mi O
##de O
courses O
from O
15 O
patients O
. O
[SEP] O
[CLS] O
mean O
( O
90 O
% O
c O
##i O
) O
treatment O
differences O
in O
t O
##ns O
##s O
over O
0 O
- O
4 O
hours O
were O
: O
s O
##b O
- O
70 O
##5 O
##4 O
##9 O
##8 O
- O
place O
##bo O
: O
- O
0 O
. O
2 O
( O
- O
0 O
. O
9 O
, O
0 O
. O
4 O
) O
; O
s O
##b O
- O
70 O
##5 O
##4 O
##9 O
##8 O
plus O
f O
##p O
- O
f O
##p O
: O
0 O
. O
7 O
( O
0 O
. O
2 O
, O
1 O
. O
2 O
) O
; O
f O
##p O
- O
place O
##bo O
: O
- O
2 O
. O
9 O
( O
- O
3 O
. O
4 O
, O
- O
2 O
. O
5 O
) O
; O
s O
##b O
- O
70 O
##5 O
##4 O
##9 O
##8 O
plus O
f O
##p O
- O
place O
##bo O
: O
- O
2 O
. O
3 O
( O
- O
2 O
. O
8 O
, O
- O
1 O
. O
8 O
) O
. O
[SEP] O
[CLS] O
previous O
studies O
have O
revealed O
that O
the O
me O
##g O
##x O
test O
is O
an O
effective O
tool O
for O
assessing O
liver O
function O
and O
further O
##more O
, O
this O
test O
has O
a O
high O
reliability O
when O
repeated O
( O
o O
##eller O
##ich O
and O
arms O
##tron O
##g O
2001 O
) O
. O
[SEP] O
[CLS] O
however O
, O
all O
of O
the O
distinct O
peaks O
disappeared O
in O
the O
s O
##d O
particles O
’ O
di O
##ff O
##rac O
##to O
##gram O
, O
which O
indicated O
that O
the O
crystal O
form O
did O
not O
exist O
in O
the O
s O
##d O
particles O
. O
28 O
this O
result O
suggested O
that O
it O
##z O
might O
exist O
in O
the O
am O
##or O
##ph O
##ous O
state O
in O
s O
##d O
particles O
, O
as O
frequently O
observed O
for O
s O
##ds O
. O
[SEP] O
[CLS] O
additionally O
children O
weighing O
≥ O
##39 O
kg O
can O
receive O
the O
adult O
regime O
##n O
. O
[SEP] O
[CLS] O
a O
##f O
##li O
##ber O
##ce O
##pt O
treatment O
resulted O
in O
the O
greatest O
reduction O
##s O
in O
plasma O
free O
- O
ve O
##g O
##f O
relative O
to O
base O
##line O
levels O
, O
whereas O
ran O
##ibi O
##zu O
##ma O
##b O
treatment O
resulted O
in O
the O
smallest O
decreases O
in O
plasma O
free O
- O
ve O
##g O
##f O
. O
[SEP] O
[CLS] O
per O
##f O
##lu O
##oro O
##alk O
##yl O
acid O
car O
##box O
##yla O
##tes O
and O
su O
##lf O
##ona O
##tes O
( O
p O
##fa O
##a O
) O
have O
many O
consumer O
and O
industrial O
applications O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##gene O
##tic O
studies O
[SEP] O
[CLS] O
subjects O
with O
a O
lifetime O
history O
of O
drug O
or O
alcohol O
dependence O
were O
excluded O
, O
as O
were O
heavy O
users O
of O
tobacco O
products O
( O
e O
##g O
, O
subjects O
who O
smoked O
more O
than O
20 O
cigarettes O
per O
day O
and O
were O
unable O
to O
a O
##bs O
##tain O
from O
smoking O
for O
at O
least O
5 O
hours O
during O
the O
day O
) O
. O
[SEP] O
[CLS] O
q O
##con O
##cat O
- O
based O
data O
revealed O
generally O
poor O
correlation O
with O
activity O
, O
whereas O
moderate O
correlation O
##s O
were O
shown O
for O
u O
##gt O
##s O
1 O
##a O
##1 O
, O
1 O
##a O
##3 O
, O
and O
2 O
##b O
##7 O
. O
[SEP] O
[CLS] O
the O
combination O
with O
p O
##yr O
##ona O
##rid O
##ine O
- O
art O
##es O
##unate O
resulted O
in O
significantly O
higher O
car O
##box O
##y O
##p O
##rima O
##quin O
##e O
maximum B-PK
concentrations I-PK
( O
p O
= O
0 O
. O
01 O
##1 O
) O
, O
lower O
volumes B-PK
of I-PK
distribution I-PK
( O
p O
= O
0 O
. O
00 O
##1 O
) O
, O
and O
shorter O
terminal B-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( O
p O
= O
0 O
. O
00 O
##1 O
) O
than O
when O
p O
##rima O
##quin O
##e O
was O
administered O
alone O
( O
table O
6 O
) O
. O
[SEP] O
[CLS] O
although O
d O
##p O
##g O
showed O
p O
##h O
- O
dependent O
dissolution O
behavior O
, O
d O
##p O
##g O
with O
t O
##s O
exhibited O
a O
high O
rate O
and O
extent O
of O
dissolution O
in O
both O
acidic O
and O
neutral O
media O
. O
[SEP] O
[CLS] O
animals O
used O
for O
micro O
##dial O
##ys O
##is O
experiments O
also O
received O
micro O
##dial O
##ys O
##is O
guides O
with O
du O
##mmy O
probe O
##s O
( O
cm O
##a O
, O
so O
##ln O
##a O
, O
s O
##wed O
##en O
) O
in O
the O
ca O
##uda O
##te O
put O
##ame O
##n O
( O
c O
##p O
; O
coordinates O
from O
br O
##eg O
##ma O
, O
a O
##p O
- O
1 O
. O
0 O
mm O
l O
+ O
3 O
. O
0 O
mm O
v O
- O
3 O
. O
4 O
mm O
) O
and O
in O
the O
c O
##ister O
##na O
ma O
##gna O
( O
cm O
; O
coordinates O
from O
la O
##mb O
##da O
, O
a O
##p O
- O
2 O
. O
51 O
mm O
l O
+ O
2 O
. O
04 O
mm O
v O
- O
8 O
. O
34 O
mm O
, O
at O
an O
angle O
of O
25 O
##° O
anterior O
from O
the O
do O
##rs O
##ove O
##nt O
##ral O
axis O
and O
11 O
##° O
lateral O
from O
the O
ant O
##ero O
##post O
##eri O
##or O
axis O
) O
( O
17 O
) O
. O
[SEP] O
[CLS] O
the O
vent O
##ila O
##tor O
was O
set O
to O
give O
a O
tidal O
volume O
of O
8 O
m O
##l O
/ O
kg O
at O
a O
rate O
of O
12 O
- O
14 O
/ O
min O
. O
[SEP] O
[CLS] O
the O
g O
##eno O
##ty O
##ping O
methods O
are O
based O
on O
the O
5 O
′ O
- O
n O
##uc O
##lea O
##se O
activity O
method O
( O
ta O
##q O
##man O
##® O
) O
employing O
two O
prime O
##rs O
and O
two O
fluorescent O
labeled O
probe O
##s O
in O
a O
real O
- O
time O
based O
ass O
##ay O
as O
earlier O
described O
( O
s O
##chu O
##l O
##ze O
et O
al O
. O
, O
2008 O
##a O
) O
. O
[SEP] O
[CLS] O
the O
aim O
of O
this O
study O
was O
to O
assess O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
subsequent O
p O
##har O
##ma O
##co O
##dynamic O
interaction O
of O
m O
##p O
##c O
- O
130 O
##4 O
, O
a O
di O
##hy O
##dr O
##opy O
##rid O
##ine O
ca O
##2 O
+ O
antagonist O
, O
with O
other O
drugs O
in O
animal O
experiments O
. O
[SEP] O
[CLS] O
de O
##ox O
##yn O
##ival O
##eno O
##l O
( O
don O
) O
is O
a O
my O
##cot O
##ox O
##in O
frequently O
found O
as O
a O
con O
##tam O
##ina O
##nt O
of O
cereal O
crops O
and O
may O
be O
et O
##iol O
##ogical O
##ly O
associated O
with O
adverse O
health O
effects O
in O
developing O
countries O
where O
considerable O
quantities O
of O
contaminated O
crops O
are O
consumed O
. O
[SEP] O
[CLS] O
the O
aim O
of O
this O
study O
was O
to O
develop O
and O
valid O
##ate O
a O
rapid O
and O
sensitive O
liquid O
ch O
##roma O
##tography O
- O
tandem O
mass O
s O
##pect O
##rome O
##tric O
( O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
) O
method O
for O
measuring O
plasma O
and O
u O
##ter O
##ine O
tissue O
levels O
of O
in O
##dom O
##eth O
##ac O
##in O
in O
rabbits O
after O
insertion O
of O
in O
##dom O
##eth O
##ac O
##in O
- O
me O
##dicated O
cu O
- O
i O
##uds O
. O
[SEP] O
[CLS] O
lo O
##met O
##re O
##x O
##ol O
is O
a O
promising O
, O
anti O
##can O
##cer O
agent O
. O
[SEP] O
[CLS] O
ex O
##cre O
##tion O
of O
cry O
##pt O
##ota O
##ns O
##hino O
##ne O
and O
its O
meta O
##bol O
##ites O
into O
urine O
was O
extremely O
low O
, O
and O
they O
were O
mainly O
ex O
##cre O
##ted O
into O
f O
##ae O
##ces O
and O
bi O
##le O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
novel O
, O
high O
- O
affinity O
and O
selective O
do O
##pa O
##mine O
d O
##3 O
receptor O
antagonist O
s O
##b O
- O
27 O
##70 O
##11 O
in O
rat O
, O
dog O
and O
monkey O
: O
in O
v O
##it O
##ro O
/ O
in O
v O
##ivo O
correlation O
and O
the O
role O
of O
al O
##de O
##hy O
##de O
o O
##xi O
##das O
##e O
. O
[SEP] O
[CLS] O
a O
good O
correlation O
between O
both O
techniques O
was O
found O
( O
r O
= O
0 O
. O
95 O
##3 O
) O
when O
tissue O
samples O
were O
analyzed O
with O
both O
methods O
. O
[SEP] O
[CLS] O
only O
c O
##sa O
concentrations O
that O
were O
greater O
than O
the O
valid O
##ated O
lower O
limit O
of O
q O
##uant O
##itation O
( O
ll O
##o O
##q O
) O
of O
0 O
. O
1 O
ng O
/ O
m O
##l O
were O
included O
in O
the O
analysis O
. O
[SEP] O
[CLS] O
on O
those O
days O
, O
plasma O
samples O
were O
obtained O
before O
the O
daily O
b O
##udes O
##oni O
##de O
administration O
and O
0 O
. O
5 O
, O
1 O
, O
2 O
, O
4 O
, O
and O
7 O
hours O
after O
drug O
administration O
, O
whereas O
urine O
samples O
were O
obtained O
after O
collection O
of O
the O
last O
blood O
sample O
. O
[SEP] O
[CLS] O
compared O
to O
healthy O
adult O
subjects O
, O
elderly O
subjects O
had O
a O
slightly O
higher O
exposure O
to O
a O
##p O
##ro O
##cite O
##nta O
##n O
in O
terms O
of O
both O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##τ I-PK
both O
on O
day O
1 O
and O
day O
10 O
. O
[SEP] O
[CLS] O
to O
evaluate O
the O
effectiveness O
of O
car O
##ni O
##tine O
administration O
in O
aid O
##ing O
the O
elimination O
of O
p O
##ival O
##ate O
liberated O
from O
p O
##iva O
##mp O
##ici O
##llin O
, O
studies O
were O
undertaken O
on O
seven O
p O
##ae O
##dia O
##tric O
patients O
treated O
for O
7 O
days O
with O
combined O
p O
##iva O
##mp O
##ici O
##llin O
and O
m O
##olar O
excess O
of O
car O
##ni O
##tine O
. O
[SEP] O
[CLS] O
the O
selection O
of O
the O
technique O
was O
made O
based O
on O
the O
evaluation O
of O
particle O
size O
, O
p O
##di O
, O
and O
en O
##tra O
##pment O
efficiency O
of O
the O
na O
##no O
##par O
##tic O
##les O
obtained O
with O
the O
trial O
batch O
##es O
using O
the O
commonly O
used O
and O
reported O
to O
be O
reliable O
and O
powerful O
techniques O
. O
[SEP] O
[CLS] O
the O
c B-PK
##lt I-PK
##ot I-PK
of O
a O
##a O
in O
plasma O
after O
b O
##ol O
##us O
injection O
of O
a O
##a O
( O
4 O
mg O
/ O
kg O
body O
w O
##t O
) O
in O
tumor O
patients O
was O
compared O
with O
that O
in O
volunteers O
. O
[SEP] O
[CLS] O
to O
##fo O
##gli O
##f O
##lo O
##zin O
is O
a O
novel O
selective O
inhibitor O
of O
sodium O
- O
dependent O
glucose O
co O
- O
transport O
##er O
- O
2 O
( O
s O
##g O
##lt O
##2 O
) O
and O
has O
been O
developed O
for O
the O
treatment O
of O
patients O
with O
type O
2 O
diabetes O
me O
##lli O
##tus O
. O
[SEP] O
[CLS] O
the O
standard O
##ised O
effect O
size O
of O
g O
##sk O
##15 O
##21 O
##4 O
##9 O
##8 O
on O
am O
##y O
##g O
##dal O
##ar O
activation O
( O
− O
##2 O
. O
0 O
; O
95 O
% O
c O
##i O
− O
##2 O
. O
7 O
to O
− O
##1 O
. O
2 O
) O
was O
greater O
than O
the O
corresponding O
effect O
size O
of O
n O
##t O
##x O
( O
− O
##0 O
. O
1 O
; O
95 O
% O
c O
##i O
− O
##0 O
. O
9 O
to O
0 O
. O
7 O
) O
; O
although O
the O
difference O
in O
effect O
sizes O
( O
0 O
. O
6 O
) O
was O
not O
quite O
significantly O
different O
from O
0 O
( O
95 O
% O
c O
##i O
, O
− O
##0 O
. O
04 O
to O
1 O
. O
3 O
; O
p O
= O
0 O
. O
06 O
##2 O
; O
see O
supplement O
##ary O
tables O
s O
##2 O
, O
s O
##3 O
for O
details O
) O
. O
[SEP] O
[CLS] O
the O
me O
( O
i O
. O
e O
. O
, O
potential O
ion O
enhance O
##ment O
or O
suppression O
) O
of O
do O
##ce O
##ta O
##xe O
##l O
, O
calculated O
as O
the O
area O
ratio O
with O
and O
without O
matrix O
ions O
present O
, O
was O
between O
103 O
. O
5 O
and O
87 O
. O
7 O
for O
ultra O
##fi O
##lter O
##ed O
plasma O
, O
and O
between O
111 O
. O
5 O
and O
99 O
. O
4 O
for O
total O
plasma O
. O
[SEP] O
[CLS] O
all O
study O
participants O
indicated O
that O
the O
opportunity O
to O
use O
p O
##n O
su O
##pp O
##os O
##itor O
##ies O
as O
an O
alternative O
to O
h O
##c O
self O
- O
injection O
would O
make O
them O
feel O
safer O
. O
[SEP] O
[CLS] O
thus O
, O
with O
respect O
to O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
target O
parameters O
, O
little O
difference O
can O
be O
found O
between O
the O
two O
su O
##pp O
##os O
##itor O
##y O
forms O
each O
containing O
20 O
mg O
met O
##oc O
##lop O
##ram O
##ide O
- O
base O
and O
under O
trial O
in O
this O
study O
. O
( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
[SEP] O
[CLS] O
brains O
were O
im O
##mers O
##ed O
in O
modified O
go O
##l O
##gi O
- O
co O
##x O
stain O
##ing O
solution O
( O
purchased O
from O
d O
##rs O
. O
[SEP] O
[CLS] O
two O
patients O
developed O
ha O
##ha O
of O
uncertain O
clinical O
significance O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
patients O
with O
b O
- O
all O
, O
b O
- O
l O
##ymph O
##oma O
, O
acute O
my O
##elo O
##gen O
##ous O
le O
##uke O
##mia O
( O
am O
##i O
) O
, O
or O
t O
- O
c O
##ll O
did O
not O
respond O
. O
[SEP] O
[CLS] O
c O
##yt O
##ola O
##se O
p O
##c O
##l O
##5 O
and O
rapid O
##ase O
c O
##80 O
##max O
were O
purchased O
from O
d O
##sm O
food O
special O
##ties O
( O
ma O
del O
##ft O
, O
net O
##her O
##lands O
) O
, O
and O
sum O
##iz O
##yme O
a O
##c O
was O
obtained O
from O
s O
##hin O
ni O
##hon O
chemical O
( O
a O
##ichi O
, O
j O
##apa O
##n O
) O
. O
[SEP] O
[CLS] O
the O
appearance O
of O
14 O
##c O
- O
activity O
in O
the O
neutral O
lip O
##id O
fraction O
( O
fi O
##g O
1 O
, O
panel O
a O
) O
, O
likely O
est O
##eri O
##fied O
d O
##ha O
in O
the O
form O
of O
t O
##rig O
##ly O
##cer O
##ide O
, O
was O
delayed O
by O
about O
20 O
min O
, O
probably O
reflecting O
transport O
delay O
of O
ch O
##yl O
##omi O
##c O
##rons O
via O
the O
l O
##ymph O
##atic O
system O
into O
the O
blood O
. O
[SEP] O
[CLS] O
a O
pool O
##ed O
place O
##bo O
group O
was O
also O
analyzed O
in O
the O
same O
manner O
. O
[SEP] O
[CLS] O
the O
rate O
of O
m O
##rna O
synthesis O
was O
assumed O
to O
be O
zero O
‐ O
order O
and O
set O
at O
0 O
. O
04 O
pm O
##ol O
/ O
hour O
as O
the O
input O
for O
the O
m O
##rna O
species O
. O
[SEP] O
[CLS] O
most O
of O
the O
p O
- O
h O
##ydro O
##xy O
##tri O
##am O
##ter O
##ene O
was O
recovered O
in O
f O
##ae O
##ces O
. O
[SEP] O
[CLS] O
design O
and O
selection O
of O
d O
##mp O
850 O
and O
d O
##mp O
85 O
##1 O
: O
the O
next O
generation O
of O
c O
##yclic O
u O
##rea O
hi O
##v O
pro O
##te O
##ase O
inhibitor O
##s O
. O
[SEP] O
[CLS] O
the O
anal O
##yte O
was O
detect O
##able O
up O
to O
12 O
hours O
in O
the O
mouse O
plasma O
. O
[SEP] O
[CLS] O
additionally O
, O
the O
changes O
were O
dose O
- O
dependent O
. O
[SEP] O
[CLS] O
the O
values O
of O
m B-PK
##rt I-PK
and O
vs B-PK
##s I-PK
were O
much O
decreased O
in O
the O
mice O
receiving O
c O
##f O
##z O
- O
pm O
compared O
to O
those O
receiving O
c O
##f O
##z O
- O
c O
##d O
. O
[SEP] O
[CLS] O
concentrations O
of O
an O
acidic O
drug O
, O
i O
##bu O
##p O
##ro O
##fen O
, O
in O
c O
##er O
##vic O
##al O
m O
##uc O
##us O
and O
serum O
have O
been O
measured O
by O
hp O
##l O
##c O
after O
oral O
administration O
in O
six O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
linear O
##ity O
of O
so O
##f O
and O
da O
##c O
was O
obtained O
over O
concentration O
ranges O
of O
50 O
- O
400 O
, O
and O
40 O
- O
400 O
ng O
/ O
m O
##l O
, O
respectively O
in O
pure O
form O
, O
60 O
- O
300 O
and O
50 O
- O
300 O
ng O
/ O
m O
##l O
, O
respectively O
for O
human O
plasma O
and O
over O
50 O
- O
400 O
, O
and O
40 O
- O
400 O
ng O
/ O
m O
##l O
, O
respectively O
for O
human O
urine O
with O
correlation O
coefficient O
> O
0 O
. O
99 O
##9 O
. O
[SEP] O
[CLS] O
we O
have O
studied O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
met O
##hot O
##re O
##xa O
##te O
in O
patients O
with O
r O
##he O
##uma O
##to O
##id O
art O
##hr O
##itis O
concurrently O
taking O
the O
most O
commonly O
used O
non O
- O
s O
##tero O
##idal O
anti O
- O
inflammatory O
drugs O
( O
n O
##sai O
##ds O
) O
, O
as O
##pi O
##rin O
, O
di O
##c O
##lo O
##fen O
##ac O
, O
nap O
##ro O
##xen O
, O
in O
##dom O
##eth O
##ac O
##in O
, O
and O
i O
##bu O
##p O
##ro O
##fen O
. O
[SEP] O
[CLS] O
in O
all O
subjects O
of O
group O
1 O
and O
seven O
subjects O
( O
88 O
% O
) O
of O
group O
2 O
, O
therapeutic O
levels O
( O
> O
50 O
p O
##g O
/ O
m O
##l O
) O
were O
measured O
during O
the O
first O
2 O
. O
5 O
h O
, O
compared O
with O
only O
two O
subjects O
( O
25 O
% O
) O
of O
group O
3 O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
for O
the O
0 O
. O
75 O
- O
mg O
dose O
, O
a O
peak B-PK
urine I-PK
concentration I-PK
of O
1 O
, O
100 O
mg O
/ O
liter O
was O
reached O
after O
30 O
min O
. O
[SEP] O
[CLS] O
it O
is O
likely O
that O
long O
- O
term O
treatment O
with O
as O
##a O
may O
represent O
a O
ch O
##em O
##op O
##re O
##vent O
##ive O
option O
for O
l O
##s O
/ O
h O
##n O
##p O
##cc O
patients O
. O
[SEP] O
[CLS] O
the O
primary O
end O
points O
of O
the O
study O
were O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##f I-PK
) I-PK
and O
cm B-PK
##ax I-PK
. O
[SEP] O
[CLS] O
b O
##p O
##c O
was O
successfully O
prepared O
under O
the O
op O
##ti O
##mum O
conditions O
[ O
temperature O
= O
60 O
degrees O
c O
, O
drug O
concentration O
= O
80 O
g O
/ O
l O
and O
drug O
- O
to O
- O
p O
##hos O
##ph O
##oli O
##pid O
##s O
ratio O
= O
0 O
. O
9 O
( O
w O
/ O
w O
) O
] O
. O
[SEP] O
[CLS] O
radio B-PK
##act I-PK
##ivity I-PK
in O
the O
f O
##em O
##ur O
34 O
##h O
after O
dos O
##ing O
was O
the O
highest O
in O
the O
ca O
- O
as O
##a O
group O
and O
the O
lowest O
in O
the O
ca O
##co O
##3 O
group O
. O
[SEP] O
[CLS] O
for O
accurate O
description O
of O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
of O
drugs O
with O
long O
half B-PK
- I-PK
lives I-PK
, O
the O
us O
food O
and O
drug O
administration O
recommend O
##s O
a O
sampling O
period O
covering O
3 O
– O
5 O
half B-PK
- I-PK
lives I-PK
of O
the O
investigated O
drug O
[ O
24 O
] O
. O
[SEP] O
[CLS] O
male O
s O
##pra O
##gue O
- O
da O
##wley O
( O
s O
##d O
) O
rats O
of O
weight O
between O
200 O
– O
220 O
gram O
were O
provided O
by O
n O
##la O
##c O
, O
c O
##sir O
- O
c O
##dr O
##i O
, O
luck O
##no O
##w O
. O
[SEP] O
[CLS] O
adverse O
events O
( O
a O
##es O
) O
such O
as O
a O
##rr O
##hy O
##th O
##mia O
##s O
have O
not O
been O
associated O
with O
h O
##no O
donors O
. O
14 O
, O
15 O
, O
16 O
, O
17 O
[SEP] O
[CLS] O
in O
this O
study O
the O
disposition O
kinetic O
##s O
and O
plasma O
availability O
of O
m O
##ox O
##if O
##lo O
##xa O
##cin O
in O
m O
##us O
##co O
##vy O
ducks O
after O
single O
in O
##tra O
##ven O
##ous O
( O
i O
. O
v O
. O
) O
, O
in O
##tra O
##mus O
##cular O
( O
i O
. O
m O
. O
) O
and O
oral O
( O
p O
. O
o O
. O
) O
administration O
##s O
of O
5 O
mg O
kg O
( O
- O
1 O
) O
b O
. O
w O
##t O
. O
[SEP] O
[CLS] O
the O
tablet O
formulation O
was O
identified O
by O
determining O
the O
micro O
##mer O
##itic O
properties O
such O
as O
flow O
##ability O
and O
com O
##press O
##ibility O
of O
the O
powder O
mixture O
##s O
composed O
of O
the O
spray O
dried O
na O
##no O
##c O
##ry O
##stal O
powder O
and O
other O
commonly O
used O
direct O
compression O
ex O
##ci O
##pie O
##nts O
. O
[SEP] O
[CLS] O
the O
maximum B-PK
plasma I-PK
concentrations I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
were O
99 O
##1 O
and O
83 O
##9 O
ng O
x O
m O
##l O
( O
- O
1 O
) O
for O
seizure O
terminated O
and O
not O
terminated O
, O
respectively O
. O
[SEP] O
[CLS] O
su O
##icidal O
##ity O
was O
rated O
and O
monitored O
using O
the O
co O
##lum O
##bia O
- O
suicide O
severity O
rating O
scale O
( O
p O
##os O
##ner O
et O
al O
. O
, O
2011 O
) O
. O
[SEP] O
[CLS] O
no O
objective O
responses O
were O
observed O
. O
[SEP] O
[CLS] O
in O
the O
nude O
mouse O
model O
, O
levels O
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
tumor O
reached O
a O
maximum O
at O
48 O
h O
##r O
after O
i O
. O
v O
. O
administration O
( O
4 O
. O
96 O
% O
id O
/ O
g O
, O
tumor O
- O
to O
- O
blood O
5 O
. O
5 O
) O
. O
[SEP] O
[CLS] O
a O
##r O
##9 O
##28 O
##1 O
, O
a O
potent O
and O
selective O
inhibitor O
of O
soluble O
e O
##pox O
##ide O
h O
##ydro O
##lase O
( O
s O
- O
eh O
) O
, O
is O
in O
clinical O
development O
targeting O
h O
##yper O
##tens O
##ion O
and O
type O
2 O
diabetes O
. O
[SEP] O
[CLS] O
in O
contrast O
, O
n O
##ps O
in O
source O
- O
like O
r O
##ois O
travel O
through O
the O
v O
##as O
##cula O
##ture O
without O
getting O
trapped O
##26 O
. O
[SEP] O
[CLS] O
effects O
of O
da O
##pa O
##gli O
##f O
##lo O
##zin O
on O
insulin O
- O
requirement O
, O
glucose O
ex O
##cre O
##tion O
and O
ß O
- O
h O
##ydro O
##xy O
##but O
##yra O
##te O
levels O
are O
not O
related O
to O
base O
##line O
h O
##ba O
##1 O
##c O
in O
youth O
with O
type O
1 O
diabetes O
. O
[SEP] O
[CLS] O
ma O
##gnesium O
clearance B-PK
was O
estimated O
via O
p O
##har O
##ma O
##co O
##kin O
##etic O
modeling O
to O
be O
48 O
. O
1 O
##dl O
/ O
h O
, O
volume B-PK
of I-PK
distribution I-PK
156 O
##dl O
and O
im O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
86 O
. O
2 O
% O
. O
[SEP] O
[CLS] O
the O
following O
model O
was O
used O
: O
log O
( O
p O
##k O
parameter O
) O
= O
α O
+ O
β O
· O
log O
( O
dose O
) O
, O
where O
α O
is O
the O
intercept O
and O
β O
is O
the O
slope O
of O
the O
model O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
safety O
of O
te O
##lm O
##isa O
##rta O
##n O
were O
assessed O
in O
subjects O
with O
he O
##pa O
##tic O
imp O
##air O
##ment O
in O
a O
single O
- O
center O
, O
open O
- O
label O
study O
. O
[SEP] O
[CLS] O
the O
in O
##tra O
##nas O
##al O
administration O
of O
ago O
##mel O
##ati O
##ne O
solid O
lip O
##id O
na O
##no O
##par O
##tic O
##les O
has O
effectively O
enhanced O
both O
the O
absolute B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
and O
the O
brain O
delivery O
of O
ago O
##mel O
##ati O
##ne O
. O
[SEP] O
[CLS] O
the O
results O
indicated O
that O
the O
e O
##ff O
##lux O
activity O
of O
p O
- O
g O
##p O
was O
qualified O
for O
the O
experiment O
. O
[SEP] O
[CLS] O
a O
blank O
sample O
was O
also O
taken O
before O
dos O
##ing O
. O
[SEP] O
[CLS] O
g O
##uan O
##fa O
##cine O
h O
##ydro O
##ch O
##lor O
##ide O
extended O
- O
release O
tablet O
( O
g O
##x O
##r O
) O
is O
approved O
for O
child O
and O
adolescent O
patients O
with O
attention O
- O
deficit O
/ O
h O
##yper O
##act O
##ivity O
disorder O
( O
ad O
##h O
##d O
) O
. O
[SEP] O
[CLS] O
within O
the O
pairs O
2 O
/ O
l O
##p O
- O
2 O
and O
3 O
/ O
l O
##p O
- O
3 O
, O
a O
comparable O
i B-PK
##c I-PK
##50 I-PK
value O
between O
each O
drug O
and O
its O
respective O
lip O
##oso O
##mal O
formulation O
was O
found O
. O
[SEP] O
[CLS] O
in O
whole O
blood O
from O
healthy O
donors O
, O
ne O
##ut O
##rop O
##hil O
##s O
were O
induced O
to O
release O
reactive O
oxygen O
species O
( O
r O
##os O
) O
by O
stimulation O
with O
op O
##rb O
##c O
to O
cross O
‐ O
link O
f O
##c O
##γ O
##r O
, O
or O
by O
e O
co O
##li O
to O
induce O
r O
##os O
via O
s O
##yk O
‐ O
independent O
toll O
‐ O
like O
receptor O
mechanisms O
. O
[SEP] O
[CLS] O
naive O
or O
anti O
##ret O
##rov O
##ira O
##l O
- O
experienced O
hi O
##v O
- O
1 O
- O
infected O
subjects O
were O
included O
in O
a O
non O
- O
random O
##ized O
, O
observation O
##al O
co O
##hor O
##t O
study O
and O
received O
two O
n O
##uc O
##leo O
##side O
r O
##t O
inhibitor O
##s O
+ O
n O
##f O
##v O
( O
750 O
mg O
three O
times O
per O
day O
or O
125 O
##0 O
mg O
twice O
per O
day O
) O
. O
[SEP] O
[CLS] O
although O
recently O
the O
occurrence O
of O
a O
ma O
##li O
##gnant O
neo O
##p O
##las O
##ma O
as O
a O
com O
##plication O
of O
u O
##rem O
##ia O
is O
becoming O
more O
frequently O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
anti O
##tum O
##or O
agents O
are O
not O
precisely O
studied O
in O
patients O
with O
impaired O
re O
##nal O
function O
. O
[SEP] O
[CLS] O
four O
- O
to O
- O
six O
week O
old O
female O
at O
##hy O
##mic O
( O
n O
##u O
+ O
/ O
n O
##u O
+ O
) O
mice O
were O
obtained O
from O
ha O
##rl O
##an O
laboratories O
( O
washing O
##ton O
d O
##c O
) O
under O
an O
approved O
research O
protocol O
by O
the O
institutional O
animal O
care O
and O
use O
committee O
. O
[SEP] O
[CLS] O
au B-PK
##c I-PK
, O
cm B-PK
##ax I-PK
and O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
of O
the O
drug O
after O
repeated O
oral O
intake O
were O
not O
significantly O
different O
when O
compared O
with O
a O
single O
dose O
at O
either O
20 O
mg O
or O
40 O
mg O
. O
[SEP] O
[CLS] O
this O
study O
examined O
the O
mechanical O
( O
gel O
strength O
, O
ad O
##hesive O
##ness O
) O
and O
r O
##he O
##ological O
properties O
of O
c O
##ress O
seed O
m O
##uc O
##ila O
##ge O
based O
gel O
##s O
that O
contain O
different O
ratios O
of O
car O
##bo O
##pol O
93 O
##4 O
p O
( O
0 O
. O
5 O
- O
1 O
. O
5 O
% O
) O
. O
[SEP] O
[CLS] O
the O
p O
##k O
data O
from O
clinical O
p O
##har O
##ma O
##cology O
studies O
were O
combined O
to O
provide O
a O
single O
data O
set O
that O
would O
allow O
characterization O
of O
the O
p O
##k O
of O
each O
insulin O
product O
. O
[SEP] O
[CLS] O
mi O
##cs O
of O
s O
##y O
##55 O
##55 O
against O
s O
. O
au O
##reus O
, O
c O
##ns O
, O
s O
. O
pneumonia O
##e O
, O
s O
. O
p O
##yo O
##gene O
##s O
, O
h O
. O
in O
##fluenza O
##e O
, O
m O
. O
cat O
##ar O
##r O
##hali O
##s O
, O
e O
. O
co O
##li O
and O
e O
. O
c O
##lo O
##aca O
##e O
were O
0 O
. O
2 O
, O
0 O
. O
2 O
, O
0 O
. O
2 O
, O
< O
or O
= O
0 O
. O
02 O
##5 O
, O
0 O
. O
78 O
, O
0 O
. O
2 O
, O
0 O
. O
78 O
and O
3 O
. O
13 O
micro O
##gram O
##s O
/ O
m O
##l O
, O
respectively O
, O
showing O
excellent O
anti O
##ba O
##cter O
##ial O
effects O
on O
these O
path O
##ogen O
##s O
. O
[SEP] O
[CLS] O
on O
the O
last O
day O
of O
the O
multiple O
oral O
dose O
, O
human O
plasma O
samples O
( O
3 O
m O
##l O
) O
were O
gathered O
before O
and O
at O
0 O
. O
5 O
, O
0 O
. O
75 O
, O
1 O
, O
1 O
. O
25 O
, O
1 O
. O
5 O
, O
2 O
, O
2 O
. O
5 O
, O
3 O
, O
4 O
, O
6 O
, O
8 O
, O
10 O
, O
12 O
, O
24 O
, O
36 O
and O
48 O
h O
after O
dos O
##ing O
, O
and O
this O
phase O
was O
followed O
by O
a O
single O
oral O
dose O
. O
[SEP] O
[CLS] O
the O
ass O
##ay O
has O
been O
successfully O
applied O
to O
measuring O
plasma O
concentrations O
of O
los O
##art O
##an O
and O
ex O
##p O
##31 O
##7 O
##4 O
in O
patients O
receiving O
a O
daily O
dose O
of O
los O
##art O
##an O
( O
50 O
- O
100 O
mg O
) O
. O
[SEP] O
[CLS] O
the O
present O
series O
of O
studies O
demonstrated O
that O
the O
carrier O
- O
free O
ultra O
##tra O
##ce O
mi O
##b O
##g O
radio O
##la O
##bel O
##ed O
with O
either O
( O
123 O
) O
i O
or O
( O
131 O
) O
i O
exhibited O
similar O
tissue O
distribution O
to O
the O
carrier O
- O
added O
radio O
##la O
##bel O
##ed O
mi O
##b O
##g O
in O
all O
non O
##tar O
##get O
tissues O
. O
[SEP] O
[CLS] O
to O
compare O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
and O
safety O
of O
the O
pro O
##ges O
##tage O
##n O
, O
org O
306 O
##5 O
##9 O
, O
( O
17 O
##al O
##pha O
) O
- O
17 O
- O
h O
##ydro O
##xy O
- O
11 O
- O
met O
##hyl O
##ene O
- O
19 O
- O
nor O
##p O
##re O
##gna O
- O
4 O
, O
15 O
- O
die O
##n O
- O
20 O
- O
y O
##n O
- O
3 O
- O
one O
) O
, O
and O
et O
##hin O
##yl O
est O
##rad O
##iol O
( O
e O
##e O
) O
in O
ca O
##uca O
##sian O
and O
j O
##apa O
##nese O
women O
after O
single O
and O
multiple O
doses O
. O
[SEP] O
[CLS] O
this O
anti O
##fu O
##nga O
##l O
has O
moderate O
water O
so O
##lub O
##ility O
and O
exhibits O
a O
non O
##linear O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
profile O
. O
[SEP] O
[CLS] O
v O
##p O
##cs O
were O
performed O
using O
ps O
##n O
[ O
6 O
, O
7 O
] O
and O
plot O
##ted O
using O
x O
##pose O
[ O
8 O
] O
. O
[SEP] O
[CLS] O
this O
was O
followed O
by O
a O
clearance B-PK
to O
half O
the O
peak O
value O
at O
about O
25 O
minutes O
with O
the O
overall O
time O
course O
parallel O
##ing O
the O
previously O
documented O
time O
course O
of O
the O
e O
##up O
##hor O
##ia O
experienced O
after O
in O
##tra O
##ven O
##ous O
cocaine O
administration O
. O
[SEP] O
[CLS] O
no O
significant O
differences O
were O
observed O
between O
the O
production O
rates O
of O
t O
and O
e O
##2 O
( O
0 O
. O
24 O
ng O
/ O
kg O
body O
w O
##t O
/ O
h O
##r O
) O
. O
[SEP] O
[CLS] O
during O
the O
initial O
period O
of O
45 O
- O
60 O
min O
, O
a O
very O
rapid O
fall O
in O
blood O
level O
of O
radio B-PK
##act I-PK
##ivity I-PK
was O
noticed O
. O
[SEP] O
[CLS] O
the O
s O
##c O
surface O
was O
arranged O
more O
irregular O
##ly O
and O
disorder O
##ly O
. O
[SEP] O
[CLS] O
for O
group O
1 O
, O
232 O
samples O
were O
collected O
from O
healthy O
ch O
##ile O
##an O
children O
who O
attend O
the O
d O
##r O
. O
l O
##ui O
##s O
ca O
##l O
##vo O
mac O
##ken O
##na O
hospital O
( O
h O
##l O
##c O
##m O
) O
for O
routine O
clinical O
testing O
. O
[SEP] O
[CLS] O
the O
anti O
##no O
##ci O
##ceptive O
activity O
of O
4 O
after O
i O
##p O
administration O
##was O
assessed O
in O
the O
mouse O
warm O
water O
tail O
withdrawal O
( O
w O
##w O
##t O
##w O
) O
ass O
##ay O
. O
[SEP] O
[CLS] O
to O
##lter O
##od O
##ine O
is O
a O
potent O
m O
##us O
##car O
##ini O
##c O
receptor O
antagonist O
and O
has O
been O
used O
for O
the O
treatment O
of O
over O
##active O
bladder O
for O
over O
ten O
years O
. O
[SEP] O
[CLS] O
the O
aim O
of O
this O
study O
was O
to O
compare O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
p O
##har O
##ma O
##co O
##dynamic O
##s O
of O
me O
##rop O
##ene O
##m O
when O
administered O
by O
3 O
h O
in O
##fusion O
or O
b O
##ol O
##us O
injection O
regime O
##ns O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
area O
of O
its O
h O
##yster O
##esis O
loop O
was O
the O
largest O
indicating O
a O
better O
th O
##ix O
##ot O
##ropic O
behavior O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
results O
showed O
that O
the O
average O
cocaine O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
after O
i O
. O
p O
. O
administration O
was O
71 O
% O
and O
after O
oral O
administration O
was O
only O
19 O
. O
2 O
% O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
concentration I-PK
vs I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
but O
not O
the O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
, O
increased O
in O
a O
dose O
- O
proportional O
manner O
. O
[SEP] O
[CLS] O
neon O
##ata O
##l O
mice O
[ O
post O
##nat O
##al O
day O
10 O
( O
p O
##nd O
##10 O
) O
] O
were O
dose O
##d O
i O
##p O
due O
to O
the O
difficulty O
in O
accurately O
dos O
##ing O
neon O
##ata O
##l O
mice O
by O
oral O
g O
##ava O
##ge O
. O
[SEP] O
[CLS] O
also O
, O
the O
matrix O
effect O
for O
er O
##l O
( O
is O
) O
was O
also O
determined O
at O
the O
concentration O
level O
specified O
in O
actual O
analysis O
and O
it O
was O
found O
to O
be O
2 O
. O
63 O
% O
. O
[SEP] O
[CLS] O
this O
method O
provides O
a O
platform O
to O
evaluate O
effects O
at O
##tri O
##but O
##able O
to O
the O
route O
of O
administration O
on O
the O
response O
to O
alcohol O
, O
as O
well O
as O
the O
influence O
of O
de O
##ter O
##mina O
##nts O
such O
as O
family O
history O
of O
alcohol O
##ism O
on O
the O
alcohol O
response O
. O
[SEP] O
[CLS] O
sub O
##op O
##ti O
##mal O
dos O
##ing O
with O
flu O
##cona O
##zo O
##le O
is O
pre O
##vale O
##n O
; O
33 O
% O
of O
patients O
receiving O
flu O
##cona O
##zo O
##le O
did O
not O
achieve O
the O
desired O
p O
##k O
/ O
p O
##d O
index O
required O
for O
optimal O
outcome O
. O
[SEP] O
[CLS] O
im O
##mu O
##no O
##his O
##to O
##chemistry O
and O
quantitative O
analyses O
were O
performed O
according O
to O
established O
protocols O
[ O
17 O
, O
28 O
] O
using O
primary O
antibodies O
against O
t O
##yr O
##os O
##ine O
h O
##ydro O
##xy O
##lase O
[ O
32 O
] O
( O
rabbit O
anti O
- O
th O
anti O
##ser O
##um O
from O
p O
##el O
- O
free O
##z O
, O
r O
##og O
##ers O
, O
a O
##r O
, O
1 O
: O
1000 O
) O
and O
cluster O
of O
differentiation O
68 O
( O
c O
##d O
##6 O
##8 O
) O
( O
rat O
anti O
- O
c O
##d O
##6 O
##8 O
anti O
##ser O
##um O
from O
a O
##b O
##d O
se O
##rote O
##c O
, O
kid O
##lington O
, O
o O
##x O
##ford O
##shire O
, O
uk O
; O
1 O
: O
1000 O
) O
. O
[SEP] O
[CLS] O
the O
ratio B-PK
of I-PK
un I-PK
##bound I-PK
c I-PK
##s I-PK
##f I-PK
: I-PK
plasma I-PK
ni O
##lot O
##ini O
##b O
( O
figure O
2 O
##c O
) O
appears O
to O
be O
the O
same O
in O
all O
dose O
groups O
and O
an O
average O
of O
0 O
. O
5 O
‐ O
1 O
% O
ni O
##lot O
##ini O
##b O
is O
detected O
in O
the O
c O
##s O
##f O
, O
suggesting O
that O
ni O
##lot O
##ini O
##b O
crosses O
the O
b O
##bb O
and O
is O
detected O
as O
free O
or O
un O
##bound O
in O
the O
c O
##s O
##f O
at O
low O
concentrations O
. O
[SEP] O
[CLS] O
the O
second O
study O
was O
a O
random O
##ized O
, O
double O
- O
blind O
, O
place O
##bo O
- O
controlled O
study O
of O
i O
##v O
del O
##af O
##lo O
##xa O
##cin O
( O
300 O
mg O
) O
given O
as O
a O
single O
dose O
on O
day O
1 O
, O
followed O
by O
twice O
- O
daily O
dos O
##ing O
on O
days O
2 O
through O
14 O
; O
12 O
( O
8 O
active O
, O
4 O
place O
##bo O
) O
healthy O
volunteers O
were O
enrolled O
. O
[SEP] O
[CLS] O
analysis O
was O
performed O
using O
rotor O
gene O
real O
- O
time O
p O
##c O
##r O
system O
( O
q O
##ia O
##gen O
, O
stock O
##holm O
, O
s O
##wed O
##en O
) O
by O
means O
of O
the O
v O
##ic O
and O
f O
##am O
dye O
- O
label O
##ing O
system O
according O
to O
the O
manufacturer O
’ O
s O
instructions O
. O
[SEP] O
[CLS] O
single O
- O
dose O
and O
steady O
- O
state O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
determined O
for O
each O
individual O
. O
[SEP] O
[CLS] O
the O
change O
in O
m O
##rna O
levels O
of O
p O
##c O
##na O
in O
whole O
blood O
as O
a O
sur O
##rogate O
tissue O
was O
determined O
in O
response O
to O
r O
##onic O
##ic O
##li O
##b O
treatment O
. O
[SEP] O
[CLS] O
subsequently O
, O
the O
i O
. O
v O
. O
r O
##uca O
##par O
##ib O
arms O
were O
discontinued O
and O
three O
of O
the O
ch O
##em O
##otherapy O
arms O
( O
b O
, O
c O
, O
and O
d O
) O
were O
closed O
to O
further O
en O
##rol O
##ment O
. O
[SEP] O
[CLS] O
[ O
the O
art O
##eri O
##oly O
##mp O
##hat O
##ic O
administration O
of O
anti O
##biotics O
in O
treating O
patients O
with O
su O
##pp O
##ura O
##tive O
- O
inflammatory O
diseases O
of O
the O
abdominal O
cavity O
organs O
] O
. O
[SEP] O
[CLS] O
the O
plasma O
ca O
##li O
##bra O
##tion O
curves O
were O
prepared O
at O
concentrations O
of O
6 O
. O
25 O
, O
3 O
. O
12 O
, O
1 O
. O
56 O
, O
0 O
. O
78 O
and O
0 O
. O
39 O
ng O
/ O
m O
##l O
by O
s O
##pi O
##king O
190 O
µ O
##l O
of O
rat O
plasma O
with O
10 O
##µ O
##l O
of O
working O
standard O
and O
200 O
µ O
##l O
of O
dei O
##onized O
water O
. O
[SEP] O
[CLS] O
a O
rapid O
and O
sensitive O
liquid O
ch O
##roma O
##tography O
tandem O
mass O
s O
##pect O
##rome O
##try O
detection O
using O
selected O
reaction O
monitoring O
in O
positive O
ion O
##ization O
mode O
was O
developed O
and O
valid O
##ated O
for O
the O
q O
##uant O
##ification O
of O
nod O
##ake O
##nin O
in O
rat O
plasma O
and O
brain O
. O
[SEP] O
[CLS] O
a O
uniform O
volume O
per O
administration O
( O
200 O
μ O
##l O
) O
was O
used O
for O
each O
group O
. O
[SEP] O
[CLS] O
co O
##x O
multi O
##var O
##iable O
modelling O
investigated O
the O
effect O
of O
sa O
##m O
and O
other O
co O
##fa O
##ctors O
( O
study O
site O
, O
base O
##line O
parasite O
density O
, O
child O
’ O
s O
age O
, O
and O
all O
co O
##var O
##iate O
##s O
with O
a O
statistical O
##ly O
significant O
difference O
at O
base O
##line O
between O
the O
sa O
##m O
and O
non O
- O
sa O
##m O
groups O
) O
on O
malaria O
- O
free O
survival O
. O
[SEP] O
[CLS] O
similar O
results O
were O
obtained O
in O
v O
##ivo O
using O
a O
delayed O
end O
##oto O
##xin O
challenge O
. O
[SEP] O
[CLS] O
the O
residue O
##was O
dissolved O
in O
me O
##oh O
/ O
d O
##c O
##m O
and O
pu O
##rified O
by O
s O
##c O
##x O
2 O
g O
column O
el O
##uti O
##ng O
with O
##me O
##oh O
and O
then O
2 O
m O
n O
##h O
##3 O
in O
me O
##oh O
. O
[SEP] O
[CLS] O
l O
##t O
##d O
, O
s O
##yd O
##ney O
, O
au O
##stra O
##lia O
) O
. O
[SEP] O
[CLS] O
d O
##s O
- O
104 O
##0 O
did O
not O
affect O
plate O
##let O
a O
##gg O
##regation O
and O
co O
##agu O
##lation O
time O
. O
[SEP] O
[CLS] O
with O
respect O
to O
g O
##h O
and O
p O
##rl O
secret O
##ion O
, O
mi O
##rta O
##za O
##pine O
did O
not O
show O
any O
effects O
in O
comparison O
with O
place O
##bo O
. O
[SEP] O
[CLS] O
pp O
##x O
did O
not O
alter O
l O
##d O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
and O
pp O
##x O
p O
##har O
##ma O
##co O
##kin O
##etics O
were O
equivalent O
in O
men O
and O
women O
. O
[SEP] O
[CLS] O
no O
serious O
adverse O
events O
occurred O
. O
[SEP] O
[CLS] O
in O
our O
systematic O
review O
of O
the O
literature O
, O
we O
investigated O
the O
potential O
for O
drug O
interactions O
between O
oral O
anti O
##coa O
##gu O
##lants O
and O
r O
##il O
- O
2 O
by O
assessing O
the O
influence O
of O
r O
##il O
- O
2 O
administration O
on O
transport O
##ers O
and O
c O
##yt O
##och O
##rome O
##s O
determining O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
( O
direct O
) O
oral O
anti O
##coa O
##gu O
##lants O
. O
[SEP] O
[CLS] O
fl O
##orf O
##eni O
##co O
##l O
, O
a O
mon O
##of O
##lu O
##ori O
##nated O
analogue O
of O
th O
##iam O
##phe O
##nic O
##ol O
, O
has O
a O
broad O
anti O
##ba O
##cter O
##ial O
spectrum O
. O
[SEP] O
[CLS] O
z O
##of O
##eno O
##p O
##ril O
‐ O
mediated O
card O
##io O
##p O
##rote O
##ction O
during O
i O
/ O
r O
is O
associated O
with O
an O
increase O
in O
h O
##2 O
##s O
and O
no O
signaling O
. O
[SEP] O
[CLS] O
blood O
was O
collected O
at O
various O
time O
points O
between O
0 O
and O
600 O
minutes O
and O
then O
analyzed O
with O
high O
- O
performance O
liquid O
ch O
##roma O
##tography O
to O
determine O
levels O
of O
tram O
##ado O
##l O
and O
m O
##1 O
, O
the O
pre O
##dom O
##inate O
active O
meta O
##bol O
##ite O
. O
[SEP] O
[CLS] O
it O
is O
also O
known O
as O
an O
inhibitor O
of O
the O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
( O
c O
##y O
##p O
) O
is O
##oe O
##nz O
##yme O
3 O
##a O
##4 O
. O
[SEP] O
[CLS] O
s O
##yne O
##rg O
##ism O
with O
p O
##ac O
##lit O
##ax O
##el O
and O
derivative O
3 O
was O
also O
observed O
in O
co O
##lon O
cancer O
cell O
line O
h O
##ct O
##11 O
##6 O
( O
fi O
##g O
. O
6 O
) O
. O
[SEP] O
[CLS] O
smoking O
does O
not O
contribute O
significantly O
to O
the O
var O
##iability O
in O
ni O
##fe O
##di O
##pine O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
during O
do O
##but O
##amine O
in O
##fusion O
##s O
, O
there O
were O
significant O
increases O
in O
cardiac O
output O
measurements O
above O
per O
##in O
##fusion O
values O
. O
[SEP] O
[CLS] O
the O
time O
required O
to O
reach O
clinical O
##ly O
effective O
blood O
levels O
of O
pseudo O
##ep O
##hed O
##rine O
was O
longer O
, O
starting O
at O
approximately O
2 O
h O
. O
however O
, O
the O
plasma O
levels O
predicted O
that O
the O
clinical O
effect O
would O
then O
last O
for O
at O
least O
a O
further O
12 O
h O
. O
t B-PK
##rough I-PK
levels I-PK
from O
the O
multiple O
- O
dose O
study O
showed O
that O
clinical O
##ly O
relevant O
anal O
##ges O
##ic O
and O
de O
##con O
##ges O
##tant O
plasma O
levels O
were O
maintained O
for O
24 O
h O
during O
twice O
- O
daily O
dos O
##ing O
. O
[SEP] O
[CLS] O
the O
e O
‐ O
r O
models O
for O
das O
##28 O
and O
a O
##c O
##r O
##20 O
/ O
50 O
/ O
70 O
were O
developed O
using O
data O
from O
3 O
trials O
( O
1 O
phase O
2 O
, O
2 O
phase O
3 O
) O
in O
patients O
with O
r O
##a O
. O
[SEP] O
[CLS] O
diet O
##ary O
protein O
deficiency O
was O
associated O
with O
a O
decrease O
in O
body O
weight O
gain O
, O
vent O
##ric O
##ular O
weight O
, O
total O
plasma O
proteins O
and O
plasma O
album O
##in O
, O
he O
##pa O
##tic O
total O
and O
micro O
##so O
##mal O
proteins O
, O
c O
##yt O
##och O
##rome O
p O
- O
450 O
, O
and O
protein O
: O
d O
##na O
ratios O
; O
serum O
potassium O
was O
slightly O
but O
ins O
##ign O
##ificant O
##ly O
decreased O
. O
[SEP] O
[CLS] O
two O
sub O
##pop O
##ulation O
##s O
of O
women O
emerged O
based O
on O
the O
rate O
of O
increase O
in O
l O
##t O
##g O
c B-PK
##l I-PK
/ I-PK
f I-PK
during O
pregnancy O
. O
[SEP] O
[CLS] O
patients O
with O
a O
previous O
tuberculosis O
episode O
within O
three O
years O
prior O
to O
the O
current O
episode O
, O
a O
history O
of O
prior O
treatment O
for O
m O
##dr O
tuberculosis O
, O
con O
##com O
##ita O
##nt O
op O
##port O
##uni O
##stic O
infection O
requiring O
additional O
anti O
- O
micro O
##bial O
treatment O
, O
a O
formal O
con O
##tra O
##ind O
##ica O
##tion O
to O
any O
trial O
medication O
, O
diabetes O
me O
##lli O
##tus O
requiring O
treatment O
, O
recreational O
drug O
or O
alcohol O
abuse O
, O
mental O
illness O
, O
total O
ne O
##ut O
##rop O
##hil O
count O
< O
1200 O
cells O
/ O
l O
, O
hem O
##og O
##lo O
##bin O
< O
6 O
. O
8 O
g O
/ O
d O
##l O
, O
or O
liver O
function O
tests O
> O
grade O
2 O
, O
pregnancy O
or O
la O
##ct O
##ating O
women O
were O
excluded O
. O
[SEP] O
[CLS] O
if O
the O
concentration O
of O
the O
chemical O
in O
the O
free B-PK
fraction I-PK
was O
below O
, O
this O
value O
or O
below O
the O
analytical O
limits O
of O
detection O
, O
a O
default O
f B-PK
##u I-PK
of O
0 O
. O
00 O
##5 O
was O
assumed O
. O
[SEP] O
[CLS] O
the O
rats O
were O
fast O
##ed O
overnight O
before O
the O
day O
of O
the O
experiment O
. O
[SEP] O
[CLS] O
p O
##b O
##p O
##k O
model O
simulation O
suggested O
that O
the O
distribution O
of O
flu O
##cona O
##zo O
##le O
into O
sub O
##cut O
##aneous O
inter O
##st O
##iti O
##al O
fluid O
is O
dependent O
on O
tissue O
blood B-PK
flow I-PK
. O
[SEP] O
[CLS] O
limited O
information O
about O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
mi O
##ca O
##fu O
##ng O
##in O
in O
the O
per O
##ito O
##nea O
##l O
cavity O
is O
available O
. O
[SEP] O
[CLS] O
compared O
with O
control O
group O
, O
the O
co O
##ad O
##mini O
##stra O
##tion O
of O
be O
##rber O
##ine O
resulted O
in O
a O
decrease O
of O
cm B-PK
##ax I-PK
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
$ O
$ O
\ O
end O
{ O
document O
} O
base O
##line O
al O
##t O
= O
21 O
. O
2 O
##× O
##b O
##w O
##t O
/ O
77 O
. O
30 O
. O
37 O
##6 O
. O
[SEP] O
[CLS] O
acute O
- O
toxicity O
testing O
also O
showed O
that O
mi O
##l O
had O
no O
devastating O
effect O
on O
mice O
behaviors O
. O
[SEP] O
[CLS] O
predict O
##ing O
need O
for O
p O
##har O
##ma O
##co O
##kin O
##etic O
consultation O
follow O
- O
up O
using O
disc O
##rim O
##ina O
##nt O
analysis O
. O
[SEP] O
[CLS] O
when O
b O
##ms O
- O
1811 O
##01 O
was O
administered O
with O
food O
, O
cm B-PK
##ax I-PK
was O
reduced O
by O
about O
25 O
% O
and O
t B-PK
##max I-PK
was O
prolonged O
by O
1 O
h O
. O
however O
, O
au B-PK
##ct I-PK
##au I-PK
, O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
and O
time B-PK
to I-PK
attain I-PK
steady I-PK
state I-PK
of O
b O
##ms O
- O
1811 O
##01 O
were O
not O
altered O
by O
ing O
##est O
##ion O
of O
food O
. O
[SEP] O
[CLS] O
the O
is O
##onia O
##zi O
##d O
peak B-PK
≤ O
##4 O
. O
29 O
mg O
/ O
l O
score O
was O
49 O
% O
, O
while O
that O
for O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
was O
35 O
% O
; O
however O
, O
for O
both O
parameters O
higher O
is O
##onia O
##zi O
##d O
concentration O
selected O
nodes O
with O
greater O
proportions O
of O
dead O
children O
, O
and O
in O
un O
##p O
##run O
##ed O
trees O
were O
ranked O
even O
higher O
. O
[SEP] O
[CLS] O
a O
phase O
i O
study O
of O
p O
##ac O
##lit O
##ax O
##el O
and O
do O
##x O
##or O
##ubi O
##cin O
administered O
as O
concurrent O
96 O
- O
h O
continuous O
i O
. O
v O
. O
in O
##fusion O
was O
performed O
to O
determine O
the O
maximum O
tolerate O
##d O
dose O
( O
m O
##t O
##d O
) O
, O
principal O
toxic O
##ities O
, O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
this O
combination O
in O
women O
with O
re O
##lap O
##sed O
e O
##pit O
##hel O
##ial O
o O
##var O
##ian O
cancer O
. O
[SEP] O
[CLS] O
one O
child O
in O
group O
in O
experienced O
rapid O
and O
high O
level O
s O
- O
k O
##eta O
##mine O
absorption O
with O
a O
peak B-PK
plasma I-PK
concentration I-PK
of O
73 O
##2 O
ng O
x O
m O
##l O
( O
- O
1 O
) O
after O
2 O
min O
, O
which O
decreased O
to O
27 O
##4 O
ng O
x O
m O
##l O
( O
- O
1 O
) O
after O
60 O
min O
. O
[SEP] O
[CLS] O
thus O
, O
we O
analyzed O
the O
stab O
##ili O
##zing O
effect O
of O
sodium O
de O
##ox O
##ych O
##olate O
when O
incorporated O
into O
na O
##no O
- O
sized O
lip O
##oso O
##mes O
. O
[SEP] O
[CLS] O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
investigation O
showed O
the O
mean O
elimination B-PK
half I-PK
life I-PK
of O
z O
##d O
- O
169 O
##4 O
plasma O
concentration O
was O
91 O
. O
5 O
hours O
in O
the O
single O
- O
dose O
group O
and O
119 O
. O
1 O
hours O
in O
the O
repeated O
dose O
group O
. O
[SEP] O
[CLS] O
where O
em B-PK
##ax I-PK
is O
the O
maximum B-PK
effect I-PK
and O
e B-PK
##c I-PK
##50 I-PK
is O
the O
if O
##n O
- O
α O
concentration B-PK
that I-PK
produces I-PK
50 I-PK
% I-PK
of I-PK
the I-PK
maximum I-PK
effect I-PK
. O
[SEP] O
[CLS] O
the O
low O
cumulative O
curves O
of O
the O
two O
su O
##cci O
##ny O
##l O
- O
s O
##n O
##38 O
derivatives O
in O
50 O
% O
plasma O
and O
25 O
% O
liver O
ho O
##mo O
##gen O
##ate O
reflected O
fast O
in O
v O
##ivo O
elimination O
. O
[SEP] O
[CLS] O
the O
prepared O
films O
were O
evaluated O
for O
their O
tens O
##ile O
strength O
, O
thickness O
uniform O
##ity O
, O
di O
##sin O
##te O
##gration O
time O
( O
in O
v O
##it O
##ro O
and O
in O
v O
##ivo O
) O
, O
in O
v O
##it O
##ro O
dissolution O
, O
and O
moisture O
content O
. O
[SEP] O
[CLS] O
dos O
##age O
, O
dos O
##ing O
regime O
##n O
, O
and O
the O
last O
blood O
sampling O
time O
were O
set O
to O
match O
the O
actual O
clinical O
trial O
in O
phase O
i O
studies O
in O
j O
##apa O
##nese O
and O
non O
‐ O
j O
##apa O
##nese O
healthy O
subjects O
. O
[SEP] O
[CLS] O
in O
this O
report O
, O
we O
describe O
the O
development O
and O
valid O
##ation O
of O
a O
limited O
- O
sampling O
model O
for O
car O
##bo O
##p O
##lat O
##in O
from O
77 O
p O
##har O
##ma O
##co O
##kin O
##etic O
curves O
, O
when O
car O
##bo O
##p O
##lat O
##in O
is O
used O
in O
combination O
with O
p O
##ac O
##lit O
##ax O
##el O
. O
[SEP] O
[CLS] O
d O
##l O
was O
obtained O
from O
ca O
##di O
##la O
pharmaceutical O
##s O
, O
in O
##dia O
. O
[SEP] O
[CLS] O
such O
a O
process O
compares O
well O
to O
the O
estimated O
di O
##sso O
##ciation O
rate O
constant O
( O
k O
( O
off O
) O
) O
of O
the O
com O
##t O
- O
op O
##ica O
##po O
##ne O
molecular O
complex O
( O
k O
( O
off O
) O
= O
1 O
. O
9 O
× O
10 O
( O
- O
6 O
) O
s O
( O
- O
1 O
) O
) O
. O
[SEP] O
[CLS] O
this O
analysis O
was O
performed O
on O
patients O
diagnosed O
with O
pulmonary O
tuberculosis O
from O
two O
clinical O
studies O
: O
the O
phase O
ii O
##i O
r O
##if O
##aq O
##uin O
study O
( O
registration O
number O
is O
##rc O
##t O
##n O
##44 O
##15 O
##30 O
##44 O
) O
( O
26 O
) O
and O
the O
two O
- O
stage O
activity O
- O
safety O
study O
of O
daily O
r O
##if O
##ap O
##ent O
##ine O
( O
27 O
) O
, O
referred O
to O
here O
as O
the O
daily O
r O
##pe O
study O
( O
clinical O
##tri O
##als O
. O
go O
##v O
registration O
number O
n O
##ct O
##00 O
##8 O
##14 O
##6 O
##7 O
##1 O
) O
. O
[SEP] O
[CLS] O
there O
is O
sufficient O
evidence O
supporting O
the O
protective O
role O
of O
the O
n O
##rf O
##2 O
- O
mediated O
pathway O
against O
o O
##xi O
##da O
##tive O
stress O
and O
inflammation O
. O
28 O
recent O
research O
has O
shown O
that O
n O
##rf O
##2 O
has O
multiple O
functions O
, O
including O
acute O
and O
trans O
##ient O
stress O
responses O
to O
o O
##xi O
##da O
##tive O
insults O
. O
29 O
ho O
- O
1 O
gene O
expression O
is O
mainly O
regulated O
by O
the O
n O
##rf O
##2 O
anti O
##ox O
##ida O
##nt O
response O
element O
( O
are O
) O
pathway O
, O
and O
induction O
of O
this O
enzyme O
protects O
cells O
from O
injury O
and O
death O
caused O
by O
o O
##xi O
##da O
##tive O
stress O
. O
30 O
n O
##rf O
##2 O
expression O
was O
found O
to O
have O
increased O
post O
- O
c O
##sa O
administration O
, O
parallel O
##ing O
the O
enhanced O
anti O
##ox O
##ida O
##nt O
capacity O
, O
but O
surprisingly O
not O
the O
inflammatory O
changes O
in O
re O
##nal O
tissues O
. O
[SEP] O
[CLS] O
therapeutic O
intervention O
controls O
increased O
i O
##op O
, O
but O
ne O
##uro O
##p O
##rote O
##ction O
is O
unavailable O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
ratio I-PK
( O
- O
) O
/ O
( O
+ O
) O
was O
1 O
. O
52 O
+ O
- O
0 O
. O
36 O
and O
1 O
. O
32 O
+ O
- O
0 O
. O
17 O
after O
single O
doses O
and O
steady O
- O
state O
, O
respectively O
( O
p O
greater O
than O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
milk O
penetration O
of O
di O
##f O
##lo O
##xa O
##cin O
after O
a O
long O
- O
acting O
formulation O
for O
sub O
##cut O
##aneous O
administration O
to O
la O
##ct O
##ating O
goats O
. O
[SEP] O
[CLS] O
to O
further O
investigate O
the O
effect O
of O
the O
p O
##h O
on O
the O
h O
##ydro O
##lysis O
of O
d O
##m O
##f O
to O
mm O
##f O
, O
0 O
. O
1 O
m O
sodium O
phosphate O
buffer O
##s O
with O
p O
##h O
values O
ranging O
from O
6 O
. O
5 O
– O
8 O
were O
spike O
##d O
with O
d O
##m O
##f O
and O
the O
combination O
of O
d O
##m O
##f O
and O
me O
##f O
. O
[SEP] O
[CLS] O
to O
estimate O
the O
population O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
low O
- O
dose O
met O
##hot O
##re O
##xa O
##te O
( O
m O
##t O
##x O
) O
in O
j O
##apa O
##nese O
patients O
using O
non O
##me O
##m O
, O
a O
computer O
program O
designed O
for O
anal O
##ys O
##ing O
drug O
p O
##har O
##ma O
##co O
##kin O
##etics O
in O
study O
populations O
through O
pool O
##ing O
of O
data O
. O
[SEP] O
[CLS] O
safety O
and O
efficacy O
were O
evaluated O
in O
all O
patients O
who O
received O
one O
or O
more O
doses O
of O
study O
treatment O
. O
[SEP] O
[CLS] O
using O
a O
perfect O
##si O
##l O
c O
##18 O
column O
( O
4 O
. O
6 O
× O
150 O
mm O
, O
5 O
μ O
##m O
particle O
size O
) O
, O
a O
variety O
of O
mobile O
phases O
comprising O
several O
combinations O
of O
a O
##que O
##ous O
( O
0 O
. O
01 O
m O
potassium O
di O
##hy O
##dr O
##ogen O
phosphate O
buffer O
or O
dei O
##onized O
water O
) O
and O
organic O
solvent O
##s O
( O
met O
##han O
##ol O
or O
ace O
##ton O
##it O
##ril O
##e O
) O
were O
tested O
to O
provide O
sufficient O
resolution O
between O
do O
##x O
##or O
##ubi O
##cin O
, O
is O
and O
plasma O
interfering O
peaks O
. O
[SEP] O
[CLS] O
hence O
, O
o O
##x O
##car O
##ba O
##ze O
##pine O
can O
be O
generally O
applied O
using O
the O
same O
dos O
##age O
and O
administration O
for O
the O
treatment O
of O
partial O
onset O
seizure O
##s O
in O
p O
##ediatric O
patients O
, O
regardless O
of O
ethnicity O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
, O
the O
album O
##in O
binding O
m O
##oi O
##ety O
resulted O
in O
prolonged O
circulation O
and O
higher O
α O
##v O
##β O
##6 O
- O
targeted O
up O
##take O
. O
[SEP] O
[CLS] O
e O
##c O
##g O
parameters O
for O
any O
patient O
and O
time O
##point O
were O
considered O
valid O
if O
they O
were O
based O
on O
at O
least O
two O
valid O
replica O
##te O
e O
##c O
##gs O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
180 I-PK
) I-PK
for O
m O
##3 O
##g O
and O
m O
##6 O
##g O
were O
similar O
in O
the O
two O
patient O
groups O
, O
as O
were O
the O
peak B-PK
meta I-PK
##bol I-PK
##ite I-PK
concentrations I-PK
and O
times B-PK
to I-PK
peak I-PK
concentrations I-PK
. O
[SEP] O
[CLS] O
side O
- O
effects O
were O
frequent O
, O
but O
neither O
their O
severity O
nor O
their O
occurrence O
could O
be O
related O
to O
plasma O
levels O
or O
to O
the O
rate O
of O
increase O
in O
plasma O
concentration O
of O
the O
drug O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
by O
re O
##tro O
- O
orbital O
bleeding O
from O
the O
two O
groups O
at O
the O
indicated O
time O
intervals O
. O
[SEP] O
[CLS] O
these O
results O
directly O
support O
our O
observation O
that O
do O
##xy O
##cy O
##cline O
potent O
##ly O
in O
##hibit O
##s O
ma O
##mm O
##os O
##phere O
formation O
, O
by O
blocking O
the O
c O
##lon O
##al O
expansion O
of O
c O
##s O
##cs O
and O
reduces O
an O
##oi O
##kis O
- O
resistance O
. O
[SEP] O
[CLS] O
my O
##oto O
##nia O
was O
induced O
in O
the O
rat O
by O
injection O
of O
ant O
##hra O
##ce O
##n O
- O
9 O
- O
car O
##box O
##yl O
##ic O
acid O
, O
a O
muscle O
chloride O
channel O
block O
##er O
. O
[SEP] O
[CLS] O
in O
a O
double O
‐ O
blind O
, O
random O
##ized O
, O
multiple O
‐ O
ascending O
‐ O
dose O
( O
mad O
) O
study O
, O
8 O
healthy O
subjects O
per O
panel O
( O
3 O
active O
: O
1 O
place O
##bo O
) O
received O
5 O
weekly O
s O
##c O
doses O
of O
l O
##uli O
##zu O
##ma O
##b O
at O
6 O
. O
25 O
, O
12 O
. O
5 O
, O
or O
37 O
. O
5 O
mg O
( O
all O
6 O
. O
25 O
‐ O
mg O
panel O
subjects O
received O
place O
##bo O
in O
weeks O
2 O
and O
4 O
) O
, O
or O
place O
##bo O
. O
[SEP] O
[CLS] O
flow O
rate O
of O
100 O
μ O
##l O
/ O
min O
was O
maintained O
. O
[SEP] O
[CLS] O
peak B-PK
concentrations I-PK
of O
sts O
for O
the O
250 O
mg O
/ O
m O
##l O
dose O
was O
found O
to O
be O
7 O
. O
27 O
mg O
/ O
m O
##l O
with O
a O
standard O
de O
##viation O
of O
0 O
. O
83 O
. O
[SEP] O
[CLS] O
the O
steady B-PK
- I-PK
state I-PK
maximum I-PK
plasma I-PK
concentrations I-PK
( I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
, I-PK
s I-PK
##s I-PK
) I-PK
; O
mean O
± O
standard O
de O
##viation O
) O
of O
lobe O
##gli O
##ta O
##zone O
and O
met O
##form O
##in O
alone O
were O
29 O
. O
38 O
± O
5 O
. O
25 O
ng O
/ O
m O
##l O
and O
1661 O
. O
84 O
± O
47 O
##1 O
. O
88 O
ng O
/ O
m O
##l O
, O
respectively O
; O
the O
c B-PK
( I-PK
ma I-PK
##x I-PK
, I-PK
s I-PK
##s I-PK
) I-PK
during O
co O
- O
administration O
were O
27 O
. O
15 O
± O
5 O
. O
75 O
ng O
/ O
m O
##l O
and O
1779 O
. O
92 O
± O
405 O
. O
20 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
physiological O
##ly O
based O
p O
##har O
##ma O
##co O
##kin O
##etic O
modeling O
of O
sa O
##liva O
##ry O
concentrations O
for O
non O
##in O
##vasive O
bio O
##mon O
##itor O
##ing O
of O
2 O
, O
4 O
- O
di O
##ch O
##lor O
##op O
##hen O
##ox O
##ya O
##ce O
##tic O
acid O
( O
2 O
, O
4 O
- O
d O
) O
. O
[SEP] O
[CLS] O
all O
subjects O
received O
a O
single O
dose O
of O
study O
drug O
according O
to O
their O
assigned O
treatment O
. O
[SEP] O
[CLS] O
results O
differed O
only O
moderately O
between O
the O
injection O
sites O
( O
right O
and O
left O
g O
##lut O
##eal O
mass O
) O
in O
the O
same O
animal O
. O
[SEP] O
[CLS] O
a O
non O
##sign O
##ificant O
delay O
in O
t B-PK
##max I-PK
. O
[SEP] O
[CLS] O
the O
ca O
##li O
##bra O
##tion O
plot O
revealed O
linear O
##ity O
in O
the O
concentration O
range O
of O
1 O
– O
300 O
μ O
##g O
/ O
m O
##l O
with O
the O
correlation O
coefficient O
of O
0 O
. O
99 O
##9 O
##6 O
. O
[SEP] O
[CLS] O
comparisons O
of O
ethnic O
and O
gender O
differences O
in O
the O
distribution O
of O
all O
##eli O
##c O
frequencies O
among O
g O
##eno O
##type O
##s O
, O
and O
/ O
or O
gender O
differences O
and O
tests O
for O
hard O
##y O
- O
we O
##in O
##berg O
equilibrium O
were O
carried O
out O
using O
the O
ch O
##i O
- O
square O
test O
. O
[SEP] O
[CLS] O
the O
re O
##gression O
equation O
for O
the O
ca O
##li O
##bra O
##tion O
curve O
of O
e O
##chin O
##os O
##ide O
a O
in O
h O
##bs O
##s O
and O
plasma O
were O
, O
respectively O
, O
y O
= O
52 O
##8 O
##8 O
##8 O
##4 O
##x O
− O
231 O
##8 O
. O
7 O
( O
r O
##2 O
= O
0 O
. O
99 O
##8 O
##8 O
) O
and O
y O
= O
306 O
##6 O
##8 O
##x O
+ O
30 O
. O
70 O
##7 O
( O
r O
##2 O
= O
0 O
. O
99 O
##9 O
##1 O
) O
. O
[SEP] O
[CLS] O
to O
improve O
therapeutic O
effects O
and O
pro O
##long O
the O
systemic O
circulation O
time O
of O
sa O
##l O
b O
, O
lip O
##oso O
##mes O
, O
composed O
of O
so O
##y O
##be O
##an O
p O
##hos O
##pha O
##ti O
##dy O
##l O
##cho O
##line O
and O
ch O
##ole O
##ster O
##ol O
were O
prepared O
by O
reverse O
- O
phase O
e O
##va O
##por O
##ation O
method O
. O
[SEP] O
[CLS] O
mean O
r B-PK
##au I-PK
##c I-PK
values O
for O
r O
##d O
##c O
- O
99 O
##86 O
/ O
sa O
##m O
were O
0 O
. O
31 O
##4 O
, O
0 O
. O
81 O
##8 O
, O
and O
0 O
. O
98 O
##1 O
following O
in O
##tra O
##ven O
##ous O
, O
sub O
##ling O
##ual O
, O
and O
oral O
administration O
of O
sa O
##m O
, O
respectively O
. O
[SEP] O
[CLS] O
c O
##y O
##c O
##los O
##por O
##in O
a O
treatment O
resulted O
in O
a O
significant O
increase O
in O
elimination B-PK
half I-PK
- I-PK
life I-PK
, O
mean B-PK
residence I-PK
time I-PK
and O
area B-PK
under I-PK
the I-PK
concentration I-PK
versus I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
of O
un O
##bound O
b O
##aic O
##ale O
##in O
in O
the O
brain O
. O
[SEP] O
[CLS] O
the O
ad O
##van O
##4 O
sub O
##rout O
##ine O
was O
used O
during O
the O
model O
development O
process O
. O
[SEP] O
[CLS] O
sodium O
or O
##th O
##ova O
##na O
##date O
( O
na O
##3 O
##vo O
##4 O
) O
was O
used O
as O
a O
at O
##pas O
##e O
inhibitor O
. O
[SEP] O
[CLS] O
serum O
concentrations O
after O
the O
first O
480 O
mg O
in O
##fusion O
( O
month O
4 O
) O
rapidly O
approached O
steady B-PK
- I-PK
state I-PK
concentration I-PK
levels I-PK
( O
≥ O
##90 O
% O
) O
of O
480 O
mg O
q O
##4 O
##w O
and O
were O
maintained O
for O
the O
entire O
treatment O
duration O
( O
figure O
2 O
and O
supplement O
##ary O
table O
s O
##1 O
, O
available O
at O
an O
##nal O
##s O
of O
on O
##cology O
online O
) O
. O
[SEP] O
[CLS] O
the O
six O
liquid O
preparation O
were O
a O
##que O
##ous O
solution O
, O
an O
organic O
solvent O
complex O
( O
la O
##no O
##xi O
##cap O
##s O
fill O
) O
for O
which O
solvent O
assisted O
absorption O
has O
been O
suggested O
, O
dig O
##ox O
##in O
el O
##ix O
##ir O
, O
and O
three O
different O
solutions O
each O
comprising O
a O
single O
organic O
solvent O
in O
the O
concentration O
used O
in O
la O
##no O
##xi O
##cap O
##s O
plus O
water O
to O
make O
up O
the O
balance O
. O
[SEP] O
[CLS] O
the O
predict O
##ive O
performance O
of O
each O
model O
was O
evaluated O
using O
the O
model O
prediction O
error O
( O
p O
##e O
) O
, O
mean O
prediction O
error O
( O
m O
##pe O
) O
, O
mean O
absolute O
prediction O
error O
( O
map O
##e O
) O
, O
prediction O
- O
corrected O
visual O
predict O
##ive O
check O
( O
p O
##c O
##v O
##p O
##c O
) O
, O
and O
normal O
##ized O
prediction O
distribution O
errors O
( O
n O
##p O
##de O
) O
. O
[SEP] O
[CLS] O
it O
is O
possible O
that O
no O
unchanged O
k O
##eto O
##p O
##ro O
##fen O
, O
nap O
##ro O
##xen O
, O
or O
probe O
##ne O
##cid O
is O
ex O
##cre O
##ted O
in O
urine O
. O
[SEP] O
[CLS] O
to O
determine O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
for O
me O
##lo O
##xi O
##cam O
, O
a O
non O
##ster O
##oid O
##al O
anti O
- O
inflammatory O
drug O
, O
in O
horses O
. O
[SEP] O
[CLS] O
in O
a O
similar O
manner O
, O
simple O
all O
##ome O
##try O
predicted O
the O
human O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
des O
- O
c O
##icles O
##oni O
##de O
( O
c B-PK
##l I-PK
/ I-PK
f I-PK
, O
v B-PK
##d I-PK
/ I-PK
f I-PK
, O
t B-PK
( I-PK
½ I-PK
) I-PK
, O
and O
k B-PK
##el I-PK
) O
within O
a O
two O
- O
to O
three O
##fold O
range O
of O
the O
observed O
values O
. O
[SEP] O
[CLS] O
a O
total O
of O
100 O
µ O
##l O
micro O
##so O
##mal O
protein O
and O
100 O
µ O
##l O
probe O
drugs O
were O
added O
with O
250 O
µ O
##l O
phosphate O
buffer O
in O
a O
brown O
cent O
##ri O
##fu O
##ge O
tube O
, O
v O
##ortex O
- O
mixed O
for O
1 O
min O
, O
and O
in O
##cu O
##bate O
##d O
at O
37 O
° O
##c O
water O
. O
[SEP] O
[CLS] O
( O
this O
study O
has O
been O
registered O
at O
clinical O
##tri O
##als O
. O
go O
##v O
under O
registration O
no O
. O
n O
##ct O
##00 O
##64 O
##0 O
##8 O
##8 O
##7 O
. O
) O
. O
[SEP] O
[CLS] O
trans O
##c O
##rani O
##al O
magnetic O
stimulation O
was O
used O
to O
probe O
the O
acute O
effect O
of O
a O
single O
oral O
dose O
of O
various O
do O
##pa O
##mine O
##rg O
##ic O
( O
le O
##vo O
##do O
##pa O
, O
se O
##leg O
##ili O
##ne O
, O
br O
##omo O
##cript O
##ine O
) O
and O
anti O
##do O
##pa O
##mine O
##rg O
##ic O
drugs O
( O
su O
##l O
##pi O
##ride O
, O
ha O
##lop O
##eri O
##do O
##l O
) O
on O
motor O
cortex O
ex O
##ci O
##ta O
##bility O
in O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
met O
##form O
##in O
anti O
##tum O
##or O
effects O
were O
tested O
by O
i O
##vis O
. O
[SEP] O
[CLS] O
following O
i O
##v O
administration O
of O
s O
##ch O
59 O
##8 O
##8 O
##4 O
, O
the O
compound O
is O
rapidly O
de O
##ph O
##os O
##ph O
##ory O
##lated O
to O
s O
##ch O
207 O
##9 O
##6 O
##2 O
which O
is O
then O
h O
##ydro O
##ly O
##zed O
to O
s O
##ch O
56 O
##5 O
##9 O
##2 O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
analyzed O
by O
p O
##ks O
##ol O
##ver O
following O
the O
instruction O
. O
[SEP] O
[CLS] O
hp O
##l O
##c O
grade O
ace O
##ton O
##it O
##ril O
##e O
, O
met O
##han O
##ol O
, O
or O
##th O
##op O
##hos O
##ph O
##ori O
##c O
acid O
, O
and O
water O
were O
obtained O
from O
me O
##rc O
##k O
kg O
##aa O
( O
g O
##erman O
##y O
) O
. O
[SEP] O
[CLS] O
regulatory O
activities O
of O
2 O
beta O
- O
( O
3 O
- O
h O
##ydro O
##xy O
##p O
##rop O
##ox O
##y O
) O
- O
1 O
alpha O
, O
25 O
- O
di O
##hy O
##dr O
##ox O
##y O
##vi O
##tam O
##in O
d O
##3 O
[ O
ed O
- O
71 O
] O
, O
a O
novel O
synthetic O
vitamin O
d O
##3 O
derivative O
, O
on O
calcium O
metabolism O
were O
investigated O
. O
[SEP] O
[CLS] O
the O
amounts O
of O
g O
##c O
##v O
en O
##tra O
##pped O
in O
the O
micro O
##sp O
##here O
##s O
were O
sufficient O
to O
administer O
therapeutic O
##ally O
relevant O
doses O
in O
60 O
micro O
##l O
of O
the O
formulation O
. O
[SEP] O
[CLS] O
di O
##ar O
##r O
##hea O
was O
observed O
at O
similar O
rates O
in O
both O
o O
##xa O
##lip O
##lat O
##in O
( O
6 O
/ O
48 O
patients O
, O
13 O
% O
) O
and O
i O
##rino O
##teca O
##n O
treated O
patients O
( O
4 O
/ O
30 O
patients O
, O
13 O
% O
) O
. O
[SEP] O
[CLS] O
they O
were O
im O
##mers O
##ed O
in O
100 O
m O
##l O
of O
medium O
at O
37 O
± O
0 O
. O
5 O
° O
##c O
under O
stirring O
( O
150 O
rpm O
) O
. O
[SEP] O
[CLS] O
est O
##imation O
errors O
on O
clearance B-PK
were O
within O
+ O
- O
8 O
% O
for O
adults O
and O
+ O
- O
13 O
% O
for O
children O
( O
95 O
% O
limits O
of O
agreement O
) O
. O
[SEP] O
[CLS] O
in O
v O
##ivo O
kinetic O
studies O
in O
rats O
indicated O
53 O
% O
release O
of O
nor O
##f O
##lo O
##xa O
##cin O
in O
plasma O
at O
the O
end O
of O
8 O
##h O
. O
[SEP] O
[CLS] O
this O
was O
a O
single O
- O
center O
study O
with O
an O
open O
, O
random O
##ized O
double O
- O
way O
crossover O
design O
. O
[SEP] O
[CLS] O
for O
the O
preliminary O
toxicity O
test O
, O
at O
least O
500 O
cells O
were O
evaluated O
to O
determine O
the O
c O
##yt O
##oki O
##nes O
##is O
- O
blocked O
proliferation O
index O
( O
c O
##b O
##pi O
) O
at O
each O
dose O
level O
and O
the O
control O
. O
[SEP] O
[CLS] O
administration O
of O
e O
##a O
‐ O
230 O
is O
safe O
and O
results O
in O
at O
##ten O
##uation O
of O
the O
systemic O
inflammatory O
response O
in O
humans O
. O
[SEP] O
[CLS] O
in O
further O
studies O
using O
pre O
##c O
##lini O
##cal O
models O
, O
in O
v O
##ivo O
administration O
of O
y O
##s O
##11 O
##0 O
resulted O
in O
in O
##hibition O
of O
t O
##umour O
cell O
growth O
, O
migration O
and O
invasion O
, O
and O
enhanced O
survival O
of O
mouse O
x O
##eno O
##gra O
##ft O
models O
in O
##oc O
##ulated O
with O
r O
##cc O
or O
m O
##pm O
( O
in O
##amo O
##to O
, O
et O
al O
, O
2007 O
; O
ok O
##amo O
##to O
et O
al O
, O
2014 O
; O
ya O
##mamoto O
et O
al O
, O
2014 O
) O
. O
[SEP] O
[CLS] O
among O
the O
10 O
patients O
with O
re O
##nal O
imp O
##air O
##ment O
, O
three O
had O
moderate O
imp O
##air O
##ment O
and O
three O
had O
severe O
imp O
##air O
##ment O
. O
[SEP] O
[CLS] O
that O
is O
when O
i O
would O
forget O
to O
drink O
them O
, O
but O
when O
i O
was O
home O
i O
was O
able O
to O
drink O
them O
every O
day O
. O
[SEP] O
[CLS] O
our O
results O
indicate O
the O
efficacy O
of O
c O
##ef O
##tri O
##ax O
##one O
against O
experimental O
c O
##ep O
##hal O
##os O
##por O
##in O
- O
resistant O
p O
##ne O
##um O
##oc O
##oc O
##cal O
o O
##titis O
and O
provide O
a O
basis O
for O
the O
clinical O
use O
of O
single O
- O
dose O
c O
##ef O
##tri O
##ax O
##one O
against O
p O
##ne O
##um O
##oc O
##oc O
##cal O
o O
##titis O
media O
. O
[SEP] O
[CLS] O
at O
8 O
mg O
kg O
- O
1 O
in O
the O
multiple O
- O
dose O
co O
##hor O
##t O
, O
the O
day O
4 O
geometric O
mean O
au B-PK
##c I-PK
##0 I-PK
- I-PK
24 I-PK
was O
57 O
. O
9 O
μ O
##g O
* O
h O
m O
##l O
- O
1 O
. O
[SEP] O
[CLS] O
according O
to O
a O
previous O
report O
[ O
28 O
] O
, O
m O
##21 O
was O
in O
##ferred O
to O
be O
3 O
- O
h O
##ydro O
##xy O
##hip O
##uri O
##c O
acid O
. O
[SEP] O
[CLS] O
compared O
with O
base O
##line O
, O
the O
median O
plasma O
4 O
##β O
- O
oh O
##c O
/ O
ch O
##ol O
ratio O
increased O
at O
the O
4th O
( O
257 O
% O
) O
, O
16th O
( O
29 O
##1 O
% O
) O
and O
48 O
##th O
( O
165 O
% O
) O
week O
( O
p O
< O
0 O
. O
000 O
##1 O
) O
. O
[SEP] O
[CLS] O
dose O
- O
limiting O
toxic O
##ities O
included O
r O
##ash O
, O
fatigue O
and O
vomit O
##ing O
. O
[SEP] O
[CLS] O
to O
investigate O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
10 O
micro O
##g O
and O
25 O
micro O
##g O
17 O
##bet O
##a O
- O
est O
##rad O
##iol O
( O
e O
##2 O
) O
v O
##agi O
##nal O
tablets O
in O
post O
##men O
##op O
##aus O
##al O
women O
with O
v O
##agi O
##nal O
at O
##rop O
##hy O
. O
[SEP] O
[CLS] O
the O
first O
and O
last O
authors O
of O
identified O
studies O
were O
contacted O
and O
invited O
to O
join O
this O
pool O
##ed O
analysis O
by O
contributing O
individual O
patient O
data O
to O
the O
worldwide O
anti O
##mal O
##aria O
##l O
resistance O
network O
( O
w O
##war O
##n O
) O
re O
##pository O
as O
part O
of O
a O
study O
group O
if O
their O
studies O
were O
prospective O
su O
##lf O
##ado O
##xin O
##e O
and O
p O
##yr O
##ime O
##tham O
##ine O
studies O
of O
non O
##p O
##re O
##gnant O
a O
##f O
##rica O
##n O
patients O
with O
un O
##com O
##plicate O
##d O
p O
. O
f O
##al O
##ci O
##par O
##um O
infection O
, O
especially O
children O
under O
the O
age O
of O
5 O
years O
. O
[SEP] O
[CLS] O
this O
study O
was O
a O
random O
##ized O
2 O
‐ O
way O
cross O
‐ O
over O
clinical O
trial O
utilizing O
4 O
adult O
an O
##gus O
steer O
##s O
fitted O
previously O
with O
surgical O
##ly O
imp O
##lanted O
duo O
##den O
##al O
can O
##nu O
##la O
##e O
placed O
or O
##ad O
to O
the O
bi O
##lia O
##ry O
and O
pan O
##cre O
##atic O
duct O
##s O
. O
[SEP] O
[CLS] O
comparative O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
pipe O
##rac O
##ill O
##in O
in O
normal O
##s O
and O
in O
patients O
with O
re O
##nal O
failure O
. O
[SEP] O
[CLS] O
mi O
##son O
##ida O
##zo O
##le O
, O
a O
h O
##y O
##pox O
##ic O
cell O
se O
##ns O
##iti O
##zer O
, O
enhance O
##s O
the O
anti O
##tum O
##or O
effects O
of O
c O
##y O
##c O
##lop O
##hos O
##pha O
##mi O
##de O
in O
pre O
##c O
##lini O
##cal O
studies O
. O
[SEP] O
[CLS] O
samples O
were O
analyzed O
on O
a O
the O
##rm O
##o O
scientific O
t O
##s O
##q O
quantum O
ultra O
mass O
s O
##pect O
##rome O
##ter O
( O
wa O
##lt O
##ham O
, O
ma O
, O
us O
##a O
) O
interface O
##d O
to O
a O
waters O
a O
##c O
##qui O
##ty O
up O
##l O
##c O
system O
( O
mi O
##lf O
##ord O
, O
ma O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
co O
##agu O
##lation O
was O
activated O
using O
commercially O
available O
re O
##age O
##nts O
containing O
re O
##comb O
##ina O
##nt O
tissue O
factor O
( O
t O
##f O
, O
final O
concentration O
5 O
pm O
) O
, O
p O
##hos O
##ph O
##oli O
##pid O
##s O
( O
final O
concentration O
4 O
µ O
##m O
) O
, O
in O
the O
presence O
or O
absence O
of O
soluble O
th O
##rom O
##bo O
##mo O
##du O
##lin O
( O
t O
##m O
, O
the O
concentration O
of O
which O
is O
not O
revealed O
by O
the O
manufacturer O
) O
. O
[SEP] O
[CLS] O
in O
both O
sessions O
, O
art O
##erial O
plasma O
samples O
were O
obtained O
. O
[SEP] O
[CLS] O
the O
total O
amount O
of O
q O
##c O
samples O
was O
no O
less O
than O
5 O
% O
of O
the O
test O
samples O
in O
the O
same O
batch O
. O
[SEP] O
[CLS] O
administration O
of O
a O
single O
in O
##tra O
##ven O
##ous O
b O
##ol O
##us O
dose O
of O
f O
##xa O
##i O
##16 O
##l O
was O
safe O
and O
tolerate O
##d O
at O
all O
dose O
levels O
tested O
, O
with O
no O
dose O
- O
limiting O
toxicity O
or O
serious O
adverse O
events O
. O
[SEP] O
[CLS] O
compared O
to O
the O
three O
- O
compartment O
model O
, O
clearance B-PK
values O
were O
over O
##est O
##imated O
by O
the O
s O
##ch O
##wart O
##z O
approach O
( O
bias O
6 O
. O
5 O
m O
##l O
/ O
min O
) O
, O
resulting O
in O
limited O
effects O
on O
re O
##gression O
coefficients O
of O
the O
bi O
##s O
equations O
( O
e O
. O
g O
. O
, O
proportional O
##ity O
factor O
of O
bi O
##s O
##2 O
changed O
from O
76 O
##7 O
to O
720 O
) O
. O
[SEP] O
[CLS] O
the O
results O
are O
similar O
to O
those O
obtained O
with O
c O
##q O
( O
figure O
2 O
##c O
, O
d O
) O
. O
[SEP] O
[CLS] O
plasma O
concentration O
- O
time O
curves O
were O
plot O
##ted O
. O
[SEP] O
[CLS] O
we O
suggest O
that O
the O
described O
method O
is O
suitable O
to O
analyze O
sa O
##liva O
and O
plasma O
samples O
of O
small O
volumes O
for O
therapeutic O
drug O
monitoring O
( O
t O
##d O
##m O
) O
and O
p O
##har O
##ma O
##co O
##kin O
##etic O
studies O
in O
p O
##ediatric O
patients O
. O
[SEP] O
[CLS] O
however O
, O
35 O
- O
40 O
million O
people O
bear O
the O
infection O
worldwide O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
ve O
##rap O
##ami O
##l O
and O
its O
active O
meta O
##bol O
##ite O
nor O
##ver O
##apa O
##mi O
##l O
in O
patients O
with O
he O
##pa O
##top O
##athy O
. O
[SEP] O
[CLS] O
in O
##hibition O
of O
notch O
pathway O
signaling O
was O
demonstrated O
at O
these O
doses O
. O
[SEP] O
[CLS] O
in O
addition O
, O
g O
##l O
##p O
‐ O
1 O
suppress O
##es O
g O
##lu O
##ca O
##gon O
release O
from O
pan O
##cre O
##atic O
α O
‐ O
cells O
and O
slow O
##s O
gas O
##tric O
empty O
##ing O
. O
[SEP] O
[CLS] O
a O
graphic O
approach O
provides O
the O
recommended O
dose O
for O
any O
selected O
probability O
of O
attain O
##ing O
the O
p O
##k O
/ O
p O
##d O
efficacy O
target O
or O
to O
evaluate O
the O
cumulative O
fraction O
of O
response O
for O
any O
dos O
##ing O
regime O
##n O
in O
this O
population O
. O
[SEP] O
[CLS] O
no O
in O
##tra O
##patient O
dose O
es O
##cal O
##ation O
beyond O
the O
original O
assigned O
co O
##hor O
##t O
was O
permitted O
. O
[SEP] O
[CLS] O
the O
effect O
of O
ch O
##lor O
##ine O
substitution O
on O
the O
disposition O
of O
p O
##oly O
##ch O
##lor O
##inated O
bi O
##phe O
##ny O
##ls O
following O
der O
##mal O
administration O
. O
[SEP] O
[CLS] O
the O
mobile O
phase O
consisted O
of O
0 O
. O
1 O
% O
form O
##ic O
acid O
: O
ace O
##ton O
##it O
##ril O
##e O
( O
25 O
: O
75 O
, O
v O
/ O
v O
) O
. O
[SEP] O
[CLS] O
the O
primary O
d O
##lt O
and O
m O
##t O
##d O
analysis O
was O
performed O
on O
all O
e O
##val O
##ua O
##ble O
patients O
who O
signed O
the O
informed O
consent O
and O
who O
did O
not O
miss O
≥ O
##7 O
days O
of O
treatment O
during O
the O
first O
cycle O
of O
treatment O
or O
had O
a O
d O
##lt O
. O
[SEP] O
[CLS] O
the O
majority O
of O
infections O
were O
mild O
respiratory O
infections O
. O
[SEP] O
[CLS] O
each O
formulation O
contained O
800 O
mg O
i O
##bu O
##p O
##ro O
##fen O
. O
[SEP] O
[CLS] O
our O
results O
showed O
that O
this O
immune O
prop O
##hyl O
##actic O
strategy O
influences O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
of O
b O
[ O
a O
] O
p O
and O
further O
studies O
to O
investigate O
their O
effects O
on O
chemical O
car O
##cin O
##ogen O
##esis O
are O
warrant O
##ed O
. O
[SEP] O
[CLS] O
delta O
##met O
##hr O
##in O
, O
a O
widely O
used O
type O
ii O
p O
##yre O
##th O
##roid O
insect O
##icide O
, O
is O
a O
relatively O
potent O
ne O
##uro O
##to O
##xi O
##can O
##t O
. O
[SEP] O
[CLS] O
f O
##ent O
##any O
##l O
( O
20 O
μ O
##g O
/ O
kg O
) O
was O
administered O
i O
##v O
, O
and O
blood O
samples O
were O
collected O
over O
time O
to O
measure O
plasma O
f O
##ent O
##any O
##l O
concentrations O
for O
p O
##har O
##ma O
##co O
##kin O
##etic O
calculations O
. O
[SEP] O
[CLS] O
adverse O
events O
( O
a O
##es O
) O
were O
assessed O
per O
common O
terminology O
criteria O
for O
adverse O
events O
v O
##3 O
. O
0 O
; O
tumor O
responses O
were O
assessed O
by O
response O
evaluation O
criteria O
in O
solid O
tumors O
. O
[SEP] O
[CLS] O
en O
##roll O
##ees O
were O
male O
or O
female O
ages O
≥ O
6 O
and O
≤ O
75 O
years O
with O
a O
confirmed O
diagnosis O
of O
primary O
im O
##mu O
##no O
##de O
##ficiency O
, O
a O
history O
of O
h O
##y O
##po O
##gam O
##ma O
##g O
##lo O
##bul O
##ine O
##mia O
( O
i O
. O
e O
. O
, O
i O
##gg O
< O
500 O
mg O
/ O
d O
##l O
) O
or O
def O
##icient O
anti O
##body O
production O
prior O
to O
i O
##gg O
replacement O
therapy O
. O
[SEP] O
[CLS] O
the O
plasma O
levels O
of O
the O
unchanged O
drug O
showed O
that O
do O
##xa O
##min O
##ol O
was O
very O
rapidly O
eliminated O
and O
meta O
##bol O
##ized O
. O
[SEP] O
[CLS] O
a O
reproductive O
screening O
test O
of O
ha O
##wth O
##orn O
. O
[SEP] O
[CLS] O
met O
##han O
##ol O
toxic O
##oki O
##net O
##ics O
were O
examined O
in O
pregnant O
s O
##pra O
##gue O
- O
da O
##wley O
rats O
and O
c O
##d O
- O
1 O
mice O
to O
explore O
the O
possibility O
of O
g O
##esta O
##tional O
- O
associated O
alterations O
in O
metabolism O
and O
disposition O
. O
[SEP] O
[CLS] O
sixty O
- O
nine O
patients O
were O
enrolled O
, O
including O
20 O
patients O
at O
the O
m O
##t O
##d O
. O
[SEP] O
[CLS] O
the O
mean O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
48 I-PK
) I-PK
were O
13 O
. O
6 O
+ O
- O
5 O
. O
0 O
ng O
. O
h O
/ O
m O
##l O
and O
13 O
. O
3 O
+ O
- O
4 O
. O
7 O
ng O
. O
h O
/ O
m O
##l O
for O
the O
test O
and O
reference O
treatment O
, O
respectively O
; O
the O
corresponding O
estimated O
treatment O
ratio O
for O
test O
: O
reference O
was O
1 O
. O
01 O
##1 O
, O
95 O
% O
c O
##i O
: O
0 O
. O
86 O
##6 O
to O
1 O
. O
142 O
. O
[SEP] O
[CLS] O
total O
protein O
was O
measured O
by O
the O
bra O
##dford O
ass O
##ay O
( O
bio O
‐ O
r O
##ad O
, O
her O
##cule O
##s O
, O
ca O
) O
using O
b O
##ov O
##ine O
serum O
album O
##in O
as O
a O
standard O
. O
[SEP] O
[CLS] O
similarly O
, O
a O
bi O
##pha O
##si O
##c O
model O
best O
described O
the O
data O
for O
the O
formation O
of O
pen O
##to O
##xi O
##fy O
##llin O
##e O
from O
l O
##s O
##f O
. O
[SEP] O
[CLS] O
the O
presence O
of O
ve O
##g O
##f O
in O
samples O
, O
at O
expected O
physiological O
concentrations O
, O
did O
not O
marked O
##ly O
interfere O
in O
the O
q O
##uant O
##ification O
of O
be O
##va O
##ci O
##zu O
##ma O
##b O
. O
[SEP] O
[CLS] O
the O
injection O
schemes O
are O
presented O
in O
figure O
1 O
. O
[SEP] O
[CLS] O
briefly O
, O
200 O
μ O
##l O
of O
plasma O
was O
extracted O
twice O
with O
200 O
- O
μ O
##l O
te O
##rt O
- O
but O
##yl O
met O
##hyl O
et O
##her O
. O
[SEP] O
[CLS] O
thus O
, O
age O
is O
a O
de O
##ter O
##mina O
##nt O
of O
the O
steady B-PK
- I-PK
state I-PK
concentrations I-PK
of O
sa O
##lic O
##yla O
##te O
m O
##oi O
##eti O
##es O
but O
ace O
##ty O
##lator O
p O
##hen O
##otype O
plays O
a O
greater O
role O
in O
determining O
the O
serum O
concentration O
of O
su O
##lf O
##ap O
##yr O
##id O
##ine O
, O
which O
has O
greater O
therapeutic O
implications O
in O
r O
##he O
##uma O
##tology O
. O
[SEP] O
[CLS] O
atom O
##ox O
##eti O
##ne O
has O
been O
considered O
as O
an O
ago O
##nist O
replacement O
therapy O
for O
cocaine O
. O
[SEP] O
[CLS] O
therefore O
, O
it O
is O
important O
to O
examine O
the O
antagonist O
##ic O
effects O
on O
u O
##rina O
##tion O
associated O
with O
me O
##det O
##omi O
##dine O
use O
. O
[SEP] O
[CLS] O
the O
composition O
started O
out O
at O
5 O
% O
mobile O
phase O
b O
and O
increased O
linear O
##ly O
to O
70 O
% O
mobile O
phase O
b O
by O
7 O
min O
. O
[SEP] O
[CLS] O
q O
##uant O
##ification O
of O
p O
##x O
in O
rat O
plasma O
: O
an O
l O
##c O
- O
m O
##s O
/ O
m O
##s O
ass O
##ay O
was O
developed O
to O
determine O
the O
concentrations O
of O
p O
##x O
in O
rat O
plasma O
. O
[SEP] O
[CLS] O
when O
the O
b O
##16 O
##f O
##10 O
tumors O
had O
reached O
a O
volume O
of O
about O
500 O
mm O
##3 O
, O
the O
c O
##5 O
##7 O
##b O
##l O
/ O
6 O
j O
tumor O
- O
bearing O
mice O
were O
randomly O
and O
equally O
divided O
into O
three O
groups O
, O
which O
received O
free O
p O
##ac O
##lit O
##ax O
##el O
solution O
, O
c O
##l O
- O
p O
##t O
##x O
, O
or O
t O
##l O
- O
p O
##t O
##x O
administered O
as O
a O
single O
dose O
of O
10 O
mg O
p O
##ac O
##lit O
##ax O
##el O
/ O
kg O
body O
weight O
via O
the O
tail O
vein O
. O
[SEP] O
[CLS] O
children O
had O
been O
referred O
from O
their O
general O
practitioners O
( O
g O
##ps O
) O
, O
school O
‐ O
and O
community O
‐ O
based O
doctors O
, O
or O
p O
##ediatric O
##ians O
. O
[SEP] O
[CLS] O
however O
, O
the O
increase O
was O
ins O
##ign O
##ificant O
when O
compared O
to O
animals O
treated O
with O
fl O
##x O
alone O
. O
[SEP] O
[CLS] O
the O
potential O
for O
a O
drug O
interaction O
between O
c O
##y O
##c O
##los O
##por O
##in O
a O
and O
p O
##hen O
##yt O
##oi O
##n O
was O
investigated O
in O
rats O
. O
[SEP] O
[CLS] O
thus O
, O
the O
anti O
- O
em O
##t O
pathway O
or O
the O
method O
of O
in O
##hibit O
##ing O
of O
t O
##g O
##f O
- O
β O
##1 O
signaling O
could O
provide O
a O
novel O
potential O
target O
for O
the O
treatment O
of O
pulmonary O
fi O
##bro O
##sis O
. O
[SEP] O
[CLS] O
sixteen O
healthy O
subjects O
( O
8 O
men O
and O
8 O
women O
; O
mean O
age O
##± O
##s O
##d O
: O
28 O
. O
6 O
##± O
##6 O
. O
2 O
years O
; O
range O
: O
25 O
– O
51 O
years O
) O
were O
included O
. O
[SEP] O
[CLS] O
generally O
, O
the O
optimization O
of O
particle O
size O
is O
dependent O
on O
the O
therapeutic O
purpose O
. O
[SEP] O
[CLS] O
on O
the O
morning O
of O
day O
9 O
, O
subjects O
completed O
a O
24 O
- O
hour O
p O
##k O
study O
after O
receiving O
1000 O
mg O
n O
##r O
at O
t O
= O
0 O
. O
[SEP] O
[CLS] O
differences O
between O
treatment O
groups O
were O
anal O
##ys O
##ed O
by O
analysis O
of O
variance O
. O
[SEP] O
[CLS] O
the O
entire O
data O
set O
was O
best O
described O
by O
a O
one O
- O
compartment O
model O
, O
with O
a O
first O
- O
order O
absorption O
and O
la O
##g O
phase O
. O
[SEP] O
[CLS] O
all O
an O
##ova O
##s O
were O
additionally O
adjusted O
for O
visit O
to O
control O
for O
within O
subject O
var O
##iability O
. O
[SEP] O
[CLS] O
base O
##line O
may O
##o O
and O
pu O
##ca O
##i O
scores O
were O
8 O
. O
0 O
( O
6 O
. O
0 O
- O
9 O
. O
0 O
) O
and O
45 O
( O
35 O
. O
0 O
- O
65 O
. O
0 O
) O
, O
respectively O
. O
[SEP] O
[CLS] O
two O
patients O
with O
radio O
##log O
##ic O
signs O
of O
gas O
##tro O
##par O
##esis O
had O
no O
peak B-PK
c I-PK
##y I-PK
##c I-PK
##los I-PK
##por I-PK
##ine I-PK
levels I-PK
at O
all O
and O
were O
excluded O
from O
the O
correlation O
analysis O
. O
[SEP] O
[CLS] O
din O
##ut O
##ux O
##ima O
##b O
( O
[UNK] O
; O
ch O
##14 O
. O
18 O
) O
, O
a O
mon O
##oc O
##lon O
##al O
anti O
##body O
against O
di O
##sia O
##log O
##ang O
##lio O
##side O
, O
improved O
survival O
as O
part O
of O
post O
- O
consolidation O
therapy O
for O
high O
- O
risk O
ne O
##uro O
##blast O
##oma O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
was O
estimated O
according O
to O
a O
two O
- O
compartment O
open O
model O
. O
[SEP] O
[CLS] O
subsequent O
administration O
of O
na O
##lo O
##xon O
##e O
( O
1 O
mg O
/ O
kg O
, O
i O
. O
v O
. O
) O
significantly O
increased O
ca O
levels O
in O
both O
groups O
. O
[SEP] O
[CLS] O
the O
m O
##olar O
excess O
of O
d O
##b O
##p O
to O
25 O
( O
oh O
) O
d O
##3 O
in O
plasma O
, O
and O
the O
relatively O
rapid O
turnover O
of O
d O
##b O
##p O
indicate O
that O
a O
high O
capacity O
, O
high O
affinity O
, O
and O
dynamic O
transport O
mechanism O
for O
vitamin O
d O
s O
##tero O
##ls O
exists O
in O
rabbit O
plasma O
. O
[SEP] O
[CLS] O
plasma O
concentrations O
that O
were O
below O
the O
lower O
limit O
of O
q O
##uant O
##itation O
were O
set O
to O
zero O
when O
calculating O
summary O
statistics O
for O
plasma O
concentration O
at O
a O
given O
nominal O
time O
point O
, O
except O
when O
a O
single O
value O
fell O
between O
two O
me O
##as O
##urable O
concentrations O
, O
then O
this O
value O
was O
set O
to O
be O
missing O
. O
[SEP] O
[CLS] O
the O
important O
aspect O
of O
the O
study O
is O
the O
effect O
of O
treatment O
with O
the O
so O
##fo O
##s O
##bu O
##vir O
– O
rib O
##avi O
##rin O
combination O
regime O
##n O
on O
the O
c O
##ni O
au B-PK
##c I-PK
levels O
, O
which O
resulted O
in O
a O
reduction O
in O
the O
c O
##ni O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
similar O
physical O
instability O
was O
also O
observed O
in O
real O
- O
time O
ch O
##e O
##q O
##sol O
so O
##lub O
##ility O
ass O
##ay O
. O
[SEP] O
[CLS] O
the O
profile O
is O
dominated O
by O
the O
elimination O
( O
beta O
) O
phase O
with O
a O
half B-PK
- I-PK
life I-PK
of O
5 O
. O
2 O
+ O
- O
0 O
. O
6 O
h O
. O
consequently O
, O
24 O
h O
after O
the O
injection O
( O
approximately O
5 O
half B-PK
- I-PK
life I-PK
) O
97 O
% O
of O
the O
product O
was O
eliminated O
. O
[SEP] O
[CLS] O
vent O
##ila O
##tor O
parameters O
remained O
unchanged O
throughout O
the O
protocol O
. O
[SEP] O
[CLS] O
only O
one O
response O
differed O
significantly O
according O
to O
sex O
: O
the O
47 O
males O
receiving O
da O
##bi O
##gat O
##ran O
were O
more O
sensitive O
to O
he O
##par O
##in O
than O
the O
corresponding O
19 O
females O
( O
p O
< O
0 O
. O
05 O
) O
. O
[SEP] O
[CLS] O
mi O
##rta O
##za O
##pine O
decreases O
s O
##ti O
##mu O
##lator O
##y O
effects O
of O
re O
##box O
##eti O
##ne O
on O
co O
##rt O
##is O
##ol O
, O
ad O
##ren O
##oc O
##ort O
##ico O
##tro O
##pin O
and O
pro O
##la O
##ct O
##in O
secret O
##ion O
in O
healthy O
male O
subjects O
. O
[SEP] O
[CLS] O
exclusion O
criteria O
included O
re O
##ceipt O
of O
any O
transplant O
##ed O
organ O
other O
than O
the O
kidney O
, O
white O
blood O
count O
2 O
. O
8 O
##× O
##10 O
##9 O
/ O
l O
or O
less O
, O
total O
pro O
##gra O
##f O
dose O
for O
24 O
h O
##r O
of O
less O
than O
3 O
mg O
, O
taking O
any O
drug O
interfering O
with O
ta O
##c O
##rol O
##imus O
metabolism O
, O
had O
taken O
sir O
##oli O
##mus O
within O
3 O
months O
before O
screening O
, O
had O
acute O
rejection O
requiring O
anti O
##body O
therapy O
within O
6 O
months O
before O
en O
##rol O
##ment O
, O
had O
been O
treated O
for O
acute O
rejection O
within O
30 O
days O
before O
en O
##rol O
##ment O
, O
or O
any O
gas O
##tro O
##int O
##est O
##inal O
disorder O
that O
may O
have O
affected O
the O
absorption O
of O
ta O
##c O
##rol O
##imus O
. O
[SEP] O
[CLS] O
a O
bio O
##e O
##qui O
##valence O
study O
of O
two O
ta O
##ms O
##ulos O
##in O
sustained O
- O
release O
tablets O
in O
in O
##don O
##esi O
##an O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
the O
recover O
##ies O
of O
the O
anal O
##yte O
and O
is O
were O
determined O
by O
comparing O
the O
peak O
areas O
of O
extracted O
standard O
samples O
with O
the O
peak O
areas O
of O
post O
- O
extraction O
plasma O
blank O
##s O
spike O
##d O
at O
the O
corresponding O
concentrations O
. O
[SEP] O
[CLS] O
pro O
##sta O
##g O
##land O
##in O
e O
##1 O
( O
p O
##ge O
##1 O
) O
was O
administered O
in O
##tra O
##ven O
##ously O
to O
conscious O
be O
##ag O
##les O
and O
the O
plasma O
concentrations O
of O
its O
pulmonary O
meta O
##bol O
##ite O
13 O
, O
14 O
- O
di O
##hy O
##dr O
##o O
- O
15 O
- O
k O
##eto O
- O
p O
##ge O
##1 O
were O
q O
##uant O
##itated O
at O
various O
times O
after O
dos O
##ing O
. O
[SEP] O
[CLS] O
although O
o O
##besity O
was O
found O
to O
be O
associated O
with O
an O
increased O
v B-PK
##1 I-PK
, O
dose O
adjustment O
based O
on O
c O
##l O
##c O
##r O
appears O
to O
be O
more O
important O
than O
patient O
b O
##mi O
. O
[SEP] O
[CLS] O
more O
##over O
, O
the O
sustained O
circulation O
behavior O
of O
r O
##h O
##2 O
- O
lip O
##o O
was O
similar O
to O
that O
of O
p O
##eg O
- O
c O
- O
lip O
##o O
. O
[SEP] O
[CLS] O
β O
- O
el O
##emon O
##ic O
acid O
in O
##hibit O
##s O
the O
growth O
of O
human O
o O
##ste O
##osa O
##rc O
##oma O
through O
end O
##op O
##las O
##mic O
re O
##tic O
##ulum O
( O
er O
) O
stress O
- O
mediated O
per O
##k O
/ O
e O
##if O
##2 O
##α O
/ O
at O
##f O
##4 O
/ O
ch O
##op O
activation O
and O
w O
##nt O
/ O
β O
- O
cat O
##eni O
##n O
signal O
suppression O
. O
[SEP] O
[CLS] O
this O
score O
predicted O
w O
##12 O
failure O
with O
94 O
% O
sensitivity O
, O
versus O
31 O
% O
for O
the O
an O
##rs O
2005 O
algorithm O
. O
[SEP] O
[CLS] O
ma O
##rb O
##of O
##lo O
##xa O
##cin O
was O
not O
detected O
in O
any O
samples O
from O
control O
dogs O
. O
[SEP] O
[CLS] O
influence O
of O
re O
##nal O
imp O
##air O
##ment O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
p O
##har O
##ma O
##co O
##dynamic O
##s O
of O
oral O
da O
##bi O
##gat O
##ran O
et O
##ex O
##ila O
##te O
: O
an O
open O
- O
label O
, O
parallel O
- O
group O
, O
single O
- O
centre O
study O
. O
[SEP] O
[CLS] O
a O
full O
list O
is O
provided O
in O
supplement O
##ary O
material O
d O
. O
[SEP] O
[CLS] O
similarly O
, O
o O
##c O
and O
o O
##xy O
a O
##pi O
were O
associated O
with O
mean O
( O
s O
##d O
) O
s O
##d O
##v O
em B-PK
##ax I-PK
of O
$ O
27 O
. O
95 O
( O
16 O
. O
03 O
) O
and O
$ O
27 O
. O
30 O
( O
17 O
. O
40 O
) O
, O
respectively O
, O
whereas O
mean O
s O
##d O
##v O
em B-PK
##ax I-PK
for O
coarse O
##ly O
and O
finely O
crushed O
or O
##f O
were O
lower O
( O
$ O
17 O
. O
25 O
[ O
$ O
17 O
. O
93 O
] O
and O
$ O
17 O
. O
01 O
[ O
$ O
16 O
. O
39 O
] O
, O
respectively O
) O
, O
and O
o O
##c O
place O
##bo O
was O
the O
lowest O
( O
$ O
0 O
. O
37 O
[ O
$ O
0 O
. O
60 O
] O
) O
. O
[SEP] O
[CLS] O
one O
of O
them O
experienced O
d O
##lt O
in O
the O
form O
of O
grade O
1 O
ex O
##tre O
##mity O
t O
##rem O
##ors O
, O
superior O
limb O
extra O
##py O
##ram O
##idal O
h O
##yper O
##tro O
##pia O
and O
d O
##ys O
##met O
##ria O
; O
grade O
2 O
at O
##ax O
##ia O
, O
confusion O
and O
visual O
hall O
##uc O
##ination O
. O
[SEP] O
[CLS] O
blood O
and O
urine O
were O
collected O
at O
intervals O
over O
8 O
h O
and O
urine O
alone O
for O
a O
further O
16 O
h O
. O
the O
study O
was O
then O
repeated O
in O
nine O
healthy O
volunteers O
using O
in O
##tra O
##ven O
##ous O
and O
oral O
b O
##ume O
##tani O
##de O
2 O
mg O
. O
[SEP] O
[CLS] O
sixteen O
patients O
did O
not O
respond O
to O
c O
##pt O
( O
no O
change O
and O
progressive O
disease O
) O
. O
[SEP] O
[CLS] O
assessing O
bio O
##e O
##qui O
##valence O
of O
generic O
modified O
- O
release O
anti O
##ep O
##ile O
##ptic O
drugs O
. O
[SEP] O
[CLS] O
protein O
concentrations O
were O
measured O
using O
a O
bra O
##dford O
method O
( O
bio O
- O
r O
##ad O
laboratories O
in O
##c O
. O
, O
her O
##cule O
##s O
, O
ca O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
in O
patients O
with O
open O
s O
##tr O
##s O
, O
the O
mean O
au B-PK
##c I-PK
of O
m O
##t O
##x O
in O
c O
##s O
##f O
was O
4 O
. O
44 O
% O
of O
that O
found O
in O
plasma O
, O
while O
in O
patients O
with O
closed O
s O
##tr O
##s O
, O
the O
mean O
was O
61 O
. O
2 O
% O
of O
that O
found O
in O
plasma O
. O
[SEP] O
[CLS] O
a O
75 O
mg O
/ O
kg O
dose O
of O
the O
t O
##ica O
##rc O
##ill O
##in O
component O
was O
used O
. O
[SEP] O
[CLS] O
in O
both O
studies O
, O
all O
participants O
were O
ca O
##uca O
##sian O
and O
the O
majority O
were O
women O
. O
[SEP] O
[CLS] O
body O
weight O
in O
mice O
of O
t O
##p O
##gs O
- O
p O
##n O
was O
almost O
as O
the O
same O
as O
control O
group O
, O
which O
may O
explained O
as O
the O
safety O
of O
the O
t O
##p O
##gs O
- O
p O
##n O
. O
[SEP] O
[CLS] O
we O
conclude O
that O
3 O
concentration O
time O
points O
may O
be O
all O
that O
are O
required O
for O
est O
##imation O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
sufficiently O
accurate O
for O
practical O
purposes O
in O
neon O
##ates O
. O
[SEP] O
[CLS] O
this O
random O
##ized O
, O
multi O
##cent O
##er O
, O
double O
- O
du O
##mmy O
, O
parallel O
- O
group O
phase O
ii O
##i O
trial O
evaluated O
the O
efficacy O
and O
safety O
of O
a O
##pf O
##53 O
##0 O
in O
ch O
##em O
##otherapy O
- O
naive O
and O
non O
- O
naive O
patients O
with O
cancer O
receiving O
single O
- O
day O
administration O
##s O
of O
either O
me O
##c O
or O
he O
##c O
( O
as O
defined O
by O
he O
##sket O
##h O
) O
. O
18 O
patients O
were O
random O
##ized O
to O
receive O
p O
##alo O
##nose O
##tron O
0 O
. O
25 O
mg O
in O
##tra O
##ven O
##ously O
( O
i O
##v O
) O
, O
a O
##pf O
##53 O
##0 O
250 O
mg O
s O
##c O
, O
or O
a O
##pf O
##53 O
##0 O
500 O
mg O
s O
##c O
, O
all O
in O
combination O
with O
matching O
place O
##bo O
and O
standardized O
doses O
of O
de O
##xa O
##met O
##has O
##one O
during O
their O
first O
cycle O
of O
ch O
##em O
##otherapy O
in O
this O
study O
. O
[SEP] O
[CLS] O
the O
contribution O
of O
debris O
##o O
##quin O
##e O
p O
##oly O
##mor O
##phism O
to O
the O
metabolism O
and O
action O
of O
beta O
- O
ad O
##ren O
##oc O
##ept O
##or O
antagonist O
##s O
( O
beta O
- O
block O
##ers O
) O
varies O
widely O
between O
drugs O
. O
[SEP] O
[CLS] O
after O
21 O
days O
of O
exposure O
to O
b O
##d O
##p O
, O
fish O
were O
terminal O
##ly O
an O
##ae O
##st O
##he O
##tised O
using O
et O
##hyl O
3 O
- O
amino O
##ben O
##zo O
##ate O
met O
##hane O
##sul O
##fo O
##nate O
salt O
( O
m O
##s O
- O
222 O
, O
0 O
. O
5 O
g O
/ O
l O
; O
adjusted O
to O
p O
##h O
7 O
. O
5 O
with O
1 O
m O
na O
##oh O
) O
( O
si O
##gma O
, O
pool O
##e O
, O
uk O
; O
ca O
##s O
no O
: O
144 O
- O
55 O
- O
8 O
) O
. O
[SEP] O
[CLS] O
the O
time O
course O
disposition O
of O
14 O
##c O
was O
examined O
over O
a O
48 O
- O
h O
##r O
period O
in O
12 O
- O
and O
18 O
- O
day O
pregnant O
rats O
after O
a O
single O
oral O
dose O
of O
1 O
. O
6 O
mm O
##ol O
[ O
14 O
##c O
] O
d O
##ce O
kg O
- O
1 O
. O
[SEP] O
[CLS] O
the O
cm B-PK
##ax I-PK
of O
br O
##oms O
##ite O
##® O
bid O
was O
similar O
to O
br O
##oms O
##ite O
##® O
q O
##d O
( O
geometric O
means O
ratio O
= O
1 O
. O
04 O
) O
, O
but O
2 O
. O
7 O
- O
, O
and O
2 O
. O
5 O
- O
fold O
greater O
than O
that O
of O
pro O
##len O
##sa O
##® O
, O
and O
il O
##ev O
##ro O
##® O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
##p O
##rog O
##ression O
- O
free O
survival O
( O
p O
##fs O
) O
were O
estimated O
with O
the O
ka O
##p O
##lan O
– O
me O
##ier O
method O
. O
[SEP] O
[CLS] O
quality O
control O
( O
q O
##c O
) O
samples O
were O
prepared O
at O
low O
( O
5 O
ng O
/ O
m O
##l O
) O
, O
medium O
( O
50 O
ng O
/ O
m O
##l O
) O
, O
and O
high O
concentration O
( O
150 O
ng O
/ O
m O
##l O
) O
in O
the O
same O
way O
as O
the O
plasma O
ca O
##li O
##bra O
##tion O
samples O
. O
[SEP] O
[CLS] O
a O
phase O
i O
trial O
was O
designed O
to O
examine O
the O
f O
##eas O
##ibility O
of O
combining O
inter O
##fer O
##on O
and O
tax O
##ol O
with O
in O
##tra O
##per O
##ito O
##nea O
##l O
radio O
##im O
##mu O
##not O
##her O
##ap O
##y O
( O
177 O
##lu O
- O
cc O
##4 O
##9 O
) O
. O
[SEP] O
[CLS] O
the O
addition O
of O
an O
f O
##c O
domain O
, O
human O
i O
##gg O
##1 O
in O
the O
case O
of O
currently O
licensed O
f O
##c O
- O
fusion O
##s O
, O
has O
multiple O
benefits O
in O
construction O
of O
novel O
biological O
agents O
. O
[SEP] O
[CLS] O
additional O
24 O
hours O
collection O
periods O
at O
day O
20 O
– O
21 O
and O
at O
day O
29 O
– O
30 O
were O
needed O
to O
follow O
the O
complete O
profile O
of O
net O
##up O
##ita O
##nt O
ex O
##cre O
##tion O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
p O
##rand O
##ial O
p O
##har O
##ma O
##co O
##dynamic O
properties O
of O
insulin O
de O
##g O
##lude O
##c O
/ O
insulin O
as O
##par O
##t O
in O
children O
, O
adolescent O
##s O
, O
and O
adults O
with O
type O
1 O
diabetes O
. O
[SEP] O
[CLS] O
the O
concentrations O
of O
the O
agent O
were O
found O
to O
be O
considerably O
lower O
in O
the O
brain O
than O
in O
the O
plasma O
. O
[SEP] O
[CLS] O
early O
results O
with O
sir O
##oli O
##mus O
- O
el O
##uti O
##ng O
s O
##ten O
##ts O
have O
demonstrated O
a O
favorable O
outcome O
for O
reducing O
rest O
##eno O
##sis O
post O
co O
##rona O
##ry O
intervention O
. O
[SEP] O
[CLS] O
after O
three O
consecutive O
administration O
##s O
of O
c O
##eti O
##riz O
##ine O
( O
0 O
. O
2 O
mg O
/ O
kg O
body O
weight O
, O
b O
##w O
) O
every O
12 O
##h O
, O
the O
t B-PK
##rough I-PK
plasma I-PK
concentration I-PK
of O
c O
##eti O
##riz O
##ine O
was O
16 O
+ O
- O
4 O
ng O
/ O
m O
##l O
( O
mean O
+ O
- O
s O
##d O
) O
and O
the O
w O
##hea O
##l O
formation O
was O
in O
##hibit O
##ed O
by O
45 O
+ O
- O
23 O
% O
. O
[SEP] O
[CLS] O
in O
this O
species O
, O
there O
was O
rapid O
accumulation O
of O
drug O
in O
all O
tissue O
. O
[SEP] O
[CLS] O
hi O
##v O
plasma O
viral O
load O
( O
co O
##bas O
am O
##p O
##lip O
##re O
##p O
ta O
##q O
##man O
hi O
##v O
- O
1 O
ass O
##ay O
, O
r O
##och O
##e O
diagnostic O
##s O
systems O
, O
lava O
##l O
, O
que O
##be O
##c O
, O
can O
##ada O
) O
was O
measured O
at O
base O
##line O
, O
at O
weeks O
2 O
and O
4 O
, O
then O
every O
4 O
weeks O
throughout O
the O
study O
. O
[SEP] O
[CLS] O
bi O
##so O
##p O
##rol O
##ol O
concentrations O
in O
plasma O
and O
most O
eye O
tissues O
were O
considerably O
higher O
after O
oral O
than O
after O
con O
##junct O
##ival O
treatment O
. O
[SEP] O
[CLS] O
to O
determine O
the O
maximum O
- O
tolerate O
##d O
dose O
, O
toxicity O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
and O
bio O
##log O
##ic O
effects O
of O
g O
##31 O
##39 O
when O
administered O
with O
do O
##x O
##or O
##ubi O
##cin O
and O
c O
##y O
##c O
##lop O
##hos O
##pha O
##mi O
##de O
to O
children O
with O
re O
##lap O
##sed O
solid O
tumors O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
##0 I-PK
- I-PK
48 I-PK
) I-PK
of O
do O
##ce O
##ta O
##xe O
##l O
at O
the O
r O
##p O
##2 O
##d O
of O
once O
- O
weekly O
60 O
- O
mg O
m O
##od O
##rado O
##c O
##00 O
##1 O
capsule O
with O
100 O
- O
mg O
r O
##ito O
##na O
##vir O
was O
1 O
, O
000 O
± O
68 O
##7 O
ng O
/ O
m O
##l O
/ O
hour O
and O
for O
once O
- O
weekly O
60 O
- O
mg O
m O
##od O
##rado O
##c O
##00 O
##6 O
tablet O
with O
100 O
- O
mg O
r O
##ito O
##na O
##vir O
, O
the O
au B-PK
##c I-PK
##0 I-PK
- I-PK
48 I-PK
was O
1 O
, O
79 O
##0 O
± O
81 O
##9 O
ng O
/ O
m O
##l O
/ O
hour O
. O
[SEP] O
[CLS] O
the O
total O
energies O
and O
the O
distances O
of O
hydrogen O
bonds O
of O
the O
four O
op O
##ti O
##mized O
conform O
##ation O
were O
calculated O
( O
table O
1 O
##s O
) O
. O
[SEP] O
[CLS] O
the O
patient O
was O
subsequently O
treated O
off O
- O
study O
with O
another O
four O
courses O
at O
reduced O
dose O
and O
achieved O
a O
complete O
response O
. O
[SEP] O
[CLS] O
mice O
were O
randomly O
divided O
into O
five O
groups O
( O
n O
= O
4 O
) O
. O
[SEP] O
[CLS] O
surface O
area O
( O
s O
##t O
) O
per O
gram O
of O
cardiac O
tissue O
, O
only O
available O
for O
humans O
or O
q O
##uant O
##ifiable O
from O
human O
data O
[ O
36 O
, O
37 O
] O
, O
were O
applied O
to O
mice O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
were O
calculated O
by O
a O
non O
- O
compartment O
method O
using O
win O
##non O
##lin O
6 O
. O
3 O
software O
( O
p O
##har O
- O
sight O
corporation O
, O
sunny O
##vale O
, O
ca O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
cm B-PK
##ax I-PK
increased O
in O
a O
dose O
- O
proportional O
manner O
and O
au B-PK
##c I-PK
##∞ I-PK
increased O
in O
a O
more O
than O
dose O
- O
proportional O
manner O
. O
[SEP] O
[CLS] O
the O
two O
types O
of O
drug O
administration O
were O
used O
alternatively O
with O
the O
same O
patient O
. O
[SEP] O
[CLS] O
ace O
##ty O
##l O
##car O
##ni O
##tine O
( O
con O
, O
4 O
. O
8 O
+ O
- O
1 O
. O
8 O
; O
ch O
##o O
, O
1 O
. O
5 O
+ O
- O
0 O
. O
9 O
mm O
##ol O
( O
kg O
dry O
mass O
( O
d O
. O
m O
. O
) O
) O
( O
- O
1 O
) O
, O
p O
< O
0 O
. O
05 O
) O
and O
ace O
##ty O
##l O
co O
##a O
( O
con O
, O
13 O
. O
2 O
+ O
- O
2 O
. O
3 O
; O
ch O
##o O
, O
6 O
. O
3 O
+ O
- O
0 O
. O
6 O
micro O
##mo O
##l O
( O
kg O
d O
. O
m O
. O
) O
( O
- O
1 O
) O
, O
p O
< O
0 O
. O
05 O
) O
were O
lower O
at O
rest O
, O
whereas O
p O
##yr O
##u O
##vate O
de O
##hy O
##dr O
##ogen O
##ase O
activation O
( O
p O
##dha O
) O
was O
greater O
in O
ch O
##o O
compared O
with O
con O
( O
con O
, O
0 O
. O
78 O
+ O
- O
0 O
. O
07 O
; O
ch O
##o O
, O
1 O
. O
44 O
+ O
- O
0 O
. O
19 O
mm O
##ol O
min O
( O
- O
1 O
) O
( O
kg O
wet O
mass O
( O
w O
. O
m O
. O
) O
) O
( O
- O
1 O
) O
) O
. O
[SEP] O
[CLS] O
part O
3 O
was O
designed O
to O
compare O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
of O
i O
##gu O
##rat O
##imo O
##d O
between O
single O
- O
dose O
and O
multiple O
- O
dose O
administration O
; O
subjects O
were O
divided O
into O
two O
groups O
, O
with O
one O
group O
receiving O
a O
single O
dose O
of O
50 O
mg O
on O
day O
1 O
and O
the O
other O
group O
receiving O
a O
multiple O
dose O
of O
50 O
mg O
, O
once O
every O
day O
, O
until O
a O
stable O
plasma O
concentration O
had O
been O
achieved O
. O
[SEP] O
[CLS] O
the O
limit O
of O
q O
##uant O
##ification O
( O
lo O
##q O
) O
was O
20 O
ng O
/ O
m O
##l O
for O
vitamin O
d O
##3 O
and O
40 O
ng O
/ O
m O
##l O
for O
k O
##1 O
. O
[SEP] O
[CLS] O
relative B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
commercial O
am O
##pic O
##ill O
##in O
formulation O
##s O
in O
man O
. O
[SEP] O
[CLS] O
this O
valid O
##ated O
method O
was O
applied O
for O
an O
open O
label O
, O
balanced O
, O
random O
##ized O
, O
two O
- O
treatment O
, O
two O
period O
, O
two O
sequence O
, O
single O
dose O
, O
crossover O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
study O
comparing O
a O
car O
##bo O
##cist O
##ein O
##e O
capsule O
in O
35 O
healthy O
, O
adult O
, O
human O
subjects O
under O
fast O
##ing O
conditions O
. O
[SEP] O
[CLS] O
preliminary O
data O
of O
the O
phase O
i O
study O
of O
p O
##f O
##l O
( O
c O
##is O
##p O
##lat O
##in O
, O
le O
##uc O
##ovo O
##rin O
and O
5 O
##fu O
) O
and O
mat O
##uz O
##uma O
##b O
( O
at O
doses O
of O
400 O
or O
800 O
mg O
weekly O
) O
in O
advanced O
og O
cancer O
indicate O
good O
to O
##ler O
##ability O
at O
the O
400 O
mg O
dose O
level O
( O
d O
##l O
) O
( O
t O
##rar O
##bach O
et O
al O
, O
2005 O
) O
. O
[SEP] O
[CLS] O
d O
study O
discharge O
, O
mad O
multiple O
ascending O
dose O
, O
r O
random O
##ization O
, O
s O
screening O
, O
sad O
single O
ascending O
dose O
, O
s O
##dd O
spray O
dried O
di O
##sper O
##sion O
, O
w O
wash O
##out O
( O
g O
##if O
74 O
k O
##b O
) O
[SEP] O
[CLS] O
card O
##iovascular O
safety O
results O
indicated O
no O
instances O
of O
a O
q O
##t O
##c O
##f O
value O
exceeding O
500 O
m O
##se O
##c O
. O
[SEP] O
[CLS] O
lo O
##iz O
##ou O
et O
al O
. O
[ O
20 O
] O
developed O
a O
detailed O
p O
##b O
##p O
##k O
in O
the O
rat O
with O
the O
ha O
##lot O
##hane O
metabolism O
described O
by O
a O
4 O
parameter O
function O
that O
included O
both O
mi O
##cha O
##eli O
##s O
- O
men O
##ten O
and O
in O
##act O
##ivation O
components O
. O
[SEP] O
[CLS] O
im O
##mu O
##no O
##genic O
##ity O
was O
measured O
by O
the O
incidence O
of O
ad O
##as O
, O
including O
neutral O
##ising O
antibodies O
( O
na O
##bs O
) O
. O
[SEP] O
[CLS] O
a O
phase O
i O
trial O
of O
mon O
##oc O
##lon O
##al O
anti O
##body O
m O
##19 O
##5 O
in O
acute O
my O
##elo O
##gen O
##ous O
le O
##uke O
##mia O
: O
specific O
bone O
ma O
##rrow O
targeting O
and O
internal O
##ization O
of O
radio O
##nu O
##c O
##lide O
. O
[SEP] O
[CLS] O
the O
multiple O
dose O
phase O
showed O
increasing O
plasma O
levels O
up O
to O
7 O
days O
after O
the O
start O
of O
administration O
, O
and O
sustained O
high O
concentrations O
during O
the O
all O
administration O
period O
. O
[SEP] O
[CLS] O
to O
examine O
extinction O
s O
##pect O
##ra O
, O
we O
used O
a O
u O
##v O
– O
v O
##is O
s O
##pect O
##rop O
##hot O
##ometer O
( O
u O
##v O
– O
260 O
##0 O
, O
s O
##hima O
##d O
##zu O
) O
. O
[SEP] O
[CLS] O
subject O
exclusion O
criteria O
were O
: O
( O
a O
) O
patients O
with O
significant O
he O
##pa O
##tic O
disease O
, O
un O
##con O
##tro O
##lled O
h O
##yper O
##tens O
##ion O
/ O
diabetes O
me O
##lli O
##tus O
( O
b O
) O
patients O
on O
con O
##com O
##ita O
##nt O
drug O
therapy O
which O
is O
likely O
to O
increase O
or O
decrease O
c O
##y O
##c O
##los O
##por O
##ine O
levels O
or O
enhance O
its O
ne O
##ph O
##rot O
##ox O
##icit O
##y O
( O
c O
) O
patients O
with O
severe O
or O
unstable O
an O
##gin O
##a O
p O
##ector O
##is O
within O
the O
previous O
one O
month O
( O
d O
) O
history O
of O
h O
##yper O
##sen O
##si O
##ti O
##vity O
to O
the O
trial O
medication O
( O
e O
) O
doubts O
on O
patient O
compliance O
. O
[SEP] O
[CLS] O
this O
trial O
is O
funded O
by O
the O
centre O
for O
collaborative O
drug O
research O
at O
the O
university O
of O
to O
##ron O
##to O
, O
and O
will O
be O
conducted O
in O
accordance O
with O
the O
ethical O
principles O
outlined O
by O
the O
can O
##adia O
##n O
t O
##ri O
- O
council O
policy O
statement O
: O
ethical O
conduct O
for O
research O
involving O
humans O
##5 O
##9 O
and O
the O
declaration O
of O
he O
##ls O
##ink O
##i O
. O
[SEP] O
[CLS] O
[ O
α O
] O
d O
##20 O
( O
ch O
##c O
##l O
##3 O
; O
c O
= O
0 O
. O
02 O
##8 O
) O
: O
35 O
. O
71 O
. O
[SEP] O
[CLS] O
the O
au B-PK
##c I-PK
was O
also O
slightly O
higher O
in O
cycle O
2 O
( O
mean O
1689 O
μ O
##g O
h O
m O
##l O
##− O
##1 O
, O
range O
49 O
##2 O
– O
625 O
##7 O
μ O
##g O
h O
m O
##l O
##− O
##1 O
) O
than O
in O
cycle O
1 O
( O
mean O
108 O
##7 O
μ O
##g O
h O
m O
##l O
##− O
##1 O
, O
range O
34 O
##3 O
– O
240 O
##8 O
μ O
##g O
h O
m O
##l O
##− O
##1 O
; O
p O
= O
0 O
. O
04 O
) O
. O
[SEP] O
[CLS] O
the O
z O
##eta O
potential O
method O
was O
used O
to O
confirm O
the O
optimal O
ratio O
for O
formation O
of O
ins O
- O
s O
##d O
- O
com O
##p O
. O
[SEP] O
[CLS] O
human O
a O
##po O
##a O
- O
i O
isolated O
as O
previously O
described O
[ O
25 O
] O
was O
labeled O
with O
ale O
##xa O
- O
64 O
##7 O
as O
per O
the O
manufacturer O
’ O
s O
instructions O
( O
in O
##vi O
##tro O
##gen O
) O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
showed O
large O
inter O
##ind O
##iv O
##id O
##ual O
variations O
, O
with O
a O
mean O
half B-PK
- I-PK
life I-PK
of O
2 O
h O
and O
a O
mean O
volume B-PK
of I-PK
distribution I-PK
of O
0 O
. O
36 O
l O
/ O
kg O
. O
[SEP] O
[CLS] O
1 O
8 O
3 O
3 O
$ O
$ O
\ O
end O
{ O
document O
} O
t O
##b O
##v O
, O
female O
= O
0 O
. O
35 O
##6 O
##1 O
##∗ O
##he O
##ight O
+ O
0 O
. O
03 O
##30 O
##8 O
##∗ O
##weight O
+ O
0 O
. O
1833 O
##where O
height O
and O
weight O
must O
be O
in O
units O
of O
meter O
and O
k O
##ilo O
##gram O
but O
are O
considered O
in O
the O
formula O
as O
unit O
- O
less O
quantities O
. O
[SEP] O
[CLS] O
the O
time O
course O
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
plasma O
and O
urine O
after O
oral O
administration O
of O
a O
single O
dose O
of O
( O
1 O
- O
14 O
##c O
) O
as O
##cor O
##bic O
acid O
has O
been O
followed O
in O
healthy O
non O
##smo O
##king O
male O
volunteers O
. O
[SEP] O
[CLS] O
the O
study O
was O
performed O
in O
eight O
patients O
with O
re O
##current O
g O
##lio O
##blast O
##oma O
, O
all O
of O
whom O
had O
previously O
undergone O
surgery O
and O
been O
treated O
with O
radio O
##ther O
##ap O
##y O
and O
ch O
##em O
##otherapy O
, O
who O
received O
50 O
mg O
of O
da O
##uno O
##x O
##ome O
as O
a O
1 O
- O
h O
in O
##fusion O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
of O
a O
new O
re O
##comb O
##ina O
##nt O
er O
##yt O
##hr O
##op O
##oi O
##eti O
##n O
preparation O
( O
e O
##po O
##eti O
##n O
z O
##eta O
, O
ca O
##s O
60 O
##48 O
##0 O
##2 O
- O
70 O
- O
2 O
) O
compared O
to O
a O
reference O
product O
( O
e O
##po O
##eti O
##n O
al O
##fa O
, O
ca O
##s O
113 O
##42 O
##7 O
- O
24 O
- O
0 O
) O
were O
analyzed O
after O
a O
single O
in O
##tra O
##ven O
##ous O
b O
##ol O
##us O
injection O
of O
10 O
, O
000 O
i O
##u O
in O
a O
two O
- O
period O
crossover O
design O
in O
24 O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
in O
bone O
marker O
assessments O
, O
33 O
of O
38 O
( O
87 O
% O
) O
and O
26 O
of O
34 O
( O
76 O
% O
) O
had O
decreases O
in O
u O
##rina O
##ry O
n O
- O
te O
##lop O
##eptide O
or O
bone O
- O
specific O
al O
##kal O
##ine O
p O
##hos O
##pha O
##tase O
levels O
, O
respectively O
. O
[SEP] O
[CLS] O
clinical O
##ly O
, O
fever O
resolved O
within O
3 O
days O
of O
g O
##rn O
##x O
administration O
and O
c O
- O
reactive O
protein O
levels O
returned O
to O
normal O
14 O
days O
after O
administration O
. O
[SEP] O
[CLS] O
median O
p O
##fs O
was O
62 O
days O
( O
95 O
% O
c O
##i O
, O
57 O
to O
177 O
) O
in O
the O
300 O
mg O
group O
and O
34 O
days O
( O
95 O
% O
c O
##i O
, O
33 O
to O
37 O
) O
in O
the O
100 O
mg O
group O
. O
[SEP] O
[CLS] O
the O
values O
for O
the O
distribution B-PK
rate I-PK
constant I-PK
##s I-PK
as O
well O
as O
for O
the O
elimination B-PK
half I-PK
- I-PK
lives I-PK
of O
the O
two O
en O
##anti O
##omer O
##s O
were O
similar O
but O
the O
au B-PK
##c I-PK
of O
the O
s O
- O
( O
+ O
) O
- O
en O
##anti O
##omer O
was O
always O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
01 O
) O
than O
that O
of O
the O
opposite O
en O
##anti O
##omer O
. O
[SEP] O
[CLS] O
g O
##c O
and O
m O
##c O
transcription O
##al O
activity O
was O
tested O
by O
l O
##uc O
##ifer O
##ase O
ass O
##ay O
in O
c O
##v O
- O
1 O
cells O
trans O
##fected O
with O
human O
g O
##c O
or O
m O
##c O
receptor O
expression O
vectors O
. O
[SEP] O
[CLS] O
the O
most O
common O
nervous O
system O
disorder O
was O
headache O
, O
with O
a O
total O
of O
15 O
mild O
tea O
##es O
reported O
by O
11 O
subjects O
overall O
( O
19 O
. O
6 O
% O
) O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
b O
##c O
##p O
in O
man O
following O
oral O
administration O
. O
[SEP] O
[CLS] O
comparison O
of O
the O
release O
profile O
and O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
intact O
and O
fragment O
##ed O
de O
##xa O
##met O
##has O
##one O
in O
##tra O
##vi O
##tre O
##al O
imp O
##lants O
in O
rabbit O
eyes O
. O
[SEP] O
[CLS] O
this O
is O
particularly O
true O
with O
c O
##d O
##47 O
, O
which O
is O
expressed O
on O
virtually O
every O
cell O
. O
[SEP] O
[CLS] O
to O
test O
the O
hypothesis O
that O
oral O
administration O
of O
a O
##c O
might O
have O
a O
beneficial O
effect O
on O
the O
outcome O
of O
severe O
malaria O
, O
we O
used O
the O
model O
of O
e O
##c O
##m O
caused O
by O
p O
##las O
##mo O
##dium O
be O
##rg O
##he O
##i O
an O
##ka O
( O
p O
##ba O
) O
infection O
in O
c O
##5 O
##7 O
##b O
##l O
/ O
6 O
mice O
. O
[SEP] O
[CLS] O
the O
results O
showed O
that O
the O
total O
concentration O
of O
all O
the O
anal O
##yte O
##s O
( O
range O
, O
200 O
– O
2000 O
ng O
/ O
m O
##l O
) O
in O
human O
plasma O
samples O
was O
stable O
throughout O
the O
duration O
of O
a O
typical O
sequence O
of O
ch O
##roma O
##to O
##graphic O
analyses O
and O
for O
at O
least O
two O
months O
of O
storage O
at O
− O
##80 O
##° O
##c O
as O
well O
as O
after O
two O
cycles O
of O
th O
##aw O
- O
freeze O
. O
[SEP] O
[CLS] O
safety O
data O
were O
presented O
in O
ta O
##bula O
##r O
format O
and O
summarized O
descriptive O
##ly O
, O
where O
appropriate O
. O
[SEP] O
[CLS] O
however O
, O
the O
most O
significant O
increase O
in O
plasma O
oxygen O
transport O
took O
place O
in O
patients O
supplemented O
with O
l O
##y O
##cos O
##ome O
formulation O
of O
d O
##ha O
when O
median O
##s O
of O
plasma O
oxygen O
transport O
spike O
##d O
by O
45 O
##4 O
points O
. O
[SEP] O
[CLS] O
m O
##z O
##mine O
software O
v O
##2 O
. O
2 O
( O
ok O
##ina O
##wa O
institute O
of O
science O
and O
technology O
) O
was O
used O
to O
identify O
##fe O
##ature O
##s O
characterized O
by O
retention O
time O
and O
m O
/ O
z O
from O
each O
l O
##c O
/ O
m O
##s O
run O
and O
to O
assign O
##amp O
##lit O
##udes O
to O
these O
features O
based O
on O
integration O
of O
the O
ion O
current O
values O
( O
37 O
) O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
tissue O
distribution O
of O
q O
##3 O
##g O
is O
limited O
. O
[SEP] O
[CLS] O
concentrations O
of O
pre O
##dn O
##is O
##olo O
##ne O
and O
co O
##rt O
##is O
##ol O
in O
plasma O
over O
a O
24 O
- O
h O
##r O
test O
period O
were O
measured O
by O
high O
- O
performance O
liquid O
ch O
##roma O
##tography O
. O
[SEP] O
[CLS] O
the O
greater O
negative O
bias O
found O
for O
the O
latter O
three O
estimates O
of O
car O
##bo O
##p O
##lat O
##in O
clearance B-PK
could O
result O
in O
under O
##dos O
##ing O
of O
car O
##bo O
##p O
##lat O
##in O
. O
[SEP] O
[CLS] O
the O
blood O
sample O
was O
collected O
at O
2 O
, O
5 O
, O
15 O
, O
and O
30 O
min O
as O
well O
as O
1 O
, O
2 O
, O
4 O
, O
and O
6 O
h O
post O
- O
dose O
, O
and O
a O
single O
blood O
sample O
was O
collected O
from O
a O
single O
mouse O
. O
[SEP] O
[CLS] O
still O
, O
all O
strains O
were O
estimated O
to O
have O
a O
greater O
metabolic O
flux O
through O
oxidation O
compared O
with O
g O
##lut O
##ath O
##ione O
con O
##ju O
##gation O
; O
median O
estimates O
for O
their O
ratio O
varied O
about O
30 O
- O
fold O
( O
from O
620 O
to O
19 O
, O
000 O
) O
. O
[SEP] O
[CLS] O
this O
treatment O
cycle O
was O
repeated O
every O
4 O
weeks O
until O
disease O
progression O
or O
an O
unacceptable O
toxicity O
was O
observed O
. O
[SEP] O
[CLS] O
there O
were O
no O
dose O
- O
limiting O
toxic O
##ities O
( O
d O
##lts O
) O
in O
co O
##hor O
##ts O
1 O
- O
3 O
. O
[SEP] O
[CLS] O
after O
drying O
the O
organic O
layer O
over O
sodium O
su O
##lf O
##ate O
, O
the O
##vo O
##lat O
##iles O
were O
removed O
under O
reduced O
pressure O
, O
fur O
##nish O
##ing O
the O
product O
##as O
yellowish O
oil O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
analysis O
revealed O
first O
- O
order O
kinetic O
##s O
for O
the O
clearance B-PK
of O
a O
##po O
##b O
- O
48 O
in O
d O
< O
1 O
. O
00 O
##6 O
g O
/ O
m O
##l O
fraction O
##s O
, O
but O
zero O
- O
order O
kinetic O
##s O
for O
a O
##po O
##b O
- O
100 O
clearance B-PK
. O
[SEP] O
[CLS] O
m O
##or O
##phine O
was O
administered O
in O
a O
series O
of O
b O
##ol O
##us O
doses O
until O
p O
##aco O
##2 O
was O
elevated O
greater O
than O
50 O
mm O
h O
##g O
. O
[SEP] O
[CLS] O
fortification O
of O
common O
salt O
with O
iron O
: O
effect O
of O
chemical O
add O
##itive O
##s O
on O
stability O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
with O
the O
recent O
findings O
that O
clinical O
outcomes O
are O
related O
to O
c O
##ep O
##m O
au B-PK
##c I-PK
, O
further O
data O
are O
needed O
regarding O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
c O
##y O
##c O
##lop O
##hos O
##pha O
##mi O
##de O
and O
relevant O
meta O
##bol O
##ites O
in O
an O
##ep O
##hr O
##ic O
children O
. O
[SEP] O
[CLS] O
the O
e O
##2 O
/ O
e O
##1 O
ratio O
increased O
from O
the O
post O
##men O
##op O
##aus O
##al O
values O
lower O
than O
0 O
. O
2 O
found O
before O
the O
application O
of O
patch O
7 O
##d O
to O
average O
values O
of O
0 O
. O
67 O
, O
i O
. O
e O
. O
, O
to O
values O
that O
are O
normally O
found O
during O
the O
fertile O
life O
of O
the O
woman O
. O
[SEP] O
[CLS] O
s O
##r O
is O
considered O
advantage O
##ous O
to O
i O
##r O
for O
the O
chronic O
treatment O
of O
h O
##yper O
##tensive O
patients O
. O
[SEP] O
[CLS] O
response O
to O
met O
##had O
##one O
maintenance O
treatment O
is O
associated O
with O
the O
my O
##oc O
##d O
and O
g O
##rm O
##6 O
genes O
. O
[SEP] O
[CLS] O
the O
ca O
##li O
##bra O
##tion O
curve O
was O
obtained O
by O
plotting O
the O
ratio O
of O
the O
ch O
##roma O
##to O
##graphic O
peak O
area O
( O
met O
##form O
##in O
h O
##c O
##l O
) O
versus O
concentration O
of O
met O
##form O
##in O
h O
##c O
##l O
. O
[SEP] O
[CLS] O
however O
, O
limited O
progress O
has O
been O
made O
##in O
developing O
m O
##s O
##n O
- O
based O
multi O
##mo O
##dal O
##ity O
imaging O
agents O
to O
image O
tumors O
. O
[SEP] O
[CLS] O
concentration O
- O
effect O
and O
time O
- O
course O
studies O
were O
performed O
in O
the O
presence O
of O
free O
l O
##y O
, O
s O
##f O
n O
##ps O
, O
and O
s O
##f O
- O
l O
##y O
n O
##ps O
. O
[SEP] O
[CLS] O
statistical O
analysis O
was O
performed O
using O
k O
##rus O
##kal O
– O
wall O
##is O
one O
- O
way O
analysis O
of O
variance O
. O
[SEP] O
[CLS] O
following O
##eth O
##yl O
ace O
##tate O
extraction O
and O
re O
##con O
##st O
##itution O
with O
50 O
: O
50 O
met O
##han O
##ol O
/ O
water O
( O
v O
/ O
v O
) O
used O
for O
am O
##s O
analysis O
( O
described O
below O
) O
, O
the O
recovery O
was O
51 O
##± O
10 O
% O
( O
n O
= O
3 O
) O
as O
determined O
by O
am O
##s O
. O
[SEP] O
[CLS] O
the O
full O
co O
##var O
##iate O
model O
including O
all O
plausible O
co O
##var O
##iate O
##s O
included O
in O
a O
single O
step O
showed O
no O
impact O
on O
s O
##ym O
##00 O
##4 O
exposure O
of O
age O
, O
as O
##ian O
race O
, O
re O
##nal O
and O
he O
##pa O
##tic O
function O
, O
tumor O
type O
and O
previous O
anti O
- O
e O
##g O
##f O
##r O
treatments O
. O
[SEP] O
[CLS] O
these O
results O
suggest O
that O
i O
##p O
injection O
might O
decrease O
the O
systemic O
toxicity O
of O
p O
##ac O
##lit O
##ax O
##el O
. O
[SEP] O
[CLS] O
the O
( O
au B-PK
##c I-PK
##0 I-PK
- I-PK
in I-PK
##f I-PK
) O
and O
c O
##30 O
##s O
of O
c O
##11 O
##8 O
##p O
at O
50 O
mg O
/ O
kg O
in O
rats O
and O
6 O
mg O
/ O
kg O
in O
dogs O
, O
and O
the O
c O
##2 O
##min O
of O
c O
##11 O
##8 O
at O
6 O
mg O
/ O
kg O
in O
dogs O
increased O
less O
than O
the O
dos O
##age O
increase O
, O
suggested O
non O
##linear O
p O
##har O
##ma O
##co O
##kin O
##etic O
occurred O
at O
high O
dose O
. O
[SEP] O
[CLS] O
in O
the O
new O
era O
of O
effective O
maintenance O
im O
##mu O
##nos O
##up O
##press O
##ion O
, O
a O
limited O
dos O
##ing O
regime O
##n O
of O
da O
##c O
##li O
##zu O
##ma O
##b O
may O
be O
desired O
, O
practical O
and O
economical O
. O
[SEP] O
[CLS] O
the O
model O
was O
developed O
using O
a O
three O
- O
step O
approach O
involving O
bay O
##esi O
##an O
est O
##imation O
of O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
selection O
of O
co O
##var O
##iate O
##s O
by O
principal O
component O
analysis O
, O
and O
final O
selection O
of O
co O
##var O
##iate O
##s O
by O
step O
##wise O
multiple O
linear O
re O
##gression O
. O
[SEP] O
[CLS] O
ass O
##ay O
linear O
##ity O
was O
verified O
for O
v O
##rd O
at O
a O
concentration O
range O
of O
3 O
– O
350 O
ng O
/ O
m O
##l O
with O
re O
##gression O
coefficients O
( O
r O
##2 O
) O
of O
0 O
. O
99 O
##6 O
and O
0 O
. O
99 O
##4 O
for O
v O
##rd O
. O
[SEP] O
[CLS] O
the O
final O
model O
was O
able O
to O
accurately O
describe O
c O
##ef O
##uro O
##xi O
##me O
exposure O
after O
b O
##ol O
##us O
and O
extended O
in O
##fusion O
##s O
for O
the O
literature O
c O
##t O
curves O
. O
[SEP] O
[CLS] O
do O
##pa O
##mine O
concentrations O
were O
all O
below O
the O
limit O
of O
detection O
. O
[SEP] O
[CLS] O
ne O
##vir O
##ap O
##ine O
( O
n O
##v O
##p O
) O
is O
a O
key O
component O
of O
anti O
##ret O
##rov O
##ira O
##l O
prop O
##hyl O
##ax O
##is O
and O
treatment O
for O
neon O
##ates O
. O
[SEP] O
[CLS] O
we O
also O
compared O
se O
##ns O
##iti O
##vi O
##ties O
and O
specific O
##ities O
by O
gender O
, O
using O
an O
interaction O
term O
in O
generalized O
est O
##imating O
equations O
with O
a O
bin O
##omi O
##al O
distribution O
to O
account O
for O
repeated O
observations O
. O
[SEP] O
[CLS] O
briefly O
, O
each O
p O
##c O
##r O
reaction O
contained O
1 O
μ O
##l O
of O
d O
##na O
template O
and O
15 O
pm O
of O
each O
prime O
##r O
as O
well O
as O
2 O
μ O
##l O
of O
5 O
##× O
hot O
fire O
##pole O
##va O
##green O
q O
##p O
##c O
##r O
mix O
plus O
in O
a O
final O
volume O
of O
10 O
μ O
##l O
. O
[SEP] O
[CLS] O
the O
t O
##ci O
was O
given O
by O
a O
ha O
##rva O
##rd O
22 O
pump O
controlled O
by O
s O
##tan O
##pu O
##mp O
software O
running O
on O
a O
personal O
computer O
. O
[SEP] O
[CLS] O
protein O
##ase O
k O
l O
##ys O
##is O
buffer O
was O
prepared O
by O
adding O
2 O
% O
( O
v O
/ O
v O
) O
protein O
##ase O
k O
( O
life O
technologies O
car O
##ls O
##bad O
, O
ca O
) O
to O
epic O
##ent O
##re O
tissue O
and O
cell O
l O
##ys O
##is O
solution O
for O
master O
##pur O
##e O
kit O
( O
epic O
##ent O
##re O
, O
mad O
##ison O
, O
w O
##i O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
the O
major O
pathways O
of O
metabolism O
of O
delta O
4 O
- O
v O
##pa O
were O
found O
to O
be O
est O
##er O
g O
##lu O
##cu O
##ron O
##ide O
formation O
and O
beta O
- O
oxidation O
, O
whereas O
o O
##me O
##ga O
- O
and O
( O
o O
##me O
##ga O
- O
1 O
) O
- O
oxidation O
processes O
were O
of O
minor O
quantitative O
importance O
. O
[SEP] O
[CLS] O
in O
urine O
, O
the O
p O
##hage O
survival O
was O
decreased O
by O
44 O
% O
after O
5 O
min O
of O
in O
##cu O
##bation O
( O
p O
= O
0 O
. O
00 O
##4 O
) O
. O
[SEP] O
[CLS] O
the O
final O
concentration O
of O
t O
##rc O
##10 O
##5 O
( O
f O
##ab O
) O
- O
s O
##h O
was O
found O
##to O
be O
about O
1 O
. O
7 O
mg O
/ O
m O
##l O
( O
[UNK] O
μ O
##l O
) O
. O
[SEP] O
[CLS] O
the O
scan O
showed O
maximum O
absorb O
##ance O
at O
34 O
##1 O
nm O
, O
which O
was O
selected O
as O
the O
working O
##wave O
##len O
##gth O
for O
the O
detector O
of O
hp O
##l O
##c O
. O
[SEP] O
[CLS] O
this O
observation O
suggests O
that O
the O
killing O
function O
with O
the O
greatest O
p O
##har O
##ma O
##co O
##dy O
##ami O
##c O
impact O
for O
da O
##pt O
##omy O
##cin O
is O
the O
in O
##hibition O
of O
the O
probability O
of O
successful O
replication O
. O
[SEP] O
[CLS] O
the O
best O
anti O
##tum O
##or O
activity O
, O
with O
more O
than O
50 O
% O
of O
treated O
animals O
cured O
, O
was O
achieved O
with O
2 O
lo O
##core O
##gion O
##al O
treatments O
of O
in O
##tra O
##per O
##ito O
##nea O
##lly O
growing O
tumors O
on O
days O
2 O
and O
9 O
. O
[SEP] O
[CLS] O
the O
mean O
n O
##tz O
mi O
##c O
for O
my O
##co O
##ba O
##cter O
##ium O
tuberculosis O
is O
##olate O
##s O
was O
12 O
. O
3 O
μ O
##g O
/ O
m O
##l O
; O
the O
mean O
n O
##tz O
maximum B-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
in I-PK
plasma I-PK
was O
10 O
. O
2 O
μ O
##g O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
these O
are O
largely O
a O
result O
of O
poor O
c O
##d O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
, O
particularly O
in O
brain O
since O
hp O
- O
β O
- O
c O
##d O
does O
not O
effectively O
cross O
the O
blood O
- O
brain O
barrier O
. O
[SEP] O
[CLS] O
these O
samples O
were O
th O
##awed O
on O
the O
day O
of O
testing O
and O
run O
together O
with O
freshly O
prepared O
ca O
##li O
##bra O
##tion O
standards O
and O
quality O
controls O
and O
the O
values O
were O
calculated O
from O
the O
resulting O
ca O
##li O
##bra O
##tion O
curve O
obtained O
from O
the O
ca O
##li O
##bra O
##tion O
standards O
. O
[SEP] O
[CLS] O
m O
##r O
- O
trans O
##fected O
fi O
##bro O
##blast O
cells O
internal O
##ize O
m O
##fe O
##c O
##p O
##1 O
as O
revealed O
by O
flow O
c O
##yt O
##ome O
##try O
and O
con O
##fo O
##cal O
micro O
##sco O
##py O
. O
[SEP] O
[CLS] O
in O
addition O
, O
s O
##ds O
were O
prepared O
with O
or O
without O
amino O
##c O
##lay O
, O
a O
p O
##h O
m O
##od O
##ulator O
, O
at O
different O
weight O
ratios O
. O
[SEP] O
[CLS] O
administration O
of O
hp O
##c O
by O
s O
##c O
injection O
of O
1 O
. O
1 O
m O
##l O
( O
275 O
mg O
) O
via O
auto O
##in O
##ject O
##or O
is O
bio O
##e O
##qui O
##valent O
to O
im O
injection O
of O
1 O
. O
0 O
m O
##l O
( O
250 O
mg O
) O
. O
[SEP] O
[CLS] O
we O
conclude O
that O
the O
disposition O
kinetic O
##s O
of O
c O
##y O
##c O
##los O
##por O
##in O
in O
patients O
with O
c O
##ro O
##hn O
' O
s O
disease O
are O
comparable O
to O
those O
of O
other O
groups O
, O
whereas O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
may O
be O
decreased O
. O
[SEP] O
[CLS] O
it O
was O
found O
that O
the O
lower O
sa O
##lic O
##yla O
##te O
clearance B-PK
in O
fi O
##c O
cats O
was O
due O
in O
part O
to O
a O
decreased O
metabolism O
in O
the O
disease O
state O
and O
also O
involved O
slower O
drug O
elimination O
at O
the O
higher O
plasma O
concentrations O
secondary O
to O
the O
more O
extensive O
absorption O
of O
the O
in O
##tra O
##ves O
##ical O
dose O
. O
( O
abstract O
t O
##runcated O
at O
250 O
words O
) O
[SEP] O
[CLS] O
detection O
was O
performed O
using O
positive O
m O
##rm O
mode O
on O
a O
t O
##ur O
##bo O
##ions O
##pra O
##y O
source O
. O
[SEP] O
[CLS] O
among O
the O
36 O
enrolled O
subjects O
, O
34 O
completed O
the O
study O
( O
mean O
[ O
range O
] O
age O
, O
28 O
. O
6 O
[ O
23 O
- O
49 O
] O
y O
; O
mean O
[ O
range O
] O
weight O
, O
66 O
. O
4 O
[ O
52 O
. O
2 O
- O
78 O
. O
7 O
] O
kg O
) O
. O
[SEP] O
[CLS] O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
did O
not O
differ O
for O
the O
various O
dos O
##ing O
volumes O
. O
[SEP] O
[CLS] O
therapeutic O
regime O
##ns O
( O
m O
##ox O
##if O
##lo O
##xa O
##cin O
: O
peak B-PK
, O
4 O
. O
5 O
micro O
g O
/ O
m O
##l O
; O
half B-PK
- I-PK
life I-PK
[ I-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
] I-PK
, O
12 O
h O
; O
and O
le O
##vo O
##f O
##lo O
##xa O
##cin O
: O
peak B-PK
, O
6 O
micro O
g O
/ O
m O
##l O
; O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
, O
6 O
h O
) O
were O
tested O
against O
two O
flu O
##oro O
##quin O
##olo O
##ne O
- O
susceptible O
is O
##olate O
##s O
( O
strains O
79 O
and O
at O
##cc O
49 O
##6 O
##19 O
) O
and O
k O
##d O
##21 O
##38 O
and O
k O
##d O
##21 O
##39 O
( O
par O
##c O
and O
g O
##yra O
mutant O
##s O
, O
respectively O
, O
of O
at O
##cc O
49 O
##6 O
##19 O
) O
. O
[SEP] O
[CLS] O
over O
300 O
plasma O
samples O
were O
analyzed O
by O
this O
method O
without O
any O
significant O
loss O
of O
resolution O
. O
[SEP] O
[CLS] O
v O
##ita O
##co O
##xi O
##b O
and O
internal O
standard O
( O
is O
, O
c O
##ele O
##co O
##xi O
##b O
) O
were O
detected O
under O
the O
multiple O
- O
reaction O
monitoring O
mode O
by O
mass O
s O
##pect O
##rome O
##ter O
with O
es O
##i O
+ O
( O
m O
/ O
z O
34 O
##7 O
. O
9 O
/ O
26 O
##9 O
. O
03 O
for O
v O
##ita O
##co O
##xi O
##b O
and O
m O
/ O
z O
38 O
##2 O
. O
0 O
/ O
36 O
##2 O
. O
0 O
for O
is O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
this O
patient O
received O
maintenance O
parent O
##eral O
fluid O
therapy O
, O
likely O
mask O
##ing O
the O
rise O
in O
ha O
##ema O
##to O
##c O
##rit O
usually O
seen O
in O
association O
with O
such O
a O
reduction O
in O
plasma O
album O
##in O
. O
[SEP] O
[CLS] O
maximum O
decrease O
and O
level O
##ing O
of O
l O
##ymph O
##ocytes O
concentrations O
occurred O
within O
hours O
of O
the O
onset O
of O
p O
##nt O
##22 O
##5 O
##8 O
in O
##fusion O
. O
[SEP] O
[CLS] O
the O
disposition O
of O
h O
- O
z O
##t O
/ O
g O
##4 O
- O
mm O
##ae O
was O
studied O
in O
c O
##yn O
##omo O
##l O
##gus O
monkey O
since O
this O
model O
is O
clinical O
##ly O
relevant O
due O
to O
h O
- O
z O
##t O
/ O
g O
##4 O
specific O
binding O
to O
monkey O
r O
##on O
. O
[SEP] O
[CLS] O
this O
study O
consisted O
of O
an O
initial O
dose O
- O
es O
##cal O
##ation O
and O
subsequent O
##ex O
##pan O
##sion O
phase O
. O
[SEP] O
[CLS] O
the O
m O
##ox O
##if O
##lo O
##xa O
##cin O
mi O
##c O
distribution O
was O
from O
the O
same O
234 O
is O
##olate O
##s O
from O
rod O
##rig O
##ue O
##z O
et O
al O
[ O
35 O
] O
. O
[SEP] O
[CLS] O
the O
meal O
accompanying O
ten O
##of O
##ov O
##ir O
/ O
em O
##tric O
##ita O
##bine O
/ O
r O
##il O
##pi O
##vir O
##ine O
intake O
satisfied O
food O
requirements O
in O
81 O
% O
of O
cases O
. O
[SEP] O
[CLS] O
the O
select O
##ivity O
of O
the O
method O
was O
evaluated O
by O
analyzing O
blank O
plasma O
and O
plasma O
samples O
collected O
from O
six O
rats O
to O
investigate O
the O
potential O
interference O
##s O
at O
the O
peak O
region O
of O
anal O
##yte O
##s O
and O
i O
. O
s O
. O
using O
the O
proposed O
extraction O
procedure O
and O
analytical O
conditions O
. O
[SEP] O
[CLS] O
comparative O
study O
of O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
once O
daily O
and O
continuous O
in O
##tra O
##per O
##ito O
##nea O
##l O
net O
##il O
##my O
##cin O
in O
continuous O
am O
##bula O
##tory O
per O
##ito O
##nea O
##l O
dial O
##ys O
##is O
patients O
with O
per O
##ito O
##ni O
##tis O
. O
[SEP] O
[CLS] O
these O
data O
illustrate O
that O
r O
##u O
- O
th O
##io O
- O
ch O
##ry O
##sin O
and O
ch O
##ry O
##sin O
affect O
ha O
##em O
##ost O
##asis O
with O
similar O
efficacy O
in O
mice O
. O
[SEP] O
[CLS] O
each O
sample O
, O
properly O
loaded O
onto O
the O
sample O
disc O
, O
was O
scanned O
in O
the O
range O
of O
400 O
– O
4 O
, O
000 O
cm O
##− O
##1 O
. O
[SEP] O
[CLS] O
subjects O
included O
in O
the O
study O
had O
at O
least O
2 O
detect O
##able O
th O
##c O
and O
related O
meta O
##bol O
##ite O
plasma O
concentrations O
during O
serial O
blood O
draw O
over O
a O
10 O
- O
12 O
h O
study O
period O
. O
[SEP] O
[CLS] O
although O
this O
study O
was O
not O
designed O
to O
assess O
efficacy O
, O
repeat O
imaging O
was O
performed O
and O
evaluated O
using O
re O
##cist O
every O
two O
cycles O
. O
[SEP] O
[CLS] O
win O
##non O
##lin O
was O
used O
for O
non O
##com O
##par O
##tment O
##al O
analysis O
, O
compartment O
##al O
modeling O
, O
and O
statistics O
, O
and O
non O
##me O
##m O
was O
used O
for O
visual O
predict O
##ive O
checks O
. O
[SEP] O
[CLS] O
inter O
- O
and O
in O
##tra O
##ind O
##iv O
##id O
##ual O
var O
##iability O
was O
assessed O
, O
and O
the O
effects O
of O
co O
##var O
##iate O
##s O
were O
q O
##uant O
##ified O
using O
a O
non O
##linear O
mixed O
- O
effects O
modeling O
approach O
( O
non O
##me O
##m O
) O
. O
[SEP] O
[CLS] O
the O
% O
bias O
in O
recovery O
calculation O
at O
ll O
##o O
##q O
level O
was O
least O
( O
< O
15 O
% O
) O
for O
un O
##weight O
##ed O
and O
weighted O
ca O
##li O
##bra O
##tion O
curve O
when O
a O
weight O
of O
1 O
/ O
x O
and O
1 O
/ O
x O
##2 O
was O
applied O
. O
[SEP] O
[CLS] O
as O
a O
result O
, O
11 O
meta O
##bol O
##ites O
of O
act O
##eo O
##side O
, O
7 O
meta O
##bol O
##ites O
of O
is O
##oa O
##ct O
##eo O
##side O
, O
and O
11 O
meta O
##bol O
##ites O
of O
2 O
' O
- O
ace O
##ty O
##la O
##ct O
##eo O
##side O
were O
identified O
respectively O
. O
[SEP] O
[CLS] O
tribe O
##ndi O
##mi O
##dine O
is O
a O
broad O
- O
spectrum O
ant O
##hel O
##min O
##thi O
##c O
available O
in O
chin O
##a O
, O
which O
is O
currently O
being O
pursued O
for O
u O
. O
s O
. O
food O
and O
drug O
administration O
approval O
for O
soil O
- O
transmitted O
helm O
##int O
##h O
infections O
. O
[SEP] O
[CLS] O
development O
, O
optimization O
, O
and O
evaluation O
of O
carved O
##ilo O
##l O
- O
loaded O
solid O
lip O
##id O
na O
##no O
##par O
##tic O
##les O
for O
in O
##tra O
##nas O
##al O
drug O
delivery O
. O
[SEP] O
[CLS] O
subgroup O
comparisons O
were O
made O
using O
the O
new O
##man O
– O
k O
##eu O
##ls O
multiple O
comparisons O
. O
[SEP] O
[CLS] O
the O
solid O
s O
##med O
##ds O
was O
formulated O
by O
spray O
drying O
liquid O
s O
##med O
##ds O
with O
the O
solid O
carrier O
( O
calcium O
si O
##lica O
##te O
) O
. O
[SEP] O
[CLS] O
since O
the O
binding O
of O
drugs O
to O
plasma O
proteins O
can O
significantly O
after O
the O
intensity O
of O
p O
##har O
##ma O
##cological O
and O
toxic O
##ological O
effects O
of O
drugs O
, O
we O
studied O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
three O
drugs O
in O
patients O
with O
h O
##y O
##po O
##al O
##bu O
##mine O
##mia O
secondary O
to O
the O
ne O
##ph O
##rot O
##ic O
syndrome O
, O
but O
with O
relatively O
normal O
re O
##nal O
function O
. O
[SEP] O
[CLS] O
total O
exposure O
, O
measured O
by O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
- I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
, O
was O
generated O
for O
the O
da O
##as O
, O
r O
##ito O
##na O
##vir O
, O
and O
rib O
##avi O
##rin O
using O
population O
p O
##har O
##ma O
##co O
##kin O
##etic O
modeling O
of O
data O
( O
n O
= O
209 O
##3 O
patients O
) O
from O
6 O
phase O
3 O
studies O
and O
1 O
phase O
2 O
study O
. O
[SEP] O
[CLS] O
one O
patient O
in O
the O
1200 O
mg O
q O
##d O
dose O
level O
( O
p O
##ic O
) O
experienced O
2 O
d O
##lts O
( O
grade O
3 O
d O
##ys O
##art O
##hr O
##ia O
and O
muscular O
weakness O
) O
. O
[SEP] O
[CLS] O
to O
assess O
the O
effects O
of O
c O
##y O
##p O
##3 O
##a O
##5 O
gene O
p O
##oly O
##mor O
##phism O
##s O
on O
drug O
metabolism O
, O
the O
present O
study O
constructed O
a O
p O
##k O
prediction O
model O
by O
expressing O
c O
##y O
##p O
##3 O
##a O
##5 O
gene O
p O
##oly O
##mor O
##phism O
vectors O
in O
sa O
##cc O
##har O
##omy O
##ces O
c O
##ere O
##vis O
##iae O
. O
[SEP] O
[CLS] O
the O
clinical O
efficacy O
was O
evaluated O
based O
on O
the O
clinical O
response O
, O
categorized O
into O
a O
clinical O
success O
and O
clinical O
failure O
. O
[SEP] O
[CLS] O
to O
improve O
the O
poor O
so O
##lub O
##ility O
of O
f O
##v O
##s O
, O
f O
. O
ve O
##lut O
##ip O
##es O
s O
##tero O
##l O
lip O
##oso O
##me O
( O
f O
##v O
##s O
##l O
) O
was O
originally O
prepared O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
daily O
in O
the O
morning O
( O
08 O
##00 O
hours O
) O
beginning O
the O
day O
after O
surgery O
. O
[SEP] O
[CLS] O
cocaine O
and O
its O
meta O
##bol O
##ites O
were O
determined O
using O
3 O
##h O
- O
cocaine O
as O
a O
trace O
##r O
, O
followed O
by O
ho O
##mo O
##gen O
##ization O
and O
solvent O
extraction O
of O
tissues O
, O
and O
quantitative O
analysis O
by O
hp O
##tl O
##c O
and O
l O
##s O
##c O
. O
[SEP] O
[CLS] O
even O
though O
individual O
monitoring O
of O
serum O
if O
##n O
t O
##iter O
##s O
emphasized O
, O
for O
a O
given O
dose O
, O
marked O
quantitative O
variations O
of O
the O
observed B-PK
maximum I-PK
concentrations I-PK
, O
their O
mean O
values O
were O
found O
to O
be O
dose O
- O
dependent O
( O
35 O
##8 O
+ O
- O
167 O
u O
/ O
m O
##l O
at O
30 O
. O
10 O
( O
6 O
) O
u O
and O
104 O
##4 O
+ O
- O
59 O
##9 O
u O
/ O
m O
##l O
at O
100 O
. O
10 O
( O
6 O
) O
u O
doses O
) O
. O
[SEP] O
[CLS] O
the O
mean O
diameter O
of O
the O
s O
##ma O
- O
p O
##t O
##x O
mice O
##lle O
was O
195 O
##± O
##12 O
. O
3 O
nm O
as O
determined O
by O
dynamic O
light O
scattering O
. O
[SEP] O
[CLS] O
brain O
accumulation O
of O
sun O
##iti O
##ni O
##b O
is O
effectively O
restricted O
by O
both O
m O
##ua O
##b O
##c O
##b O
##1 O
and O
m O
##ua O
##b O
##c O
##g O
##2 O
activity O
. O
[SEP] O
[CLS] O
the O
effect O
of O
the O
day O
( O
day O
22 O
versus O
day O
1 O
) O
or O
the O
cycle O
( O
cycle O
2 O
versus O
cycle O
1 O
) O
on O
the O
exposure O
( O
cm B-PK
##ax I-PK
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
) O
after O
dose O
normal O
##isation O
and O
log O
transformation O
was O
assessed O
using O
a O
pro O
##c O
mixed O
procedure O
of O
sa O
##s O
software O
with O
the O
patient O
taken O
as O
random O
effect O
and O
with O
day O
and O
cycle O
as O
fixed O
effects O
. O
[SEP] O
[CLS] O
the O
valid O
##ated O
ass O
##ay O
has O
been O
successfully O
applied O
to O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
of O
c O
##li O
##gos O
##iba O
##n O
in O
rat O
plasma O
after O
in O
##tra O
##ven O
##ous O
and O
oral O
administration O
. O
[SEP] O
[CLS] O
in O
the O
course O
of O
method O
development O
, O
the O
main O
focus O
was O
the O
optimal O
detection O
and O
q O
##uant O
##ification O
of O
the O
meta O
##bol O
##ite O
m O
##1 O
. O
[SEP] O
[CLS] O
compared O
with O
other O
ace O
inhibitor O
##s O
, O
which O
are O
mainly O
ex O
##cre O
##ted O
through O
the O
kidney O
, O
the O
plasma O
concentration O
of O
the O
active O
di O
##ac O
##id O
meta O
##bol O
##ite O
was O
hardly O
influenced O
by O
re O
##nal O
function O
. O
[SEP] O
[CLS] O
routine O
his O
##to O
##logical O
methodology O
was O
undertaken O
which O
involved O
may O
##er O
' O
s O
hem O
##ato O
##xy O
##lin O
and O
e O
##os O
##in O
stain O
##ing O
procedure O
. O
[SEP] O
[CLS] O
following O
an O
overnight O
fast O
of O
at O
least O
10 O
h O
, O
all O
subjects O
received O
a O
single O
oral O
dose O
of O
33 O
mg O
kg O
##− O
##1 O
of O
d O
##f O
##p O
, O
provided O
as O
500 O
mg O
f O
##er O
##rip O
##ro O
##x O
tablets O
rounded O
to O
the O
nearest O
half O
‐ O
tablet O
( O
250 O
mg O
) O
. O
[SEP] O
[CLS] O
the O
ad O
##r O
was O
local O
adverse O
reaction O
in O
four O
subjects O
, O
that O
is O
, O
mild O
injection O
site O
h O
##yper O
##ae O
##mia O
, O
which O
started O
within O
16 O
– O
45 O
min O
since O
in O
##tra O
##ven O
##ous O
in O
##fusion O
, O
and O
resolved O
30 O
min O
after O
the O
end O
of O
in O
##tra O
##ven O
##ous O
in O
##fusion O
. O
[SEP] O
[CLS] O
overall O
, O
drug O
exposure O
was O
reduced O
( O
l O
##p O
##v O
- O
33 O
% O
, O
e O
##f O
##v O
- O
15 O
% O
, O
r O
##ito O
##na O
##vir O
- O
17 O
% O
) O
compared O
to O
well O
- O
no O
##uri O
##shed O
controls O
( O
p O
< O
0 O
. O
00 O
##1 O
) O
, O
at O
##tri O
##but O
##able O
to O
decreased O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
. O
[SEP] O
[CLS] O
thereafter O
, O
the O
ratio O
increased O
to O
0 O
. O
79 O
at O
48 O
h O
post O
- O
dose O
, O
the O
last O
e O
##val O
##ua O
##ble O
time O
point O
. O
[SEP] O
[CLS] O
all O
physiological O
parameters O
for O
a O
reference O
man O
, O
woman O
and O
rat O
that O
are O
independent O
of O
the O
chemical O
and O
constitute O
a O
constant O
part O
of O
the O
model O
equations O
( O
app O
##end O
##ix O
a O
##1 O
in O
supplement O
##ary O
material O
) O
. O
[SEP] O
[CLS] O
the O
data O
was O
fitted O
into O
k O
##ors O
##meyer O
- O
p O
##ep O
##pas O
equation O
. O
[SEP] O
[CLS] O
of O
the O
62 O
random O
##ized O
subjects O
( O
74 O
% O
male O
) O
, O
59 O
completed O
the O
study O
and O
three O
subjects O
discontinued O
( O
all O
during O
the O
place O
##bo O
+ O
am O
##ox O
##ici O
##llin O
arm O
) O
, O
including O
one O
due O
to O
an O
a O
##e O
. O
[SEP] O
[CLS] O
together O
, O
these O
results O
demonstrate O
that O
f O
##etal O
mouse O
and O
rat O
p O
##ht O
##hala O
##te O
exposure O
both O
induce O
immediate O
early O
gene O
expression O
and O
disrupt O
semi O
##nife O
##rous O
cord O
and O
go O
##no O
##cy O
##te O
development O
. O
[SEP] O
[CLS] O
events O
were O
regarded O
generally O
“ O
related O
” O
to O
b O
##c O
- O
81 O
##9 O
in O
case O
their O
time O
relationship O
to O
b O
##c O
- O
81 O
##9 O
treatment O
was O
not O
in O
##com O
##pa O
##tible O
or O
making O
a O
casual O
connection O
imp O
##ro O
##ba O
##ble O
. O
[SEP] O
[CLS] O
separation O
was O
carried O
out O
applying O
- O
20 O
k O
##v O
in O
50 O
mm O
phosphate O
buffer O
, O
p O
##h O
3 O
. O
5 O
, O
containing O
10 O
% O
v O
/ O
v O
a O
##c O
##n O
and O
30 O
mg O
/ O
m O
##l O
su O
##lf O
##ated O
- O
β O
- O
c O
##y O
##c O
##lo O
##de O
##x O
##tri O
##n O
( O
s O
- O
β O
- O
c O
##d O
) O
. O
[SEP] O
[CLS] O
it O
is O
concluded O
that O
the O
ace O
##ty O
##lation O
of O
h O
##yd O
##ral O
##azi O
##ne O
in O
man O
is O
a O
capacity O
- O
limited O
process O
. O
[SEP] O
[CLS] O
the O
time O
intervals O
of O
blood O
collection O
were O
identical O
for O
all O
groups O
: O
5 O
min O
before O
the O
first O
injection O
of O
the O
sample O
, O
and O
7 O
, O
15 O
, O
30 O
, O
45 O
, O
65 O
, O
and O
90 O
min O
after O
. O
[SEP] O
[CLS] O
automated O
radios O
##ynth O
##esis O
afforded O
radio O
##tra O
##cer O
[ O
18 O
##f O
] O
d O
##c O
##f O
##py O
##l O
in O
decay O
- O
corrected O
radio O
##chemical O
yields O
of O
23 O
± O
5 O
% O
( O
n O
= O
10 O
) O
within O
55 O
min O
, O
including O
hp O
##l O
##c O
pu O
##rification O
. O
[SEP] O
[CLS] O
m O
##f O
, O
c O
##pm O
, O
e O
##p O
, O
em O
, O
m O
##p O
, O
s O
##m O
, O
s O
##b O
, O
s O
##r O
and O
j O
##r O
##h O
have O
been O
engaged O
by O
f O
##ae O
##s O
farm O
##a O
s O
. O
a O
. O
as O
experts O
for O
various O
aspects O
of O
the O
studies O
( O
pet O
technique O
, O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
statistical O
methods O
) O
. O
[SEP] O
[CLS] O
the O
mass O
transitions O
for O
α O
- O
mg O
was O
m O
/ O
z O
41 O
##1 O
. O
21 O
→ O
35 O
##4 O
. O
85 O
( O
collision O
energy O
of O
20 O
e O
##v O
and O
collision O
cell O
exit O
potential O
of O
25 O
e O
##v O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
for O
the O
10 O
- O
mg O
es O
##ome O
##pra O
##zo O
##le O
dose O
, O
the O
geometric O
mean O
body O
- O
weight O
- O
normal B-PK
##ized I-PK
apparent I-PK
oral I-PK
clearance I-PK
was O
approximately O
50 O
% O
higher O
in O
the O
younger O
group O
compared O
with O
the O
older O
group O
( O
0 O
. O
40 O
and O
0 O
. O
25 O
l O
/ O
h O
x O
kg O
( O
- O
1 O
) O
, O
respectively O
) O
. O
[SEP] O
[CLS] O
given O
the O
early O
disco O
##ntin O
##uation O
of O
the O
first O
three O
patients O
, O
the O
protocol O
was O
amended O
to O
short O
##en O
the O
first O
cycle O
to O
a O
14 O
- O
day O
cycle O
to O
obtain O
a O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
after O
14 O
days O
of O
multiple O
dos O
##ing O
of O
l O
##y O
##24 O
##5 O
##75 O
##46 O
. O
[SEP] O
[CLS] O
the O
mechanism O
of O
von O
will O
##eb O
##rand O
factor O
( O
v O
##w O
##f O
) O
clearance B-PK
is O
not O
fully O
understood O
. O
[SEP] O
[CLS] O
it O
is O
shown O
, O
that O
for O
oral O
administration O
the O
most O
appropriate O
is O
an O
am O
##or O
##ph O
##ous O
form O
obtained O
by O
rapid O
e O
##va O
##por O
##ation O
of O
a O
solvent O
from O
solution O
of O
the O
est O
##er O
. O
[SEP] O
[CLS] O
post O
ho O
##c O
ex O
##p O
##lora O
##tory O
parameters O
were O
the O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
16 I-PK
) I-PK
and O
the O
au B-PK
##c I-PK
( I-PK
0 I-PK
- I-PK
in I-PK
##finity I-PK
) I-PK
assuming O
a O
16 O
- O
hour O
application O
time O
for O
the O
21 O
- O
mg O
patch O
. O
[SEP] O
[CLS] O
by O
contrast O
, O
a O
significant O
period O
effect O
was O
found O
for O
glucose O
( O
p O
< O
0 O
. O
05 O
) O
, O
suggesting O
that O
the O
changes O
relative O
to O
day O
− O
##1 O
may O
be O
only O
partially O
explained O
by O
l O
##x O
##42 O
##11 O
treatment O
, O
because O
they O
were O
con O
##founded O
with O
time O
. O
[SEP] O
[CLS] O
z O
##b O
- O
16 O
group O
showed O
blood O
glucose O
levels O
by O
27 O
% O
lower O
than O
in O
sa O
##line O
group O
30 O
min O
after O
oral O
glucose O
administration O
( O
3 O
mg O
/ O
kg O
) O
. O
[SEP] O
[CLS] O
ca O
##lve O
##rt O
et O
al O
( O
1989 O
) O
demonstrated O
that O
the O
total B-PK
plasma I-PK
clearance I-PK
of O
car O
##bo O
##p O
##lat O
##in O
was O
linear O
##ly O
related O
to O
the O
g O
##lo O
##mer O
##ular O
fi O
##ltration O
rate O
( O
g O
##f O
##r O
) O
and O
that O
the O
non B-PK
- I-PK
re I-PK
##nal I-PK
clearance I-PK
was O
25 O
m O
##l O
min O
##− O
##1 O
. O
[SEP] O
[CLS] O
his O
##to O
##logical O
##ly O
, O
brain O
and O
spinal O
cord O
sections O
revealed O
scattered O
micro O
##in O
##far O
##cts O
and O
minimal O
g O
##lio O
##sis O
consistent O
with O
post O
##p O
##ro O
##ced O
##ure O
changes O
in O
all O
four O
s O
##ten O
##t O
- O
treatment O
groups O
. O
[SEP] O
[CLS] O
79 O
patients O
were O
on O
mon O
##otherapy O
of O
either O
c O
##b O
##z O
or O
o O
##x O
##c O
, O
63 O
were O
on O
either O
c O
##b O
##z O
or O
o O
##x O
##c O
plus O
another O
anti O
ne O
##uro O
##pathic O
/ O
anal O
##ges O
##ic O
medication O
which O
were O
included O
in O
the O
analysis O
. O
[SEP] O
[CLS] O
finally O
, O
the O
op O
##ti O
##mized O
v O
##rd O
- O
o O
##dt O
##s O
exhibited O
increased O
oral O
absorption O
of O
v O
##rd O
and O
subsequent O
decrease O
in O
the O
time O
of O
onset O
of O
clinical O
effect O
and O
mask O
##ing O
the O
unpleasant O
taste O
. O
[SEP] O
[CLS] O
a O
total O
of O
151 O
participants O
were O
included O
in O
the O
analysis O
under O
fast O
##ed O
conditions O
, O
and O
31 O
participants O
were O
included O
in O
the O
fed O
analysis O
. O
[SEP] O
[CLS] O
the O
matrix O
effect O
and O
recovery O
yield O
were O
all O
within O
± O
##15 O
% O
, O
which O
was O
generally O
accepted O
to O
carry O
out O
the O
analysis O
of O
biological O
samples O
containing O
the O
drug O
. O
[SEP] O
[CLS] O
the O
s O
: O
r O
ratio O
of O
nor O
concentration O
was O
also O
input O
rate O
- O
dependent O
. O
[SEP] O
[CLS] O
a O
full O
method O
valid O
##ation O
of O
the O
ass O
##ay O
for O
the O
anal O
##yte O
determination O
in O
rat O
plasma O
was O
performed O
according O
to O
the O
chin O
##a O
food O
and O
drug O
administration O
guidelines O
for O
the O
pre O
##c O
##lini O
##cal O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
with O
respect O
to O
select O
##ivity O
, O
linear O
##ity O
, O
precision O
, O
accuracy O
, O
recovery O
, O
matrix O
effect O
, O
stability O
, O
and O
di O
##lution O
integrity O
[ O
11 O
] O
. O
[SEP] O
[CLS] O
the O
data O
from O
the O
dose O
- O
dependence O
study O
showed O
that O
n O
##l O
##g O
##9 O
##19 O
at O
100 O
mg O
/ O
kg O
demonstrated O
the O
maximum O
anti O
##tum O
##or O
efficacy O
. O
[SEP] O
[CLS] O
only O
a O
few O
high O
- O
purity O
v O
##w O
##f O
/ O
f O
##vi O
##ii O
concentrate O
##s O
have O
been O
extensively O
evaluated O
in O
p O
##har O
##ma O
##co O
##kin O
##etic O
( O
p O
##k O
) O
trials O
as O
well O
as O
in O
retrospective O
or O
prospective O
efficacy O
studies O
in O
v O
##w O
##d O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
anti O
##can O
##cer O
effect O
of O
am O
##b O
pre O
##tre O
##ated O
with O
t O
##ce O
##e O
was O
evaluated O
. O
[SEP] O
[CLS] O
m O
##d O
##ma O
reversed O
the O
subjective O
se O
##dation O
induced O
by O
alcohol O
but O
did O
not O
reduce O
drunken O
##ness O
feelings O
. O
[SEP] O
[CLS] O
the O
third O
phase O
appears O
to O
involve O
a O
slow O
turnover O
of O
se O
##quest O
##ered O
zinc O
( O
t B-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
greater O
than O
1 O
year O
) O
. O
[SEP] O
[CLS] O
ft O
##ir O
s O
##pect O
##ra O
showed O
chemical O
group O
of O
each O
component O
and O
interaction O
between O
components O
. O
[SEP] O
[CLS] O
samples O
were O
re O
##con O
##stituted O
in O
sample O
loading O
buffer O
of O
s O
##ds O
- O
p O
##oly O
##ac O
##ryl O
##ami O
##de O
gel O
electro O
##ph O
##ores O
##is O
and O
boiled O
for O
5 O
min O
for O
protein O
den O
##at O
##uration O
. O
[SEP] O
[CLS] O
after O
1 O
h O
##r O
, O
three O
test O
groups O
including O
##2 O
. O
5 O
, O
5 O
and O
10 O
mg O
/ O
kg O
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
were O
administered O
oral O
##ly O
once O
a O
day O
for O
three O
##con O
##se O
##cut O
##ive O
days O
, O
respectively O
. O
[SEP] O
[CLS] O
in O
clinical O
trials O
, O
both O
agents O
have O
shown O
some O
activity O
as O
second O
- O
line O
agents O
( O
measured O
by O
clinical O
benefit O
as O
well O
as O
reduction O
in O
ps O
##a O
) O
, O
supporting O
the O
concept O
of O
a O
more O
selective O
inhibitor O
of O
the O
17 O
##α O
- O
h O
##ydro O
##xy O
##lase O
/ O
c O
##17 O
, O
20 O
- O
l O
##yas O
##e O
enzyme O
( O
oh O
, O
2002 O
) O
. O
[SEP] O
[CLS] O
three O
aids O
patients O
experienced O
severe O
di O
##ar O
##r O
##hea O
following O
the O
oral O
dose O
; O
four O
patients O
had O
mild O
di O
##ar O
##r O
##hea O
following O
the O
i O
. O
v O
. O
dose O
. O
[SEP] O
[CLS] O
the O
mice O
were O
sacrificed O
at O
72 O
days O
after O
the O
6th O
injection O
. O
[SEP] O
[CLS] O
twenty O
- O
five O
volunteers O
were O
screened O
, O
and O
17 O
of O
them O
were O
random O
##ized O
. O
[SEP] O
[CLS] O
du O
##14 O
##5 O
and O
ca O
##co O
- O
2 O
cells O
were O
culture O
##d O
in O
eagle O
' O
s O
minimum O
essential O
medium O
( O
em O
##em O
) O
. O
[SEP] O
[CLS] O
of O
these O
patients O
, O
29 O
( O
69 O
% O
) O
had O
r O
##ai O
stage O
i O
to O
ii O
disease O
. O
[SEP] O
[CLS] O
data O
from O
three O
studies O
of O
healthy O
individuals O
with O
p O
##k O
measurements O
of O
plasma O
and O
urine O
after O
single O
dose O
or O
at O
steady O
- O
state O
were O
used O
in O
this O
study O
. O
[SEP] O
[CLS] O
ethanol O
did O
not O
modify O
the O
effect O
of O
am O
##is O
##ulp O
##ride O
on O
plasma O
pro O
##la O
##ct O
##in O
, O
and O
the O
plasma O
concentrations O
of O
am O
##is O
##ulp O
##ride O
were O
little O
changed O
by O
ethanol O
. O
[SEP] O
[CLS] O
animals O
were O
kept O
in O
a O
temperature O
- O
controlled O
environment O
with O
a O
12 O
- O
hour O
light O
/ O
12 O
- O
hour O
dark O
cycle O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
, O
including O
area B-PK
under I-PK
the I-PK
curve I-PK
from I-PK
0 I-PK
##h I-PK
to I-PK
the I-PK
last I-PK
measured I-PK
point I-PK
24 I-PK
##h I-PK
[ I-PK
au I-PK
##c I-PK
( I-PK
( I-PK
0 I-PK
- I-PK
24 I-PK
) I-PK
) I-PK
] I-PK
, O
area B-PK
under I-PK
the I-PK
curve I-PK
from I-PK
0 I-PK
##h I-PK
to I-PK
infinite I-PK
time I-PK
[ I-PK
au I-PK
##c I-PK
( I-PK
( I-PK
0 I-PK
- I-PK
∞ I-PK
) I-PK
) I-PK
] I-PK
, O
peak B-PK
plasma I-PK
concentration I-PK
( I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
) I-PK
, O
time B-PK
to I-PK
reach I-PK
c I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
( I-PK
t I-PK
( I-PK
ma I-PK
##x I-PK
) I-PK
) I-PK
, O
oral B-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
, O
oral B-PK
volume I-PK
of I-PK
distribution I-PK
( I-PK
v I-PK
( I-PK
d I-PK
) I-PK
) I-PK
and O
elimination B-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
( I-PK
1 I-PK
/ I-PK
2 I-PK
) I-PK
) I-PK
, O
were O
determined O
following O
a O
single O
oral O
dose O
of O
los O
##art O
##an O
. O
[SEP] O
[CLS] O
at O
about O
84 O
minutes O
after O
a O
b O
##ol O
##us O
injection O
of O
1 O
g O
dose O
of O
c O
##d O
##z O
##m O
, O
the O
drug O
was O
transferred O
well O
into O
tissues O
of O
internal O
g O
##eni O
##tal O
organs O
and O
remained O
there O
at O
therapeutic O
levels O
for O
285 O
minutes O
. O
[SEP] O
[CLS] O
we O
prepared O
r O
##t O
##v O
isn O
##p O
g O
##ran O
##ules O
by O
using O
our O
novel O
isn O
##p O
na O
##note O
##ch O
##nology O
, O
as O
shown O
in O
figure O
1 O
##b O
. O
[SEP] O
[CLS] O
applications O
of O
surf O
##act O
##ant O
in O
ni O
##oso O
##mal O
drug O
delivery O
were O
explored O
using O
c O
##ef O
##ix O
##ime O
as O
model O
. O
[SEP] O
[CLS] O
the O
super O
##nat O
##ant O
was O
collected O
, O
and O
its O
concentration O
was O
determined O
using O
high O
performance O
liquid O
ch O
##roma O
##tography O
at O
270 O
nm O
. O
[SEP] O
[CLS] O
o O
##xy O
##co O
##don O
##e O
is O
an O
op O
##io O
##id O
ago O
##nist O
largely O
prescribed O
for O
the O
treatment O
of O
moderate O
to O
severe O
pain O
. O
[SEP] O
[CLS] O
in O
this O
single O
- O
dose O
study O
, O
when O
p O
##elle O
##ts O
from O
m O
##s O
- O
s O
##nt O
were O
crushed O
, O
na O
##lt O
##re O
##xon O
##e O
appeared O
to O
be O
completely O
released O
and O
available O
to O
mit O
##igate O
m O
##or O
##phine O
- O
induced O
effects O
. O
[SEP] O
[CLS] O
our O
in O
v O
##it O
##ro O
studies O
had O
demonstrated O
that O
bi O
##l O
##r O
35 O
##5 O
was O
extensively O
meta O
##bol O
##ized O
by O
c O
##yt O
##och O
##rome O
p O
##45 O
##0 O
3 O
##a O
. O
[SEP] O
[CLS] O
the O
associated O
apparent B-PK
terminal I-PK
elimination I-PK
half I-PK
- I-PK
life I-PK
( I-PK
t I-PK
##1 I-PK
/ I-PK
2 I-PK
) I-PK
was O
calculated O
as O
t O
##1 O
/ O
2 O
= O
l O
##n O
##2 O
/ O
l O
##z O
. O
[SEP] O
[CLS] O
competitive O
binding O
ass O
##ays O
were O
performed O
to O
examine O
direct O
binding O
of O
fl O
##av O
##ono O
##id O
g O
##lu O
##cu O
##ron O
##ides O
and O
a O
##gly O
##con O
##es O
to O
human O
er O
##s O
. O
[SEP] O
[CLS] O
serum O
bio O
##chemical O
parameters O
indicate O
that O
liver O
and O
kidney O
function O
were O
not O
remarkably O
affected O
, O
and O
m O
##or O
##phological O
changes O
in O
the O
liver O
and O
s O
##ple O
##en O
were O
ne O
##gli O
##gible O
. O
[SEP] O
[CLS] O
the O
recommended O
oral O
di O
##f O
##lo O
##mote O
##can O
dose O
for O
phase O
ii O
studies O
is O
0 O
. O
27 O
mg O
/ O
day O
x O
5 O
every O
3 O
weeks O
. O
[SEP] O
[CLS] O
cellular O
distribution O
of O
drugs O
was O
observed O
by O
c O
##ls O
##m O
imaging O
. O
[SEP] O
[CLS] O
eleven O
rats O
contributed O
p O
##k O
data O
. O
[SEP] O
[CLS] O
this O
study O
demonstrated O
that O
p O
##b O
##p O
##k O
is O
a O
useful O
tool O
to O
predict O
human O
p O
##k O
when O
inter O
##sp O
##ec O
##ies O
extra O
##pol O
##ation O
is O
not O
applicable O
. O
[SEP] O
[CLS] O
experiments O
were O
performed O
on O
a O
q O
- O
to O
##f O
instrument O
, O
operated O
in O
the O
m O
##s O
/ O
m O
##s O
mode O
. O
[SEP] O
[CLS] O
co O
##bal O
##ami O
##n O
and O
ho O
##lot O
##c O
declined O
on O
average O
with O
47 O
and O
56 O
% O
relative O
to O
concentrations O
at O
the O
end O
of O
supplement O
##ation O
for O
the O
group O
assessed O
at O
7 O
months O
post O
- O
supplement O
##ation O
. O
[SEP] O
[CLS] O
the O
in O
v O
##ivo O
and O
in O
v O
##it O
##ro O
experiments O
showed O
good O
relevance O
and O
consistency O
. O
[SEP] O
[CLS] O
all O
statistical O
analyses O
were O
performed O
using O
s O
##ys O
##tat O
13 O
( O
s O
##ys O
##tat O
software O
in O
##c O
, O
ch O
##ica O
##go O
, O
us O
##a O
) O
. O
[SEP] O
[CLS] O
a O
pool O
##ed O
re O
##gression O
of O
the O
combined O
cc O
##ip O
and O
zero O
- O
order O
data O
confirmed O
that O
the O
co O
##var O
##iate O
, O
height O
( O
cm O
) O
, O
was O
related O
in O
linear O
fashion O
to O
c B-PK
##l I-PK
##1 I-PK
. O
[SEP] O
[CLS] O
oral O
m O
##r O
##x O
- O
i O
was O
well O
tolerate O
##d O
at O
single O
doses O
of O
up O
to O
1 O
, O
200 O
and O
800 O
mg O
q O
##12 O
##h O
for O
up O
to O
28 O
days O
; O
all O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
, O
and O
there O
was O
no O
drug O
disco O
##ntin O
##uation O
due O
to O
adverse O
events O
. O
[SEP] O
[CLS] O
the O
matrix O
effect O
was O
evaluated O
by O
comparing O
the O
anal O
##yte O
/ O
internal O
standard O
peak O
ratios O
dissolved O
with O
blank O
matrix O
extract O
against O
those O
dissolved O
with O
the O
mobile O
phase O
at O
high O
, O
medium O
and O
low O
levels O
. O
[SEP] O
[CLS] O
the O
literature O
search O
identified O
a O
total O
of O
35 O
pub O
##med O
records O
, O
148 O
em O
##base O
records O
and O
70 O
clinical O
trials O
( O
figure O
1 O
) O
. O
[SEP] O
[CLS] O
a O
significant O
linear O
correlation O
in O
the O
values O
of O
f O
##e O
p O
##hen O
##ols O
and O
f O
##eh O
##2 O
##o O
and O
those O
of O
f O
##e O
p O
##hen O
##ols O
and O
f O
##e O
u O
##rea O
was O
documented O
. O
[SEP] O
[CLS] O
the O
highest O
enzyme O
levels O
were O
found O
after O
4 O
d O
of O
starvation O
following O
the O
7 O
d O
of O
treatment O
and O
6 O
d O
of O
recovery O
. O
[SEP] O
[CLS] O
no O
acute O
rejection O
or O
mortality O
occurred O
during O
the O
follow O
- O
up O
period O
. O
[SEP] O
[CLS] O
thus O
, O
at O
low O
concentrations O
very O
small O
differences O
in O
population O
‐ O
predicted O
and O
observed O
times O
of O
reaching O
the O
ll O
##o O
##q O
level O
led O
to O
very O
large O
fold O
differences O
between O
the O
observed O
( O
d O
##v O
) O
and O
predicted O
concentrations O
( O
pre O
##d O
) O
, O
which O
may O
look O
like O
out O
##liers O
in O
log O
– O
log O
figures O
. O
[SEP] O
[CLS] O
the O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
, O
ca B-PK
##v I-PK
, I-PK
s I-PK
##s I-PK
, O
and O
au B-PK
##c I-PK
##τ I-PK
, I-PK
s I-PK
##s I-PK
for O
en O
##zas O
##ta O
##uri O
##n O
and O
its O
primary O
active O
meta O
##bol O
##ite O
l O
##s O
##n O
##32 O
##60 O
##20 O
were O
14 O
and O
42 O
h O
, O
1 O
, O
210 O
and O
90 O
##7 O
nm O
##ol O
/ O
l O
, O
and O
29 O
, O
100 O
and O
21 O
, O
800 O
nm O
##ol O
• O
h O
/ O
l O
, O
respectively O
. O
[SEP] O
[CLS] O
results O
were O
correlated O
to O
explain O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
the O
main O
drugs O
administered O
. O
[SEP] O
[CLS] O
the O
animals O
were O
divided O
into O
four O
experimental O
groups O
( O
n O
= O
6 O
/ O
group O
) O
. O
[SEP] O
[CLS] O
anti O
- O
an O
##gio O
##genic O
drugs O
that O
target O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
( O
ve O
##g O
##f O
) O
signaling O
pathways O
caused O
h O
##yper O
##tens O
##ion O
as O
an O
adverse O
effect O
in O
clinical O
studies O
. O
[SEP] O
[CLS] O
to O
##xin O
##s O
complex O
were O
prepared O
from O
concentrated O
super O
##nat O
##ants O
of O
cultures O
grown O
for O
6 O
days O
in O
an O
##ae O
##ro O
##bic O
culture O
tubes O
. O
[SEP] O
[CLS] O
on O
the O
basis O
of O
the O
in O
##tra O
##ven O
##ous O
injection O
study O
, O
systemic B-PK
bio I-PK
##ava I-PK
##ila I-PK
##bility I-PK
averaged O
66 O
% O
and O
70 O
% O
for O
the O
75 O
mg O
and O
three O
25 O
mg O
tablets O
respectively O
. O
[SEP] O
[CLS] O
the O
ch O
##roma O
##to O
##graphic O
conditions O
were O
modified O
from O
our O
recent O
methods O
for O
the O
q O
##uant O
##ification O
of O
various O
s O
##til O
##ben O
##es O
[ O
8 O
, O
9 O
, O
10 O
, O
11 O
, O
12 O
, O
13 O
, O
14 O
] O
. O
[SEP] O
[CLS] O
drug O
and O
statistics O
( O
das O
) O
software O
( O
version O
3 O
. O
0 O
) O
was O
used O
to O
calculate O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
parameters O
. O
[SEP] O
[CLS] O
the O
absorption B-PK
half I-PK
- I-PK
time I-PK
for O
total O
p O
##oly O
##ch O
##lor O
##inated O
bi O
##phe O
##ny O
##l O
in O
s O
##wine O
was O
1 O
. O
13 O
h O
##r O
while O
that O
for O
sheep O
was O
3 O
. O
83 O
h O
##r O
. O
[SEP] O
[CLS] O
v O
##al O
- O
g O
##c O
##v O
and O
v O
##al O
- O
v O
##al O
- O
g O
##c O
##v O
in O
##hibit O
##ed O
re O
##tina O
##l O
up O
##take O
of O
[ O
3 O
##h O
] O
g O
##ly O
- O
sa O
##r O
by O
43 O
% O
and O
37 O
% O
, O
respectively O
, O
suggesting O
that O
these O
pro O
##dr O
##ugs O
may O
be O
substrates O
of O
the O
re O
##tina O
##l O
p O
##eptide O
transport O
system O
. O
[SEP] O
[CLS] O
we O
therefore O
undertook O
the O
development O
of O
a O
radio O
##im O
##mu O
##no O
##ass O
##ay O
( O
r O
##ia O
) O
. O
[SEP] O
[CLS] O
twenty O
healthy O
subjects O
( O
10 O
male O
and O
10 O
female O
) O
of O
east O
as O
##ian O
heritage O
and O
resident O
in O
chin O
##a O
were O
enrolled O
. O
[SEP] O
[CLS] O
video O
recordings O
of O
ca O
##lves O
walking O
through O
a O
1 O
x O
3 O
m O
alley O
were O
collected O
on O
d O
- O
2 O
, O
- O
1 O
, O
immediately O
after O
cast O
##ration O
, O
30 O
, O
60 O
, O
90 O
, O
120 O
, O
150 O
, O
240 O
min O
and O
on O
d O
1 O
, O
2 O
, O
3 O
, O
5 O
, O
7 O
, O
10 O
, O
14 O
, O
21 O
and O
28 O
after O
cast O
##ration O
. O
[SEP] O
[CLS] O
results O
obtained O
show O
that O
1 O
) O
in O
##test O
##inal O
absorption O
kinetic O
##s O
of O
am O
##ox O
##ici O
##llin O
follows O
a O
zero O
- O
order O
process O
, O
which O
further O
sub O
##stant O
##iate O
##s O
the O
existence O
of O
a O
sat O
##urable O
carrier O
- O
mediated O
process O
for O
this O
anti O
##biotic O
in O
humans O
and O
2 O
) O
calcium O
channel O
blockade O
significantly O
enhance O
##s O
both O
absorption B-PK
rate I-PK
( O
by O
70 O
% O
) O
and O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
am O
##ox O
##ici O
##llin O
( O
by O
21 O
. O
4 O
% O
) O
without O
modify O
##ing O
its O
distribution O
or O
elimination O
. O
[SEP] O
[CLS] O
compound O
5 O
( O
35 O
mg O
, O
quantitative O
yield O
) O
was O
obtained O
using O
the O
compound O
4 O
( O
35 O
mg O
, O
0 O
. O
1 O
mm O
##ol O
) O
as O
starting O
material O
in O
the O
same O
experimental O
conditions O
previously O
described O
for O
compound O
2 O
. O
[SEP] O
[CLS] O
if O
no O
acute O
all O
##ergic O
reaction O
occurred O
after O
the O
first O
in O
##fusion O
, O
patients O
received O
subsequent O
in O
##fusion O
##s O
without O
pre O
##med O
##ica O
##tion O
, O
at O
the O
investigator O
' O
s O
discretion O
. O
[SEP] O
[CLS] O
additional O
samples O
were O
obtained O
on O
day O
8 O
, O
15 O
, O
22 O
and O
28 O
of O
cycle O
1 O
. O
[SEP] O
[CLS] O
s O
##tero O
##id O
and O
mm O
##f O
therapy O
was O
the O
same O
as O
the O
ta O
##c O
##rol O
##imus O
regime O
##n O
. O
[SEP] O
[CLS] O
tissues O
( O
brain O
, O
liver O
and O
s O
##ple O
##en O
) O
and O
serum O
were O
obtained O
from O
the O
surviving O
g O
##uin O
##ea O
pigs O
at O
the O
end O
of O
the O
study O
for O
j O
##un O
##v O
- O
specific O
r O
##t O
- O
p O
##c O
##r O
analysis O
, O
as O
well O
as O
his O
##top O
##ath O
##ology O
. O
[SEP] O
[CLS] O
kidney O
ex O
##cre O
##tion O
of O
h O
##bo O
##cs O
is O
greatly O
diminished O
compared O
to O
that O
of O
un O
##mo O
##dified O
h O
##b O
, O
but O
the O
liver O
remains O
a O
primary O
site O
of O
cat O
##ab O
##olis O
##m O
. O
[SEP] O
[CLS] O
ni O
##rap O
##ari O
##b O
- O
be O
##va O
##ci O
##zu O
##ma O
##b O
showed O
promising O
activity O
; O
part O
2 O
( O
vs O
be O
##va O
##ci O
##zu O
##ma O
##b O
) O
was O
recently O
reported O
and O
phase O
ii O
##i O
comparison O
with O
standard O
- O
of O
- O
care O
therapy O
is O
planned O
. O
[SEP] O
[CLS] O
the O
er O
##yt O
##hr O
##op O
##oi O
##eti O
##n O
mi O
##met O
##ic O
anti O
##body O
fusion O
protein O
c O
##nto O
52 O
##8 O
was O
developed O
as O
a O
novel O
anti O
##body O
fusion O
protein O
by O
constructing O
an O
active O
hem O
##ato O
##po O
##iet O
##ic O
p O
##eptide O
onto O
an O
i O
##gg O
##1 O
- O
based O
s O
##ca O
##ff O
##old O
. O
[SEP] O
[CLS] O
the O
hem O
##og O
##lo O
##bin O
de O
##ple O
##tion O
- O
re O
##ple O
##tion O
method O
was O
used O
in O
w O
##ista O
##r O
rats O
. O
[SEP] O
[CLS] O
the O
tubes O
were O
v O
##ortex O
##ed O
for O
1 O
min O
, O
and O
cent O
##ri O
##fu O
##ged O
at O
10 O
, O
000 O
rpm O
for O
10 O
min O
. O
[SEP] O
[CLS] O
dogs O
( O
n O
= O
7 O
) O
were O
an O
##est O
##he O
##tized O
with O
ha O
##lot O
##hane O
( O
1 O
. O
5 O
% O
) O
in O
oxygen O
. O
[SEP] O
[CLS] O
this O
study O
confirms O
that O
lip O
##oso O
##me O
charge O
is O
critical O
to O
promote O
its O
accumulation O
in O
the O
brain O
in O
##far O
##ct O
after O
m O
##ca O
##ot O
. O
[SEP] O
[CLS] O
plasma O
and O
er O
##yt O
##hr O
##oc O
##yte O
concentrations O
of O
me O
##rca O
##pt O
##op O
##uri O
##ne O
after O
oral O
administration O
in O
children O
. O
[SEP] O
[CLS] O
the O
instrument O
system O
was O
a O
waters O
a O
##c O
##qui O
##ty O
series O
up O
##l O
##c O
equipped O
with O
an O
auto O
##sa O
##mple O
##r O
, O
a O
column O
heat O
##er O
, O
a O
binary O
pump O
coupled O
to O
a O
x O
##evo O
t O
##q O
- O
s O
triple O
- O
q O
##uad O
##rup O
##ole O
mass O
s O
##pect O
##rome O
##ter O
with O
an O
electro O
##sp O
##ray O
ion O
##ization O
source O
( O
waters O
, O
mi O
##lf O
##ord O
, O
ma O
) O
. O
[SEP] O
[CLS] O
the O
flow O
rate O
was O
set O
at O
1 O
. O
0 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
met O
##hyl O
5 O
- O
ni O
##tro O
- O
1 O
##h O
- O
in O
##do O
##le O
- O
3 O
- O
car O
##box O
##yla O
##te O
( O
200 O
mg O
, O
0 O
. O
91 O
mm O
##ol O
) O
used O
h O
##ydro O
##lysis O
reaction O
( O
2 O
n O
na O
##oh O
water O
solution O
) O
to O
afford O
d O
##x O
- O
01 O
- O
04 O
( O
white O
solid O
, O
172 O
mg O
, O
yield O
92 O
% O
) O
. O
[SEP] O
[CLS] O
m O
##1 O
was O
the O
major O
drug O
- O
related O
component O
in O
plasma O
and O
urine O
, O
accounting O
for O
up O
to O
95 O
. O
8 O
% O
of O
radio B-PK
##act I-PK
##ivity I-PK
in O
plasma O
. O
[SEP] O
[CLS] O
there O
were O
no O
local O
reactions O
( O
in O
##fusion O
site O
) O
or O
evidence O
of O
th O
##rom O
##bos O
##is O
at O
high O
doses O
in O
rats O
and O
monkeys O
. O
[SEP] O
[CLS] O
con O
##com O
##ita O
##nt O
im O
##mu O
##nos O
##up O
##press O
##ion O
may O
affect O
the O
my O
##co O
##phe O
##no O
##late O
m O
##of O
##eti O
##l O
exposure O
. O
[SEP] O
[CLS] O
the O
average O
elimination B-PK
half I-PK
- I-PK
life I-PK
after O
p O
##o O
dos O
##ing O
was O
4 O
. O
6 O
hours O
and O
similar O
to O
the O
half B-PK
- I-PK
life I-PK
observed O
after O
i O
##v O
dos O
##ing O
. O
[SEP] O
[CLS] O
in O
this O
study O
, O
we O
examined O
the O
potential O
of O
dynamic O
contrast O
- O
enhanced O
magnetic O
resonance O
imaging O
( O
d O
##ce O
- O
m O
##ri O
) O
for O
assessment O
of O
radiation O
injury O
to O
the O
par O
##ot O
##id O
glands O
. O
[SEP] O
[CLS] O
a O
valid O
##ated O
liquid O
ch O
##roma O
##tography O
– O
tandem O
mass O
s O
##pect O
##rome O
##try O
method O
was O
used O
for O
the O
ex O
##ci O
##pie O
##nt O
p O
##eptide O
( O
m O
##l O
##p O
) O
. O
[SEP] O
[CLS] O
the O
mean O
plasma B-PK
elimination I-PK
half I-PK
- I-PK
lives I-PK
of O
the O
various O
dos O
##age O
forms O
were O
in O
the O
range O
24 O
. O
5 O
- O
25 O
. O
4 O
h O
. O
[SEP] O
[CLS] O
after O
surgery O
, O
each O
rat O
was O
given O
0 O
. O
25 O
m O
##l O
of O
s O
##c O
2 O
. O
27 O
% O
en O
##rol O
##f O
##lo O
##xa O
##cine O
once O
daily O
for O
three O
days O
as O
pre O
##ca O
##ution O
against O
infection O
. O
[SEP] O
[CLS] O
safety O
, O
to O
##ler O
##ability O
, O
p O
##har O
##ma O
##co O
##kin O
##etics O
, O
and O
p O
##har O
##ma O
##co O
##dynamic O
##s O
of O
the O
novel O
γ O
- O
secret O
##ase O
m O
##od O
##ulator O
, O
e O
##22 O
##12 O
, O
in O
healthy O
human O
subjects O
. O
[SEP] O
[CLS] O
influence O
of O
racial O
differences O
on O
effects O
of O
ran O
##iti O
##dine O
and O
c O
##ime O
##ti O
##dine O
on O
i O
##bu O
##p O
##ro O
##fen O
p O
##har O
##ma O
##co O
##kin O
##etics O
. O
[SEP] O
[CLS] O
results O
: O
the O
p O
##hy O
##si O
##co O
##chemical O
studies O
showed O
that O
the O
r O
##ca O
/ O
c O
##d O
complexes O
were O
well O
incorporated O
into O
c O
##p O
##ns O
resulted O
in O
na O
##nos O
##ized O
particles O
( O
215 O
. O
22 O
and O
189 O
. O
13 O
nm O
) O
with O
ho O
##mo O
##gen O
##ous O
size O
distribution O
( O
p O
##di O
: O
0 O
. O
203 O
and O
0 O
. O
182 O
) O
with O
relatively O
high O
incorporation O
capacity O
( O
76 O
. O
11 O
and O
68 O
. O
18 O
% O
) O
for O
the O
c O
##p O
##n O
##1 O
and O
c O
##p O
##n O
##2 O
formulation O
##s O
respectively O
. O
[SEP] O
[CLS] O
r O
##adi O
##x O
in O
##ula O
##e O
is O
endemic O
to O
chin O
##a O
and O
has O
been O
used O
in O
traditional O
medicine O
to O
treat O
upper O
body O
pain O
, O
em O
##esis O
and O
di O
##ar O
##r O
##hoe O
##a O
, O
and O
to O
eliminate O
parasite O
##s O
. O
[SEP] O
[CLS] O
mean O
c O
##ef O
##uro O
##xi O
##me O
levels O
in O
serum O
were O
greater O
than O
8 O
micro O
##gram O
/ O
m O
##l O
for O
3 O
h O
in O
group O
1 O
, O
for O
6 O
h O
in O
group O
2 O
, O
and O
for O
30 O
h O
in O
group O
3 O
. O
[SEP] O
[CLS] O
the O
lip O
##id O
em O
##ul O
##sions O
contained O
radio O
##la O
##bel O
##ed O
trio O
##lein O
( O
to O
) O
and O
ch O
##ole O
##ster O
##yl O
o O
##lea O
##te O
( O
co O
) O
to O
trace O
plasma B-PK
clearance I-PK
##s I-PK
. O
[SEP] O
[CLS] O
further O
studies O
are O
required O
to O
explore O
the O
efficacy O
and O
op O
##ti O
##mized O
dos O
##age O
regime O
##n O
of O
this O
promising O
combination O
. O
[SEP] O
[CLS] O
the O
column O
e O
##ff O
##lue O
##nt O
was O
monitored O
using O
a O
4000 O
q O
##tra O
##p O
##® O
##l O
##c O
/ O
m O
##s O
/ O
m O
##s O
( O
a O
##b O
s O
##cie O
##x O
, O
to O
##ron O
##to O
, O
on O
, O
can O
##ada O
) O
. O
[SEP] O
[CLS] O
for O
each O
subject O
, O
adverse O
events O
( O
a O
##es O
) O
were O
recorded O
throughout O
the O
post O
- O
dos O
##ing O
period O
. O
[SEP] O
[CLS] O
nineteen O
healthy O
male O
volunteers O
were O
given O
daily O
160 O
mg O
prop O
##rano O
##lo O
##l O
h O
##ydro O
##ch O
##lor O
##ide O
in O
divided O
doses O
, O
either O
four O
40 O
- O
mg O
tablets O
or O
two O
80 O
- O
mg O
tablets O
, O
and O
the O
plasma O
prop O
##rano O
##lo O
##l O
concentration O
profiles O
were O
compared O
after O
one O
and O
seven O
consecutive O
days O
of O
drug O
administration O
. O
[SEP] O
[CLS] O
thereafter O
, O
the O
di O
##sper O
##sion O
was O
ultra O
##cent O
##ri O
##fu O
##ged O
at O
20 O
, O
000 O
rpm O
for O
30 O
min O
at O
10 O
##° O
##c O
, O
and O
aggregate O
##s O
were O
pu O
##rified O
by O
dial O
##ys O
##is O
bag O
and O
re O
- O
suspended O
in O
10 O
m O
##l O
of O
a O
##que O
##ous O
phase O
containing O
2 O
. O
5 O
% O
l O
##ut O
##rol O
127 O
as O
a O
na O
##no O
##par O
##tic O
##le O
stab O
##ilizer O
with O
stirring O
at O
1000 O
rpm O
for O
30 O
min O
. O
[SEP] O
[CLS] O
s O
##rc O
##d O
supplement O
##ation O
significantly O
increased O
c O
##ec O
##um O
mass O
, O
whereas O
it O
significantly O
decreased O
the O
c O
##eca O
##l O
but O
##yra O
##te O
and O
short O
- O
chain O
fatty O
acid O
( O
sum O
of O
the O
ace O
##tate O
, O
but O
##yra O
##te O
, O
and O
prop O
##ion O
##ate O
) O
concentrations O
. O
[SEP] O
[CLS] O
the O
duration O
of O
the O
muscle O
relax O
##ant O
effect O
was O
proportional O
to O
the O
log O
##ari O
##th O
##m O
of O
the O
dose O
of O
c O
##z O
##x O
. O
[SEP] O
[CLS] O
et O
##oz O
##olin O
and O
its O
meta O
##bol O
##ite O
are O
extracted O
from O
the O
plasma O
into O
di O
##ch O
##lor O
##ome O
##than O
##e O
at O
p O
##h O
9 O
and O
p O
##h O
5 O
, O
respectively O
, O
and O
the O
resulting O
residues O
are O
analyzed O
on O
a O
si O
##lica O
gel O
column O
. O
[SEP] O
[CLS] O
the O
plasma O
concentrations O
of O
5 O
- O
f O
##u O
and O
c O
##dd O
##p O
were O
not O
significantly O
different O
between O
respond O
##ers O
and O
non O
- O
respond O
##ers O
. O
[SEP] O
[CLS] O
from O
48 O
% O
to O
62 O
% O
of O
the O
dose O
was O
ex O
##cre O
##ted O
in O
the O
urine O
during O
the O
first O
48 O
hours O
after O
in O
##fusion O
. O
[SEP] O
[CLS] O
the O
study O
protocol O
was O
approved O
by O
the O
research O
ethics O
committee O
of O
be O
##iji O
##ng O
friendship O
hospital O
. O
[SEP] O
[CLS] O
the O
ace O
##ton O
##it O
##ril O
##e O
used O
was O
of O
s O
##pect O
##ros O
##copic O
grade O
and O
purchased O
from O
honey O
##well O
( O
am O
##eric O
##a O
) O
. O
[SEP] O
[CLS] O
thirty O
- O
day O
, O
open O
- O
label O
, O
fixed O
- O
sequence O
, O
p O
##har O
##ma O
##co O
##kin O
##etic O
drug O
- O
drug O
interaction O
study O
. O
[SEP] O
[CLS] O
the O
solution O
was O
cent O
##ri O
##fu O
##ged O
at O
12 O
, O
000 O
rpm O
for O
5 O
min O
to O
obtain O
the O
super O
##nat O
##ant O
. O
[SEP] O
[CLS] O
this O
disc O
##lose O
##s O
that O
such O
compounds O
may O
have O
greater O
safety O
in O
use O
, O
according O
to O
the O
data O
shown O
in O
table O
5 O
. O
[SEP] O
[CLS] O
phase O
i O
study O
of O
in O
##tra O
##ven O
##ous O
vascular O
end O
##oth O
##eli O
##al O
growth O
factor O
trap O
, O
a O
##f O
##li O
##ber O
##ce O
##pt O
, O
in O
patients O
with O
advanced O
solid O
tumors O
. O
[SEP] O
[CLS] O
during O
withdrawal O
animals O
showed O
tolerance O
as O
estimated O
with O
both O
the O
em B-PK
##ax I-PK
and O
au B-PK
##c I-PK
. O
[SEP] O
[CLS] O
four O
3 O
- O
mm O
t O
##re O
##phi O
##nation O
##s O
were O
created O
with O
a O
high O
- O
speed O
nitrogen O
- O
driven O
surgical O
drill O
( O
hall O
sur O
##gai O
##rt O
##ome O
ii O
; O
con O
##med O
l O
##in O
##vate O
##c O
, O
la O
##rgo O
, O
fl O
) O
, O
marking O
the O
corners O
of O
a O
square O
with O
sides O
2 O
cm O
in O
length O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
/ O
p O
##har O
##ma O
##co O
##dynamic O
models O
were O
developed O
from O
full O
p O
##har O
##ma O
##co O
##kin O
##etic O
and O
i O
##g O
##f O
- O
i O
profiles O
following O
so O
##ma O
##pa O
##ci O
##tan O
dos O
##ing O
( O
table O
1 O
) O
. O
[SEP] O
[CLS] O
in O
the O
bi O
##lia O
##ry O
ex O
##cre O
##tion O
, O
about O
10 O
per O
cent O
of O
the O
radio B-PK
##act I-PK
##ivity I-PK
administered O
was O
ex O
##cre O
##ted O
in O
bi O
##le O
within O
24 O
h O
##r O
. O
[SEP] O
[CLS] O
p O
##eptide O
separation O
was O
performed O
on O
a O
waters O
a O
##c O
##qui O
##ty O
up O
##l O
##c O
system O
with O
a O
reverse O
phase O
x O
##bridge O
be O
##h O
c O
##18 O
column O
( O
2 O
. O
1 O
##x O
##15 O
##0 O
mm O
, O
3 O
. O
5 O
µ O
##m O
, O
300 O
##a O
, O
waters O
) O
at O
a O
flow O
rate O
of O
300 O
µ O
##l O
min O
##− O
##1 O
in O
a O
step O
- O
wise O
gradient O
of O
0 O
. O
1 O
% O
form O
##ic O
acid O
in O
water O
and O
0 O
. O
1 O
% O
form O
##ic O
acid O
in O
ace O
##ton O
##it O
##ril O
##e O
. O
[SEP] O
[CLS] O
in O
##tra O
- O
and O
inter O
- O
day O
variation O
was O
calculated O
for O
all O
the O
five O
concentrations O
spike O
##d O
with O
blank O
plasma O
anal O
##ys O
##ed O
for O
three O
consecutive O
days O
. O
[SEP] O
[CLS] O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
et O
##hyl O
##ene O
and O
1 O
, O
3 O
- O
but O
##adi O
##ene O
were O
studied O
in O
male O
s O
##pra O
##gue O
- O
da O
##wley O
rats O
by O
use O
of O
a O
closed O
in O
##hala O
##tion O
chamber O
system O
. O
[SEP] O
[CLS] O
excluding O
children O
with O
other O
, O
un O
##con O
##tro O
##lled O
, O
potentially O
my O
##elo O
##su O
##pp O
##ress O
##ive O
influences O
the O
correlation O
between O
6 O
- O
th O
##io O
##gua O
##nine O
n O
##uc O
##leo O
##tide O
concentration O
and O
ne O
##ut O
##rop O
##enia O
improved O
( O
r O
= O
- O
0 O
. O
6 O
; O
p O
less O
than O
0 O
. O
00 O
##1 O
; O
n O
= O
37 O
) O
. O
[SEP] O
[CLS] O
stereo O
##sel O
##ec O
##tive O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
te O
##tra O
##hy O
##dr O
##op O
##al O
##mat O
##ine O
after O
oral O
administration O
of O
( O
- O
) O
- O
en O
##anti O
##omer O
and O
the O
race O
##mate O
. O
[SEP] O
[CLS] O
a O
single O
p O
##ka O
value O
of O
9 O
. O
51 O
( O
moderate O
base O
) O
, O
a O
log O
##p O
value O
of O
2 O
. O
31 O
, O
and O
a O
log O
##d O
value O
of O
0 O
. O
24 O
at O
p O
##h O
7 O
. O
4 O
were O
predicted O
for O
mph O
using O
the O
a O
##c O
##d O
lab O
so O
##lub O
##ility O
suite O
( O
advanced O
chemistry O
development O
, O
in O
##c O
. O
, O
to O
##ron O
##to O
, O
on O
##tar O
##io O
, O
can O
##ada O
) O
. O
[SEP] O
[CLS] O
the O
estimated O
half B-PK
- I-PK
life I-PK
ranged O
from O
5 O
. O
59 O
to O
6 O
. O
03 O
d O
, O
and O
statistical O
##ly O
non O
##sign O
##ificant O
en O
##anti O
##ose O
##lect O
##ive O
degradation O
was O
observed O
. O
[SEP] O
[CLS] O
effect O
of O
varying O
doses O
of O
ch O
##eno O
##de O
##ox O
##ych O
##olic O
acid O
on O
bi O
##le O
lip O
##id O
and O
bi O
##lia O
##ry O
bi O
##le O
acid O
composition O
in O
gal O
##lston O
##e O
patients O
: O
a O
dose O
- O
response O
study O
. O
[SEP] O
[CLS] O
the O
bi O
##spect O
##ral O
index O
( O
bi O
##s O
) O
was O
recorded O
##with O
a O
bi O
##s O
monitor O
. O
[SEP] O
[CLS] O
the O
most O
frequently O
reported O
r O
##omi O
##de O
##ps O
##in O
‐ O
related O
tea O
##es O
were O
nausea O
, O
decreased O
appetite O
, O
fatigue O
, O
vomit O
##ing O
, O
di O
##ar O
##r O
##hea O
, O
th O
##rom O
##bo O
##cy O
##top O
##enia O
, O
an O
##emia O
, O
d O
##ys O
##ge O
##us O
##ia O
, O
and O
h O
##y O
##po O
##kal O
##emia O
. O
[SEP] O
[CLS] O
the O
area B-PK
under I-PK
the I-PK
plasma I-PK
concentration I-PK
time I-PK
curve I-PK
( I-PK
au I-PK
##c I-PK
) I-PK
value O
was O
calculated O
to O
the O
last O
q O
##uant O
##ifiable O
sample O
( O
au B-PK
##c I-PK
##last I-PK
) O
by O
use O
of O
the O
log O
- O
linear O
trap O
##ez O
##oid O
##al O
rule O
. O
[SEP] O
[CLS] O
a O
dual O
pp O
##ar O
alpha O
/ O
gamma O
ago O
##nist O
increases O
ad O
##ip O
##one O
##ct O
##in O
and O
improve O
##s O
plasma O
lip O
##id O
profiles O
in O
healthy O
subjects O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
/ O
p O
##har O
##ma O
##co O
##dynamic O
( O
p O
##k O
/ O
p O
##d O
) O
simulation O
##s O
were O
performed O
to O
explore O
the O
ability O
of O
different O
dos O
##age O
regime O
##ns O
to O
achieve O
the O
p O
##har O
##ma O
##co O
##dynamic O
targets O
. O
[SEP] O
[CLS] O
phase O
i O
study O
of O
the O
anti O
##fo O
##late O
n O
##10 O
- O
prop O
##ar O
##gy O
##l O
- O
5 O
, O
8 O
- O
did O
##ea O
##za O
##fo O
##lic O
acid O
, O
c O
##b O
37 O
##17 O
. O
[SEP] O
[CLS] O
with O
a O
very O
small O
sample O
size O
, O
and O
low O
rate O
of O
respond O
##ers O
, O
no O
correlation O
of O
mutation O
profile O
to O
response O
was O
seen O
in O
an O
analysis O
of O
arch O
##ival O
tumor O
bio O
##ps O
##ies O
( O
data O
not O
shown O
) O
. O
[SEP] O
[CLS] O
the O
accumulation O
of O
[ O
111 O
##in O
] O
us O
##2 O
in O
the O
m O
##da O
- O
m O
##b O
- O
231 O
tumor O
was O
consistent O
with O
the O
distribution O
of O
ca O
- O
i O
##x O
and O
h O
##y O
##pox O
##ic O
regions O
, O
but O
not O
blood O
vessels O
, O
suggesting O
the O
detection O
of O
ca O
- O
i O
##x O
and O
h O
##y O
##pox O
##ia O
within O
the O
m O
##da O
- O
m O
##b O
- O
231 O
tumor O
by O
[ O
111 O
##in O
] O
us O
##2 O
. O
[SEP] O
[CLS] O
the O
diagnostic O
plots O
of O
the O
final O
population O
p O
##k O
model O
revealed O
no O
systematic O
bias O
. O
[SEP] O
[CLS] O
the O
nuclear O
p O
##elle O
##ts O
were O
re O
##sus O
##pen O
##ded O
in O
nuclear O
extraction O
re O
##age O
##nt O
( O
provided O
in O
the O
kit O
) O
, O
and O
the O
tubes O
were O
vigorously O
rocked O
at O
4 O
##° O
##c O
for O
30 O
min O
on O
a O
shaking O
platform O
. O
[SEP] O
[CLS] O
patients O
with O
the O
age O
of O
more O
than O
18 O
years O
old O
in O
any O
ward O
at O
ram O
##ath O
##ib O
##od O
##i O
hospital O
, O
ma O
##hi O
##do O
##l O
university O
, O
bang O
##ko O
##k O
, O
th O
##ail O
##and O
who O
received O
van O
##com O
##y O
##cin O
with O
complete O
data O
regarding O
dos O
##age O
regime O
##ns O
, O
serum O
drug O
concentration O
, O
and O
precise O
timing O
of O
dose O
administration O
and O
blood O
sampling O
over O
the O
entire O
course O
of O
van O
##com O
##y O
##cin O
therapy O
during O
j O
##anu O
##ary O
, O
2007 O
till O
j O
##une O
, O
2010 O
were O
included O
. O
[SEP] O
[CLS] O
study O
2 O
was O
conducted O
at O
a O
single O
center O
in O
two O
parallel O
parts O
as O
depicted O
in O
fi O
##g O
. O
3 O
. O
[SEP] O
[CLS] O
a O
total O
of O
24 O
subjects O
( O
12 O
in O
each O
co O
##hor O
##t O
) O
were O
enrolled O
in O
the O
study O
, O
and O
21 O
completed O
the O
study O
as O
planned O
. O
[SEP] O
[CLS] O
the O
study O
was O
conducted O
at O
q O
##uin O
##tile O
##s O
drug O
research O
unit O
at O
guy O
' O
s O
hospital O
, O
lo O
##ndon O
and O
hammer O
##smith O
medicines O
research O
, O
h O
##m O
##r O
l O
##t O
##d O
, O
lo O
##ndon O
, O
uk O
. O
[SEP] O
[CLS] O
16 O
as O
##a O
physical O
status O
i O
and O
ii O
patients O
scheduled O
for O
or O
##th O
##oped O
##ic O
surgery O
with O
p O
##ne O
##umatic O
tour O
##ni O
##quet O
use O
. O
[SEP] O
[CLS] O
in O
study O
1 O
, O
the O
f O
##d O
##c O
ta O
##ms O
##ulos O
##in O
had O
a O
slower O
release O
than O
commercial O
ha O
##rnal O
- O
[UNK] O
tablets O
co O
##ad O
##mini O
##stered O
with O
du O
##tas O
##ter O
##ide O
( O
fed O
and O
fast O
##ed O
state O
) O
. O
[SEP] O
[CLS] O
pen O
##but O
##olo O
##l O
: O
a O
preliminary O
review O
of O
its O
p O
##har O
##ma O
##cological O
properties O
and O
therapeutic O
efficacy O
in O
h O
##yper O
##tens O
##ion O
and O
an O
##gin O
##a O
p O
##ector O
##is O
. O
[SEP] O
[CLS] O
figure O
1 O
illustrate O
##s O
mean O
p O
##har O
##ma O
##co O
##kin O
##etic O
profiles O
of O
c O
##l O
##p O
and O
each O
meta O
##bol O
##ite O
— O
c O
##l O
##pm O
, O
h O
##3 O
and O
h O
##4 O
in O
patients O
with O
w O
##t O
/ O
w O
##t O
and O
w O
##t O
/ O
* O
1 O
##g O
g O
##eno O
##type O
##s O
. O
[SEP] O
[CLS] O
forty O
- O
two O
were O
random O
##ized O
to O
c O
##dd O
##p O
given O
before O
5 O
- O
f O
##u O
and O
41 O
to O
c O
##dd O
##p O
given O
after O
5 O
- O
f O
##u O
. O
[SEP] O
[CLS] O
p O
##ira O
##na O
was O
used O
as O
the O
modeling O
environment O
[ O
23 O
] O
and O
r O
( O
version O
3 O
. O
3 O
. O
1 O
) O
was O
used O
for O
graphical O
interpretation O
of O
the O
data O
. O
[SEP] O
[CLS] O
patients O
were O
given O
an O
oral O
solution O
of O
c O
##y O
##g O
in O
period O
ii O
( O
weeks O
2 O
- O
3 O
) O
, O
and O
a O
micro O
##em O
##ul O
##sion O
capsule O
formulation O
of O
c O
##y O
##g O
in O
period O
ii O
##i O
( O
weeks O
4 O
- O
5 O
) O
, O
with O
dose O
t O
##it O
##ration O
as O
necessary O
to O
achieve O
t B-PK
##rough I-PK
concentrations I-PK
in O
a O
pre O
##de O
##fine O
##d O
range O
, O
as O
measured O
by O
f O
##pia O
. O
[SEP] O
[CLS] O
the O
genetic O
or O
chemical O
imp O
##air O
##ment O
of O
o O
##ct O
##2 O
or O
mate O
##2 O
- O
k O
caused O
a O
significant O
increase O
in O
the O
plasma O
m O
##1 O
##a O
concentration O
in O
mice O
and O
c O
##yn O
##omo O
##l O
##gus O
monkeys O
due O
to O
the O
high O
contribution O
of O
tub O
##ular O
secret O
##ion O
to O
the O
net O
elimination O
of O
m O
##1 O
##a O
. O
[SEP] O
[CLS] O
blood O
samples O
were O
collected O
to O
0 O
, O
5 O
, O
10 O
, O
15 O
, O
45 O
, O
and O
60 O
minutes O
and O
at O
1 O
. O
5 O
, O
2 O
, O
2 O
. O
5 O
, O
3 O
, O
3 O
. O
5 O
, O
4 O
, O
5 O
, O
6 O
, O
8 O
, O
12 O
, O
24 O
, O
26 O
, O
28 O
, O
30 O
, O
40 O
, O
48 O
, O
50 O
, O
53 O
, O
and O
60 O
hours O
after O
i O
. O
v O
. O
administration O
of O
4 O
. O
5 O
mg O
of O
p O
##hen O
##yl O
##but O
##az O
##one O
per O
kg O
of O
body O
weight O
. O
[SEP] O
[CLS] O
during O
direct O
in O
##fusion O
, O
the O
mass O
s O
##pect O
##ra O
of O
the O
major O
product O
ions O
in O
the O
positive O
mode O
for O
bi O
##s O
##de O
##met O
##ho O
##xy O
##cu O
##rc O
##umi O
##n O
m O
/ O
z O
30 O
##9 O
. O
09 O
##6 O
##8 O
[ O
m O
+ O
h O
] O
+ O
to O
the O
product O
ion O
225 O
. O
07 O
##90 O
( O
figure O
2 O
##a O
) O
dem O
##eth O
##ox O
##y O
##cu O
##rc O
##umi O
##n O
m O
/ O
z O
33 O
##9 O
. O
102 O
##3 O
( O
m O
+ O
h O
) O
to O
255 O
. O
08 O
##48 O
( O
figure O
2 O
##b O
) O
and O
of O
cu O
##rc O
##umi O
##n O
m O
/ O
z O
39 O
##1 O
. O
08 O
##64 O
[ O
m O
+ O
na O
] O
, O
36 O
##9 O
. O
106 O
##6 O
( O
m O
+ O
h O
) O
to O
285 O
. O
09 O
##12 O
( O
figure O
2 O
##c O
) O
. O
[SEP] O
[CLS] O
the O
final O
concentrations O
of O
n O
##hp O
##p O
##c O
working O
solution O
was O
20 O
, O
50 O
, O
100 O
, O
250 O
, O
500 O
, O
1000 O
, O
2000 O
, O
5000 O
, O
10 O
, O
000 O
, O
and O
20 O
, O
000 O
ng O
/ O
m O
##l O
for O
standard O
ca O
##li O
##bra O
##tion O
, O
and O
40 O
, O
2000 O
, O
and O
16 O
, O
000 O
ng O
/ O
m O
##l O
for O
quality O
control O
samples O
. O
[SEP] O
[CLS] O
van O
bell O
##e O
et O
al O
. O
[ O
33 O
] O
reported O
car O
##ba O
##ma O
##ze O
##pine O
hip O
##po O
##cam O
##pus O
p O
##har O
##ma O
##co O
##kin O
##etics O
following O
a O
single O
dose O
to O
rats O
and O
this O
was O
used O
as O
a O
basis O
to O
further O
valid O
##ate O
the O
regional O
brain O
p O
##b O
##p O
##k O
model O
. O
[SEP] O
[CLS] O
concentrations O
following O
storage O
were O
compared O
with O
freshly O
prepared O
samples O
of O
the O
same O
concentrations O
. O
[SEP] O
[CLS] O
a O
blood O
specimen O
was O
obtained O
just O
before O
drug O
administration O
and O
at O
the O
time O
of O
tons O
##ille O
##ct O
##omy O
, O
together O
with O
a O
specimen O
of O
tons O
##il O
tissue O
. O
[SEP] O
[CLS] O
during O
the O
elimination O
phase O
, O
a O
secondary O
rise O
in O
met O
##hyl O
##p O
##red O
##nis O
##olo O
##ne O
concentration O
occurred O
which O
may O
be O
related O
to O
enter O
##oh O
##ep O
##atic O
circulation O
. O
[SEP] O
[CLS] O
from O
2009 O
to O
2014 O
, O
we O
conducted O
a O
d O
##b O
##rc O
##t O
including O
60 O
patients O
with O
primary O
m O
##h O
##g O
##pin O
and O
/ O
or O
as O
##ap O
receiving O
daily O
l O
##y O
##cope O
##ne O
35 O
mg O
, O
se O
##len O
##ium O
55 O
µ O
##g O
, O
and O
g O
##t O
##cs O
600 O
mg O
, O
or O
place O
##bo O
for O
6 O
months O
. O
[SEP] O
[CLS] O
for O
concentrating O
, O
this O
process O
was O
repeated O
ten O
times O
, O
and O
the O
components O
of O
the O
g O
##ins O
##eno O
##side O
##s O
in O
the O
k O
##ore O
##an O
red O
g O
##ins O
##eng O
extract O
are O
shown O
in O
table O
1 O
. O
[SEP] O
[CLS] O
out O
of O
180 O
eligible O
patients O
110 O
were O
random O
##ized O
, O
57 O
( O
51 O
. O
8 O
% O
) O
to O
top O
##ira O
##mate O
and O
53 O
( O
48 O
. O
2 O
% O
) O
to O
place O
##bo O
. O
[SEP] O
[CLS] O
the O
na O
##te O
##gli O
##ni O
##de O
meta O
##bol O
##ite O
caused O
severe O
h O
##y O
##po O
##gly O
##ce O
##mia O
in O
this O
case O
. O
[SEP] O
[CLS] O
the O
organic O
phase O
containing O
polymer O
( O
15 O
mg O
/ O
m O
##l O
) O
and O
d O
##t O
##x O
( O
5 O
w O
##t O
% O
) O
was O
added O
into O
the O
a O
##que O
##ous O
phase O
with O
a O
certain O
amount O
of O
surf O
##act O
##ant O
by O
magnetic O
stirring O
to O
get O
the O
coarse O
em O
##ul O
##sions O
. O
[SEP] O
[CLS] O
i O
##bo O
##pa O
##mine O
produces O
a O
dose O
- O
dependent O
my O
##dr O
##ias O
##is O
endowed O
with O
very O
interesting O
characteristics O
: O
rapid O
onset O
, O
marked O
pupil O
di O
##lation O
and O
rapid O
return O
to O
normal O
pupil O
##lary O
diameter O
. O
[SEP] O
[CLS] O
the O
limit O
of O
q O
##uant O
##ification O
and O
linear O
quantitative O
range O
for O
the O
six O
si O
##ly O
##mar O
##in O
fl O
##av O
##ono O
##li O
##gna O
##ns O
was O
5 O
ng O
/ O
m O
##l O
, O
and O
5 O
to O
1000 O
ng O
/ O
m O
##l O
, O
respectively O
. O
[SEP] O
[CLS] O
p O
##k O
exposure O
##s O
revealed O
a O
c O
##s O
##f O
median O
( O
i O
##q O
##r O
) O
au B-PK
##c I-PK
##0 I-PK
– I-PK
24 I-PK
of O
26 O
. O
3 O
( O
16 O
. O
6 O
to O
43 O
. O
1 O
) O
mg O
· O
h O
/ O
liter O
and O
cm B-PK
##ax I-PK
0 I-PK
– I-PK
24 I-PK
of O
6 O
. O
8 O
( O
5 O
. O
2 O
to O
9 O
. O
4 O
) O
μ O
##g O
/ O
m O
##l O
. O
[SEP] O
[CLS] O
the O
precision O
was O
calculated O
using O
the O
relative O
standard O
de O
##viation O
( O
r O
##s O
##d O
) O
with O
r O
##s O
##d O
% O
= O
( O
standard O
de O
##viation O
of O
the O
mean O
/ O
mean O
) O
× O
100 O
% O
. O
[SEP] O
[CLS] O
these O
correspond O
to O
an O
average O
half B-PK
- I-PK
life I-PK
of O
8 O
. O
0 O
h O
for O
c O
##b O
##ze O
and O
12 O
. O
4 O
h O
for O
c O
##b O
##z O
##d O
, O
which O
suggest O
elimination O
- O
rate O
- O
limited O
disappearance O
of O
c O
##b O
##z O
##d O
. O
[SEP] O
[CLS] O
systematic O
review O
: O
b O
##ace O
- O
1 O
is O
an O
emerging O
target O
for O
potential O
treatment O
of O
al O
##z O
##heimer O
' O
s O
disease O
( O
ad O
) O
. O
[SEP] O
[CLS] O
from O
the O
results O
shown O
in O
fi O
##g O
. O
6 O
, O
there O
is O
good O
evidence O
for O
sustained O
plasma O
concentrations O
of O
1 O
up O
to O
around O
1 O
h O
at O
the O
two O
higher O
dose O
levels O
and O
that O
the O
o O
##li O
##gos O
##ac O
##cha O
##ride O
is O
well O
retained O
in O
the O
plasma O
at O
these O
concentrations O
. O
[SEP] O
[CLS] O
to O
obtain O
acute O
therapy O
for O
a O
drug O
with O
narrow O
therapeutic O
window O
, O
attention O
should O
be O
given O
to O
the O
dos O
##ing O
time O
and O
food O
intake O
interactions O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
of O
plasma O
to O
##co O
##pher O
##ol O
following O
in O
##tra O
##mus O
##cular O
administration O
of O
ace O
##ty O
##lated O
alpha O
- O
to O
##co O
##pher O
##ol O
to O
sheep O
. O
[SEP] O
[CLS] O
disposition O
of O
nap O
##20 O
- O
h O
##sa O
was O
studied O
in O
rats O
and O
compared O
to O
that O
of O
equivalent O
doses O
of O
mixture O
##s O
of O
un O
##co O
##up O
##led O
drug O
and O
protein O
. O
[SEP] O
[CLS] O
the O
descending O
phase O
of O
the O
plasma O
concentration O
– O
time O
curves O
appeared O
to O
be O
bi O
##pha O
##si O
##c O
, O
characterized O
by O
a O
relatively O
rapid O
initial O
phase O
followed O
by O
a O
slower O
terminal O
phase O
( O
figure O
1 O
##a O
, O
b O
) O
. O
[SEP] O
[CLS] O
additional O
visits O
for O
screening O
procedures O
and O
/ O
or O
follow O
- O
up O
were O
scheduled O
as O
necessary O
. O
[SEP] O
[CLS] O
ne O
##rat O
##ini O
##b O
is O
a O
potent O
i O
##rre O
##versible O
pan O
- O
er O
##bb O
t O
##yr O
##os O
##ine O
kinase O
inhibitor O
that O
has O
demonstrated O
anti O
##tum O
##our O
activity O
and O
an O
acceptable O
safety O
profile O
in O
patients O
with O
human O
e O
##pid O
##er O
##mal O
growth O
factor O
receptor O
( O
her O
) O
- O
2 O
- O
positive O
breast O
cancer O
and O
other O
solid O
t O
##umour O
##s O
. O
[SEP] O
[CLS] O
owing O
to O
data O
below O
the O
limit O
of O
q O
##uant O
##ification O
( O
lo O
##q O
) O
of O
the O
p O
##k O
ass O
##ay O
or O
a O
non O
- O
credible O
p O
##k O
profile O
, O
parameters O
of O
r O
##if O
##amp O
##ici O
##n O
, O
is O
##onia O
##zi O
##d O
, O
p O
##yra O
##zin O
##ami O
##de O
and O
et O
##ham O
##but O
##ol O
could O
only O
be O
estimated O
for O
28 O
, O
30 O
, O
29 O
and O
28 O
of O
the O
children O
with O
mean O
percentage O
extra O
##pol O
##ation O
of O
the O
au B-PK
##c I-PK
##0 I-PK
– I-PK
∞ I-PK
of O
28 O
. O
6 O
% O
, O
3 O
. O
2 O
% O
, O
30 O
. O
8 O
% O
and O
10 O
. O
9 O
% O
, O
respectively O
; O
54 O
. O
4 O
% O
, O
11 O
. O
1 O
% O
, O
21 O
. O
1 O
% O
and O
10 O
. O
3 O
% O
of O
data O
##points O
for O
r O
##if O
##amp O
##ici O
##n O
, O
is O
##onia O
##zi O
##d O
, O
p O
##yra O
##zin O
##ami O
##de O
and O
et O
##ham O
##but O
##ol O
, O
respectively O
, O
were O
below O
the O
lo O
##q O
and O
were O
omitted O
from O
the O
analysis O
. O
[SEP] O
[CLS] O
tumors O
were O
processed O
and O
labeled O
with O
tandem O
- O
mass O
tag O
( O
t O
##m O
##t O
) O
− O
##10 O
- O
p O
##lex O
mass O
tag O
label O
##ing O
kits O
( O
the O
##rm O
##o O
) O
44 O
. O
[SEP] O
[CLS] O
figure O
2 O
shows O
the O
change O
in O
these O
factors O
for O
each O
patient O
. O
[SEP] O
[CLS] O
since O
activation O
and O
proliferation O
of O
he O
##pa O
##tic O
s O
##tel O
##late O
cells O
( O
h O
##s O
##cs O
) O
is O
key O
in O
progression O
of O
na O
##sh O
- O
related O
liver O
fi O
##bro O
##sis O
, O
24 O
, O
25 O
the O
activated O
h O
##s O
##c O
cell O
line O
h O
##s O
##c O
- O
t O
##6 O
was O
used O
to O
investigate O
the O
efficacy O
of O
p O
##b O
##mm O
/ O
s O
##k O
##l O
##b O
##0 O
##23 O
in O
v O
##it O
##ro O
. O
[SEP] O
[CLS] O
for O
the O
determination O
of O
les O
##in O
##ura O
##d O
and O
is O
, O
the O
positive O
- O
ion O
mode O
was O
used O
according O
to O
the O
conditions O
shown O
in O
table O
1 O
. O
[SEP] O
[CLS] O
the O
overall O
re B-PK
##nal I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
##r I-PK
) I-PK
for O
c O
##ef O
##az O
##olin O
was O
3 O
. O
6 O
times O
as O
large O
as O
c B-PK
##l I-PK
##r I-PK
for O
c O
##ef O
##pi O
##ram O
##ide O
, O
being O
in O
good O
agreement O
with O
the O
c O
##ef O
##az O
##olin O
/ O
c O
##ef O
##pi O
##ram O
##ide O
ratios O
of O
c B-PK
##lt I-PK
and O
c B-PK
##l I-PK
##r I-PK
. O
therefore O
, O
the O
long O
- O
lasting O
p O
##har O
##ma O
##co O
##kin O
##etic O
properties O
of O
c O
##ef O
##pi O
##ram O
##ide O
was O
suggested O
to O
be O
due O
to O
the O
fact O
that O
c O
##ef O
##pi O
##ram O
##ide O
undergo O
##es O
re O
##nal O
tub O
##ular O
secret O
##ion O
to O
less O
extent O
. O
[SEP] O
[CLS] O
here O
, O
we O
comparatively O
evaluated O
in O
v O
##ivo O
efficacy O
of O
g O
##e O
with O
an O
artificial O
quasi O
- O
mixture O
( O
mix O
) O
formulated O
by O
combining O
four O
most O
active O
g O
##inger O
constituents O
at O
concentrations O
equivalent O
to O
those O
present O
in O
whole O
extract O
. O
[SEP] O
[CLS] O
the O
b O
##p O
‐ O
lowering O
effect O
reached O
a O
plateau O
in O
~ O
2 O
hours O
and O
lasted O
for O
up O
to O
20 O
hours O
. O
[SEP] O
[CLS] O
the O
plasma B-PK
beta I-PK
t I-PK
/ I-PK
2 I-PK
of O
p O
##hen O
##yt O
##oi O
##n O
decreased O
dramatically O
with O
age O
, O
a O
10 O
- O
fold O
difference O
occurring O
between O
4 O
- O
and O
60 O
- O
day O
- O
old O
pu O
##ps O
. O
[SEP] O
[CLS] O
steps O
1 O
to O
5 O
are O
explained O
into O
detail O
below O
. O
[SEP] O
[CLS] O
separation O
and O
q O
##uant O
##itation O
of O
di O
##c O
##lo O
##fen O
##ac O
in O
the O
bi O
##le O
dial O
##ys O
##ates O
were O
achieved O
using O
a O
micro O
##bor O
##e O
reversed O
- O
phase O
c O
##18 O
column O
( O
150 O
##x O
##1 O
. O
0 O
mm O
i O
. O
d O
. O
; O
particle O
size O
5 O
micro O
##m O
) O
maintained O
at O
ambient O
temperature O
. O
[SEP] O
[CLS] O
the O
kinetic O
##s O
of O
the O
three O
molecules O
fitted O
a O
bi O
##com O
##par O
##tment O
##al O
model O
. O
[SEP] O
[CLS] O
healthy O
volunteers O
were O
required O
to O
be O
in O
good O
health O
on O
physical O
examination O
and O
to O
have O
normal O
vital O
sign O
measurements O
and O
were O
excluded O
if O
they O
had O
a O
positive O
test O
result O
for O
he O
##pa O
##titis O
b O
surface O
anti O
##gen O
or O
he O
##pa O
##titis O
c O
virus O
anti O
##body O
. O
[SEP] O
[CLS] O
steady O
‐ O
state O
pre O
##dos O
##e O
to O
##ci O
##li O
##zu O
##ma O
##b O
concentration O
in O
week O
24 O
was O
approximately O
18 O
μ O
##g O
/ O
m O
##l O
, O
with O
every O
‐ O
4 O
‐ O
week O
in O
##tra O
##ven O
##ous O
dos O
##ing O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etics O
and O
p O
##har O
##ma O
##co O
##dynamic O
##s O
of O
g O
##lip O
##iz O
##ide O
in O
healthy O
volunteers O
. O
[SEP] O
[CLS] O
population O
p O
##k O
analysis O
was O
performed O
using O
a O
linear O
one O
- O
compartment O
model O
involving O
total B-PK
body I-PK
clearance I-PK
( I-PK
c I-PK
##l I-PK
) I-PK
and O
volume B-PK
of I-PK
distribution I-PK
with O
an O
inter O
- O
individual O
random O
effect O
on O
c B-PK
##l I-PK
and O
a O
proportional O
residual O
errors O
to O
describe O
57 O
##8 O
plasma O
se O
##pan O
##tron O
##ium O
concentrations O
obtained O
from O
a O
total O
of O
96 O
patients O
by O
non O
##me O
##m O
version O
v O
##i O
. O
[SEP] O
[CLS] O
o O
##xa O
##ce O
##p O
##rol O
was O
not O
meta O
##bol O
##ized O
. O
[SEP] O
[CLS] O
that O
is O
widely O
used O
for O
the O
treatment O
of O
h O
##yper O
##tens O
##ion O
, O
vascular O
dem O
##ent O
##ia O
, O
and O
stroke O
. O
[SEP] O
[CLS] O
easy O
‐ O
to O
‐ O
use O
na O
##lo O
##xon O
##e O
formulation O
##s O
are O
needed O
to O
help O
address O
the O
op O
##io O
##id O
over O
##dos O
##e O
epidemic O
. O
[SEP] O
[CLS] O
dose O
and O
route O
of O
administration O
were O
selected O
on O
the O
basis O
of O
the O
effectiveness O
of O
a O
##r O
- O
t O
##ur O
##mer O
##one O
to O
control O
seizure O
generation O
in O
the O
6 O
- O
h O
##z O
ps O
##ych O
##omo O
##tor O
seizure O
test O
. O
[SEP] O
[CLS] O
the O
major O
bio O
##tra O
##ns O
##formation O
products O
are O
bi O
##phe O
##ny O
##lace O
##tate O
( O
b O
##pa O
) O
, O
which O
is O
p O
##har O
##ma O
##cological O
##ly O
active O
, O
p O
- O
h O
##ydro O
##xy O
- O
bi O
##phe O
##ny O
##lace O
##tate O
( O
p O
- O
h O
##b O
##pa O
) O
and O
alpha O
- O
amino O
##py O
##rid O
##ine O
( O
a O
##p O
) O
. O
[SEP] O
[CLS] O
the O
disposition O
of O
re O
##mo O
##xi O
##p O
##ride O
was O
evaluated O
in O
13 O
male O
chronic O
s O
##chi O
##zo O
##ph O
##ren O
##ic O
patients O
. O
[SEP] O
[CLS] O
plasma O
level O
of O
these O
drugs O
were O
analyzed O
by O
using O
flu O
##ores O
##cence O
polar O
##ization O
im O
##mu O
##no O
ass O
##ay O
( O
f O
##pia O
) O
technique O
. O
[SEP] O
[CLS] O
a O
linear O
least O
- O
squares O
re O
##gression O
analysis O
using O
1 O
/ O
x O
##2 O
as O
weight O
##ing O
factor O
will O
be O
conducted O
to O
determine O
the O
linear O
##ity O
of O
the O
ca O
##li O
##bra O
##tion O
curve O
. O
[SEP] O
[CLS] O
the O
bias O
was O
> O
20 O
% O
in O
1 O
. O
8 O
% O
of O
patients O
. O
[SEP] O
[CLS] O
about O
half O
of O
the O
patients O
were O
male O
and O
the O
median O
age O
was O
56 O
years O
( O
range O
, O
36 O
– O
73 O
years O
) O
. O
[SEP] O
[CLS] O
to O
achieve O
this O
goal O
, O
first O
, O
we O
incorporated O
a O
2 O
k O
##da O
di O
##thi O
##ol O
p O
##oly O
##eth O
##yle O
##ne O
g O
##ly O
##co O
##l O
( O
p O
##eg O
) O
to O
the O
a O
##c O
##g O
##44 O
na O
##no O
##con O
##ju O
##gate O
##s O
, O
producing O
a O
##c O
##g O
##44 O
##p O
##2 O
##k O
. O
[SEP] O
[CLS] O
the O
particle O
size O
determined O
by O
differential O
light O
scattering O
( O
d O
##ls O
) O
for O
the O
same O
batch O
was O
found O
to O
be O
158 O
. O
5 O
nm O
. O
[SEP] O
[CLS] O
we O
evaluated O
ta O
##iji O
##a O
and O
p O
##lav O
##ix O
##® O
in O
128 O
subjects O
, O
with O
64 O
in O
a O
fast O
##ed O
state O
and O
64 O
receiving O
a O
high O
- O
fat O
diet O
, O
and O
com O
##puted O
cm B-PK
##ax I-PK
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
∞ I-PK
, O
and O
au B-PK
##c I-PK
##0 I-PK
- I-PK
t I-PK
. O
[SEP] O
[CLS] O
this O
p O
##eg O
- O
pro O
##dr O
##ug O
technology O
could O
provide O
precisely O
tuned O
long O
- O
acting O
anti O
- O
di O
##abe O
##tic O
and O
anti O
- O
o O
##besity O
the O
##rap O
##ies O
and O
even O
once O
- O
monthly O
administration O
intervals O
when O
combined O
with O
other O
formulation O
strategies O
. O
[SEP] O
[CLS] O
the O
prolonged O
high O
t O
##umes O
##cent O
anti O
##biotics O
concentrations O
in O
sub O
##cut O
##aneous O
tissue O
may O
reduce O
the O
need O
to O
precisely O
give O
i O
##v O
anti O
##biotics O
30 O
– O
60 O
minutes O
before O
an O
in O
##cision O
. O
[SEP] O
[CLS] O
this O
will O
improve O
the O
translation O
##al O
value O
of O
this O
ve O
##rte O
##bra O
##te O
model O
organism O
in O
drug O
discovery O
and O
development O
. O
[SEP] O
[CLS] O
clinical O
laboratory O
measurements O
and O
12 O
- O
lead O
electro O
##card O
##io O
##gram O
intervals O
were O
assessed O
for O
general O
health O
during O
the O
21 O
- O
day O
screening O
period O
. O
[SEP] O
[CLS] O
in O
the O
control O
un O
##les O
##ioned O
un O
##tre O
##ated O
cats O
, O
the O
basal O
number O
of O
h O
##d O
##c O
im O
##mu O
##nor O
##ea O
##ctive O
neurons O
was O
moderate O
and O
symmetrical O
in O
the O
bilateral O
t O
##m O
##n O
. O
[SEP] O
[CLS] O
at O
the O
end O
of O
each O
period O
, O
blood O
was O
taken O
pre O
##dos O
##ing O
and O
for O
up O
to O
24 O
h O
post O
##dos O
##ing O
to O
measure O
the O
drug O
concentrations O
. O
[SEP] O
[CLS] O
oral O
dos O
##age O
significantly O
influenced O
maximum B-PK
plasma I-PK
concentration I-PK
( O
ng O
/ O
m O
##l O
, O
s O
: O
126 O
##7 O
, O
r O
: O
135 O
##5 O
at O
0 O
. O
5 O
mg O
/ O
kg O
; O
s O
: O
61 O
##4 O
. O
9 O
, O
r O
: O
67 O
##9 O
. O
4 O
at O
0 O
. O
25 O
mg O
/ O
kg O
; O
s O
: O
250 O
. O
5 O
, O
r O
: O
36 O
##7 O
. O
6 O
at O
0 O
. O
1 O
mg O
/ O
kg O
) O
, O
au B-PK
##c I-PK
( O
h O
* O
micro O
##g O
/ O
m O
##l O
, O
s O
: O
45 O
. O
12 O
, O
r O
: O
30 O
. O
91 O
at O
0 O
. O
5 O
mg O
/ O
kg O
; O
s O
: O
22 O
. O
98 O
: O
, O
r O
: O
18 O
. O
99 O
at O
0 O
. O
25 O
mg O
/ O
kg O
; O
s O
: O
3 O
. O
92 O
##2 O
, O
r O
: O
3 O
. O
570 O
at O
0 O
. O
1 O
mg O
/ O
kg O
) O
and O
au B-PK
##m I-PK
##c I-PK
( O
h O
* O
h O
* O
micro O
##g O
/ O
m O
##l O
, O
s O
: O
213 O
##5 O
, O
r O
: O
106 O
##2 O
at O
0 O
. O
5 O
mg O
/ O
kg O
; O
s O
: O
94 O
##3 O
. O
1 O
, O
r O
: O
59 O
##9 O
. O
9 O
at O
0 O
. O
25 O
mg O
/ O
kg O
; O
s O
: O
132 O
. O
2 O
, O
r O
: O
59 O
. O
03 O
at O
0 O
. O
1 O
mg O
/ O
kg O
) O
, O
but O
not O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
( O
s O
: O
23 O
. O
5 O
, O
r O
: O
11 O
. O
6 O
h O
) O
nor O
m B-PK
##rt I-PK
( O
s O
: O
26 O
. O
3 O
, O
r O
: O
13 O
. O
5 O
h O
) O
. O
[SEP] O
[CLS] O
mass O
transfer O
within O
the O
plasma O
( O
r O
##1 O
) O
between O
organs O
is O
calculated O
as O
organ O
specific O
blood B-PK
flow I-PK
( I-PK
q I-PK
##or I-PK
##gan I-PK
) I-PK
times O
the O
drug O
concentration O
within O
the O
plasma O
of O
the O
respective O
organ O
( O
c O
##p O
##ls O
_ O
organ O
) O
times O
the O
overall O
plasma O
fraction O
( O
1 O
− O
h O
##ct O
) O
which O
is O
one O
sub O
##tracted O
by O
the O
hem O
##ato O
##c O
##rit O
( O
h O
##ct O
) O
value O
. O
[SEP] O
[CLS] O
in O
a O
multi O
##var O
##iable O
log O
##istic O
re O
##gression O
analysis O
, O
using O
factors O
shown O
to O
be O
statistical O
##ly O
significant O
through O
un O
##iva O
##ria O
##te O
analysis O
, O
only O
con O
##com O
##ita O
##nt O
h O
##2 O
##ra O
/ O
pp O
##i O
use O
was O
an O
independent O
de O
##ter O
##mina O
##nt O
of O
a O
non O
- O
therapeutic O
p O
##osa O
##cona O
##zo O
##le O
drug O
level O
( O
p O
= O
0 O
. O
04 O
) O
( O
table O
6 O
) O
. O
[SEP] O
[CLS] O
however O
, O
au B-PK
##c I-PK
##0 I-PK
- I-PK
12 I-PK
tended O
to O
be O
higher O
for O
all O
seven O
anal O
##yte O
##s O
in O
the O
p O
- O
s O
##c O
group O
. O
[SEP] O
[CLS] O
all O
random O
##ized O
subjects O
completed O
the O
study O
. O
[SEP] O
[CLS] O
stability O
studies O
were O
performed O
according O
to O
previously O
reported O
method O
. O
[SEP] O
[CLS] O
kinetic O
analysis O
of O
the O
interactions O
of O
the O
different O
na O
##nob O
##ody O
variants O
with O
il O
- O
6 O
##r O
was O
performed O
on O
a O
bi O
##aco O
##re O
t O
##100 O
instrument O
( O
bi O
##aco O
##re O
international O
a O
##b O
, O
up O
##ps O
##ala O
, O
s O
##wed O
##en O
) O
. O
[SEP] O
[CLS] O
all O
three O
drugs O
were O
extensively O
( O
greater O
than O
99 O
% O
) O
bound O
to O
plasma O
proteins O
and O
the O
plasma O
concentration O
/ O
time O
curve O
was O
best O
described O
by O
a O
t O
##ri O
- O
ex O
##po O
##nent O
##ial O
equation O
. O
[SEP] O
[CLS] O
healthy O
volunteers O
were O
recruited O
( O
through O
advertisements O
posted O
around O
the O
medical O
center O
) O
and O
assessed O
for O
inclusion O
in O
the O
study O
. O
[SEP] O
[CLS] O
the O
total O
ch O
##roma O
##to O
##graphic O
run O
time O
was O
10 O
. O
5 O
min O
with O
the O
retention O
time O
of O
7 O
. O
1 O
min O
and O
6 O
. O
2 O
min O
for O
lo O
##r O
and O
d O
##p O
, O
respectively O
, O
and O
2 O
. O
2 O
min O
for O
both O
of O
p O
##es O
and O
pp O
##a O
. O
[SEP] O
[CLS] O
time O
for O
plasma O
al O
##fa O
##xa O
##lone O
concentration O
to O
decrease O
by O
90 O
% O
was O
predicted O
to O
range O
from O
7 O
to O
120 O
or O
113 O
minutes O
following O
a O
b O
##ol O
##us O
to O
an O
8 O
hour O
target O
- O
controlled O
or O
continuous O
rate O
in O
##fusion O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
bio B-PK
##ava I-PK
##ila I-PK
##bility I-PK
of O
the O
drug O
was O
greater O
than O
or O
equal O
to O
95 O
% O
after O
im O
injection O
. O
[SEP] O
[CLS] O
in O
addition O
, O
the O
gradient O
el O
##uti O
##ng O
mode O
was O
op O
##ti O
##mized O
to O
make O
the O
tested O
compounds O
completely O
separated O
and O
have O
good O
peak O
shapes O
, O
and O
the O
interference O
between O
the O
anal O
##yte O
and O
the O
is O
was O
avoided O
. O
[SEP] O
[CLS] O
dependence O
of O
correlation O
on O
stirring O
rate O
indicated O
the O
value O
of O
100 O
rpm O
as O
the O
most O
appropriate O
both O
in O
cases O
of O
m O
##1 O
and O
m O
##5 O
meta O
##bol O
##ites O
. O
[SEP] O
[CLS] O
on O
day O
− O
##1 O
, O
blood O
samples O
were O
collected O
at O
time O
0 O
and O
at O
15 O
, O
30 O
, O
45 O
, O
and O
60 O
min O
following O
the O
morning O
dose O
and O
every O
30 O
min O
thereafter O
for O
12 O
h O
. O
on O
day O
21 O
, O
blood O
samples O
were O
collected O
at O
the O
same O
time O
##points O
as O
for O
day O
− O
##1 O
and O
every O
2 O
h O
from O
hours O
12 O
to O
16 O
relative O
to O
the O
start O
of O
the O
in O
##fusion O
. O
[SEP] O
[CLS] O
the O
composition O
of O
the O
prepared O
a O
##e O
- O
l O
##c O
##n O
##p O
formulation O
##s O
( O
f O
##1 O
– O
f O
##14 O
) O
is O
given O
in O
table O
1 O
. O
[SEP] O
[CLS] O
plasma O
samples O
having O
bi O
##so O
##p O
##rol O
##ol O
theoretical O
##s O
concentrations O
of O
3 O
ng O
/ O
m O
##l O
, O
25 O
ng O
/ O
m O
##l O
and O
75 O
ng O
/ O
m O
##l O
were O
considered O
to O
be O
appropriate O
to O
be O
used O
to O
valid O
##ate O
the O
bio O
##ana O
##ly O
##tical O
method O
. O
[SEP] O
[CLS] O
since O
the O
in O
v O
##ivo O
recovery O
of O
d O
##f O
##c O
##r O
and O
d O
##fu O
##r O
could O
not O
be O
evaluated O
and O
considering O
that O
both O
meta O
##bol O
##ites O
behave O
similar O
to O
f O
##u O
( O
no O
plasma O
protein O
binding O
as O
shown O
below O
and O
in O
v O
##it O
##ro O
recover O
##ies O
similar O
to O
f O
##u O
) O
, O
d O
##f O
##c O
##r O
and O
d O
##fu O
##r O
were O
calculated O
using O
the O
in O
v O
##ivo O
recovery O
of O
f O
##u O
. O
[SEP] O
[CLS] O
participants O
of O
this O
project O
will O
not O
be O
identified O
in O
any O
reports O
or O
publications O
. O
[SEP] O
[CLS] O
four O
patients O
had O
grade O
2 O
th O
##rom O
##bo O
##cy O
##top O
##enia O
including O
2 O
patients O
each O
at O
4 O
. O
34 O
and O
6 O
. O
5 O
mg O
/ O
kg O
. O
[SEP] O
[CLS] O
this O
study O
evaluated O
daily O
las O
##of O
##ox O
##ife O
##ne O
for O
14 O
days O
in O
healthy O
post O
##men O
##op O
##aus O
##al O
women O
. O
[SEP] O
[CLS] O
the O
selection O
was O
based O
on O
particle O
size O
distribution O
and O
short O
- O
term O
stability O
of O
the O
result O
##ant O
c O
##l O
##x O
- O
n O
##c O
. O
[SEP] O
[CLS] O
alcohol O
, O
0 O
. O
8 O
g O
/ O
kg O
, O
caused O
the O
greatest O
performance O
imp O
##air O
##ment O
, O
followed O
closely O
by O
di O
##az O
##ep O
##am O
. O
[SEP] O
[CLS] O
3 O
- O
( O
5 O
- O
amino O
- O
1 O
, O
3 O
, O
4 O
- O
th O
##ia O
##dia O
##zo O
##l O
- O
2 O
- O
y O
##l O
) O
- O
1 O
- O
c O
##y O
##c O
##lop O
##rop O
##yl O
- O
7 O
- O
( O
4 O
- O
( O
2 O
, O
4 O
- O
di O
##ch O
##lor O
##obe O
##nz O
##oy O
##l O
) O
pipe O
##raz O
##in O
- O
1 O
- O
y O
##l O
) O
- O
6 O
- O
flu O
##oro O
##quin O
##olin O
- O
4 O
( O
1 O
##h O
) O
- O
one O
( O
3 O
##i O
) O
. O
[SEP] O
[CLS] O
this O
finding O
was O
reproduced O
( O
p O
= O
0 O
. O
01 O
##3 O
) O
after O
withdrawal O
of O
two O
patients O
with O
bleeding O
p O
##hen O
##otype O
related O
to O
their O
advanced O
art O
##hr O
##op O
##athy O
but O
normal O
t B-PK
##1 I-PK
/ I-PK
2 I-PK
and O
t B-PK
##rough I-PK
levels I-PK
. O
[SEP] O
[CLS] O
mean O
i O
##g O
##p O
##ro O
##20 O
: O
i O
##g O
##p O
##ro O
##10 O
dose O
ratio O
( O
dose O
adjustment O
coefficient O
) O
was O
1 O
. O
53 O
( O
range O
1 O
. O
26 O
- O
1 O
. O
87 O
) O
. O
[SEP] O
[CLS] O
pre O
##tar O
##get O
##ed O
radio O
##im O
##mu O
##not O
##her O
##ap O
##y O
( O
p O
##rit O
) O
based O
on O
the O
inverse O
electron O
demand O
die O
##ls O
- O
al O
##der O
( O
i O
##edd O
##a O
) O
reaction O
between O
te O
##tra O
##zine O
( O
t O
##z O
) O
and O
trans O
- O
c O
##y O
##c O
##lo O
##oc O
##ten O
##e O
( O
t O
##co O
) O
represents O
a O
promising O
strategy O
for O
lever O
##aging O
the O
affinity O
and O
specific O
##ity O
of O
antibodies O
without O
their O
p O
##har O
##ma O
##co O
##kin O
##etic O
draw O
##backs O
. O
[SEP] O
[CLS] O
however O
because O
the O
absolute O
dose O
received O
by O
the O
infant O
is O
dependent O
on O
the O
maternal O
dose O
rate O
, O
the O
risk O
- O
benefit O
ratio O
should O
be O
considered O
for O
each O
individual O
case O
. O
[SEP] O
[CLS] O
car O
##ip O
##raz O
##ine O
is O
in O
phase O
ii O
##i O
clinical O
trials O
in O
patients O
with O
s O
##chi O
##zophrenia O
and O
in O
patients O
with O
bi O
##pol O
##ar O
disorder O
. O
[SEP] O
[CLS] O
the O
in O
##hibition O
of O
clearance B-PK
through O
cross O
- O
linking O
occurs O
only O
under O
conditions O
that O
produce O
partial O
cross O
- O
linking O
of O
the O
fi O
##bri O
##n O
. O
[SEP] O
[CLS] O
the O
ma B-PK
##ximal I-PK
g I-PK
##ent I-PK
##ami I-PK
##cin I-PK
level I-PK
for O
any O
patient O
was O
2 O
. O
36 O
μ O
##g O
/ O
m O
##l O
at O
6 O
h O
, O
which O
was O
well O
below O
the O
pre O
##sp O
##ec O
##ified O
stopping O
criterion O
of O
12 O
μ O
##g O
/ O
m O
##l O
at O
6 O
h O
. O
the O
ma B-PK
##ximal I-PK
van I-PK
##com I-PK
##y I-PK
##cin I-PK
level I-PK
for O
any O
patient O
was O
0 O
. O
68 O
##4 O
μ O
##g O
/ O
m O
##l O
at O
6 O
h O
, O
well O
below O
the O
pre O
##sp O
##ec O
##ified O
stopping O
criterion O
of O
20 O
μ O
##g O
/ O
m O
##l O
. O
p O
##har O
##ma O
##co O
##kin O
##etic O
data O
are O
shown O
in O
table O
2 O
and O
fi O
##gs O
. O
1 O
and O
2 O
. O
[SEP] O
[CLS] O
inter O
##fer O
##on O
β O
- O
1 O
##a O
was O
labelled O
with O
125 O
##i O
by O
an O
##awa O
( O
wa O
##nge O
##n O
, O
s O
##witz O
##erland O
) O
and O
prepared O
in O
l O
##yo O
##phi O
##li O
##zed O
al O
##iq O
##uo O
##ts O
of O
2 O
. O
5 O
μ O
##ci O
, O
each O
containing O
25 O
ng O
of O
inter O
##fer O
##on O
β O
- O
1 O
##a O
. O
[SEP] O
[CLS] O
the O
potential O
impact O
of O
co O
##ad O
##mini O
##stra O
##tion O
of O
b O
##up O
##ar O
##lis O
##ib O
on O
bin O
##ime O
##tin O
##ib O
was O
assessed O
by O
examining O
maximum B-PK
plasma I-PK
concentration I-PK
( I-PK
cm I-PK
##ax I-PK
) I-PK
and O
area B-PK
under I-PK
the I-PK
concentration I-PK
curve I-PK
( I-PK
au I-PK
##ct I-PK
##au I-PK
) I-PK
at O
the O
same O
level O
of O
bin O
##ime O
##tin O
##ib O
across O
doses O
of O
b O
##up O
##ar O
##lis O
##ib O
on O
day O
15 O
. O
[SEP] O
[CLS] O
each O
rat O
was O
deemed O
to O
be O
im O
##mobile O
when O
it O
stopped O
s O
##c O
##rab O
##bling O
, O
remained O
floating O
still O
##y O
in O
the O
water O
and O
only O
made O
necessary O
struggling O
to O
maintain O
its O
head O
over O
water O
. O
[SEP] O
[CLS] O
of O
205 O
patients O
, O
19 O
, O
82 O
, O
and O
104 O
carried O
0 O
, O
1 O
, O
and O
2 O
active O
o O
##ct O
##1 O
all O
##ele O
##s O
, O
respectively O
. O
[SEP] O
[CLS] O
the O
d O
##ys O
##re O
##gu O
##lation O
of O
p O
##hos O
##pha O
##ti O
##dy O
##lino O
##si O
##to O
##l O
3 O
- O
kinase O
( O
p O
##i O
##3 O
##k O
) O
- O
dependent O
pathways O
is O
implicated O
in O
several O
human O
cancer O
##s O
making O
it O
an O
attractive O
target O
for O
small O
molecule O
p O
##i O
##3 O
##k O
inhibitor O
##s O
. O
[SEP] O
[CLS] O
to O
assess O
the O
effects O
of O
food O
, O
the O
subjects O
in O
the O
10 O
- O
mg O
dose O
group O
received O
a O
single O
dose O
of O
da O
- O
122 O
##9 O
10 O
mg O
after O
a O
high O
- O
fat O
meal O
, O
crossing O
over O
from O
the O
administration O
of O
da O
- O
122 O
##9 O
under O
a O
fast O
##ing O
state O
, O
after O
a O
7 O
- O
day O
wash O
##out O
period O
. O
[SEP] O
[CLS] O
then O
, O
an O
##nex O
##in O
v O
- O
fit O
##c O
and O
p O
##i O
were O
added O
, O
followed O
by O
a O
10 O
- O
min O
in O
##cu O
##bation O
at O
room O
temperature O
, O
and O
were O
analyzed O
using O
a O
flow O
c O
##yt O
##ometer O
( O
a O
##cc O
##uri O
c O
##6 O
; O
b O
##d O
company O
, O
f O
##rank O
##lin O
lakes O
, O
n O
##j O
) O
. O
[SEP] O
[CLS] O
the O
number O
of O
recruited O
mon O
##ocytes O
was O
reduced O
by O
64 O
% O
, O
whereas O
no O
significant O
effect O
on O
ne O
##ut O
##rop O
##hil O
recruitment O
was O
observed O
( O
fi O
##g O
. O
4 O
##g O
and O
supplement O
##ary O
figure O
3 O
) O
. O
[SEP] O
[CLS] O
as O
shown O
in O
figure O
2 O
, O
figure O
3 O
, O
no O
significant O
direct O
interference O
in O
the O
blank O
plasma O
traces O
was O
observed O
from O
end O
##ogen O
##ous O
substances O
in O
drug O
- O
free O
plasma O
at O
the O
retention O
time O
of O
the O
anal O
##yte O
##s O
. O
[SEP] O
[CLS] O
the O
demographic O
characteristics O
of O
the O
patients O
are O
shown O
in O
table O
1 O
. O
[SEP] O
[CLS] O
the O
o O
##ih O
/ O
( O
99 O
##m O
) O
t O
##c O
- O
ma O
##g O
##3 O
re B-PK
##nal I-PK
clearance I-PK
ratio I-PK
was O
2 O
. O
47 O
. O
[SEP] O
[CLS] O
further O
studies O
are O
needed O
to O
determine O
the O
full O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
a O
. O
f O
##rag O
##ran O
##s O
activity O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
with O
one O
- O
fourth O
of O
the O
population O
absorbing O
as O
little O
as O
30 O
% O
of O
the O
drug O
relative O
to O
others O
, O
low O
drug O
exposure O
##s O
might O
be O
responsible O
for O
treatment O
failures O
. O
[SEP] O
[CLS] O
the O
observed O
values O
were O
used O
to O
calculate O
the O
em B-PK
##ax I-PK
, I-PK
s I-PK
##s I-PK
. O
[SEP] O
[CLS] O
in O
##hibition O
of O
ni O
##fe O
##di O
##pine O
metabolism O
in O
dogs O
by O
er O
##yt O
##hr O
##omy O
##cin O
: O
difference O
between O
the O
gut O
wall O
and O
the O
liver O
. O
[SEP] O
[CLS] O
the O
is O
##oc O
##ratic O
mobile O
phase O
, O
0 O
. O
01 O
m O
potassium O
di O
##hy O
##dr O
##ogen O
or O
##th O
##o O
phosphate O
( O
p O
##h O
3 O
. O
2 O
) O
and O
ace O
##ton O
##it O
##ril O
##e O
( O
50 O
: O
50 O
, O
v O
/ O
v O
) O
was O
run O
at O
a O
flow O
rate O
of O
1 O
m O
##l O
/ O
min O
. O
[SEP] O
[CLS] O
p O
##har O
##ma O
##co O
##kin O
##etic O
study O
of O
radioactive O
anti O
##ne O
##op O
##last O
##on O
a O
##10 O
following O
oral O
administration O
in O
rats O
. O
[SEP] O
[CLS] O
performance O
of O
computer O
simulated O
in O
##hala O
##tional O
an O
##est O
##hetic O
up O
##take O
model O
in O
comparison O
with O
real O
time O
is O
##of O
##lu O
##rane O
concentration O
. O
[SEP] O
[CLS] O
no O
evidence O
of O
acute O
card O
##iot O
##ox O
##icit O
##y O
or O
of O
acute O
or O
delayed O
systemic O
toxicity O
was O
observed O
. O
[SEP] O
[CLS] O
for O
day O
1 O
, O
m O
##ds O
- O
up O
##dr O
##s O
assessments O
after O
rescue O
were O
imp O
##uted O
as O
base O
##line O
observation O
carried O
forward O
and O
motor O
state O
assessments O
were O
imp O
##uted O
as O
off O
. O
[SEP] O
[CLS] O
patients O
weighing O
< O
50 O
kg O
or O
> O
90 O
kg O
were O
excluded O
. O
[SEP] O
[CLS] O
c O
##t O
##26 O
was O
used O
to O
determine O
the O
in O
v O
##it O
##ro O
c O
##yt O
##oto O
##xi O
##city O
. O
[SEP] O
[CLS] O
the O
purpose O
of O
this O
study O
was O
to O
establish O
the O
p O
##har O
##ma O
##co O
##kin O
##etics O
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
and O
its O
meta O
##bol O
##ite O
c O
##ip O
##ro O
##f O
##lo O
##xa O
##cin O
in O
the O
plasma O
and O
inter O
##st O
##iti O
##al O
fluid O
( O
is O
##f O
) O
following O
sub O
##cut O
##aneous O
( O
s O
. O
c O
. O
) O
administration O
of O
en O
##ro O
##f O
##lo O
##xa O
##cin O
. O
[SEP] O
[CLS] O
phase O
i O
evaluation O
of O
continuous O
5 O
- O
flu O
##oro O
##ura O
##ci O
##l O
in O
##fusion O
followed O
by O
weekly O
p O
##ac O
##lit O
##ax O
##el O
in O
patients O
with O
advanced O
or O
re O
##current O
gas O
##tric O
cancer O
. O
[SEP] O
[CLS] O
p O
##eptide O
##s O
were O
initially O
evaluated O
using O
a O
competitive O
enzyme O
- O
linked O
im O
##mu O
##nos O
##or O
##bent O
ass O
##ay O
( O
el O
##isa O
) O
. O
[SEP] O
[CLS] O
a O
se O
##rous O
- O
a O
##cin O
##ar O
chemical O
transport O
ass O
##ay O
was O
established O
to O
measure O
chemical O
transport O
with O
non O
##phy O
##sio O
##logical O
( O
standard O
cell O
culture O
medium O
) O
and O
physiological O
( O
using O
sur O
##rogate O
plasma O
and O
sa O
##liva O
medium O
) O
conditions O
using O
3 O
, O
5 O
, O
6 O
- O
t O
##rich O
##lor O
##o O
- O
2 O
- O
p O
##yr O
##id O
##ino O
##l O
( O
t O
##c O
##py O
) O
a O
meta O
##bol O
##ite O
of O
the O
p O
##est O
##icide O
ch O
##lor O
##py O
##ri O
##fo O
##s O
. O
[SEP] O
[CLS] O
the O
onset O
times O
were O
the O
same O
for O
both O
the O
elderly O
and O
younger O
control O
group O
, O
but O
the O
duration O
of O
action O
of O
r O
##oc O
##uron O
##ium O
was O
significantly O
prolonged O
in O
the O
elderly O
patients O
. O
[SEP] O
[CLS] O
by O
comparing O
approximately O
e O
##qui O
##pot O
##ent O
doses O
, O
time O
to O
peak O
ant O
##agon O
##ism O
( O
onset O
) O
and O
until O
30 O
% O
of O
peak O
ant O
##agon O
##ism O
remained O
( O
duration O
) O
were O
shorter O
for O
both O
ed O
##rop O
##hon O
##ium O
and O
p O
##t O
##ma O
than O
for O
neo O
##st O
##ig O
##mine O
and O
p O
##yr O
##ido O
##st O
##ig O
##mine O
. O
[SEP] O
[CLS] O
the O
disposition O
of O
but O
##or O
##pha O
##no O
##l O
following O
in O
##tra O
##ven O
##ous O
administration O
was O
characterized O
by O
rapid O
and O
extensive O
distribution O
followed O
by O
a O
slower O
elimination O
phase O
. O
[SEP] O
[CLS] O
both O
treatments O
showed O
efficacy O
more O
than O
95 O
% O
at O
72 O
h O
, O
lower O
95 O
% O
confidence O
intervals O
were O
well O
above O
95 O
% O
of O
success O
rate O
in O
both O
treatments O
( O
table O
2 O
) O
. O
[SEP] O
[CLS] O
collectively O
, O
these O
studies O
support O
further O
development O
of O
r O
##t O
##d O
- O
1 O
for O
treatment O
of O
c O
##f O
air O
##way O
disease O
. O
[SEP] O
[CLS] O
these O
were O
also O
assessed O
for O
clearance B-PK
using O
plate O
##d O
he O
##pa O
##to O
##cy O
##tes O
over O
a O
48 O
- O
h O
time O
course O
( O
0 O
, O
4 O
, O
8 O
, O
24 O
, O
and O
48 O
h O
) O
at O
the O
1 O
µ O
##m O
chemical O
concentration O
( O
s O
##mith O
et O
al O
. O
, O
2012 O
) O
. O
[SEP] O
[CLS] O
although O
6 O
of O
9 O
participants O
who O
had O
their O
patch O
removed O
had O
at O
least O
one O
variant O
all O
##ele O
, O
this O
difference O
in O
toxicity O
was O
not O
statistical O
##ly O
significant O
across O
g O
##eno O
##type O
groups O
. O
[SEP] O
[CLS] O
initial O
clinical O
trial O
of O
a O
selective O
re O
##tino O
##id O
x O
receptor O
l O
##igan O
##d O
, O
l O
##g O
##d O
##10 O
##6 O
##9 O
. O
[SEP] O
[CLS] O
we O
also O
measured O
f O
##1 O
+ O
2 O
pro O
##th O
##rom O
##bin O
fragment O
levels O
to O
assess O
the O
effect O
of O
s O
1832 O
##6 O
on O
th O
##rom O
##bin O
generation O
in O
v O
##ivo O
. O
[SEP] O
[CLS] O
e O
##q O
##s O
. O
( O
1 O
) O
, O
( O
2 O
) O
represent O
the O
linear O
re O
##gression O
models O
for O
particle O
size O
( O
p O
. O
s O
. O
) O
using O
t O
##80 O
and O
s O
##80 O
transfers O
##ome O
##s O
, O
respectively O
, O
as O
obtained O
from O
factor O
##ial O
design O
study O
. O
( O
1 O
) O
particle O
size O
using O
##t O
##80 O
= O
2 O
. O
29 O
- O
0 O
. O
24 O
##xa O
+ O
0 O
. O
02 O
##4 O
##x O
##b O
+ O
0 O
. O
29 O
##x O
##c O
+ O
0 O
. O
47 O
##xa O
##b O
+ O
0 O
. O
23 O
##xa O
##c O
+ O
0 O
. O
43 O
##x O
##b O
##c O
) O
[ O
where O
f O
= O
21 O
. O
9 O
, O
p O
< O
0 O
. O
000 O
##1 O
and O
r O
##2 O
= O
0 O
. O
93 O
] O
( O
2 O
) O
particle O
size O
using O
##s O
##80 O
= O
2 O
. O
9 O
- O
0 O
. O
4 O
##xa O
+ O
0 O
. O
03 O
##9 O
##x O
##b O
+ O
0 O
. O
46 O
##x O
##c O
- O
0 O
. O
18 O
##xa O
##b O
- O
3 O
. O
12 O
##xa O
##c O
- O
0 O
. O
52 O
##x O
##b O
##c O
[ O
where O
f O
= O
15 O
. O
28 O
, O
p O
< O
0 O
. O
000 O
##1 O
and O
r O
##2 O
= O
0 O
. O
91 O
] O
[SEP] O
[CLS] O
to O
measure O
the O
effect O
of O
compounds O
on O
worm O
c O
##p O
activity O
in O
v O
##ivo O
[ O
36 O
] O
, O
one O
ha O
##ms O
##ter O
from O
each O
of O
the O
treatment O
and O
vehicle O
groups O
was O
sacrificed O
8 O
h O
post O
- O
treatment O
. O
[SEP] O
[CLS] O
the O
aim O
of O
the O
study O
is O
to O
apply O
a O
multi O
##par O
##ame O
##tric O
method O
for O
the O
quantitative O
est O
##imation O
of O
mouse O
models O
with O
different O
degrees O
of O
hind O
##lim O
##b O
is O
##che O
##mia O
based O
on O
a O
dynamic O
flu O
##ores O
##cence O
imaging O
- O
based O
strategy O
. O
[SEP] O
[CLS] O
augmented O
re B-PK
##nal I-PK
clearance I-PK
in O
patients O
with O
f O
##eb O
##ril O
##e O
ne O
##ut O
##rop O
##enia O
is O
associated O
with O
increased O
risk O
for O
sub O
##ther O
##ap O
##eu O
##tic O
concentrations O
of O
van O
##com O
##y O
##cin O
. O
[SEP] O
[CLS] O
procedures O
were O
performed O
in O
40 O
female O
w O
##ista O
##r O
rats O
weighing O
250 O
– O
280 O
g O
. O
s O
##tre O
##pt O
##oz O
##oto O
##cin O
- O
ni O
##cot O
##ina O
##mi O
##de O
- O
induced O
rat O
model O
of O
t O
##2 O
##d O
was O
used O
( O
24 O
, O
25 O
) O
. O
[SEP] O
[CLS] O
however O
, O
the O
actions O
of O
this O
transport O
##er O
can O
contribute O
to O
resistance O
to O
a O
broad O
range O
of O
more O
than O
300 O
compounds O
##45 O
. O
[SEP] O
[CLS] O
the O
metabolic O
activity O
in O
rat O
micro O
##some O
##s O
was O
much O
higher O
than O
that O
in O
human O
micro O
##some O
##s O
within O
the O
clinical O
##ly O
observed O
plasma O
range O
. O
[SEP] O
[CLS] O
a O
total O
of O
97 O
p O
##har O
##ma O
##co O
##kin O
##etic O
profiles O
were O
obtained O
following O
the O
first O
administration O
of O
bus O
##ulf O
##an O
or O
after O
the O
second O
dose O
for O
3 O
patients O
( O
therapeutic O
monitoring O
could O
not O
be O
performed O
on O
the O
first O
dose O
and O
standard O
dose O
was O
administered O
on O
first O
and O
second O
dose O
) O
. O
[SEP] O
[CLS] O
cardiac O
toxicity O
of O
any O
grade O
was O
reported O
. O
[SEP] O
[CLS] O
mean O
cumulative B-PK
amounts I-PK
of I-PK
a I-PK
##g I-PK
##10 I-PK
‐ I-PK
a I-PK
##g I-PK
ex I-PK
##cre I-PK
##ted I-PK
in I-PK
urine I-PK
over O
72 O
hours O
after O
dos O
##ing O
ranged O
from O
approximately O
21 O
. O
27 O
to O
270 O
. O
9 O
mg O
and O
increased O
with O
increasing O
dose O
of O
a O
##g O
##10 O
administered O
and O
represented O
approximately O
19 O
. O
5 O
% O
to O
23 O
. O
5 O
% O
of O
the O
dose O
of O
a O
##g O
##10 O
administered O
following O
a O
single O
dose O
of O
50 O
to O
800 O
mg O
a O
##g O
##10 O
. O
[SEP] O
[CLS] O
the O
plasma O
concentrations O
of O
o O
##xy O
##co O
##don O
##e O
and O
its O
meta O
##bol O
##ites O
were O
affected O
significantly O
by O
presence O
or O
absence O
of O
a O
##p O
##re O
##pit O
##ant O
. O
[SEP] O
[CLS] O
blank O
plasma O
showed O
no O
significant O
interfering O
peaks O
at O
the O
retention O
times O
of O
each O
anal O
##yte O
( O
fi O
##g O
. O
3 O
##a O
) O
. O
[SEP] O
[CLS] O
adverse O
events O
were O
recorded O
through O
the O
study O
. O
[SEP] O
[CLS] O
rats O
were O
allocated O
into O
four O
groups O
: O
normal O
group O
( O
n O
= O
5 O
) O
, O
a O
##p O
model O
group O
( O
n O
= O
5 O
) O
, O
a O
##p O
model O
with O
l O
##h O
##d O
group O
( O
n O
= O
5 O
) O
, O
and O
a O
##p O
model O
with O
m O
##l O
##h O
##d O
group O
( O
n O
= O
5 O
) O
. O
[SEP] O
[CLS] O
the O
study O
setup O
is O
illustrated O
in O
figure O
##1 O
##b O
. O
[SEP] O
[CLS] O
formulation O
and O
in O
v O
##ivo O
evaluation O
of O
membrane O
- O
moderate O
##d O
trans O
##der O
##mal O
therapeutic O
systems O
of O
ni O
##card O
##ip O
##ine O
h O
##ydro O
##ch O
##lor O
##ide O
using O
car O
##von O
##e O
as O
a O
penetration O
enhance O
##r O
. O
[SEP] O
[CLS] O
the O
results O
were O
explained O
on O
the O
basis O
of O
previous O
results O
from O
our O
laboratory O
relating O
to O
the O
product O
en O
##anti O
##ose O
##lect O
##ivity O
of O
the O
formation O
of O
the O
su O
##lf O
##oxide O
and O
the O
substrate O
en O
##anti O
##ose O
##lect O
##ivity O
of O
the O
subsequent O
formation O
of O
the O
su O
##lf O
##one O
. O
[SEP] O
[CLS] O
as O
an O
alternative O
to O
current O
methods O
of O
local O
nerve O
block O
, O
we O
studied O
the O
f O
##eas O
##ibility O
of O
producing O
ankle O
block O
in O
the O
rat O
with O
i O
##v O
injection O
of O
magnetic O
na O
##no O
##par O
##tic O
##les O
( O
m O
##n O
##ps O
) O
associated O
with O
r O
##op O
##iva O
##ca O
##ine O
and O
application O
of O
a O
magnet O
at O
the O
ankle O
. O
[SEP] O
[CLS] O
information O
on O
the O
p O
##har O
##ma O
##co O
##kin O
##etic O
profile O
of O
l O
##d O
##x O
in O
children O
with O
ad O
##h O
##d O
is O
lacking O
. O
[SEP] O
[CLS] O
di O
##ssi O
##mi O
##lar O
##ity O
factor O
( O
f O
##1 O
) O
given O
in O
su O
##pa O
##c O
guidelines O
for O
modified O
dos O
##age O
forms O
was O
used O
to O
further O
justify O
the O
selection O
of O
best O
formulation O
which O
showed O
least O
significance O
during O
multiple O
t O
- O
test O
at O
p O
> O
0 O
. O
05 O
. O
[SEP] O
[CLS] O
the O
kinetic O
##s O
of O
five O
c O
##is O
##p O
##lat O
##in O
analog O
##s O
binding O
to O
human O
plasma O
fraction O
##s O
possessing O
a O
molecular O
weight O
greater O
than O
50 O
, O
000 O
da O
##lton O
##s O
were O
studied O
. O
[SEP] O
[CLS] O
the O
ex O
##cre O
##ted O
radio B-PK
##act I-PK
##ivity I-PK
was O
profile O
##d O
using O
radio O
##ch O
##roma O
##tography O
, O
and O
approximately O
31 O
% O
was O
structural O
##ly O
characterized O
as O
rub O
##ox O
##ista O
##uri O
##n O
or O
n O
- O
des O
##met O
##hyl O
rub O
##ox O
##ista O
##uri O
##n O
. O
[SEP] O

